<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB01238</drugbank-id>
  <drugbank-id>APRD00638</drugbank-id>
  <name>Aripiprazole</name>
  <description>Aripiprazole is an atypical antipsychotic orally indicated for treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's[Label]. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania[Label]. Aripiprazole exerts its effects through agonism of dopaminic and 5-HT1A receptors and antagonism of alpha adrenergic and 5-HT2A receptors[Label,A4393]. Aripiprazole was given FDA approval on November 15, 2002[L6136].</description>
  <cas-number>129722-12-9</cas-number>
  <unii>82VFR53I78</unii>
  <average-mass>448.385</average-mass>
  <monoisotopic-mass>447.148032537</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A4393</ref-id>
        <pubmed-id>17848919</pubmed-id>
        <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
      </article>
      <article>
        <ref-id>A31184</ref-id>
        <pubmed-id>18332080</pubmed-id>
        <citation>Bauman JN, Frederick KS, Sawant A, Walsky RL, Cox LM, Obach RS, Kalgutkar AS: Comparison of the bioactivation potential of the antidepressant and hepatotoxin nefazodone with aripiprazole, a structural analog and marketed drug. Drug Metab Dispos. 2008 Jun;36(6):1016-29. doi: 10.1124/dmd.108.020545. Epub 2008 Mar 10.</citation>
      </article>
      <article>
        <ref-id>A177904</ref-id>
        <pubmed-id>17965519</pubmed-id>
        <citation>Kubo M, Koue T, Maune H, Fukuda T, Azuma J: Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet. 2007 Oct;22(5):358-66.</citation>
      </article>
      <article>
        <ref-id>A177910</ref-id>
        <pubmed-id>26589880</pubmed-id>
        <citation>Prommer E: Aripiprazole. Am J Hosp Palliat Care. 2017 Mar;34(2):180-185. doi: 10.1177/1049909115612800. Epub 2016 Jul 10.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L6136</ref-id>
        <title>FDA Drug Approval Package: Aripiprazole</title>
        <url>https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-436_Abilify.cfm</url>
      </link>
      <link>
        <ref-id>L6145</ref-id>
        <title>Clinicaltrails.gov: National Pregnancy Registry for Atypical Antipsychotics</title>
        <url>https://clinicaltrials.gov/ct2/show/NCT01246765</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Aripiprazole is indicated for manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, treatment of schizophrenia, treatment of Tourette's disorder, and as an adjunctive treatment of major depressive disorder[Label]. An injectable formulation of aripiprazole is indicated for agitation associated with schizophrenia or bipolar mania[Label].</indication>
  <pharmacodynamics>Aripiprazole has high affinity for serotonin type 2 (5HT2), dopamine type 2 (D2), alpha1 and 2 adrenergic, and H1 histaminergic receptors[Label,A4393]. It also acts on a number of other receptors with lower affinity[Label,A4393]. The exact method by which aripiprazole's action on these receptors translates to a clinically relevant effect is not yet known[Label].</pharmacodynamics>
  <mechanism-of-action>The antipsychotic action of aripiprazole is likely due to the agonism of D2 and 5-HT1A receptors though the exact mechanism has not been defined[Label,A4393]. Some adverse effects may be due to action on other receptors[Label]. For example, orthostatic hypotension may be explained by antagonism of the adrenergic alpha1 receptors[Label,A4393].</mechanism-of-action>
  <toxicity>Studies on the safety and effectiveness of aripiprazole in pregnancy have not been performed, though there is currently a national pregnancy registry for mothers currently taking aripiprazole in pregnancy[Label,L6145]. In other studies of antipsychotic medication in pregnancy, children are at risk of extrapyramidal or withdrawal symptoms[Label]. In animal studies of pregnancy, aripiprazole was associated with a number of malformations and fetal death at doses higher than the maximum recommended human dose[Label]. Aripiprazole should only be prescribed in pregnancy if the benefits outweigh the risks[Label]. Neonates with third trimester exposure to aripiprazole may show extrapyramidal or withdrawal symptoms of varying severity[Label]. These symptoms may resolve in hours or require extended hospital care[Label]. Aripiprazole's effect on labor and delivery has not been investigated[Label]. Aripiprazole is present in human breast milk and so patients should either stop breastfeeding or stop taking aripiprazole depending on the risk and benefit to mother and child[Label]. Pharmacokinetic properties in patients 10-17 years of age are similar to that of adults once body weight has been corrected for[Label]. No dosage adjustment is necessary in elderly patients however aripiprazole is not approved for Alzheimer's associated psychosis[Label]. Patients calssified as CYP2D6 poor metabolizers should be prescribed half the regular dose of aripiprazole[Label]. Hepatic and renal function as well as sex, race, and smoking status do not affect dosage requirements for aripiprazole[Label,A177904].</toxicity>
  <metabolism>Metabolism of aripiprazole is predominantly hepatic, mediated mostly by cytochrome P450 (CYP)3A4 and CYP2D6[Label,A31184]. These enzymes perform dehydrogenation and hydroxylation while CYP3A4 alone performs N-dealkylation[Label,A31184]. At any given time, the active metabolite dehydro-aripiprazole is approximately 40% of the drug available in plasma[Label].</metabolism>
  <absorption>Aripiprazole tablets are 87% bioavailable and reach peak plasma concentrations in 3 to 5 hours[Label]. These tablets can be taken with or without food, but a high fat meal can delay the time to max concentration by 3 hours and up to 12 hours for the active metabolite[Label].</absorption>
  <half-life>The half life of aripiprazole is 75 hours while the half life of the active metabolite is 94 hours[Label]. For populations that are poor CYP2D6 metabolizers, the half life of aripiprazole is 146 hours and these patients should be treated with half the normal dose[Label]. Other studies have reported a half life of 61.03±19.59 hours for aripiprazole and 279±299 hours for the active metabolite[A177904].</half-life>
  <protein-binding>&gt;99%[Label].</protein-binding>
  <route-of-elimination>25% of a given dose will be eliminated in urine and 55% in the feces[Label,A177910]. &lt;1% of a dose is eliminated in the urine as unmetabolized aripiprazole and approximately 18% of a dose will be eliminated in the feces unmetabolized[Label,A177910].</route-of-elimination>
  <volume-of-distribution>404L or 4.9L/kg[Label,A31184].</volume-of-distribution>
  <clearance>0.8mL/min/kg[A31184]. Other studies have reported a clearance rate of 3297±1042mL/hr[A177904].</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.</description>
    <direct-parent>Phenylpiperazines</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organoheterocyclic compounds</superclass>
    <class>Diazinanes</class>
    <subclass>Piperazines</subclass>
    <alternative-parent>Alkyl aryl ethers</alternative-parent>
    <alternative-parent>Amino acids and derivatives</alternative-parent>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Aryl chlorides</alternative-parent>
    <alternative-parent>Azacyclic compounds</alternative-parent>
    <alternative-parent>Carbonyl compounds</alternative-parent>
    <alternative-parent>Dialkylarylamines</alternative-parent>
    <alternative-parent>Dichlorobenzenes</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Hydroquinolines</alternative-parent>
    <alternative-parent>Hydroquinolones</alternative-parent>
    <alternative-parent>Lactams</alternative-parent>
    <alternative-parent>N-alkylpiperazines</alternative-parent>
    <alternative-parent>N-arylpiperazines</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organochlorides</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Secondary carboxylic acid amides</alternative-parent>
    <alternative-parent>Trialkylamines</alternative-parent>
    <substituent>1,2-dichlorobenzene</substituent>
    <substituent>Alkyl aryl ether</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl chloride</substituent>
    <substituent>Aryl halide</substituent>
    <substituent>Azacycle</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Carbonyl group</substituent>
    <substituent>Carboxamide group</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Chlorobenzene</substituent>
    <substituent>Dialkylarylamine</substituent>
    <substituent>Ether</substituent>
    <substituent>Halobenzene</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Lactam</substituent>
    <substituent>Monocyclic benzene moiety</substituent>
    <substituent>N-alkylpiperazine</substituent>
    <substituent>N-arylpiperazine</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organochloride</substituent>
    <substituent>Organohalogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenylpiperazine</substituent>
    <substituent>Quinolone</substituent>
    <substituent>Secondary carboxylic acid amide</substituent>
    <substituent>Tertiary aliphatic amine</substituent>
    <substituent>Tertiary aliphatic/aromatic amine</substituent>
    <substituent>Tertiary amine</substituent>
    <substituent>Tetrahydroquinoline</substituent>
    <substituent>Tetrahydroquinolone</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="inn">Aripiprazol</synonym>
    <synonym language="english/french" coder="inn/usan">Aripiprazole</synonym>
    <synonym language="latin" coder="inn">Aripiprazolum</synonym>
  </synonyms>
  <products>
    <product>
      <name>Abilify</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-004</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Rebel Distributors</labeller>
      <ndc-id/>
      <ndc-product-code>21695-005</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-323</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Stat Rx USA</labeller>
      <ndc-id/>
      <ndc-product-code>16590-745</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-818</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-28</started-marketing-on>
      <ended-marketing-on>2018-04-17</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3386</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-6280</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-07-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Physicians Total Care, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54868-5202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>H.J. Harkins Company</labeller>
      <ndc-id/>
      <ndc-product-code>52959-604</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-4815</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on>2018-05-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>TYA Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>64725-0007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-848</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-849</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-850</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-792</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-13</started-marketing-on>
      <ended-marketing-on>2014-06-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-991</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-09</started-marketing-on>
      <ended-marketing-on>2014-08-12</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-839</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-14</started-marketing-on>
      <ended-marketing-on>2014-08-27</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-279</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-12-14</started-marketing-on>
      <ended-marketing-on>2015-05-20</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>false</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-5121</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-4461</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-4982</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>24236-837</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-05-10</started-marketing-on>
      <ended-marketing-on>2016-03-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-171</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-17</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>35356-568</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2011-12-05</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2025</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on>2016-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on>2017-09-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2021</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on>2017-08-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on>2013-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on>2013-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Cardinal Health</labeller>
      <ndc-id/>
      <ndc-product-code>55154-2032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on>2013-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-816</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-17</started-marketing-on>
      <ended-marketing-on>2018-10-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Lake Erie Medical &amp;Surgical Supply Dba Quality Care Products Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-598</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-02-17</started-marketing-on>
      <ended-marketing-on>2018-10-29</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Lake Erie Medical Dba Quality Care Produts Llc</labeller>
      <ndc-id/>
      <ndc-product-code>49999-817</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-06-03</started-marketing-on>
      <ended-marketing-on>2014-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>PD-Rx Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55289-251</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-007</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-008</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-009</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-010</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-011</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-013</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2004-12-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>NDA021713</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-640</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021729</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-641</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-06-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021729</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-016</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2006-09-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, solution</dosage-form>
      <strength>9.75 mg/1.3mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>NDA021866</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-3387</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2002-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA021436</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02322382</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02322390</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02322404</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02322412</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02322374</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02322455</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2009-09-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Europe Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002755</ema-product-code>
      <ema-ma-number>EU/1/13/882/001</ema-ma-number>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>300 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Europe Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002755</ema-product-code>
      <ema-ma-number>EU/1/13/882/002</ema-ma-number>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>400 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Europe Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002755</ema-product-code>
      <ema-ma-number>EU/1/13/882/003</ema-ma-number>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>300 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Europe Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002755</ema-product-code>
      <ema-ma-number>EU/1/13/882/004</ema-ma-number>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>400 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Europe Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002755</ema-product-code>
      <ema-ma-number>EU/1/13/882/005</ema-ma-number>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>300 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Europe Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002755</ema-product-code>
      <ema-ma-number>EU/1/13/882/006</ema-ma-number>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>400 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Europe Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002755</ema-product-code>
      <ema-ma-number>EU/1/13/882/007</ema-ma-number>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>300 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Europe Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002755</ema-product-code>
      <ema-ma-number>EU/1/13/882/008</ema-ma-number>
      <started-marketing-on>2013-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>400 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>46602-0023</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-01</started-marketing-on>
      <ended-marketing-on>2013-04-04</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for suspension, extended release</dosage-form>
      <strength>300 mg/1.5mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>NDA202971</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code>46602-0024</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-09-01</started-marketing-on>
      <ended-marketing-on>2013-04-04</ended-marketing-on>
      <dosage-form>Injection, powder, lyophilized, for suspension, extended release</dosage-form>
      <strength>400 mg/2.0mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>NDA202971</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-018</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>300 mg/1.5mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>NDA202971</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-019</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-02-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>400 mg/1.9mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>NDA202971</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>300 mg/1.5mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>NDA202971</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-072</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit</dosage-form>
      <strength>400 mg/1.9mL</strength>
      <route>Intramuscular</route>
      <fda-application-number>NDA202971</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02420864</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release; Kit</dosage-form>
      <strength>300 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02420872</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-03-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release; Kit</dosage-form>
      <strength>400 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02445018</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>300 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify Maintena</name>
      <labeller>Otsuka Pharmaceutical Co., Ltd.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02445026</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, for suspension, extended release</dosage-form>
      <strength>400 mg</strength>
      <route>Intramuscular</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Abilify MyCite</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-029</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207202</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify MyCite</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-030</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207202</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify MyCite</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-031</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207202</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify MyCite</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-032</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207202</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify MyCite</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-033</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207202</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abilify MyCite</name>
      <labeller>Otsuka America Pharmaceutical, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>59148-034</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA207202</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Apo-aripiprazole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02471086</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-aripiprazole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02471094</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-aripiprazole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02471108</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-aripiprazole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02471116</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-aripiprazole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02471124</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Apo-aripiprazole</name>
      <labeller>Apotex Corporation</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02471132</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2015-05-20</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2015-05-20</ended-marketing-on>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-853</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-08-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Carilion Materials Management</labeller>
      <ndc-id/>
      <ndc-product-code>68151-4459</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Trigen Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13811-679</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Trigen Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13811-680</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Trigen Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13811-681</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Trigen Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13811-682</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Trigen Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13811-683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Trigen Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13811-684</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-517</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-24</started-marketing-on>
      <ended-marketing-on>2016-12-24</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Trigen Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13811-692</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Trigen Laboratories, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>13811-693</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-950</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-302</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205363</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205363</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-304</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205363</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-305</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205363</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-306</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205363</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Solco healthcare U.S., LLC</labeller>
      <ndc-id/>
      <ndc-product-code>43547-307</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205363</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-313</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-20</started-marketing-on>
      <ended-marketing-on>2016-09-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-133</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-06</started-marketing-on>
      <ended-marketing-on>2017-11-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-134</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-06</started-marketing-on>
      <ended-marketing-on>2017-11-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-135</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-06</started-marketing-on>
      <ended-marketing-on>2017-11-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078608</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-136</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-06</started-marketing-on>
      <ended-marketing-on>2017-11-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078708</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-137</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-06</started-marketing-on>
      <ended-marketing-on>2017-11-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078708</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-138</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-06</started-marketing-on>
      <ended-marketing-on>2017-11-01</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078708</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-873</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-6999</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2018-10-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7003</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2018-10-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7017</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2018-10-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7108</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2018-10-11</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-334</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-15</started-marketing-on>
      <ended-marketing-on>2018-05-21</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-180</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-147</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-140</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aphena Pharma Solutions Tennessee, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>43353-148</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-091</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Pak</labeller>
      <ndc-id/>
      <ndc-product-code>50268-092</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-095</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-12</started-marketing-on>
      <ended-marketing-on>2018-08-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-096</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-12</started-marketing-on>
      <ended-marketing-on>2018-08-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-097</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-12</started-marketing-on>
      <ended-marketing-on>2018-08-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-098</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-12</started-marketing-on>
      <ended-marketing-on>2018-08-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-099</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-12</started-marketing-on>
      <ended-marketing-on>2018-08-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Av Kare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>42291-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-04-12</started-marketing-on>
      <ended-marketing-on>2018-08-14</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Unit Dose Services</labeller>
      <ndc-id/>
      <ndc-product-code>50436-0897</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Sciegen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50228-330</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207240</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Sciegen Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50228-331</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207240</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>43598-733</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207240</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Dr Reddy's Laboratories</labeller>
      <ndc-id/>
      <ndc-product-code>43598-734</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207240</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2691</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-436</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Remedy Repack</labeller>
      <ndc-id/>
      <ndc-product-code>61786-496</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3070</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3073</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>63629-7774</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Denton Pharma, Inc. Dba Northwind Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>70934-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3941</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Lake Erie Medical DBA Quality Care Products LLC</labeller>
      <ndc-id/>
      <ndc-product-code>55700-399</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Exelan Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-044</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Exelan Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Exelan Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-046</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Exelan Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-047</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Exelan Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-048</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Exelan Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>76282-049</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Doh Central Pharmacy</labeller>
      <ndc-id/>
      <ndc-product-code>53808-1101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1247</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>NCS HealthCare of KY, Inc dba Vangard Labs</labeller>
      <ndc-id/>
      <ndc-product-code>0615-8259</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1129</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1263</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>McKesson Corporation dba SKY Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>63739-413</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2790</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on>2017-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2824</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-2848</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on>2017-06-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1871</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1870</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-431</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-432</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-433</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-434</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-435</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ascend Laboratories, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>67877-430</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0412</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0895</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0609</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>bryant ranch prepack</labeller>
      <ndc-id/>
      <ndc-product-code>71335-0667</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7613</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2019-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7569</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2019-04-30</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7580</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078608</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7581</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2019-12-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078708</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7582</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2020-01-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078708</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Teva Pharmaceuticals USA, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0093-7583</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2019-07-31</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078708</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Atlantic Biologicals Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210479</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4160</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-6921</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7076</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-03</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7006</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7063</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Preferred Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68788-7162</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0675</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0678</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078608</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0673</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0676</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0683</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-08-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4381</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2149</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2150</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2164</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2163</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0759</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0765</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0896</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-12-12</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0884</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-11-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0976</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1065</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1144</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-04-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078607</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1155</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-05-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1246</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-06-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078708</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2281</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-08-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1303</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-13</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1295</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1432</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090165</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1433</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090165</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1434</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090165</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1435</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090165</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1452</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1453</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1454</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1455</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1456</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Cadila Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code>70771-1451</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-087</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090165</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-088</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090165</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-089</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090165</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-090</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090165</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-082</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-083</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-084</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-085</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-086</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Zydus Pharmaceuticals (USA) Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68382-439</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-06-04</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA090472</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-122</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-123</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-124</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-125</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-126</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Macleods Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>33342-127</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Lannett Company, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54838-570</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204171</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-783</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-784</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-785</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-786</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-787</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Northstar RxLLC</labeller>
      <ndc-id/>
      <ndc-product-code>16714-788</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-03-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-254</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-255</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-256</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-257</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-258</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-259</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1317</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1327</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-260</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>46708-261</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-05-21</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Apotex Corp</labeller>
      <ndc-id/>
      <ndc-product-code>60505-3075</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Apotex Corp</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2673</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Apotex Corp</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2674</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Apotex Corp</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2675</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Apotex Corp</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2676</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Apotex Corp</labeller>
      <ndc-id/>
      <ndc-product-code>60505-2677</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Nucare Pharmaceuticals,inc.</labeller>
      <ndc-id/>
      <ndc-product-code>68071-5062</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1421</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-09-18</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-216</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-217</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-218</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-219</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-220</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Torrent Pharmaceuticals Limited</labeller>
      <ndc-id/>
      <ndc-product-code>13668-221</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-051</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206174</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-052</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206174</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-053</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206174</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-054</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206174</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-055</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206174</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Ajanta Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>27241-056</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-05-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206174</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6509</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6510</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6511</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6512</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6513</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-157</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-168</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-179</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-191</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-202</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>American Health Packaging</labeller>
      <ndc-id/>
      <ndc-product-code>60687-213</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-06-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-661</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-662</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-663</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-664</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-665</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>65862-666</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203908</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1624</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-278</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-279</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-280</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-281</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-282</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Accord Healthcare, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>16729-283</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-02-14</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206251</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Dr.Reddy’s Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>43598-554</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Dr.Reddy’s Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>43598-555</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Dr.Reddy’s Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>43598-556</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Dr.Reddy’s Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>43598-557</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Dr.Reddy’s Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>43598-558</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Dr.Reddy’s Laboratories Inc</labeller>
      <ndc-id/>
      <ndc-product-code>43598-559</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Atlantic Biologicals Corps</labeller>
      <ndc-id/>
      <ndc-product-code>17856-0680</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-446</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-447</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-448</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-449</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-450</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Golden State Medical Supply, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>60429-451</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-07-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1794</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1859</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206174</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1822</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-24</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Proficient Rx LP</labeller>
      <ndc-id/>
      <ndc-product-code>63187-965</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-1814</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-4665</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-02-27</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA207105</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6655</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on>2015-04-28</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Major Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code>0904-6656</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA201519</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-896</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-897</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-898</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-899</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-901</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-902</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-06-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Safecor Health, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>48433-115</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Safecor Health, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>48433-116</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Safecor Health, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>48433-117</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Safecor Health, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>48433-118</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Safecor Health, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>48433-119</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Safecor Health, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>48433-120</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-12-01</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA078583</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-097</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-098</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-099</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-102</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202101</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2471</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204111</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2475</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Amneal Pharmaceuticals LLC</labeller>
      <ndc-id/>
      <ndc-product-code>65162-893</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-08-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA203906</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Apotex Corp.</labeller>
      <ndc-id/>
      <ndc-product-code>60505-0404</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-10-08</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204094</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Camber Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>31722-819</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Camber Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>31722-820</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Camber Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>31722-827</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Camber Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>31722-828</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Camber Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>31722-829</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Camber Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>31722-830</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2015-04-28</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205064</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>ScieGen Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>50228-324</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>ScieGen Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>50228-325</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>ScieGen Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>50228-326</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>ScieGen Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>50228-327</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>ScieGen Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>50228-328</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>ScieGen Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code>50228-329</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-09-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA206383</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-103</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Alembic Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>62332-104</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2016-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202102</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>OrchidPharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>42043-400</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202547</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>OrchidPharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code>42043-401</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-11-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA202547</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Aurobindo Pharma Limited</labeller>
      <ndc-id/>
      <ndc-product-code>59651-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-29</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>1 mg/1mL</strength>
      <route>Oral</route>
      <fda-application-number>ANDA210479</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-0970</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2508</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-26</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA205363</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>REMEDYREPACK INC.</labeller>
      <ndc-id/>
      <ndc-product-code>70518-2514</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-12-31</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA204838</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02488000</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>2 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02488019</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02488027</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02488035</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02488043</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aripiprazole</name>
      <labeller>Pro Doc Limitee</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02488051</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-07-09</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/001</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/002</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/003</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/004</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/005</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/006</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/007</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/008</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/009</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/010</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/011</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/012</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/013</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/014</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/015</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/016</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/017</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/018</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/019</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/020</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/021</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/022</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/023</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/024</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/025</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Accord</name>
      <labeller>Accord Healthcare Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004021</ema-product-code>
      <ema-ma-number>EU/1/15/1045/026</ema-ma-number>
      <started-marketing-on>2015-11-16</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/001</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/002</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/003</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/004</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/005</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/006</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/007</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/008</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/009</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/010</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/011</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/012</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/013</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/014</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/015</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/016</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/017</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/018</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/019</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Mylan Pharma</name>
      <labeller>Mylan S.A.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003803</ema-product-code>
      <ema-ma-number>EU/1/15/1005/020</ema-ma-number>
      <started-marketing-on>2015-06-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/001</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/002</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/003</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/004</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/005</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/006</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/007</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/008</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/009</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/010</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/011</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/012</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/013</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/014</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/015</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/016</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/017</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/018</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/019</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/020</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/021</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/022</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/023</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/024</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/025</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/026</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/027</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/028</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/029</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/030</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/031</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/032</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/033</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/034</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/035</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/036</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/037</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/038</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/039</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/040</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/041</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/042</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/043</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/044</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/045</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/046</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/047</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>20 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/048</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/049</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/050</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/051</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/052</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/053</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/054</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/055</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/056</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/057</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/058</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/059</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/060</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Sandoz</name>
      <labeller>Sandoz</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/004008</ema-product-code>
      <ema-ma-number>EU/1/15/1029/061</ema-ma-number>
      <started-marketing-on>2015-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/001</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/002</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/003</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/004</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/005</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>5 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/006</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/007</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/008</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/009</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/010</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/011</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/012</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/013</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/014</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/015</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/016</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/017</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/018</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/019</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/020</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/021</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/022</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/023</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>10 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/024</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/025</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/026</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>15 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/027</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/028</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Aripiprazole Zentiva</name>
      <labeller>Zentiva, K.S.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/003899</ema-product-code>
      <ema-ma-number>EU/1/15/1009/029</ema-ma-number>
      <started-marketing-on>2015-06-25</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, orally disintegrating</dosage-form>
      <strength>30 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Auro-aripiprazole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460025</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-aripiprazole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460033</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-aripiprazole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460041</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-aripiprazole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460068</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-aripiprazole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460076</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Auro-aripiprazole</name>
      <labeller>Auro Pharma Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02460084</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-aripiprazole</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02483556</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-aripiprazole</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02483564</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-aripiprazole</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02483572</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-aripiprazole</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02483580</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-aripiprazole</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02483599</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Mint-aripiprazole</name>
      <labeller>Mint Pharmaceuticals Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02483602</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-aripiprazole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02466635</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-aripiprazole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02466643</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-aripiprazole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02466651</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-aripiprazole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02466678</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-aripiprazole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02466686</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PMS-aripiprazole</name>
      <labeller>Pharmascience Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02466694</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-aripiprazole</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02479346</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-aripiprazole</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02479354</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-aripiprazole</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02479362</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-aripiprazole</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02479370</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-aripiprazole</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02479389</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Riva-aripiprazole</name>
      <labeller>Laboratoire Riva Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02479397</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Aripiprazole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473658</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Aripiprazole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473666</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Aripiprazole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473674</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Aripiprazole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473682</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Aripiprazole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473690</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Sandoz Aripiprazole</name>
      <labeller>Sandoz Canada Incorporated</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02473704</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-aripiprazole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464144</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-aripiprazole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464152</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-aripiprazole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464160</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-aripiprazole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464179</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-aripiprazole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464187</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Teva-aripiprazole</name>
      <labeller>TEVA Canada Limited</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464195</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-07-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Abilitat</name>
      <company/>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Accord</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Mylan Pharma</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Sandoz</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole Zentiva</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify MyCite</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify MyCite</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify MyCite</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify MyCite</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify MyCite</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify MyCite</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify Maintena</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Abilify</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Apo-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Auro-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Teva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>PMS-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Sandoz Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Riva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Riva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Riva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Riva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Riva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Riva-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Mint-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Mint-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Mint-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Mint-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Mint-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Mint-aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
    <mixture>
      <name>Aripiprazole</name>
      <ingredients>Aripiprazole</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Bristol-Myers Squibb Co.</name>
      <url>http://www.bms.com</url>
    </packager>
    <packager>
      <name>Bryant Ranch Prepack</name>
      <url>http://bryantranchprepack.com</url>
    </packager>
    <packager>
      <name>Cardinal Health</name>
      <url>http://www.cardinal.com</url>
    </packager>
    <packager>
      <name>Comprehensive Consultant Services Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>DispenseXpress Inc.</name>
      <url/>
    </packager>
    <packager>
      <name>E.R. Squibb and Sons LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Murfreesboro Pharmaceutical Nursing Supply</name>
      <url>http://www.unitdosesupply.com</url>
    </packager>
    <packager>
      <name>Otsuka America</name>
      <url>http://www.otsuka-us.com</url>
    </packager>
    <packager>
      <name>PD-Rx Pharmaceuticals Inc.</name>
      <url>http://www.pdrx.com</url>
    </packager>
    <packager>
      <name>Physician Partners Ltd.</name>
      <url>http://www.pplpho.org</url>
    </packager>
    <packager>
      <name>Physicians Total Care Inc.</name>
      <url>http://www.physicianstotalcare.com</url>
    </packager>
    <packager>
      <name>Quality Care</name>
      <url/>
    </packager>
    <packager>
      <name>Rebel Distributors Corp.</name>
      <url>http://www.rebelrx.com</url>
    </packager>
    <packager>
      <name>Remedy Repack</name>
      <url>http://www.remedyrepack.com</url>
    </packager>
    <packager>
      <name>Resource Optimization and Innovation LLC</name>
      <url/>
    </packager>
    <packager>
      <name>Southwood Pharmaceuticals</name>
      <url>http://www.southwoodhealthcare.com</url>
    </packager>
    <packager>
      <name>Stat Rx Usa</name>
      <url>http://statrxusa.exporterus.com</url>
    </packager>
  </packagers>
  <manufacturers/>
  <prices>
    <price>
      <description>Abilify 9.7 mg/1.3 ml vial</description>
      <cost currency="USD">16.04</cost>
      <unit>ml</unit>
    </price>
    <price>
      <description>Abilify discmelt 10 mg tablet</description>
      <cost currency="USD">20.39</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Abilify discmelt 15 mg tablet</description>
      <cost currency="USD">20.39</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Abilify 20 mg tablet</description>
      <cost currency="USD">21.99</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Abilify 2 mg tablet</description>
      <cost currency="USD">22.25</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Abilify 10 mg tablet</description>
      <cost currency="USD">23.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Abilify 5 mg tablet</description>
      <cost currency="USD">23.53</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Abilify 15 mg tablet</description>
      <cost currency="USD">26.07</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Abilify 30 mg tablet</description>
      <cost currency="USD">32.12</cost>
      <unit>tablet</unit>
    </price>
    <price>
      <description>Abilify Discmelt 30 10 mg Dispersible Tablet Box</description>
      <cost currency="USD">636.3</cost>
      <unit>box</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Adrenergic alpha-1 Receptor Antagonists</category>
      <mesh-id>D058668</mesh-id>
    </category>
    <category>
      <category>Adrenergic alpha-Antagonists</category>
      <mesh-id>D000317</mesh-id>
    </category>
    <category>
      <category>Adrenergic Antagonists</category>
      <mesh-id>D018674</mesh-id>
    </category>
    <category>
      <category>Agents producing tachycardia</category>
      <mesh-id/>
    </category>
    <category>
      <category>Agents that produce hypertension</category>
      <mesh-id/>
    </category>
    <category>
      <category>Anticholinergic Agents</category>
      <mesh-id>D018680</mesh-id>
    </category>
    <category>
      <category>Antidepressive Agents</category>
      <mesh-id>D000928</mesh-id>
    </category>
    <category>
      <category>Antipsychotic Agents</category>
      <mesh-id>D014150</mesh-id>
    </category>
    <category>
      <category>Antipsychotic Agents (Second Generation [Atypical])</category>
      <mesh-id/>
    </category>
    <category>
      <category>Central Nervous System Agents</category>
      <mesh-id>D002491</mesh-id>
    </category>
    <category>
      <category>Central Nervous System Depressants</category>
      <mesh-id>D002492</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A4 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A5 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 CYP3A7 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dopamine Agents</category>
      <mesh-id>D015259</mesh-id>
    </category>
    <category>
      <category>Dopamine Agonists</category>
      <mesh-id>D018491</mesh-id>
    </category>
    <category>
      <category>Dopamine Antagonists</category>
      <mesh-id>D018492</mesh-id>
    </category>
    <category>
      <category>Dopamine D2 Receptor Antagonists</category>
      <mesh-id>D065127</mesh-id>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>Histamine Antagonists</category>
      <mesh-id>D006633</mesh-id>
    </category>
    <category>
      <category>Histamine H1 Antagonists</category>
      <mesh-id>D006634</mesh-id>
    </category>
    <category>
      <category>Hyperglycemia-Associated Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Muscarinic Antagonists</category>
      <mesh-id>D018727</mesh-id>
    </category>
    <category>
      <category>Nervous System</category>
      <mesh-id>D009420</mesh-id>
    </category>
    <category>
      <category>Neurotoxic agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Neurotransmitter Agents</category>
      <mesh-id>D018377</mesh-id>
    </category>
    <category>
      <category>Piperazines</category>
      <mesh-id>D010879</mesh-id>
    </category>
    <category>
      <category>Potential QTc-Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Psycholeptics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Psychotropic Drugs</category>
      <mesh-id>D011619</mesh-id>
    </category>
    <category>
      <category>QTc Prolonging Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>QTc shortening agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Quinolines</category>
      <mesh-id>D011804</mesh-id>
    </category>
    <category>
      <category>Quinolones</category>
      <mesh-id>D015363</mesh-id>
    </category>
    <category>
      <category>Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome</category>
      <mesh-id>D020230</mesh-id>
    </category>
    <category>
      <category>Serotonin 5-HT1 Receptor Agonists</category>
      <mesh-id>D058825</mesh-id>
    </category>
    <category>
      <category>Serotonin 5-HT1 Receptor Antagonists</category>
      <mesh-id>D058829</mesh-id>
    </category>
    <category>
      <category>Serotonin 5-HT2 Receptor Antagonists</category>
      <mesh-id>D058830</mesh-id>
    </category>
    <category>
      <category>Serotonin Agents</category>
      <mesh-id>D018490</mesh-id>
    </category>
    <category>
      <category>Serotonin Receptor Agonists</category>
      <mesh-id>D017366</mesh-id>
    </category>
    <category>
      <category>Serotonin Receptor Antagonists</category>
      <mesh-id>D012702</mesh-id>
    </category>
    <category>
      <category>Tranquilizing Agents</category>
      <mesh-id>D014149</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, solution</form>
      <route>Intramuscular</route>
      <strength>9.75 mg/1.3mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>15 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>2 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>2 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>30 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>5 mg/1</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>300 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>400 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release; kit</form>
      <route>Intramuscular</route>
      <strength>300 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, for suspension, extended release; kit</form>
      <route>Intramuscular</route>
      <strength>400 mg</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>300 mg/1.5mL</strength>
    </dosage>
    <dosage>
      <form>Injection, powder, lyophilized, for suspension, extended release</form>
      <route>Intramuscular</route>
      <strength>400 mg/2.0mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intramuscular</route>
      <strength>300 mg/1.5mL</strength>
    </dosage>
    <dosage>
      <form>Kit</form>
      <route>Intramuscular</route>
      <strength>400 mg/1.9mL</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Oral</route>
      <strength>1 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>10 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>15 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>20 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>30 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>10 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>15 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>30 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>5 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength>20 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>10 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>15 mg</strength>
    </dosage>
    <dosage>
      <form>Tablet, orally disintegrating</form>
      <route>Oral</route>
      <strength>30 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="N05AX12">
      <level code="N05AX">Other antipsychotics</level>
      <level code="N05A">ANTIPSYCHOTICS</level>
      <level code="N05">PSYCHOLEPTICS</level>
      <level code="N">NERVOUS SYSTEM</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>28:16.08.04</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>6a7p</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB01238.pdf?1556665214</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB01238.pdf?1556724056</msds>
  <patents>
    <patent>
      <number>5006528</number>
      <country>United States</country>
      <approved>1991-04-09</approved>
      <expires>2014-10-20</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7053092</number>
      <country>United States</country>
      <approved>2006-05-30</approved>
      <expires>2022-01-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8642600</number>
      <country>United States</country>
      <approved>2014-02-04</approved>
      <expires>2022-07-28</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>8759350</number>
      <country>United States</country>
      <approved>2014-06-24</approved>
      <expires>2027-03-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9125939</number>
      <country>United States</country>
      <approved>2015-09-08</approved>
      <expires>2026-07-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9089567</number>
      <country>United States</country>
      <approved>2015-07-28</approved>
      <expires>2022-01-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8017615</number>
      <country>United States</country>
      <approved>2011-09-13</approved>
      <expires>2024-12-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>8580796</number>
      <country>United States</country>
      <approved>2013-11-12</approved>
      <expires>2023-03-25</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>8642760</number>
      <country>United States</country>
      <approved>2014-02-04</approved>
      <expires>2023-03-25</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>6977257</number>
      <country>United States</country>
      <approved>2005-12-20</approved>
      <expires>2022-10-24</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>8518421</number>
      <country>United States</country>
      <approved>2013-08-27</approved>
      <expires>2021-07-24</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>7115587</number>
      <country>United States</country>
      <approved>2006-10-03</approved>
      <expires>2025-01-21</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>7550445</number>
      <country>United States</country>
      <approved>2009-06-23</approved>
      <expires>2025-01-21</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>8030313</number>
      <country>United States</country>
      <approved>2011-10-04</approved>
      <expires>2024-10-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8338427</number>
      <country>United States</country>
      <approved>2012-12-25</approved>
      <expires>2025-03-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8338428</number>
      <country>United States</country>
      <approved>2012-12-25</approved>
      <expires>2023-08-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8759351</number>
      <country>United States</country>
      <approved>2014-06-24</approved>
      <expires>2023-08-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7807680</number>
      <country>United States</country>
      <approved>2010-10-05</approved>
      <expires>2024-10-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8993761</number>
      <country>United States</country>
      <approved>2015-03-31</approved>
      <expires>2022-09-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8722679</number>
      <country>United States</country>
      <approved>2014-05-13</approved>
      <expires>2024-10-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8399469</number>
      <country>United States</country>
      <approved>2013-03-19</approved>
      <expires>2025-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9193685</number>
      <country>United States</country>
      <approved>2015-11-24</approved>
      <expires>2033-10-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8796276</number>
      <country>United States</country>
      <approved>2014-08-05</approved>
      <expires>2030-06-24</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9034867</number>
      <country>United States</country>
      <approved>2015-05-19</approved>
      <expires>2032-11-07</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8431576</number>
      <country>United States</country>
      <approved>2013-04-30</approved>
      <expires>2030-10-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9387182</number>
      <country>United States</country>
      <approved>2016-07-12</approved>
      <expires>2023-12-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9359302</number>
      <country>United States</country>
      <approved>2016-06-07</approved>
      <expires>2022-09-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9358207</number>
      <country>United States</country>
      <approved>2016-06-07</approved>
      <expires>2020-04-12</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9526726</number>
      <country>United States</country>
      <approved>2016-12-27</approved>
      <expires>2035-03-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9452131</number>
      <country>United States</country>
      <approved>2016-09-27</approved>
      <expires>2035-03-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8945005</number>
      <country>United States</country>
      <approved>2015-02-03</approved>
      <expires>2029-08-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8847766</number>
      <country>United States</country>
      <approved>2014-09-30</approved>
      <expires>2030-03-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9787511</number>
      <country>United States</country>
      <approved>2017-10-10</approved>
      <expires>2034-09-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8674825</number>
      <country>United States</country>
      <approved>2014-03-18</approved>
      <expires>2029-04-09</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9270503</number>
      <country>United States</country>
      <approved>2016-02-23</approved>
      <expires>2034-09-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9268909</number>
      <country>United States</country>
      <approved>2016-02-23</approved>
      <expires>2033-10-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8956288</number>
      <country>United States</country>
      <approved>2015-02-17</approved>
      <expires>2029-07-06</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9444503</number>
      <country>United States</country>
      <approved>2016-09-13</approved>
      <expires>2027-11-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8547248</number>
      <country>United States</country>
      <approved>2013-10-01</approved>
      <expires>2030-12-18</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9577864</number>
      <country>United States</country>
      <approved>2017-02-21</approved>
      <expires>2033-10-03</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8545402</number>
      <country>United States</country>
      <approved>2013-10-01</approved>
      <expires>2030-04-27</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9433371</number>
      <country>United States</country>
      <approved>2016-09-06</approved>
      <expires>2029-09-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8114021</number>
      <country>United States</country>
      <approved>2012-02-14</approved>
      <expires>2026-11-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9320455</number>
      <country>United States</country>
      <approved>2016-04-26</approved>
      <expires>2031-12-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9119554</number>
      <country>United States</country>
      <approved>2015-09-01</approved>
      <expires>2028-12-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9258035</number>
      <country>United States</country>
      <approved>2016-02-09</approved>
      <expires>2029-03-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8258962</number>
      <country>United States</country>
      <approved>2012-09-04</approved>
      <expires>2030-11-25</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>7978064</number>
      <country>United States</country>
      <approved>2011-07-12</approved>
      <expires>2026-09-14</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8718193</number>
      <country>United States</country>
      <approved>2014-05-06</approved>
      <expires>2029-12-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>8961412</number>
      <country>United States</country>
      <approved>2015-02-24</approved>
      <expires>2030-11-17</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9060708</number>
      <country>United States</country>
      <approved>2015-06-23</approved>
      <expires>2029-03-05</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9149577</number>
      <country>United States</country>
      <approved>2015-10-06</approved>
      <expires>2029-12-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9941931</number>
      <country>United States</country>
      <approved>2018-04-10</approved>
      <expires>2030-11-04</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10097388</number>
      <country>United States</country>
      <approved>2018-10-09</approved>
      <expires>2034-09-19</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Avoid alcohol (possible additive effect to CNS).</food-interaction>
    <food-interaction>Food has no significant effect on absorption.</food-interaction>
    <food-interaction>Take without regard to meals.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB12130</drugbank-id>
      <name>Lorlatinib</name>
      <description>The metabolism of Lorlatinib can be increased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00082</drugbank-id>
      <name>Pegvisomant</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Pegvisomant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00136</drugbank-id>
      <name>Calcitriol</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Calcitriol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00241</drugbank-id>
      <name>Butalbital</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Butalbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00252</drugbank-id>
      <name>Phenytoin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Phenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00301</drugbank-id>
      <name>Flucloxacillin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Flucloxacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00307</drugbank-id>
      <name>Bexarotene</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Bexarotene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00312</drugbank-id>
      <name>Pentobarbital</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Pentobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Acetaminophen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Terfenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00357</drugbank-id>
      <name>Aminoglutethimide</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Aminoglutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00394</drugbank-id>
      <name>Beclomethasone dipropionate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Beclomethasone dipropionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00400</drugbank-id>
      <name>Griseofulvin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Griseofulvin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00418</drugbank-id>
      <name>Secobarbital</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Secobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Cerivastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Meperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00474</drugbank-id>
      <name>Methohexital</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Methohexital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00485</drugbank-id>
      <name>Dicloxacillin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Dicloxacillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00531</drugbank-id>
      <name>Cyclophosphamide</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Cyclophosphamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00559</drugbank-id>
      <name>Bosentan</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Bosentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Methotrexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00564</drugbank-id>
      <name>Carbamazepine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Carbamazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00591</drugbank-id>
      <name>Fluocinolone acetonide</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Fluocinolone acetonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00599</drugbank-id>
      <name>Thiopental</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Thiopental.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00603</drugbank-id>
      <name>Medroxyprogesterone acetate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Medroxyprogesterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00607</drugbank-id>
      <name>Nafcillin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Nafcillin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00615</drugbank-id>
      <name>Rifabutin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Rifabutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00624</drugbank-id>
      <name>Testosterone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Testosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00625</drugbank-id>
      <name>Efavirenz</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Efavirenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00636</drugbank-id>
      <name>Clofibrate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Clofibrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00648</drugbank-id>
      <name>Mitotane</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Mitotane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00745</drugbank-id>
      <name>Modafinil</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Modafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00754</drugbank-id>
      <name>Ethotoin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Ethotoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00769</drugbank-id>
      <name>Hydrocortamate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Hydrocortamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00773</drugbank-id>
      <name>Etoposide</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Etoposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00776</drugbank-id>
      <name>Oxcarbazepine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Oxcarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00783</drugbank-id>
      <name>Estradiol</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Estradiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00794</drugbank-id>
      <name>Primidone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Primidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00849</drugbank-id>
      <name>Methylphenobarbital</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Methylphenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Terbinafine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00949</drugbank-id>
      <name>Felbamate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Felbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00957</drugbank-id>
      <name>Norgestimate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Norgestimate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01011</drugbank-id>
      <name>Metyrapone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Metyrapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Topotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Probenecid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Rifampicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01083</drugbank-id>
      <name>Orlistat</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Orlistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Pioglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Sulfinpyrazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01174</drugbank-id>
      <name>Phenobarbital</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Phenobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01181</drugbank-id>
      <name>Ifosfamide</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Ifosfamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01201</drugbank-id>
      <name>Rifapentine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Rifapentine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01220</drugbank-id>
      <name>Rifaximin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Rifaximin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01221</drugbank-id>
      <name>Ketamine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Ketamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01229</drugbank-id>
      <name>Paclitaxel</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Paclitaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01320</drugbank-id>
      <name>Fosphenytoin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Fosphenytoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of Aripiprazole can be increased when combined with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Cefradine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01351</drugbank-id>
      <name>Amobarbital</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Amobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01352</drugbank-id>
      <name>Aprobarbital</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Aprobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01394</drugbank-id>
      <name>Colchicine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Colchicine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01483</drugbank-id>
      <name>Barbital</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Barbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01609</drugbank-id>
      <name>Deferasirox</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Deferasirox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01645</drugbank-id>
      <name>Genistein</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Genistein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Tesmilifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04911</drugbank-id>
      <name>Oritavancin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Oritavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06413</drugbank-id>
      <name>Armodafinil</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Armodafinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06414</drugbank-id>
      <name>Etravirine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Etravirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06442</drugbank-id>
      <name>Avasimibe</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Avasimibe.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06636</drugbank-id>
      <name>Isavuconazonium</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Isavuconazonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Artemether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Lumefantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06717</drugbank-id>
      <name>Fosaprepitant</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Fosaprepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06739</drugbank-id>
      <name>Seratrodast</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Seratrodast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08899</drugbank-id>
      <name>Enzalutamide</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Enzalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08905</drugbank-id>
      <name>Formestane</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Formestane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Glycerol phenylbutyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08911</drugbank-id>
      <name>Trametinib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Trametinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08912</drugbank-id>
      <name>Dabrafenib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Dabrafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09001</drugbank-id>
      <name>Barbexaclone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Barbexaclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09054</drugbank-id>
      <name>Idelalisib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Idelalisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09119</drugbank-id>
      <name>Eslicarbazepine acetate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Eslicarbazepine acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09280</drugbank-id>
      <name>Lumacaftor</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Lumacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09330</drugbank-id>
      <name>Osimertinib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Osimertinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11487</drugbank-id>
      <name>Dexamethasone isonicotinate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Dexamethasone isonicotinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Asunaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Isavuconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11750</drugbank-id>
      <name>Clobetasol</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Clobetasol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11767</drugbank-id>
      <name>Sarilumab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Sarilumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11901</drugbank-id>
      <name>Apalutamide</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Apalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11943</drugbank-id>
      <name>Delafloxacin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Delafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12015</drugbank-id>
      <name>Alpelisib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Alpelisib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12267</drugbank-id>
      <name>Brigatinib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Brigatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13943</drugbank-id>
      <name>Testosterone cypionate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Testosterone cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13944</drugbank-id>
      <name>Testosterone enanthate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Testosterone enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13952</drugbank-id>
      <name>Estradiol acetate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Estradiol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13953</drugbank-id>
      <name>Estradiol benzoate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Estradiol benzoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13954</drugbank-id>
      <name>Estradiol cypionate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Estradiol cypionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13955</drugbank-id>
      <name>Estradiol dienanthate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Estradiol dienanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13956</drugbank-id>
      <name>Estradiol valerate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Estradiol valerate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14538</drugbank-id>
      <name>Hydrocortisone aceponate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Hydrocortisone aceponate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14539</drugbank-id>
      <name>Hydrocortisone acetate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Hydrocortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14545</drugbank-id>
      <name>Hydrocortisone succinate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Hydrocortisone succinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14568</drugbank-id>
      <name>Ivosidenib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Ivosidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>The metabolism of Warfarin can be increased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00163</drugbank-id>
      <name>Vitamin E</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Vitamin E.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14575</drugbank-id>
      <name>Eslicarbazepine</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Eslicarbazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00764</drugbank-id>
      <name>Mometasone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Mometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00366</drugbank-id>
      <name>Doxylamine</name>
      <description>Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00470</drugbank-id>
      <name>Dronabinol</name>
      <description>Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00450</drugbank-id>
      <name>Droperidol</name>
      <description>Droperidol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00653</drugbank-id>
      <name>Magnesium sulfate</name>
      <description>The therapeutic efficacy of Aripiprazole can be increased when used in combination with Magnesium sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00765</drugbank-id>
      <name>Metyrosine</name>
      <description>Aripiprazole may increase the sedative activities of Metyrosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01017</drugbank-id>
      <name>Minocycline</name>
      <description>Minocycline may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00486</drugbank-id>
      <name>Nabilone</name>
      <description>Nabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>Orphenadrine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09117</drugbank-id>
      <name>Paraldehyde</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08883</drugbank-id>
      <name>Perampanel</name>
      <description>Perampanel may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>Aripiprazole may increase the sedative activities of Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06201</drugbank-id>
      <name>Rufinamide</name>
      <description>The risk or severity of adverse effects can be increased when Rufinamide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09072</drugbank-id>
      <name>Sodium oxybate</name>
      <description>Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09034</drugbank-id>
      <name>Suvorexant</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01041</drugbank-id>
      <name>Thalidomide</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08897</drugbank-id>
      <name>Aclidinium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Aclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>Aripiprazole may increase the anticholinergic activities of Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The risk or severity of urinary retention can be increased when Aripiprazole is combined with Mirabegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00761</drugbank-id>
      <name>Potassium chloride</name>
      <description>The risk or severity of gastrointestinal ulceration can be increased when Aripiprazole is combined with Potassium chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09527</drugbank-id>
      <name>Secretin porcine</name>
      <description>The therapeutic efficacy of Secretin porcine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00273</drugbank-id>
      <name>Topiramate</name>
      <description>The risk or severity of hyperthermia and oligohydrosis can be increased when Aripiprazole is combined with Topiramate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Umeclidinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00035</drugbank-id>
      <name>Desmopressin</name>
      <description>The risk or severity of hypertension can be increased when Desmopressin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The risk or severity of hypertension can be increased when Icosapent is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The risk or severity of hypertension can be increased when Mesalazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The risk or severity of hypertension can be increased when Indomethacin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The risk or severity of hypertension can be increased when Nabumetone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The risk or severity of hypertension can be increased when Ketorolac is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The risk or severity of hypertension can be increased when Tenoxicam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The risk or severity of hypertension can be increased when Tolmetin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The risk or severity of hypertension can be increased when Piroxicam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00561</drugbank-id>
      <name>Doxapram</name>
      <description>The risk or severity of hypertension can be increased when Doxapram is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The risk or severity of hypertension can be increased when Fenoprofen is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The risk or severity of hypertension can be increased when Sulindac is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The risk or severity of hypertension can be increased when Flurbiprofen is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The risk or severity of hypertension can be increased when Etodolac is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The risk or severity of hypertension can be increased when Mefenamic acid is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The risk or severity of hypertension can be increased when Naproxen is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The risk or severity of hypertension can be increased when Sulfasalazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The risk or severity of hypertension can be increased when Carprofen is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00830</drugbank-id>
      <name>Phenmetrazine</name>
      <description>The risk or severity of hypertension can be increased when Phenmetrazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The risk or severity of hypertension can be increased when Diflunisal is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of hypertension can be increased when Salicylic acid is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The risk or severity of hypertension can be increased when Meclofenamic acid is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>The risk or severity of hypertension can be increased when Dopamine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The risk or severity of hypertension can be increased when Oxaprozin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of hypertension can be increased when Ketoprofen is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The risk or severity of hypertension can be increased when Balsalazide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02032</drugbank-id>
      <name>1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04581</drugbank-id>
      <name>1-benzylimidazole</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with 1-benzylimidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06763</drugbank-id>
      <name>Saralasin</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Saralasin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08841</drugbank-id>
      <name>Tyramine</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Tyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09205</drugbank-id>
      <name>Moxisylyte</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Moxisylyte.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11481</drugbank-id>
      <name>Atipamezole</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Atipamezole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12551</drugbank-id>
      <name>Idazoxan</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Idazoxan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13064</drugbank-id>
      <name>Tramazoline</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Tramazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13341</drugbank-id>
      <name>Fenozolone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Fenozolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13453</drugbank-id>
      <name>Xenon</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Xenon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Buflomedil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13852</drugbank-id>
      <name>Mefenorex</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Mefenorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Quinoline Yellow WS.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The risk or severity of hypertension can be increased when Valdecoxib is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The risk or severity of hypertension can be increased when Diclofenac is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The risk or severity of hypertension can be increased when Meloxicam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The risk or severity of hypertension can be increased when Ibuprofen is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12371</drugbank-id>
      <name>Siponimod</name>
      <description>The risk or severity of hypertension can be increased when Aripiprazole is combined with Siponimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06262</drugbank-id>
      <name>Droxidopa</name>
      <description>Aripiprazole may increase the hypertensive activities of Droxidopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06288</drugbank-id>
      <name>Amisulpride</name>
      <description>Aripiprazole may increase the antipsychotic activities of Amisulpride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00422</drugbank-id>
      <name>Methylphenidate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The risk or severity of adverse effects can be increased when Metoclopramide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09097</drugbank-id>
      <name>Quinagolide</name>
      <description>The therapeutic efficacy of Quinagolide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00391</drugbank-id>
      <name>Sulpiride</name>
      <description>Aripiprazole may increase the antipsychotic activities of Sulpiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00895</drugbank-id>
      <name>Benzylpenicilloyl polylysine</name>
      <description>Aripiprazole may decrease effectiveness of Benzylpenicilloyl polylysine as a diagnostic agent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06698</drugbank-id>
      <name>Betahistine</name>
      <description>The therapeutic efficacy of Betahistine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00070</drugbank-id>
      <name>Hyaluronidase (ovine)</name>
      <description>The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The risk or severity of adverse effects can be increased when Methadone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14507</drugbank-id>
      <name>Lithium citrate</name>
      <description>Lithium citrate may increase the neurotoxic activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14506</drugbank-id>
      <name>Lithium hydroxide</name>
      <description>Lithium hydroxide may increase the neurotoxic activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>Mequitazine may increase the arrhythmogenic activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>Dapoxetine may increase the orthostatic hypotensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The serum concentration of Aripiprazole can be increased when it is combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00986</drugbank-id>
      <name>Glycopyrronium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Glycopyrronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00601</drugbank-id>
      <name>Linezolid</name>
      <description>The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08815</drugbank-id>
      <name>Lurasidone</name>
      <description>Aripiprazole may increase the hypotensive activities of Lurasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The serum concentration of Aripiprazole can be increased when it is combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00083</drugbank-id>
      <name>Botulinum toxin type A</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum toxin type A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00040</drugbank-id>
      <name>Glucagon</name>
      <description>Aripiprazole may increase the gastrointestinal motility reducing activities of Glucagon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00042</drugbank-id>
      <name>Botulinum Toxin Type B</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Botulinum Toxin Type B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>Aripiprazole may increase the serotonergic activities of Mirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09272</drugbank-id>
      <name>Eluxadoline</name>
      <description>The risk or severity of constipation can be increased when Aripiprazole is combined with Eluxadoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09290</drugbank-id>
      <name>Ramosetron</name>
      <description>The risk or severity of constipation can be increased when Aripiprazole is combined with Ramosetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>Aripiprazole may increase the hypotensive activities of Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00232</drugbank-id>
      <name>Methyclothiazide</name>
      <description>Aripiprazole may increase the hypotensive activities of Methyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00384</drugbank-id>
      <name>Triamterene</name>
      <description>Aripiprazole may increase the hypotensive activities of Triamterene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00421</drugbank-id>
      <name>Spironolactone</name>
      <description>Aripiprazole may increase the hypotensive activities of Spironolactone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00594</drugbank-id>
      <name>Amiloride</name>
      <description>Aripiprazole may increase the hypotensive activities of Amiloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00631</drugbank-id>
      <name>Clofarabine</name>
      <description>Aripiprazole may increase the hypotensive activities of Clofarabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00742</drugbank-id>
      <name>Mannitol</name>
      <description>Aripiprazole may increase the hypotensive activities of Mannitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00883</drugbank-id>
      <name>Isosorbide dinitrate</name>
      <description>Aripiprazole may increase the hypotensive activities of Isosorbide dinitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>Aripiprazole may increase the hypotensive activities of Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>Aripiprazole may increase the hypotensive activities of Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01020</drugbank-id>
      <name>Isosorbide mononitrate</name>
      <description>Aripiprazole may increase the hypotensive activities of Isosorbide mononitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>Aripiprazole may increase the hypotensive activities of Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01143</drugbank-id>
      <name>Amifostine</name>
      <description>Aripiprazole may increase the hypotensive activities of Amifostine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>Aripiprazole may increase the hypotensive activities of Diclofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01282</drugbank-id>
      <name>Carbetocin</name>
      <description>Aripiprazole may increase the hypotensive activities of Carbetocin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01612</drugbank-id>
      <name>Amyl Nitrite</name>
      <description>Aripiprazole may increase the hypotensive activities of Amyl Nitrite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04899</drugbank-id>
      <name>Nesiritide</name>
      <description>Aripiprazole may increase the hypotensive activities of Nesiritide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08822</drugbank-id>
      <name>Azilsartan medoxomil</name>
      <description>Aripiprazole may increase the hypotensive activities of Azilsartan medoxomil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08935</drugbank-id>
      <name>Obinutuzumab</name>
      <description>Aripiprazole may increase the hypotensive activities of Obinutuzumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09077</drugbank-id>
      <name>Dinutuximab</name>
      <description>Aripiprazole may increase the hypotensive activities of Dinutuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09112</drugbank-id>
      <name>Nitrous acid</name>
      <description>Aripiprazole may increase the hypotensive activities of Nitrous acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09279</drugbank-id>
      <name>Fimasartan</name>
      <description>Aripiprazole may increase the hypotensive activities of Fimasartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09292</drugbank-id>
      <name>Sacubitril</name>
      <description>Aripiprazole may increase the hypotensive activities of Sacubitril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00296</drugbank-id>
      <name>Ropivacaine</name>
      <description>Aripiprazole may increase the hypotensive activities of Ropivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>Aripiprazole may increase the hypotensive activities of Bupivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>Aripiprazole may increase the hypotensive activities of Methazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01002</drugbank-id>
      <name>Levobupivacaine</name>
      <description>Aripiprazole may increase the hypotensive activities of Levobupivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Ethanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00484</drugbank-id>
      <name>Brimonidine</name>
      <description>Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01105</drugbank-id>
      <name>Sibutramine</name>
      <description>The risk or severity of adverse effects can be increased when Sibutramine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Levomilnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13233</drugbank-id>
      <name>Alaproclate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Alaproclate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01531</drugbank-id>
      <name>Desomorphine</name>
      <description>The risk or severity of adverse effects can be increased when Desomorphine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The risk or severity of adverse effects can be increased when Tramadol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00295</drugbank-id>
      <name>Morphine</name>
      <description>The risk or severity of adverse effects can be increased when Morphine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The risk or severity of adverse effects can be increased when Codeine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00327</drugbank-id>
      <name>Hydromorphone</name>
      <description>The risk or severity of adverse effects can be increased when Hydromorphone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The risk or severity of adverse effects can be increased when Oxycodone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00611</drugbank-id>
      <name>Butorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Butorphanol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00652</drugbank-id>
      <name>Pentazocine</name>
      <description>The risk or severity of adverse effects can be increased when Pentazocine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00708</drugbank-id>
      <name>Sufentanil</name>
      <description>The risk or severity of adverse effects can be increased when Sufentanil is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00844</drugbank-id>
      <name>Nalbuphine</name>
      <description>The risk or severity of adverse effects can be increased when Nalbuphine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00854</drugbank-id>
      <name>Levorphanol</name>
      <description>The risk or severity of adverse effects can be increased when Levorphanol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00899</drugbank-id>
      <name>Remifentanil</name>
      <description>The risk or severity of adverse effects can be increased when Remifentanil is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01081</drugbank-id>
      <name>Diphenoxylate</name>
      <description>The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The risk or severity of adverse effects can be increased when Oxymorphone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01209</drugbank-id>
      <name>Dezocine</name>
      <description>The risk or severity of adverse effects can be increased when Dezocine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01433</drugbank-id>
      <name>Methadyl acetate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methadyl acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01450</drugbank-id>
      <name>Dihydroetorphine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydroetorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01452</drugbank-id>
      <name>Diamorphine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Diamorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethylmorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01497</drugbank-id>
      <name>Etorphine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Etorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01529</drugbank-id>
      <name>Dextromoramide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dextromoramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01535</drugbank-id>
      <name>Carfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Carfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydrocodeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01555</drugbank-id>
      <name>Alphacetylmethadol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Alphacetylmethadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01565</drugbank-id>
      <name>Dihydromorphine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dihydromorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06738</drugbank-id>
      <name>Ketobemidone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ketobemidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08861</drugbank-id>
      <name>DPDPE</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with DPDPE.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09174</drugbank-id>
      <name>Lofentanil</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lofentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Opium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11609</drugbank-id>
      <name>Normethadone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Normethadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12492</drugbank-id>
      <name>Piritramide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Piritramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13160</drugbank-id>
      <name>Alphaprodine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Alphaprodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13478</drugbank-id>
      <name>Meptazinol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Meptazinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13605</drugbank-id>
      <name>Phenoperidine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenoperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13606</drugbank-id>
      <name>Phenazocine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenazocine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13787</drugbank-id>
      <name>Tilidine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tilidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15360</drugbank-id>
      <name>Carfentanil, C-11</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Carfentanil, C-11.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00802</drugbank-id>
      <name>Alfentanil</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Alfentanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00813</drugbank-id>
      <name>Fentanyl</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fentanyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00704</drugbank-id>
      <name>Naltrexone</name>
      <description>The risk or severity of adverse effects can be increased when Naltrexone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01459</drugbank-id>
      <name>Bezitramide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Bezitramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13454</drugbank-id>
      <name>Nicomorphine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Nicomorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15465</drugbank-id>
      <name>Benzhydrocodone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzhydrocodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01227</drugbank-id>
      <name>Levacetylmethadol</name>
      <description>The risk or severity of adverse effects can be increased when Levacetylmethadol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00809</drugbank-id>
      <name>Tropicamide</name>
      <description>The risk or severity of adverse effects can be increased when Tropicamide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00979</drugbank-id>
      <name>Cyclopentolate</name>
      <description>The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01161</drugbank-id>
      <name>Chloroprocaine</name>
      <description>The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01496</drugbank-id>
      <name>Barbituric acid derivative</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Barbituric acid derivative.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11181</drugbank-id>
      <name>Homatropine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Homatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09271</drugbank-id>
      <name>Cimetropium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cimetropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00562</drugbank-id>
      <name>Benzthiazide</name>
      <description>The serum concentration of Benzthiazide can be increased when it is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01325</drugbank-id>
      <name>Quinethazone</name>
      <description>The serum concentration of Quinethazone can be increased when it is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13989</drugbank-id>
      <name>Epitizide</name>
      <description>The serum concentration of Epitizide can be increased when it is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00190</drugbank-id>
      <name>Carbidopa</name>
      <description>The therapeutic efficacy of Carbidopa can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00323</drugbank-id>
      <name>Tolcapone</name>
      <description>The therapeutic efficacy of Tolcapone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00340</drugbank-id>
      <name>Metixene</name>
      <description>The therapeutic efficacy of Metixene can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00376</drugbank-id>
      <name>Trihexyphenidyl</name>
      <description>The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00387</drugbank-id>
      <name>Procyclidine</name>
      <description>The therapeutic efficacy of Procyclidine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>The therapeutic efficacy of Entacapone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The therapeutic efficacy of Biperiden can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The therapeutic efficacy of Amantadine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02105</drugbank-id>
      <name>3,5-Dinitrocatechol</name>
      <description>The therapeutic efficacy of 3,5-Dinitrocatechol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06535</drugbank-id>
      <name>Etilevodopa</name>
      <description>The therapeutic efficacy of Etilevodopa can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08954</drugbank-id>
      <name>Ifenprodil</name>
      <description>The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08997</drugbank-id>
      <name>Dexetimide</name>
      <description>The therapeutic efficacy of Dexetimide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11632</drugbank-id>
      <name>Opicapone</name>
      <description>The therapeutic efficacy of Opicapone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12783</drugbank-id>
      <name>Benserazide</name>
      <description>The therapeutic efficacy of Benserazide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13252</drugbank-id>
      <name>Tropatepine</name>
      <description>The therapeutic efficacy of Tropatepine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13313</drugbank-id>
      <name>Melevodopa</name>
      <description>The therapeutic efficacy of Melevodopa can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13413</drugbank-id>
      <name>Phenglutarimide</name>
      <description>The therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13448</drugbank-id>
      <name>Mazaticol</name>
      <description>The therapeutic efficacy of Mazaticol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13468</drugbank-id>
      <name>Etybenzatropine</name>
      <description>The therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13502</drugbank-id>
      <name>Budipine</name>
      <description>The therapeutic efficacy of Budipine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13619</drugbank-id>
      <name>Bornaprine</name>
      <description>The therapeutic efficacy of Bornaprine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13636</drugbank-id>
      <name>Etanautine</name>
      <description>The therapeutic efficacy of Etanautine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15130</drugbank-id>
      <name>Dexpramipexole</name>
      <description>The therapeutic efficacy of Dexpramipexole can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>Aripiprazole may increase the serotonergic activities of Methylene blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00332</drugbank-id>
      <name>Ipratropium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ipratropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00221</drugbank-id>
      <name>Isoetharine</name>
      <description>The therapeutic efficacy of Isoetharine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00397</drugbank-id>
      <name>Phenylpropanolamine</name>
      <description>The therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00816</drugbank-id>
      <name>Orciprenaline</name>
      <description>The therapeutic efficacy of Orciprenaline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00867</drugbank-id>
      <name>Ritodrine</name>
      <description>The therapeutic efficacy of Ritodrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00901</drugbank-id>
      <name>Bitolterol</name>
      <description>The therapeutic efficacy of Bitolterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00938</drugbank-id>
      <name>Salmeterol</name>
      <description>The therapeutic efficacy of Salmeterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The therapeutic efficacy of Formoterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01064</drugbank-id>
      <name>Isoprenaline</name>
      <description>The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01102</drugbank-id>
      <name>Arbutamine</name>
      <description>The therapeutic efficacy of Arbutamine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The therapeutic efficacy of Arformoterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01288</drugbank-id>
      <name>Fenoterol</name>
      <description>The therapeutic efficacy of Fenoterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01291</drugbank-id>
      <name>Pirbuterol</name>
      <description>The therapeutic efficacy of Pirbuterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01363</drugbank-id>
      <name>Ephedra sinica root</name>
      <description>The therapeutic efficacy of Ephedra sinica root can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01364</drugbank-id>
      <name>Ephedrine</name>
      <description>The therapeutic efficacy of Ephedrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01366</drugbank-id>
      <name>Procaterol</name>
      <description>The therapeutic efficacy of Procaterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01407</drugbank-id>
      <name>Clenbuterol</name>
      <description>The therapeutic efficacy of Clenbuterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01537</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyphenethylamine</name>
      <description>The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05039</drugbank-id>
      <name>Indacaterol</name>
      <description>The therapeutic efficacy of Indacaterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05395</drugbank-id>
      <name>Amibegron</name>
      <description>The therapeutic efficacy of Amibegron can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06190</drugbank-id>
      <name>Solabegron</name>
      <description>The therapeutic efficacy of Solabegron can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06694</drugbank-id>
      <name>Xylometazoline</name>
      <description>The therapeutic efficacy of Xylometazoline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06711</drugbank-id>
      <name>Naphazoline</name>
      <description>The therapeutic efficacy of Naphazoline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06814</drugbank-id>
      <name>Protokylol</name>
      <description>The therapeutic efficacy of Protokylol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08925</drugbank-id>
      <name>Adrafinil</name>
      <description>The therapeutic efficacy of Adrafinil can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08941</drugbank-id>
      <name>Isoxsuprine</name>
      <description>The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08957</drugbank-id>
      <name>Hexoprenaline</name>
      <description>The therapeutic efficacy of Hexoprenaline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08985</drugbank-id>
      <name>Etilefrine</name>
      <description>The therapeutic efficacy of Etilefrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09080</drugbank-id>
      <name>Olodaterol</name>
      <description>The therapeutic efficacy of Olodaterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09082</drugbank-id>
      <name>Vilanterol</name>
      <description>The therapeutic efficacy of Vilanterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09203</drugbank-id>
      <name>Synephrine</name>
      <description>The therapeutic efficacy of Synephrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09273</drugbank-id>
      <name>Doxofylline</name>
      <description>The therapeutic efficacy of Doxofylline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11278</drugbank-id>
      <name>DL-Methylephedrine</name>
      <description>The therapeutic efficacy of DL-Methylephedrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11373</drugbank-id>
      <name>Amitraz</name>
      <description>The therapeutic efficacy of Amitraz can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11541</drugbank-id>
      <name>Ractopamine</name>
      <description>The therapeutic efficacy of Ractopamine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11587</drugbank-id>
      <name>Etafedrine</name>
      <description>The therapeutic efficacy of Etafedrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11871</drugbank-id>
      <name>PF-00610355</name>
      <description>The therapeutic efficacy of PF-00610355 can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12100</drugbank-id>
      <name>Abediterol</name>
      <description>The therapeutic efficacy of Abediterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12248</drugbank-id>
      <name>Tulobuterol</name>
      <description>The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12526</drugbank-id>
      <name>Batefenterol</name>
      <description>The therapeutic efficacy of Batefenterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12779</drugbank-id>
      <name>Higenamine</name>
      <description>The therapeutic efficacy of Higenamine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12846</drugbank-id>
      <name>Reproterol</name>
      <description>The therapeutic efficacy of Reproterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13251</drugbank-id>
      <name>Octopamine</name>
      <description>The therapeutic efficacy of Octopamine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13378</drugbank-id>
      <name>Norfenefrine</name>
      <description>The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13398</drugbank-id>
      <name>Oxyfedrine</name>
      <description>The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13559</drugbank-id>
      <name>Rimiterol</name>
      <description>The therapeutic efficacy of Rimiterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13692</drugbank-id>
      <name>Tretoquinol</name>
      <description>The therapeutic efficacy of Tretoquinol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13777</drugbank-id>
      <name>Prenalterol</name>
      <description>The therapeutic efficacy of Prenalterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13781</drugbank-id>
      <name>Xamoterol</name>
      <description>The therapeutic efficacy of Xamoterol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14752</drugbank-id>
      <name>Racephedrine</name>
      <description>The therapeutic efficacy of Racephedrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>Bufuralol may increase the orthostatic hypotensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>Bopindolol may increase the orthostatic hypotensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>Befunolol may increase the orthostatic hypotensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>Arotinolol may increase the orthostatic hypotensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>Levobetaxolol may increase the orthostatic hypotensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>Anisodamine may increase the orthostatic hypotensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>Mepindolol may increase the orthostatic hypotensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>Tertatolol may increase the orthostatic hypotensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00382</drugbank-id>
      <name>Tacrine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Tacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00392</drugbank-id>
      <name>Profenamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Profenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00483</drugbank-id>
      <name>Gallamine triethiodide</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Gallamine triethiodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Cisplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00527</drugbank-id>
      <name>Cinchocaine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Cinchocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Nizatidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Galantamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00677</drugbank-id>
      <name>Isoflurophate</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Isoflurophate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00711</drugbank-id>
      <name>Diethylcarbamazine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Diethylcarbamazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00871</drugbank-id>
      <name>Terbutaline</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Terbutaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00888</drugbank-id>
      <name>Mechlorethamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Mechlorethamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00941</drugbank-id>
      <name>Hexafluronium</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Hexafluronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00944</drugbank-id>
      <name>Demecarium</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Demecarium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00981</drugbank-id>
      <name>Physostigmine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Physostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00989</drugbank-id>
      <name>Rivastigmine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Rivastigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01010</drugbank-id>
      <name>Edrophonium</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Edrophonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Memantine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01122</drugbank-id>
      <name>Ambenonium</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Ambenonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01199</drugbank-id>
      <name>Tubocurarine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Tubocurarine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01245</drugbank-id>
      <name>Decamethonium</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Decamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01337</drugbank-id>
      <name>Pancuronium</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Pancuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01338</drugbank-id>
      <name>Pipecuronium</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Pipecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01381</drugbank-id>
      <name>Ginkgo biloba</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Ginkgo biloba.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01400</drugbank-id>
      <name>Neostigmine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Neostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01408</drugbank-id>
      <name>Bambuterol</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Bambuterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02365</drugbank-id>
      <name>1,10-Phenanthroline</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with 1,10-Phenanthroline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04572</drugbank-id>
      <name>Thiotepa</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Thiotepa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04864</drugbank-id>
      <name>Huperzine A</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Huperzine A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04892</drugbank-id>
      <name>Phenserine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Phenserine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05386</drugbank-id>
      <name>Regramostim</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Regramostim.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06692</drugbank-id>
      <name>Aprotinin</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Aprotinin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06756</drugbank-id>
      <name>Glycine betaine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Glycine betaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11390</drugbank-id>
      <name>Coumaphos</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Coumaphos.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11397</drugbank-id>
      <name>Dichlorvos</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Dichlorvos.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11412</drugbank-id>
      <name>Fenthion</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Fenthion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11473</drugbank-id>
      <name>Metrifonate</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Metrifonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12482</drugbank-id>
      <name>Acotiamide</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Acotiamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13058</drugbank-id>
      <name>Methanesulfonyl Fluoride</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Methanesulfonyl Fluoride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13495</drugbank-id>
      <name>Paraoxon</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Paraoxon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13503</drugbank-id>
      <name>Tyrothricin</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Tyrothricin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13668</drugbank-id>
      <name>Ipidacrine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Ipidacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13694</drugbank-id>
      <name>Distigmine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Distigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14031</drugbank-id>
      <name>Tretamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Tretamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15317</drugbank-id>
      <name>Posiphen</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Posiphen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00545</drugbank-id>
      <name>Pyridostigmine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Pyridostigmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02845</drugbank-id>
      <name>Methylphosphinic Acid</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Methylphosphinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The therapeutic efficacy of Lactulose can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01046</drugbank-id>
      <name>Lubiprostone</name>
      <description>The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01378</drugbank-id>
      <name>Magnesium cation</name>
      <description>The therapeutic efficacy of Magnesium cation can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01593</drugbank-id>
      <name>Zinc</name>
      <description>The therapeutic efficacy of Zinc can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01638</drugbank-id>
      <name>Sorbitol</name>
      <description>The therapeutic efficacy of Sorbitol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04816</drugbank-id>
      <name>Dantron</name>
      <description>The therapeutic efficacy of Dantron can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04823</drugbank-id>
      <name>Oxyphenisatin</name>
      <description>The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04824</drugbank-id>
      <name>Phenolphthalein</name>
      <description>The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07715</drugbank-id>
      <name>Emodin</name>
      <description>The therapeutic efficacy of Emodin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08890</drugbank-id>
      <name>Linaclotide</name>
      <description>The therapeutic efficacy of Linaclotide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09020</drugbank-id>
      <name>Bisacodyl</name>
      <description>The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09219</drugbank-id>
      <name>Bisoxatin</name>
      <description>The therapeutic efficacy of Bisoxatin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The therapeutic efficacy of Magnesium trisilicate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09287</drugbank-id>
      <name>Polyethylene glycol</name>
      <description>The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09311</drugbank-id>
      <name>Polycarbophil</name>
      <description>The therapeutic efficacy of Polycarbophil can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09413</drugbank-id>
      <name>Monopotassium phosphate</name>
      <description>The therapeutic efficacy of Monopotassium phosphate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09414</drugbank-id>
      <name>Dipotassium phosphate</name>
      <description>The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09449</drugbank-id>
      <name>Sodium phosphate, monobasic</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09462</drugbank-id>
      <name>Glycerin</name>
      <description>The therapeutic efficacy of Glycerin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09472</drugbank-id>
      <name>Sodium sulfate</name>
      <description>The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09484</drugbank-id>
      <name>Sodium fluorophosphate</name>
      <description>The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11057</drugbank-id>
      <name>Mineral oil</name>
      <description>The therapeutic efficacy of Mineral oil can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11059</drugbank-id>
      <name>Carboxymethylcellulose</name>
      <description>The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11089</drugbank-id>
      <name>Docusate</name>
      <description>The therapeutic efficacy of Docusate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11097</drugbank-id>
      <name>Plantago seed</name>
      <description>The therapeutic efficacy of Plantago seed can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11110</drugbank-id>
      <name>Magnesium citrate</name>
      <description>The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11113</drugbank-id>
      <name>Castor oil</name>
      <description>The therapeutic efficacy of Castor oil can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11189</drugbank-id>
      <name>Magnesium glycinate</name>
      <description>The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11228</drugbank-id>
      <name>Methylcellulose</name>
      <description>The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11365</drugbank-id>
      <name>Sennosides</name>
      <description>The therapeutic efficacy of Sennosides can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12942</drugbank-id>
      <name>Lactitol</name>
      <description>The therapeutic efficacy of Lactitol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13170</drugbank-id>
      <name>Plecanatide</name>
      <description>The therapeutic efficacy of Plecanatide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13526</drugbank-id>
      <name>Pentaerithrityl</name>
      <description>The therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13707</drugbank-id>
      <name>Sodium tartrate</name>
      <description>The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14232</drugbank-id>
      <name>Deacetylbisacodyl</name>
      <description>The therapeutic efficacy of Deacetylbisacodyl can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14482</drugbank-id>
      <name>Sodium ascorbate</name>
      <description>The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14499</drugbank-id>
      <name>Potassium sulfate</name>
      <description>The therapeutic efficacy of Potassium sulfate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14502</drugbank-id>
      <name>Sodium phosphate, dibasic</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14503</drugbank-id>
      <name>Sodium phosphate, monobasic, unspecified form</name>
      <description>The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14504</drugbank-id>
      <name>Sodium phosphate, dibasic, unspecified form</name>
      <description>The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14513</drugbank-id>
      <name>Magnesium</name>
      <description>The therapeutic efficacy of Magnesium can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14585</drugbank-id>
      <name>Plantago ovata seed</name>
      <description>The therapeutic efficacy of Plantago ovata seed can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14627</drugbank-id>
      <name>Oxyphenisatin acetate</name>
      <description>The therapeutic efficacy of Oxyphenisatin acetate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14684</drugbank-id>
      <name>Calcium polycarbophil</name>
      <description>The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14963</drugbank-id>
      <name>Konjac mannan</name>
      <description>The therapeutic efficacy of Konjac mannan can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15477</drugbank-id>
      <name>Alloin</name>
      <description>The therapeutic efficacy of Alloin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15478</drugbank-id>
      <name>Frangula purshiana bark</name>
      <description>The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11622</drugbank-id>
      <name>Dehydrocholic acid</name>
      <description>The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06480</drugbank-id>
      <name>Prucalopride</name>
      <description>The therapeutic efficacy of Prucalopride can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00434</drugbank-id>
      <name>Cyproheptadine</name>
      <description>Cyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00662</drugbank-id>
      <name>Trimethobenzamide</name>
      <description>Trimethobenzamide may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01106</drugbank-id>
      <name>Levocabastine</name>
      <description>Levocabastine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00219</drugbank-id>
      <name>Oxyphenonium</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00354</drugbank-id>
      <name>Buclizine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Buclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00383</drugbank-id>
      <name>Oxyphencyclimine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00424</drugbank-id>
      <name>Hyoscyamine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00462</drugbank-id>
      <name>Methscopolamine bromide</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00505</drugbank-id>
      <name>Tridihexethyl</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00517</drugbank-id>
      <name>Anisotropine methylbromide</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Anisotropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00670</drugbank-id>
      <name>Pirenzepine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00725</drugbank-id>
      <name>Homatropine methylbromide</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00767</drugbank-id>
      <name>Benzquinamide</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Benzquinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00782</drugbank-id>
      <name>Propantheline</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Propantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00804</drugbank-id>
      <name>Dicyclomine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methantheline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00942</drugbank-id>
      <name>Cycrimine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Cycrimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01148</drugbank-id>
      <name>Flavoxate</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01231</drugbank-id>
      <name>Diphenidol</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Diphenidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01625</drugbank-id>
      <name>Isopropamide</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04843</drugbank-id>
      <name>Mepenzolate</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06787</drugbank-id>
      <name>Hexocyclium</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08801</drugbank-id>
      <name>Dimetindene</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09007</drugbank-id>
      <name>Chlorphenoxamine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09262</drugbank-id>
      <name>Imidafenacin</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Imidafenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09300</drugbank-id>
      <name>Butylscopolamine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11235</drugbank-id>
      <name>Thonzylamine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11315</drugbank-id>
      <name>Methscopolamine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12086</drugbank-id>
      <name>Oxitropium</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Oxitropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12554</drugbank-id>
      <name>Mebeverine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13254</drugbank-id>
      <name>Prifinium</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Prifinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13351</drugbank-id>
      <name>Piperidolate</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13369</drugbank-id>
      <name>Benzilone</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Benzilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13380</drugbank-id>
      <name>Difemerine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Difemerine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13507</drugbank-id>
      <name>Poldine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Poldine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13542</drugbank-id>
      <name>Bevonium</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Bevonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13581</drugbank-id>
      <name>Rociverine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Rociverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13666</drugbank-id>
      <name>Tiemonium iodide</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Tiemonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13678</drugbank-id>
      <name>Dihexyverine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13695</drugbank-id>
      <name>Penthienate</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Penthienate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13720</drugbank-id>
      <name>Diphemanil</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13738</drugbank-id>
      <name>Camylofin</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Camylofin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13759</drugbank-id>
      <name>Fenpiverinium</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Fenpiverinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13769</drugbank-id>
      <name>Emetonium iodide</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Emetonium iodide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13844</drugbank-id>
      <name>Pipenzolate</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13850</drugbank-id>
      <name>Timepidium</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Timepidium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14718</drugbank-id>
      <name>Pyrazolam</name>
      <description>Pyrazolam may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00967</drugbank-id>
      <name>Desloratadine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Alimemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01355</drugbank-id>
      <name>Hexobarbital</name>
      <description>Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00593</drugbank-id>
      <name>Ethosuximide</name>
      <description>Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01154</drugbank-id>
      <name>Thiamylal</name>
      <description>Thiamylal may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01198</drugbank-id>
      <name>Zopiclone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Zopiclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00235</drugbank-id>
      <name>Milrinone</name>
      <description>The risk or severity of hypotension, dyspepsia, and headache can be increased when Milrinone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The risk or severity of hypotension, dyspepsia, and headache can be increased when Pentoxifylline is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of hypotension, dyspepsia, and headache can be increased when Dipyridamole is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>The risk or severity of hypotension, dyspepsia, and headache can be increased when Ibudilast is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06267</drugbank-id>
      <name>Udenafil</name>
      <description>The risk or severity of hypotension, dyspepsia, and headache can be increased when Udenafil is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11792</drugbank-id>
      <name>Mirodenafil</name>
      <description>The risk or severity of hypotension, dyspepsia, and headache can be increased when Mirodenafil is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The risk or severity of hypotension, dyspepsia, and headache can be increased when Sildenafil is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06237</drugbank-id>
      <name>Avanafil</name>
      <description>The risk or severity of hypotension, dyspepsia, and headache can be increased when Avanafil is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04838</drugbank-id>
      <name>Cyclandelate</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Cyclandelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05885</drugbank-id>
      <name>Seletracetam</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Seletracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06152</drugbank-id>
      <name>Nylidrin</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Nylidrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06446</drugbank-id>
      <name>Dotarizine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Dotarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Tranilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08162</drugbank-id>
      <name>Fasudil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Fasudil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Agmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09089</drugbank-id>
      <name>Trimebutine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Trimebutine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09090</drugbank-id>
      <name>Pinaverium</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Pinaverium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09229</drugbank-id>
      <name>Aranidipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Aranidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09230</drugbank-id>
      <name>Azelnidipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Azelnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09232</drugbank-id>
      <name>Cilnidipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Cilnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09234</drugbank-id>
      <name>Darodipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Darodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09240</drugbank-id>
      <name>Niludipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Niludipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11960</drugbank-id>
      <name>Carboxyamidotriazole</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Carboxyamidotriazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12923</drugbank-id>
      <name>Gallopamil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Gallopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13488</drugbank-id>
      <name>Bencyclane</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Bencyclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13766</drugbank-id>
      <name>Lidoflazine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Lidoflazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13835</drugbank-id>
      <name>Caroverine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Caroverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13961</drugbank-id>
      <name>Fish oil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Fish oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14064</drugbank-id>
      <name>Emopamil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Emopamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14065</drugbank-id>
      <name>Lomerizine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Lomerizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14066</drugbank-id>
      <name>Tetrandrine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Tetrandrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00007</drugbank-id>
      <name>Leuprolide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Leuprolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00014</drugbank-id>
      <name>Goserelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Goserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00207</drugbank-id>
      <name>Azithromycin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Azithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00218</drugbank-id>
      <name>Moxifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Moxifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Oxaliplatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00544</drugbank-id>
      <name>Fluorouracil</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fluorouracil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00556</drugbank-id>
      <name>Perflutren</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Perflutren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Cinnarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00572</drugbank-id>
      <name>Atropine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Atropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00640</drugbank-id>
      <name>Adenosine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Adenosine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00743</drugbank-id>
      <name>Gadobenic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Gadobenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00779</drugbank-id>
      <name>Nalidixic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Nalidixic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00827</drugbank-id>
      <name>Cinoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Cinoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00922</drugbank-id>
      <name>Levosimendan</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Levosimendan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00978</drugbank-id>
      <name>Lomefloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Lomefloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01113</drugbank-id>
      <name>Papaverine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Papaverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01155</drugbank-id>
      <name>Gemifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Gemifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01165</drugbank-id>
      <name>Ofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01599</drugbank-id>
      <name>Probucol</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Probucol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02638</drugbank-id>
      <name>Terlipressin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Terlipressin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04825</drugbank-id>
      <name>Prenylamine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Prenylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04957</drugbank-id>
      <name>Azimilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Azimilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05223</drugbank-id>
      <name>Pracinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pracinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05488</drugbank-id>
      <name>Technetium Tc-99m ciprofloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Technetium Tc-99m ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06160</drugbank-id>
      <name>Garenoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Garenoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06200</drugbank-id>
      <name>Tedisamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Tedisamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06334</drugbank-id>
      <name>Tucidinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Tucidinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06402</drugbank-id>
      <name>Telavancin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Telavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06600</drugbank-id>
      <name>Nemonoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Nemonoxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08799</drugbank-id>
      <name>Antazoline</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Antazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08903</drugbank-id>
      <name>Bedaquiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Bedaquiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08980</drugbank-id>
      <name>Fendiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fendiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08992</drugbank-id>
      <name>Eperisone</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Eperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09555</drugbank-id>
      <name>Dexchlorpheniramine maleate</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Dexchlorpheniramine maleate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11640</drugbank-id>
      <name>Amifampridine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Amifampridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11830</drugbank-id>
      <name>Mocetinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Mocetinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11841</drugbank-id>
      <name>Entinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Entinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12174</drugbank-id>
      <name>CUDC-101</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with CUDC-101.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12286</drugbank-id>
      <name>Simendan</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Simendan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12376</drugbank-id>
      <name>Ricolinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ricolinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12523</drugbank-id>
      <name>Mizolastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Mizolastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12565</drugbank-id>
      <name>Abexinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Abexinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12877</drugbank-id>
      <name>Oxatomide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Oxatomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13261</drugbank-id>
      <name>Sitafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Sitafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13500</drugbank-id>
      <name>Otilonium</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Otilonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13546</drugbank-id>
      <name>Nizofenone</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Nizofenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13652</drugbank-id>
      <name>Bunaftine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Bunaftine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13653</drugbank-id>
      <name>Lorcainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Lorcainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13679</drugbank-id>
      <name>Dexchlorpheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Dexchlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14063</drugbank-id>
      <name>Dexverapamil</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Dexverapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Clemastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00308</drugbank-id>
      <name>Ibutilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ibutilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00365</drugbank-id>
      <name>Grepafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Grepafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00539</drugbank-id>
      <name>Toremifene</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Toremifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00685</drugbank-id>
      <name>Trovafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Trovafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01208</drugbank-id>
      <name>Sparfloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Sparfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01405</drugbank-id>
      <name>Temafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Temafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05294</drugbank-id>
      <name>Vandetanib</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Vandetanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06176</drugbank-id>
      <name>Romidepsin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Romidepsin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09083</drugbank-id>
      <name>Ivabradine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ivabradine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11978</drugbank-id>
      <name>Glasdegib</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Glasdegib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13725</drugbank-id>
      <name>Terodiline</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Terodiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01169</drugbank-id>
      <name>Arsenic trioxide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Arsenic trioxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Dofetilide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00181</drugbank-id>
      <name>Baclofen</name>
      <description>The risk or severity of adverse effects can be increased when Baclofen is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00189</drugbank-id>
      <name>Ethchlorvynol</name>
      <description>The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00202</drugbank-id>
      <name>Succinylcholine</name>
      <description>The risk or severity of adverse effects can be increased when Succinylcholine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00228</drugbank-id>
      <name>Enflurane</name>
      <description>The risk or severity of adverse effects can be increased when Enflurane is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00237</drugbank-id>
      <name>Butabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Butabarbital is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Atomoxetine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00292</drugbank-id>
      <name>Etomidate</name>
      <description>The risk or severity of adverse effects can be increased when Etomidate is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00306</drugbank-id>
      <name>Talbutal</name>
      <description>The risk or severity of adverse effects can be increased when Talbutal is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00315</drugbank-id>
      <name>Zolmitriptan</name>
      <description>The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00341</drugbank-id>
      <name>Cetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Cetirizine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00347</drugbank-id>
      <name>Trimethadione</name>
      <description>The risk or severity of adverse effects can be increased when Trimethadione is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>The risk or severity of adverse effects can be increased when Palonosetron is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00405</drugbank-id>
      <name>Dexbrompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00416</drugbank-id>
      <name>Metocurine iodide</name>
      <description>The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00423</drugbank-id>
      <name>Methocarbamol</name>
      <description>The risk or severity of adverse effects can be increased when Methocarbamol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00427</drugbank-id>
      <name>Triprolidine</name>
      <description>The risk or severity of adverse effects can be increased when Triprolidine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00463</drugbank-id>
      <name>Metharbital</name>
      <description>The risk or severity of adverse effects can be increased when Metharbital is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00565</drugbank-id>
      <name>Cisatracurium</name>
      <description>The risk or severity of adverse effects can be increased when Cisatracurium is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00579</drugbank-id>
      <name>Mazindol</name>
      <description>The risk or severity of adverse effects can be increased when Mazindol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00617</drugbank-id>
      <name>Paramethadione</name>
      <description>The risk or severity of adverse effects can be increased when Paramethadione is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00645</drugbank-id>
      <name>Dyclonine</name>
      <description>The risk or severity of adverse effects can be increased when Dyclonine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00660</drugbank-id>
      <name>Metaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Metaxalone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00669</drugbank-id>
      <name>Sumatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Sumatriptan is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>The risk or severity of adverse effects can be increased when Moricizine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00697</drugbank-id>
      <name>Tizanidine</name>
      <description>The risk or severity of adverse effects can be increased when Tizanidine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00728</drugbank-id>
      <name>Rocuronium</name>
      <description>The risk or severity of adverse effects can be increased when Rocuronium is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00732</drugbank-id>
      <name>Atracurium besylate</name>
      <description>The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00737</drugbank-id>
      <name>Meclizine</name>
      <description>The risk or severity of adverse effects can be increased when Meclizine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00740</drugbank-id>
      <name>Riluzole</name>
      <description>The risk or severity of adverse effects can be increased when Riluzole is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00747</drugbank-id>
      <name>Scopolamine</name>
      <description>The risk or severity of adverse effects can be increased when Scopolamine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00748</drugbank-id>
      <name>Carbinoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00753</drugbank-id>
      <name>Isoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Isoflurane is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>The risk or severity of adverse effects can be increased when Dolasetron is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00768</drugbank-id>
      <name>Olopatadine</name>
      <description>The risk or severity of adverse effects can be increased when Olopatadine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00771</drugbank-id>
      <name>Clidinium</name>
      <description>The risk or severity of adverse effects can be increased when Clidinium is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00832</drugbank-id>
      <name>Phensuximide</name>
      <description>The risk or severity of adverse effects can be increased when Phensuximide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00835</drugbank-id>
      <name>Brompheniramine</name>
      <description>The risk or severity of adverse effects can be increased when Brompheniramine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00889</drugbank-id>
      <name>Granisetron</name>
      <description>The risk or severity of adverse effects can be increased when Granisetron is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00906</drugbank-id>
      <name>Tiagabine</name>
      <description>The risk or severity of adverse effects can be increased when Tiagabine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of adverse effects can be increased when Zonisamide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The risk or severity of adverse effects can be increased when Almotriptan is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00950</drugbank-id>
      <name>Fexofenadine</name>
      <description>The risk or severity of adverse effects can be increased when Fexofenadine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00952</drugbank-id>
      <name>Naratriptan</name>
      <description>The risk or severity of adverse effects can be increased when Naratriptan is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00953</drugbank-id>
      <name>Rizatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Rizatriptan is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00962</drugbank-id>
      <name>Zaleplon</name>
      <description>The risk or severity of adverse effects can be increased when Zaleplon is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00969</drugbank-id>
      <name>Alosetron</name>
      <description>The risk or severity of adverse effects can be increased when Alosetron is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00980</drugbank-id>
      <name>Ramelteon</name>
      <description>The risk or severity of adverse effects can be increased when Ramelteon is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00985</drugbank-id>
      <name>Dimenhydrinate</name>
      <description>The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00998</drugbank-id>
      <name>Frovatriptan</name>
      <description>The risk or severity of adverse effects can be increased when Frovatriptan is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>The risk or severity of adverse effects can be increased when Acetophenazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01065</drugbank-id>
      <name>Melatonin</name>
      <description>The risk or severity of adverse effects can be increased when Melatonin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01068</drugbank-id>
      <name>Clonazepam</name>
      <description>The risk or severity of adverse effects can be increased when Clonazepam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01080</drugbank-id>
      <name>Vigabatrin</name>
      <description>The risk or severity of adverse effects can be increased when Vigabatrin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01107</drugbank-id>
      <name>Methyprylon</name>
      <description>The risk or severity of adverse effects can be increased when Methyprylon is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01121</drugbank-id>
      <name>Phenacemide</name>
      <description>The risk or severity of adverse effects can be increased when Phenacemide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01135</drugbank-id>
      <name>Doxacurium</name>
      <description>The risk or severity of adverse effects can be increased when Doxacurium is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01159</drugbank-id>
      <name>Halothane</name>
      <description>The risk or severity of adverse effects can be increased when Halothane is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01176</drugbank-id>
      <name>Cyclizine</name>
      <description>The risk or severity of adverse effects can be increased when Cyclizine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01189</drugbank-id>
      <name>Desflurane</name>
      <description>The risk or severity of adverse effects can be increased when Desflurane is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01202</drugbank-id>
      <name>Levetiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Levetiracetam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01219</drugbank-id>
      <name>Dantrolene</name>
      <description>The risk or severity of adverse effects can be increased when Dantrolene is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01226</drugbank-id>
      <name>Mivacurium</name>
      <description>The risk or severity of adverse effects can be increased when Mivacurium is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of adverse effects can be increased when Sevoflurane is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01336</drugbank-id>
      <name>Metocurine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Metocurine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01339</drugbank-id>
      <name>Vecuronium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Vecuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01353</drugbank-id>
      <name>Butobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Butobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01354</drugbank-id>
      <name>Heptabarbital</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Heptabarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01437</drugbank-id>
      <name>Glutethimide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Glutethimide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01440</drugbank-id>
      <name>gamma-Hydroxybutyric acid</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with gamma-Hydroxybutyric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01489</drugbank-id>
      <name>Camazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Camazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01495</drugbank-id>
      <name>Dichloralphenazone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dichloralphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01501</drugbank-id>
      <name>Difenoxin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Difenoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01511</drugbank-id>
      <name>Delorazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Delorazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01534</drugbank-id>
      <name>Chlorhexadol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorhexadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01547</drugbank-id>
      <name>Drotebanol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Drotebanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01553</drugbank-id>
      <name>Cloxazolam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cloxazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01559</drugbank-id>
      <name>Clotiazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Clotiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01563</drugbank-id>
      <name>Chloral hydrate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloral hydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01589</drugbank-id>
      <name>Quazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Quazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01594</drugbank-id>
      <name>Cinolazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cinolazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01616</drugbank-id>
      <name>Alverine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Alverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02234</drugbank-id>
      <name>S-Ethylisothiourea</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with S-Ethylisothiourea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02852</drugbank-id>
      <name>Domoic Acid</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Domoic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04165</drugbank-id>
      <name>Valpromide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Valpromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04819</drugbank-id>
      <name>Methapyrilene</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methapyrilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04821</drugbank-id>
      <name>Nomifensine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Nomifensine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04827</drugbank-id>
      <name>Urethane</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Urethane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04833</drugbank-id>
      <name>Methaqualone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methaqualone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04834</drugbank-id>
      <name>Rapacuronium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Rapacuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04885</drugbank-id>
      <name>Cilansetron</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cilansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04888</drugbank-id>
      <name>Bifeprunox</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Bifeprunox.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04903</drugbank-id>
      <name>Pagoclone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pagoclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04908</drugbank-id>
      <name>Flibanserin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Flibanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04917</drugbank-id>
      <name>Renzapride</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Renzapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04953</drugbank-id>
      <name>Ezogabine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ezogabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05227</drugbank-id>
      <name>APD791</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with APD791.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05232</drugbank-id>
      <name>Tetrodotoxin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrodotoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05246</drugbank-id>
      <name>Methsuximide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methsuximide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05541</drugbank-id>
      <name>Brivaracetam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Brivaracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05542</drugbank-id>
      <name>Naronapride</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Naronapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05562</drugbank-id>
      <name>Naluzotan</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Naluzotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05607</drugbank-id>
      <name>PRX-08066</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with PRX-08066.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with BL-1020.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05710</drugbank-id>
      <name>Gantacurium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Gantacurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06077</drugbank-id>
      <name>Lumateperone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lumateperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06109</drugbank-id>
      <name>YKP-1358</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with YKP-1358.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06218</drugbank-id>
      <name>Lacosamide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lacosamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06264</drugbank-id>
      <name>Tolperisone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tolperisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06282</drugbank-id>
      <name>Levocetirizine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Levocetirizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06283</drugbank-id>
      <name>Ziconotide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ziconotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06470</drugbank-id>
      <name>Clomethiazole</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Clomethiazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06527</drugbank-id>
      <name>Tramiprosate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tramiprosate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06529</drugbank-id>
      <name>Ocinaplon</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ocinaplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06554</drugbank-id>
      <name>Gaboxadol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Gaboxadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06594</drugbank-id>
      <name>Agomelatine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Agomelatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06660</drugbank-id>
      <name>Saredutant</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Saredutant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06690</drugbank-id>
      <name>Nitrous oxide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrous oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06701</drugbank-id>
      <name>Dexmethylphenidate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dexmethylphenidate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06716</drugbank-id>
      <name>Fospropofol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fospropofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06753</drugbank-id>
      <name>Triclofos</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Triclofos.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzyl alcohol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06797</drugbank-id>
      <name>Mebutamate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Mebutamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08059</drugbank-id>
      <name>Wortmannin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Wortmannin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08329</drugbank-id>
      <name>Sulthiame</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Sulthiame.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08810</drugbank-id>
      <name>Cinitapride</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cinitapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08839</drugbank-id>
      <name>Serotonin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Serotonin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08872</drugbank-id>
      <name>Gabapentin enacarbil</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Gabapentin enacarbil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08892</drugbank-id>
      <name>Arbaclofen Placarbil</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Arbaclofen Placarbil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08910</drugbank-id>
      <name>Pomalidomide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pomalidomide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08996</drugbank-id>
      <name>Dimetacrine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dimetacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyamemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09011</drugbank-id>
      <name>Beclamide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Beclamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09014</drugbank-id>
      <name>Captodiame</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Captodiame.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09017</drugbank-id>
      <name>Brotizolam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Brotizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09021</drugbank-id>
      <name>Benzoctamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzoctamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09042</drugbank-id>
      <name>Tedizolid phosphate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tedizolid phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09071</drugbank-id>
      <name>Tasimelteon</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tasimelteon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09184</drugbank-id>
      <name>Edivoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Edivoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09186</drugbank-id>
      <name>Nisoxetine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Nisoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09187</drugbank-id>
      <name>Lortalamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lortalamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09190</drugbank-id>
      <name>Talopram</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Talopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09194</drugbank-id>
      <name>Etoperidone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Etoperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09223</drugbank-id>
      <name>Blonanserin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Blonanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09247</drugbank-id>
      <name>Iproclozide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Iproclozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11156</drugbank-id>
      <name>Pyrantel</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pyrantel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11371</drugbank-id>
      <name>Alfaxalone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Alfaxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11428</drugbank-id>
      <name>Medetomidine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Medetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11477</drugbank-id>
      <name>Xylazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Xylazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Propiopromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11543</drugbank-id>
      <name>Romifidine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Romifidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11549</drugbank-id>
      <name>Tiletamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiletamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11552</drugbank-id>
      <name>Tricaine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tricaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11556</drugbank-id>
      <name>Detomidine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Detomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11582</drugbank-id>
      <name>Thiocolchicoside</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiocolchicoside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11675</drugbank-id>
      <name>Mosapride</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Mosapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11686</drugbank-id>
      <name>Iferanserin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Iferanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11699</drugbank-id>
      <name>Tropisetron</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tropisetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11755</drugbank-id>
      <name>Tetrahydrocannabivarin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrahydrocannabivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11859</drugbank-id>
      <name>Brexanolone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Brexanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11868</drugbank-id>
      <name>Etiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Etiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11889</drugbank-id>
      <name>Lanicemine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lanicemine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11957</drugbank-id>
      <name>Idalopirdine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Idalopirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12071</drugbank-id>
      <name>Vabicaserin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Vabicaserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12105</drugbank-id>
      <name>Imagabalin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Imagabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12110</drugbank-id>
      <name>m-Chlorophenylpiperazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with m-Chlorophenylpiperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12111</drugbank-id>
      <name>MK-212</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with MK-212.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12131</drugbank-id>
      <name>Vinpocetine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Vinpocetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Sarpogrelate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12177</drugbank-id>
      <name>Eplivanserin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Eplivanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12229</drugbank-id>
      <name>Cerlapirdine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cerlapirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12308</drugbank-id>
      <name>Eltanolone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Eltanolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12338</drugbank-id>
      <name>Carisbamate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Carisbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12361</drugbank-id>
      <name>Piclozotan</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Piclozotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12395</drugbank-id>
      <name>Esreboxetine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Esreboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12427</drugbank-id>
      <name>Orvepitant</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Orvepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12537</drugbank-id>
      <name>Benzodiazepine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzodiazepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12576</drugbank-id>
      <name>AZD-3043</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with AZD-3043.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12590</drugbank-id>
      <name>Indiplon</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Indiplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12725</drugbank-id>
      <name>TD-8954</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with TD-8954.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12883</drugbank-id>
      <name>Eltoprazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Eltoprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12951</drugbank-id>
      <name>Pivagabine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pivagabine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12958</drugbank-id>
      <name>Prothipendyl</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Prothipendyl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12989</drugbank-id>
      <name>Neosaxitoxin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Neosaxitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13099</drugbank-id>
      <name>Valnoctamide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Valnoctamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13114</drugbank-id>
      <name>Amitriptylinoxide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Amitriptylinoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13196</drugbank-id>
      <name>Valerian</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Valerian.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Butaperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13219</drugbank-id>
      <name>Medifoxamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Medifoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13221</drugbank-id>
      <name>Apronalide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Apronalide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13234</drugbank-id>
      <name>Propanidid</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Propanidid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13246</drugbank-id>
      <name>Quinupramine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Quinupramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13253</drugbank-id>
      <name>Proxibarbal</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Proxibarbal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13295</drugbank-id>
      <name>Atracurium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Atracurium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13303</drugbank-id>
      <name>Febarbamate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Febarbamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13323</drugbank-id>
      <name>Trichloroethylene</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Trichloroethylene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13324</drugbank-id>
      <name>Tetrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13331</drugbank-id>
      <name>Pyrithyldione</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pyrithyldione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13354</drugbank-id>
      <name>Phenprobamate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenprobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13357</drugbank-id>
      <name>Styramate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Styramate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13362</drugbank-id>
      <name>Pheneturide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pheneturide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13370</drugbank-id>
      <name>Bromisoval</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromisoval.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13377</drugbank-id>
      <name>Vinbarbital</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Vinbarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorproethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13384</drugbank-id>
      <name>Melitracen</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Melitracen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13396</drugbank-id>
      <name>Neocitrullamon</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Neocitrullamon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13402</drugbank-id>
      <name>Acetylglycinamide chloral hydrate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Acetylglycinamide chloral hydrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13403</drugbank-id>
      <name>Oxypertine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxypertine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13414</drugbank-id>
      <name>Fenyramidol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fenyramidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiazinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13457</drugbank-id>
      <name>Oxaflozane</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxaflozane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13505</drugbank-id>
      <name>Emepronium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Emepronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13534</drugbank-id>
      <name>Gedocarnil</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Gedocarnil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13541</drugbank-id>
      <name>Iprazochrome</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Iprazochrome.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13554</drugbank-id>
      <name>Moperone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Moperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13557</drugbank-id>
      <name>Thiopropazate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiopropazate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13572</drugbank-id>
      <name>Emylcamate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Emylcamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13577</drugbank-id>
      <name>Allobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Allobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13584</drugbank-id>
      <name>Gallamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Gallamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13588</drugbank-id>
      <name>Naftidrofuryl</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Naftidrofuryl.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13598</drugbank-id>
      <name>Diethyl ether</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Diethyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13623</drugbank-id>
      <name>Fabomotizole</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fabomotizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13642</drugbank-id>
      <name>Pridinol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pridinol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13648</drugbank-id>
      <name>Alcuronium</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Alcuronium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13662</drugbank-id>
      <name>Hexapropymate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Hexapropymate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13676</drugbank-id>
      <name>Mosapramine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Mosapramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13687</drugbank-id>
      <name>Niaprazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Niaprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13690</drugbank-id>
      <name>Vinyl ether</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Vinyl ether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13733</drugbank-id>
      <name>Methylpentynol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Methylpentynol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13737</drugbank-id>
      <name>Cyclobarbital</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyclobarbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13745</drugbank-id>
      <name>Fazadinium bromide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fazadinium bromide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13754</drugbank-id>
      <name>Mephenoxalone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Mephenoxalone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13770</drugbank-id>
      <name>Vinylbital</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Vinylbital.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13782</drugbank-id>
      <name>Imipramine oxide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Imipramine oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13799</drugbank-id>
      <name>Ethadione</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13805</drugbank-id>
      <name>Reposal</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Reposal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13817</drugbank-id>
      <name>Carbromal</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Carbromal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13837</drugbank-id>
      <name>Doxefazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Doxefazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13872</drugbank-id>
      <name>Lormetazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lormetazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13948</drugbank-id>
      <name>N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13984</drugbank-id>
      <name>Cyclopropane</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cyclopropane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13993</drugbank-id>
      <name>MRK-409</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with MRK-409.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with 5-methoxy-N,N-dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14050</drugbank-id>
      <name>Cannabidivarin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cannabidivarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14672</drugbank-id>
      <name>Oxazepam acetate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxazepam acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14715</drugbank-id>
      <name>Cinazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cinazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14719</drugbank-id>
      <name>Bentazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Bentazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15197</drugbank-id>
      <name>RSV-604</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with RSV-604.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15203</drugbank-id>
      <name>JNJ-26489112</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with JNJ-26489112.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00211</drugbank-id>
      <name>Midodrine</name>
      <description>The therapeutic efficacy of Midodrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The therapeutic efficacy of Norepinephrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00388</drugbank-id>
      <name>Phenylephrine</name>
      <description>The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00610</drugbank-id>
      <name>Metaraminol</name>
      <description>The therapeutic efficacy of Metaraminol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00723</drugbank-id>
      <name>Methoxamine</name>
      <description>The therapeutic efficacy of Methoxamine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00841</drugbank-id>
      <name>Dobutamine</name>
      <description>The therapeutic efficacy of Dobutamine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00935</drugbank-id>
      <name>Oxymetazoline</name>
      <description>The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01579</drugbank-id>
      <name>Phendimetrazine</name>
      <description>The therapeutic efficacy of Phendimetrazine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06706</drugbank-id>
      <name>Isometheptene</name>
      <description>The therapeutic efficacy of Isometheptene can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06764</drugbank-id>
      <name>Tetryzoline</name>
      <description>The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09202</drugbank-id>
      <name>Cirazoline</name>
      <description>The therapeutic efficacy of Cirazoline can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11124</drugbank-id>
      <name>Racepinephrine</name>
      <description>The therapeutic efficacy of Racepinephrine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13345</drugbank-id>
      <name>Dihydroergocristine</name>
      <description>Dihydroergocristine may increase the vasoconstricting activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13399</drugbank-id>
      <name>Terguride</name>
      <description>Terguride may increase the vasoconstricting activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>Lysergic acid diethylamide may increase the vasoconstricting activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01253</drugbank-id>
      <name>Ergometrine</name>
      <description>Ergometrine may increase the vasoconstricting activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00247</drugbank-id>
      <name>Methysergide</name>
      <description>Methysergide may increase the vasoconstricting activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00346</drugbank-id>
      <name>Alfuzosin</name>
      <description>Alfuzosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00699</drugbank-id>
      <name>Nicergoline</name>
      <description>Nicergoline may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>Tamsulosin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00777</drugbank-id>
      <name>Propiomazine</name>
      <description>Propiomazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Periciazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Thioproperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06207</drugbank-id>
      <name>Silodosin</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Silodosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12230</drugbank-id>
      <name>Bunazosin</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bunazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12278</drugbank-id>
      <name>Propiverine</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Propiverine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Bucindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>Promazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>Trifluoperazine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00875</drugbank-id>
      <name>Flupentixol</name>
      <description>Flupentixol may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>Quetiapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06153</drugbank-id>
      <name>Pizotifen</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Pizotifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Asenapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>Aripiprazole may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole lauroxil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>Olanzapine may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>Risperidone may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00230</drugbank-id>
      <name>Pregabalin</name>
      <description>The therapeutic efficacy of Aripiprazole can be increased when used in combination with Pregabalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00721</drugbank-id>
      <name>Procaine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Procaine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00614</drugbank-id>
      <name>Furazolidone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Furazolidone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01168</drugbank-id>
      <name>Procarbazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Procarbazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01367</drugbank-id>
      <name>Rasagiline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Rasagiline is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The risk or severity of serotonin syndrome can be increased when Safinamide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08550</drugbank-id>
      <name>7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline</name>
      <description>The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09243</drugbank-id>
      <name>Hydracarbazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Hydracarbazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09246</drugbank-id>
      <name>Benmoxin</name>
      <description>The risk or severity of serotonin syndrome can be increased when Benmoxin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09248</drugbank-id>
      <name>Mebanazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Mebanazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09249</drugbank-id>
      <name>Octamoxin</name>
      <description>The risk or severity of serotonin syndrome can be increased when Octamoxin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09250</drugbank-id>
      <name>Pheniprazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Pheniprazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09251</drugbank-id>
      <name>Phenoxypropazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Phenoxypropazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09252</drugbank-id>
      <name>Pivhydrazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Pivhydrazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09253</drugbank-id>
      <name>Safrazine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Safrazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09254</drugbank-id>
      <name>Caroxazone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Caroxazone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13875</drugbank-id>
      <name>Harmaline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Harmaline is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13876</drugbank-id>
      <name>Brofaromine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Brofaromine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Minaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Selegiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Moclobemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01247</drugbank-id>
      <name>Isocarboxazid</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Isocarboxazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04017</drugbank-id>
      <name>Clorgiline</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Clorgiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Iproniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04820</drugbank-id>
      <name>Nialamide</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Nialamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09244</drugbank-id>
      <name>Pirlindole</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Pirlindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09245</drugbank-id>
      <name>Toloxatone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Toloxatone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00150</drugbank-id>
      <name>Tryptophan</name>
      <description>The risk or severity of adverse effects can be increased when Tryptophan is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00186</drugbank-id>
      <name>Lorazepam</name>
      <description>The risk or severity of adverse effects can be increased when Lorazepam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00231</drugbank-id>
      <name>Temazepam</name>
      <description>The risk or severity of adverse effects can be increased when Temazepam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>The risk or severity of adverse effects can be increased when Reboxetine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00371</drugbank-id>
      <name>Meprobamate</name>
      <description>The risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00404</drugbank-id>
      <name>Alprazolam</name>
      <description>The risk or severity of adverse effects can be increased when Alprazolam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00408</drugbank-id>
      <name>Loxapine</name>
      <description>The risk or severity of adverse effects can be increased when Loxapine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>The risk or severity of adverse effects can be increased when Remoxipride is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00475</drugbank-id>
      <name>Chlordiazepoxide</name>
      <description>The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00546</drugbank-id>
      <name>Adinazolam</name>
      <description>The risk or severity of adverse effects can be increased when Adinazolam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00555</drugbank-id>
      <name>Lamotrigine</name>
      <description>The risk or severity of adverse effects can be increased when Lamotrigine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Fluphenazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00628</drugbank-id>
      <name>Clorazepic acid</name>
      <description>The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00690</drugbank-id>
      <name>Flurazepam</name>
      <description>The risk or severity of adverse effects can be increased when Flurazepam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00801</drugbank-id>
      <name>Halazepam</name>
      <description>The risk or severity of adverse effects can be increased when Halazepam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00837</drugbank-id>
      <name>Progabide</name>
      <description>The risk or severity of adverse effects can be increased when Progabide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00842</drugbank-id>
      <name>Oxazepam</name>
      <description>The risk or severity of adverse effects can be increased when Oxazepam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The risk or severity of adverse effects can be increased when Perphenazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00897</drugbank-id>
      <name>Triazolam</name>
      <description>The risk or severity of adverse effects can be increased when Triazolam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The risk or severity of adverse effects can be increased when Ondansetron is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The risk or severity of adverse effects can be increased when Mesoridazine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Maprotiline is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00996</drugbank-id>
      <name>Gabapentin</name>
      <description>The risk or severity of adverse effects can be increased when Gabapentin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01178</drugbank-id>
      <name>Chlormezanone</name>
      <description>The risk or severity of adverse effects can be increased when Chlormezanone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01215</drugbank-id>
      <name>Estazolam</name>
      <description>The risk or severity of adverse effects can be increased when Estazolam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01239</drugbank-id>
      <name>Chlorprothixene</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorprothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01356</drugbank-id>
      <name>Lithium cation</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lithium cation.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01445</drugbank-id>
      <name>Bufotenine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Bufotenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01463</drugbank-id>
      <name>Fencamfamin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fencamfamin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with 4-Methoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01488</drugbank-id>
      <name>Dimethyltryptamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dimethyltryptamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01544</drugbank-id>
      <name>Flunitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Flunitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01545</drugbank-id>
      <name>Ethyl loflazepate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl loflazepate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01558</drugbank-id>
      <name>Bromazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01560</drugbank-id>
      <name>Cathinone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cathinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01567</drugbank-id>
      <name>Fludiazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fludiazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01588</drugbank-id>
      <name>Prazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Prazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01595</drugbank-id>
      <name>Nitrazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Nitrazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01618</drugbank-id>
      <name>Molindone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Molindone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01623</drugbank-id>
      <name>Thiothixene</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Thiothixene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01954</drugbank-id>
      <name>Rolipram</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Rolipram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02207</drugbank-id>
      <name>7-Nitroindazole</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with 7-Nitroindazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02959</drugbank-id>
      <name>Oxitriptan</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxitriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03575</drugbank-id>
      <name>Phencyclidine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Phencyclidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04325</drugbank-id>
      <name>Phenethylamine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenethylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04599</drugbank-id>
      <name>Aniracetam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Aniracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04836</drugbank-id>
      <name>Amineptine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Amineptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04842</drugbank-id>
      <name>Fluspirilene</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluspirilene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04872</drugbank-id>
      <name>Osanetant</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Osanetant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05316</drugbank-id>
      <name>Pimavanserin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pimavanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Deramciclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06579</drugbank-id>
      <name>Adipiplon</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Adipiplon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06582</drugbank-id>
      <name>Dextofisopam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dextofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Esmirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Perospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08927</drugbank-id>
      <name>Amperozide</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Amperozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08986</drugbank-id>
      <name>Etifoxine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Etifoxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09016</drugbank-id>
      <name>Butriptyline</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Butriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09023</drugbank-id>
      <name>Benactyzine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Benactyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Vortioxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09166</drugbank-id>
      <name>Etizolam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Etizolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09185</drugbank-id>
      <name>Viloxazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Viloxazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09225</drugbank-id>
      <name>Zotepine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Zotepine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09226</drugbank-id>
      <name>RP-5063</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with RP-5063.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09286</drugbank-id>
      <name>Pipamperone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pipamperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09289</drugbank-id>
      <name>Tianeptine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tianeptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09307</drugbank-id>
      <name>Oxaprotiline</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxaprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11376</drugbank-id>
      <name>Azaperone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Azaperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11555</drugbank-id>
      <name>Zolazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Zolazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11664</drugbank-id>
      <name>Psilocybin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Psilocybin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12184</drugbank-id>
      <name>Gepirone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Gepirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12273</drugbank-id>
      <name>Ecopipam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ecopipam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12327</drugbank-id>
      <name>Salvinorin A</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Salvinorin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12401</drugbank-id>
      <name>Bromperidol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Bromperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12518</drugbank-id>
      <name>Raclopride</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Raclopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12833</drugbank-id>
      <name>Tandospirone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tandospirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12867</drugbank-id>
      <name>Benperidol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Benperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13014</drugbank-id>
      <name>Hypericin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Hypericin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13025</drugbank-id>
      <name>Tiapride</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13082</drugbank-id>
      <name>Nefiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Nefiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13225</drugbank-id>
      <name>Dibenzepin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dibenzepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13256</drugbank-id>
      <name>Clothiapine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Clothiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13273</drugbank-id>
      <name>Sultopride</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Sultopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13335</drugbank-id>
      <name>Pinazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Pinazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13352</drugbank-id>
      <name>Deanol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Deanol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13411</drugbank-id>
      <name>Lofepramine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lofepramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13437</drugbank-id>
      <name>Medazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Medazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13455</drugbank-id>
      <name>Phenibut</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenibut.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13496</drugbank-id>
      <name>Iprindole</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Iprindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13522</drugbank-id>
      <name>Mebicar</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Mebicar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13523</drugbank-id>
      <name>Veralipride</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Veralipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13550</drugbank-id>
      <name>Bifemelane</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Bifemelane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13552</drugbank-id>
      <name>Trifluperidol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Trifluperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13601</drugbank-id>
      <name>Oxiracetam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Oxiracetam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13643</drugbank-id>
      <name>Loprazolam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Loprazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13665</drugbank-id>
      <name>Fluanisone</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluanisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13791</drugbank-id>
      <name>Penfluridol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Penfluridol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13841</drugbank-id>
      <name>Clopenthixol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Clopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14028</drugbank-id>
      <name>Nordazepam</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Nordazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14509</drugbank-id>
      <name>Lithium carbonate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lithium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11637</drugbank-id>
      <name>Delamanid</name>
      <description>Aripiprazole may increase the QTc-prolonging activities of Delamanid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The therapeutic efficacy of Pitolisant can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09532</drugbank-id>
      <name>Secretin human</name>
      <description>The therapeutic efficacy of Secretin human can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The therapeutic efficacy of Aripiprazole can be increased when used in combination with Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00041</drugbank-id>
      <name>Aldesleukin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Aldesleukin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00104</drugbank-id>
      <name>Octreotide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Octreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00196</drugbank-id>
      <name>Fluconazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fluconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00199</drugbank-id>
      <name>Erythromycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Erythromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00224</drugbank-id>
      <name>Indinavir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Indinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Lovastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00248</drugbank-id>
      <name>Cabergoline</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Cabergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00255</drugbank-id>
      <name>Diethylstilbestrol</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Diethylstilbestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00270</drugbank-id>
      <name>Isradipine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Isradipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Valproic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Gefitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00320</drugbank-id>
      <name>Dihydroergotamine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dihydroergotamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00353</drugbank-id>
      <name>Methylergometrine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Methylergometrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Mefloquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00435</drugbank-id>
      <name>Nitric Oxide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nitric Oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00444</drugbank-id>
      <name>Teniposide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Teniposide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00446</drugbank-id>
      <name>Chloramphenicol</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Chloramphenicol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00481</drugbank-id>
      <name>Raloxifene</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Raloxifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Cimetidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ciprofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00549</drugbank-id>
      <name>Zafirlukast</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Zafirlukast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00588</drugbank-id>
      <name>Fluticasone propionate</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fluticasone propionate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Astemizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dextropropoxyphene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Epinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00673</drugbank-id>
      <name>Aprepitant</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Aprepitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00678</drugbank-id>
      <name>Losartan</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Losartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00681</drugbank-id>
      <name>Amphotericin B</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Amphotericin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00683</drugbank-id>
      <name>Midazolam</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Midazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00694</drugbank-id>
      <name>Daunorubicin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Daunorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00696</drugbank-id>
      <name>Ergotamine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ergotamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Amprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Delavirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00759</drugbank-id>
      <name>Tetracycline</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tetracycline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00778</drugbank-id>
      <name>Roxithromycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Roxithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Phenelzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00818</drugbank-id>
      <name>Propofol</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Propofol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00829</drugbank-id>
      <name>Diazepam</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Diazepam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00845</drugbank-id>
      <name>Clofazimine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Clofazimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00872</drugbank-id>
      <name>Conivaptan</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Conivaptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00916</drugbank-id>
      <name>Metronidazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Metronidazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00951</drugbank-id>
      <name>Isoniazid</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Isoniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00954</drugbank-id>
      <name>Dirithromycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dirithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00973</drugbank-id>
      <name>Ezetimibe</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ezetimibe.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00976</drugbank-id>
      <name>Telithromycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Telithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01029</drugbank-id>
      <name>Irbesartan</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Irbesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01059</drugbank-id>
      <name>Norfloxacin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Norfloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01072</drugbank-id>
      <name>Atazanavir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Atazanavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01085</drugbank-id>
      <name>Pilocarpine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Pilocarpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01093</drugbank-id>
      <name>Dimethyl sulfoxide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dimethyl sulfoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Pimozide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Miconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Amiodarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Bicalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Rabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Levofloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Desipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01152</drugbank-id>
      <name>Candicidin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Candicidin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01167</drugbank-id>
      <name>Itraconazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Itraconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01183</drugbank-id>
      <name>Naloxone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Naloxone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Pergolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01190</drugbank-id>
      <name>Clindamycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Clindamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01204</drugbank-id>
      <name>Mitoxantrone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Mitoxantrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01248</drugbank-id>
      <name>Docetaxel</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Docetaxel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01254</drugbank-id>
      <name>Dasatinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dasatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01259</drugbank-id>
      <name>Lapatinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Lapatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01263</drugbank-id>
      <name>Posaconazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Posaconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01264</drugbank-id>
      <name>Darunavir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Darunavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01275</drugbank-id>
      <name>Hydralazine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Hydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01369</drugbank-id>
      <name>Quinupristin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Quinupristin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01406</drugbank-id>
      <name>Danazol</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Danazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01587</drugbank-id>
      <name>Ketazolam</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ketazolam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01685</drugbank-id>
      <name>Topiroxostat</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Topiroxostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01698</drugbank-id>
      <name>Rutin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Rutin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01764</drugbank-id>
      <name>Dalfopristin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dalfopristin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01873</drugbank-id>
      <name>Epothilone D</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Epothilone D.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02520</drugbank-id>
      <name>Ditiocarb</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ditiocarb.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02701</drugbank-id>
      <name>Nicotinamide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nicotinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fusidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Resveratrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03010</drugbank-id>
      <name>Patupilone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Patupilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04070</drugbank-id>
      <name>6-Deoxyerythronolide B</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with 6-Deoxyerythronolide B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04794</drugbank-id>
      <name>Bifonazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Bifonazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04832</drugbank-id>
      <name>Zimelidine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Zimelidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04839</drugbank-id>
      <name>Cyproterone acetate</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Cyproterone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04845</drugbank-id>
      <name>Ixabepilone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ixabepilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04894</drugbank-id>
      <name>Vapreotide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Vapreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04896</drugbank-id>
      <name>Milnacipran</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Milnacipran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05482</drugbank-id>
      <name>7-ethyl-10-hydroxycamptothecin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05521</drugbank-id>
      <name>Telaprevir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Telaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05773</drugbank-id>
      <name>Trastuzumab emtansine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Trastuzumab emtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05814</drugbank-id>
      <name>GPI-1485</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with GPI-1485.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05903</drugbank-id>
      <name>KOS-1584</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with KOS-1584.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05928</drugbank-id>
      <name>Dovitinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dovitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06174</drugbank-id>
      <name>Noscapine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Noscapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06233</drugbank-id>
      <name>Ridaforolimus</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ridaforolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06268</drugbank-id>
      <name>Sitaxentan</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Sitaxentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06290</drugbank-id>
      <name>Simeprevir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Simeprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06318</drugbank-id>
      <name>AVE9633</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with AVE9633.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06342</drugbank-id>
      <name>Coltuximab ravtansine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Coltuximab ravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Indisulam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06412</drugbank-id>
      <name>Oxymetholone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Oxymetholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06419</drugbank-id>
      <name>Cethromycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Cethromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06458</drugbank-id>
      <name>Remacemide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Remacemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06469</drugbank-id>
      <name>Lestaurtinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Lestaurtinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06587</drugbank-id>
      <name>Mitemcinal</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Mitemcinal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06616</drugbank-id>
      <name>Bosutinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Bosutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06663</drugbank-id>
      <name>Pasireotide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Pasireotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06712</drugbank-id>
      <name>Nilvadipine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nilvadipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06731</drugbank-id>
      <name>Seproxetine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Seproxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06774</drugbank-id>
      <name>Capsaicin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Capsaicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06791</drugbank-id>
      <name>Lanreotide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Lanreotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07348</drugbank-id>
      <name>Brefeldin A</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Brefeldin A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08811</drugbank-id>
      <name>Tofisopam</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tofisopam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ticagrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08820</drugbank-id>
      <name>Ivacaftor</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ivacaftor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08827</drugbank-id>
      <name>Lomitapide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Lomitapide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Rilpivirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08865</drugbank-id>
      <name>Crizotinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Crizotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08870</drugbank-id>
      <name>Brentuximab vedotin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Brentuximab vedotin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08874</drugbank-id>
      <name>Fidaxomicin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fidaxomicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Linagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08896</drugbank-id>
      <name>Regorafenib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Regorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08906</drugbank-id>
      <name>Fluticasone furoate</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fluticasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08953</drugbank-id>
      <name>Indalpine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Indalpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Netupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09063</drugbank-id>
      <name>Ceritinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ceritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09073</drugbank-id>
      <name>Palbociclib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Palbociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09074</drugbank-id>
      <name>Olaparib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Olaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09099</drugbank-id>
      <name>Somatostatin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Somatostatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09101</drugbank-id>
      <name>Elvitegravir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Elvitegravir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09227</drugbank-id>
      <name>Barnidipine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Barnidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09231</drugbank-id>
      <name>Benidipine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Benidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09235</drugbank-id>
      <name>Efonidipine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Efonidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09308</drugbank-id>
      <name>Solithromycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Solithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09309</drugbank-id>
      <name>Kitasamycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Kitasamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11198</drugbank-id>
      <name>Peppermint oil</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Peppermint oil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11383</drugbank-id>
      <name>Carbomycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Carbomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11400</drugbank-id>
      <name>Doramectin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Doramectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11405</drugbank-id>
      <name>Eprinomectin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Eprinomectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11442</drugbank-id>
      <name>Oleandomycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Oleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11459</drugbank-id>
      <name>Selamectin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Selamectin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11470</drugbank-id>
      <name>Tildipirosin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tildipirosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11471</drugbank-id>
      <name>Tilmicosin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tilmicosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11475</drugbank-id>
      <name>Tylosin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tylosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11554</drugbank-id>
      <name>Tylvalosin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tylvalosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11574</drugbank-id>
      <name>Elbasvir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Elbasvir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11581</drugbank-id>
      <name>Venetoclax</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Venetoclax.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11703</drugbank-id>
      <name>Acalabrutinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Acalabrutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11730</drugbank-id>
      <name>Ribociclib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ribociclib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11752</drugbank-id>
      <name>Bryostatin 1</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Bryostatin 1.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11779</drugbank-id>
      <name>Danoprevir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Danoprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11805</drugbank-id>
      <name>Saracatinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Saracatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12010</drugbank-id>
      <name>Fostamatinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fostamatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Letermovir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12089</drugbank-id>
      <name>Lorvotuzumab mertansine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Lorvotuzumab mertansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Triclabendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12266</drugbank-id>
      <name>Epofolate</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Epofolate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12391</drugbank-id>
      <name>Sagopilone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Sagopilone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12489</drugbank-id>
      <name>Mirvetuximab Soravtansine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Mirvetuximab Soravtansine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12532</drugbank-id>
      <name>Oxetacaine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Oxetacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12582</drugbank-id>
      <name>Piperine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Piperine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13179</drugbank-id>
      <name>Troleandomycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Troleandomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13338</drugbank-id>
      <name>Flurithromycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Flurithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13409</drugbank-id>
      <name>Rokitamycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Rokitamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13456</drugbank-id>
      <name>Midecamycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Midecamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13633</drugbank-id>
      <name>Mepartricin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Mepartricin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13867</drugbank-id>
      <name>Fluticasone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fluticasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13941</drugbank-id>
      <name>Piperaquine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Piperaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13950</drugbank-id>
      <name>WIN 55212-2</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with WIN 55212-2.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13975</drugbank-id>
      <name>Black cohosh</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Black cohosh.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14019</drugbank-id>
      <name>Fosnetupitant</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fosnetupitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The metabolism of Everolimus can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00582</drugbank-id>
      <name>Voriconazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Voriconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01211</drugbank-id>
      <name>Clarithromycin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Clarithromycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fluvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08873</drugbank-id>
      <name>Boceprevir</name>
      <description>The metabolism of Boceprevir can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00107</drugbank-id>
      <name>Oxytocin</name>
      <description>The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The risk or severity of QTc prolongation can be increased when Digoxin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00467</drugbank-id>
      <name>Enoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00487</drugbank-id>
      <name>Pefloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00529</drugbank-id>
      <name>Foscarnet</name>
      <description>The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00710</drugbank-id>
      <name>Ibandronate</name>
      <description>The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00817</drugbank-id>
      <name>Rosoxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00920</drugbank-id>
      <name>Ketotifen</name>
      <description>The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>The risk or severity of QTc prolongation can be increased when Famotidine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01044</drugbank-id>
      <name>Gatifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01228</drugbank-id>
      <name>Encainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Encainide is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01426</drugbank-id>
      <name>Ajmaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ajmaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01620</drugbank-id>
      <name>Pheniramine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02546</drugbank-id>
      <name>Vorinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Vorinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04576</drugbank-id>
      <name>Fleroxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fleroxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04695</drugbank-id>
      <name>Farnesyl thiopyrophosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Farnesyl thiopyrophosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05465</drugbank-id>
      <name>Tandutinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Tandutinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06468</drugbank-id>
      <name>Cariporide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Cariporide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06699</drugbank-id>
      <name>Degarelix</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Degarelix.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06719</drugbank-id>
      <name>Buserelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Buserelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06788</drugbank-id>
      <name>Histrelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Histrelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06825</drugbank-id>
      <name>Triptorelin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Triptorelin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07780</drugbank-id>
      <name>Farnesyl diphosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Farnesyl diphosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07841</drugbank-id>
      <name>Geranylgeranyl diphosphate</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Geranylgeranyl diphosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08868</drugbank-id>
      <name>Fingolimod</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Fingolimod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08871</drugbank-id>
      <name>Eribulin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Eribulin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08936</drugbank-id>
      <name>Chlorcyclizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Chlorcyclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08972</drugbank-id>
      <name>Flumequine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Flumequine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09488</drugbank-id>
      <name>Acrivastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Acrivastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11408</drugbank-id>
      <name>Famphur</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Famphur.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11443</drugbank-id>
      <name>Orbifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Orbifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11448</drugbank-id>
      <name>Phosmet</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Phosmet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11491</drugbank-id>
      <name>Sarafloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Sarafloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11511</drugbank-id>
      <name>Difloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Difloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11591</drugbank-id>
      <name>Bilastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Bilastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11774</drugbank-id>
      <name>Pazufloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pazufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11891</drugbank-id>
      <name>CUDC-907</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with CUDC-907.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11892</drugbank-id>
      <name>Prulifloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Prulifloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12231</drugbank-id>
      <name>Temefos</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Temefos.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12645</drugbank-id>
      <name>Givinostat</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Givinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12712</drugbank-id>
      <name>Pilsicainide</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pilsicainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13358</drugbank-id>
      <name>Cibenzoline</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Cibenzoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13555</drugbank-id>
      <name>Prajmaline</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Prajmaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13627</drugbank-id>
      <name>Oxolinic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Oxolinic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13651</drugbank-id>
      <name>Lorajmine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Lorajmine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Acetyldigoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13744</drugbank-id>
      <name>Piromidic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Piromidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13772</drugbank-id>
      <name>Rufloxacin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Rufloxacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13823</drugbank-id>
      <name>Pipemidic acid</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Pipemidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14713</drugbank-id>
      <name>Inotersen</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Inotersen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00719</drugbank-id>
      <name>Azatadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Azatadine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01001</drugbank-id>
      <name>Salbutamol</name>
      <description>The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00822</drugbank-id>
      <name>Disulfiram</name>
      <description>The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00862</drugbank-id>
      <name>Vardenafil</name>
      <description>The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00440</drugbank-id>
      <name>Trimethoprim</name>
      <description>The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00825</drugbank-id>
      <name>Levomenthol</name>
      <description>The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Digitoxin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11614</drugbank-id>
      <name>Rupatadine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Rupatadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11742</drugbank-id>
      <name>Ebastine</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Ebastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05077</drugbank-id>
      <name>SLV319</name>
      <description>The risk or severity of adverse effects can be increased when SLV319 is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05372</drugbank-id>
      <name>CP-945598</name>
      <description>The risk or severity of adverse effects can be increased when CP-945598 is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06155</drugbank-id>
      <name>Rimonabant</name>
      <description>The risk or severity of adverse effects can be increased when Rimonabant is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06624</drugbank-id>
      <name>Taranabant</name>
      <description>The risk or severity of adverse effects can be increased when Taranabant is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The risk or severity of adverse effects can be increased when Cannabidiol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11903</drugbank-id>
      <name>GW842166</name>
      <description>The risk or severity of adverse effects can be increased when GW842166 is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12193</drugbank-id>
      <name>Ajulemic acid</name>
      <description>The risk or severity of adverse effects can be increased when Ajulemic acid is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12649</drugbank-id>
      <name>Ibipinabant</name>
      <description>The risk or severity of adverse effects can be increased when Ibipinabant is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13070</drugbank-id>
      <name>Surinabant</name>
      <description>The risk or severity of adverse effects can be increased when Surinabant is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The risk or severity of adverse effects can be increased when Nabiximols is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14043</drugbank-id>
      <name>Palmidrol</name>
      <description>The risk or severity of adverse effects can be increased when Palmidrol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14737</drugbank-id>
      <name>Cannabinol</name>
      <description>The risk or severity of adverse effects can be increased when Cannabinol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08167</drugbank-id>
      <name>Methylthioninium</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Methylthioninium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10676</drugbank-id>
      <name>Nutmeg</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Nutmeg.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13910</drugbank-id>
      <name>Valproate bismuth</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Valproate bismuth.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Buspirone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01235</drugbank-id>
      <name>Levodopa</name>
      <description>The absorption of Levodopa can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00455</drugbank-id>
      <name>Loratadine</name>
      <description>Aripiprazole may increase the anticholinergic activities of Loratadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06707</drugbank-id>
      <name>Levonordefrin</name>
      <description>Aripiprazole may decrease the hypertensive activities of Levonordefrin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12927</drugbank-id>
      <name>Theodrenaline</name>
      <description>Aripiprazole may decrease the hypertensive activities of Theodrenaline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13917</drugbank-id>
      <name>Deoxyepinephrine</name>
      <description>Aripiprazole may decrease the hypertensive activities of Deoxyepinephrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The therapeutic efficacy of Domperidone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Amphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00191</drugbank-id>
      <name>Phentermine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Phentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00852</drugbank-id>
      <name>Pseudoephedrine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Pseudoephedrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00865</drugbank-id>
      <name>Benzphetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Benzphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00937</drugbank-id>
      <name>Diethylpropion</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Diethylpropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Lisdexamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01365</drugbank-id>
      <name>Mephentermine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Mephentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01442</drugbank-id>
      <name>MMDA</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with MMDA.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Midomafetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01467</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylamphetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with 2,5-Dimethoxy-4-ethylamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01484</drugbank-id>
      <name>4-Bromo-2,5-dimethoxyamphetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with 4-Bromo-2,5-dimethoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01509</drugbank-id>
      <name>Tenamfetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Tenamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01556</drugbank-id>
      <name>Chlorphentermine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Chlorphentermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01566</drugbank-id>
      <name>Methylenedioxyethamphetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Methylenedioxyethamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Dextroamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Metamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09480</drugbank-id>
      <name>Iofetamine I-123</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Iofetamine I-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12080</drugbank-id>
      <name>Ritobegron</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Ritobegron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13108</drugbank-id>
      <name>Mephedrone</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Mephedrone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13624</drugbank-id>
      <name>Methoxyphenamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Methoxyphenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13703</drugbank-id>
      <name>Gepefrine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Gepefrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13940</drugbank-id>
      <name>2,5-Dimethoxy-4-ethylthioamphetamine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with 2,5-Dimethoxy-4-ethylthioamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13074</drugbank-id>
      <name>Macimorelin</name>
      <description>The therapeutic efficacy of Macimorelin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11823</drugbank-id>
      <name>Esketamine</name>
      <description>The risk or severity of hypertension can be increased when Esketamine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00395</drugbank-id>
      <name>Carisoprodol</name>
      <description>The risk or severity of adverse effects can be increased when Carisoprodol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>The risk or severity of hypertension can be increased when Solriamfetol is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13946</drugbank-id>
      <name>Testosterone undecanoate</name>
      <description>Testosterone undecanoate may increase the hypertensive activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00177</drugbank-id>
      <name>Valsartan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Valsartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Ramipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Reserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00212</drugbank-id>
      <name>Remikiren</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Remikiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00217</drugbank-id>
      <name>Bethanidine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Bethanidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00226</drugbank-id>
      <name>Guanadrel</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanadrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00275</drugbank-id>
      <name>Olmesartan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Olmesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00310</drugbank-id>
      <name>Chlorthalidone</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Chlorthalidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00325</drugbank-id>
      <name>Nitroprusside</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Nitroprusside.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00350</drugbank-id>
      <name>Minoxidil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Minoxidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Treprostinil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00393</drugbank-id>
      <name>Nimodipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Nimodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00401</drugbank-id>
      <name>Nisoldipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Nisoldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00436</drugbank-id>
      <name>Bendroflumethiazide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Bendroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Prazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Fosinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Trandolapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00524</drugbank-id>
      <name>Metolazone</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Metolazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Benazepril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00606</drugbank-id>
      <name>Cyclothiazide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Cyclothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00612</drugbank-id>
      <name>Bisoprolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Bisoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00616</drugbank-id>
      <name>Candoxatril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Candoxatril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00629</drugbank-id>
      <name>Guanabenz</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanabenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00657</drugbank-id>
      <name>Mecamylamine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Mecamylamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Moexipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00692</drugbank-id>
      <name>Phentolamine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Phentolamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00700</drugbank-id>
      <name>Eplerenone</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Eplerenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Lisinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00727</drugbank-id>
      <name>Nitroglycerin</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Nitroglycerin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00774</drugbank-id>
      <name>Hydroflumethiazide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Hydroflumethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00785</drugbank-id>
      <name>Cryptenamine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Cryptenamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Perindopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00796</drugbank-id>
      <name>Candesartan cilexetil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Candesartan cilexetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00797</drugbank-id>
      <name>Tolazoline</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Tolazoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00808</drugbank-id>
      <name>Indapamide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Indapamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00820</drugbank-id>
      <name>Tadalafil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Tadalafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00876</drugbank-id>
      <name>Eprosartan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Eprosartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00880</drugbank-id>
      <name>Chlorothiazide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Chlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Quinapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Omapatrilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00925</drugbank-id>
      <name>Phenoxybenzamine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Phenoxybenzamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00966</drugbank-id>
      <name>Telmisartan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Telmisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00968</drugbank-id>
      <name>Methyldopa</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Methyldopa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00999</drugbank-id>
      <name>Hydrochlorothiazide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Hydrochlorothiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01018</drugbank-id>
      <name>Guanfacine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanfacine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01021</drugbank-id>
      <name>Trichlormethiazide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Trichlormethiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01089</drugbank-id>
      <name>Deserpidine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Deserpidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01090</drugbank-id>
      <name>Pentolinium</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Pentolinium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01116</drugbank-id>
      <name>Trimethaphan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Trimethaphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01119</drugbank-id>
      <name>Diazoxide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Diazoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01158</drugbank-id>
      <name>Bretylium</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Bretylium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01162</drugbank-id>
      <name>Terazosin</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Terazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Rescinnamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01324</drugbank-id>
      <name>Polythiazide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Polythiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01347</drugbank-id>
      <name>Saprisartan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Saprisartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Spirapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01626</drugbank-id>
      <name>Pargyline</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Pargyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03322</drugbank-id>
      <name>Dexpropranolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Dexpropranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04831</drugbank-id>
      <name>Tienilic acid</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Tienilic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Debrisoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06403</drugbank-id>
      <name>Ambrisentan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Ambrisentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06445</drugbank-id>
      <name>Diethylnorspermine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Diethylnorspermine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06762</drugbank-id>
      <name>Pinacidil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Pinacidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Bupranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Temocapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08931</drugbank-id>
      <name>Riociguat</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Riociguat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08932</drugbank-id>
      <name>Macitentan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Macitentan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08950</drugbank-id>
      <name>Indoramin</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Indoramin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Indenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08960</drugbank-id>
      <name>Hexamethonium</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Hexamethonium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09026</drugbank-id>
      <name>Aliskiren</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Aliskiren.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09206</drugbank-id>
      <name>Trimazosin</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Trimazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09220</drugbank-id>
      <name>Nicorandil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Nicorandil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09236</drugbank-id>
      <name>Lacidipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Lacidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09239</drugbank-id>
      <name>Niguldipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Niguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09242</drugbank-id>
      <name>Moxonidine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Moxonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09363</drugbank-id>
      <name>Rauwolfia serpentina root</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Rauwolfia serpentina root.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Enalaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11362</drugbank-id>
      <name>Selexipag</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Selexipag.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11720</drugbank-id>
      <name>Angiotensin 1-7</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Angiotensin 1-7.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11738</drugbank-id>
      <name>Rilmenidine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Rilmenidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Talinolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Imidapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12054</drugbank-id>
      <name>BQ-123</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with BQ-123.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Naftopidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12093</drugbank-id>
      <name>Tetrahydropalmatine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Tetrahydropalmatine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Landiolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Ketanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12661</drugbank-id>
      <name>Urapidil</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Urapidil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12766</drugbank-id>
      <name>Cicletanine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Cicletanine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12945</drugbank-id>
      <name>Dihydralazine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Dihydralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Zofenopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13211</drugbank-id>
      <name>Guanoxan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanoxan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Delapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13374</drugbank-id>
      <name>Vincamine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Vincamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Linsidomine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13410</drugbank-id>
      <name>Guanoxabenz</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanoxabenz.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13429</drugbank-id>
      <name>Tolonidine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Tolonidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13435</drugbank-id>
      <name>Endralazine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Endralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Esatenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13452</drugbank-id>
      <name>Cadralazine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Cadralazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Cloranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13532</drugbank-id>
      <name>Cyclopenthiazide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Cyclopenthiazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13575</drugbank-id>
      <name>Bietaserpine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Bietaserpine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13604</drugbank-id>
      <name>Guanazodine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanazodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13631</drugbank-id>
      <name>Methoserpidine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Methoserpidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Epanolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13779</drugbank-id>
      <name>Guanoclor</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanoclor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13801</drugbank-id>
      <name>Muzolimine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Muzolimine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13803</drugbank-id>
      <name>Xipamide</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Xipamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13919</drugbank-id>
      <name>Candesartan</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Candesartan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14068</drugbank-id>
      <name>Dexniguldipine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Dexniguldipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Benazeprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Fosinoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Ramiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Perindoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Quinaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The risk or severity of hypotension can be increased when Lercanidipine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01054</drugbank-id>
      <name>Nitrendipine</name>
      <description>The risk or severity of hypotension can be increased when Nitrendipine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01170</drugbank-id>
      <name>Guanethidine</name>
      <description>The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanethidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00956</drugbank-id>
      <name>Hydrocodone</name>
      <description>The risk or severity of serotonin syndrome can be increased when Hydrocodone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00402</drugbank-id>
      <name>Eszopiclone</name>
      <description>The risk or severity of CNS depression can be increased when Aripiprazole is combined with Eszopiclone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The risk or severity of sedation can be increased when Clonidine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The risk or severity of QTc prolongation can be increased when Trazodone is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Donepezil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11986</drugbank-id>
      <name>Entrectinib</name>
      <description>The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Entrectinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12825</drugbank-id>
      <name>Lefamulin</name>
      <description>Lefamulin may increase the QTc-prolonging activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00924</drugbank-id>
      <name>Cyclobenzaprine</name>
      <description>The risk or severity of CNS depression can be increased when Aripiprazole is combined with Cyclobenzaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The risk or severity of serotonin syndrome can be increased when Escitalopram is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11732</drugbank-id>
      <name>Lasmiditan</name>
      <description>The risk or severity of serotonin syndrome can be increased when Aripiprazole is combined with Lasmiditan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>Quinidine may decrease the excretion rate of Aripiprazole which could result in a higher serum level.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>The therapeutic efficacy of Insulin human can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>The therapeutic efficacy of Insulin lispro can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>The therapeutic efficacy of Insulin glargine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>The therapeutic efficacy of Insulin pork can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>The therapeutic efficacy of Glimepiride can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>The therapeutic efficacy of Acarbose can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>The therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>The therapeutic efficacy of Miglitol can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The therapeutic efficacy of Nateglinide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>The therapeutic efficacy of Tolazamide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>The therapeutic efficacy of Repaglinide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The therapeutic efficacy of Phenformin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>The therapeutic efficacy of Glipizide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>The therapeutic efficacy of Gliclazide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>The therapeutic efficacy of Gliquidone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>The therapeutic efficacy of Exenatide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>The therapeutic efficacy of Mecasermin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>The therapeutic efficacy of Glisoxepide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>The therapeutic efficacy of Insulin aspart can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>The therapeutic efficacy of Insulin detemir can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>The therapeutic efficacy of Insulin glulisine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>The therapeutic efficacy of Glymidine can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>The therapeutic efficacy of Buformin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>The therapeutic efficacy of Voglibose can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>The therapeutic efficacy of NN344 can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>The therapeutic efficacy of AMG-222 can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>The therapeutic efficacy of Bisegliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The therapeutic efficacy of Alogliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>The therapeutic efficacy of Liraglutide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>The therapeutic efficacy of Gosogliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>The therapeutic efficacy of Glibornuride can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>The therapeutic efficacy of Benfluorex can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>The therapeutic efficacy of Albiglutide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>The therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>The therapeutic efficacy of Netoglitazone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>The therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>The therapeutic efficacy of Insulin beef can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>The therapeutic efficacy of Insulin degludec can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>The therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>The therapeutic efficacy of Insulin tregopil can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>The therapeutic efficacy of Ipragliflozin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>The therapeutic efficacy of Dutogliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>The therapeutic efficacy of Allicin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>The therapeutic efficacy of Tofogliflozin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11936</drugbank-id>
      <name>Bempedoic acid</name>
      <description>The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>The therapeutic efficacy of Teneligliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>The therapeutic efficacy of Omarigliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>The therapeutic efficacy of Carmegliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>The therapeutic efficacy of Gemigliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>The therapeutic efficacy of Anagliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>The therapeutic efficacy of Evogliptin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>The therapeutic efficacy of Remogliflozin etabonate can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>The therapeutic efficacy of Carbutamide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>The therapeutic efficacy of Guar gum can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>The therapeutic efficacy of Metahexamide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>The therapeutic efficacy of Semaglutide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>The therapeutic efficacy of Taspoglutide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>The therapeutic efficacy of Englitazone can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>The therapeutic efficacy of Tirzepatide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>The therapeutic efficacy of Gastric inhibitory polypeptide can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>The risk or severity of adverse effects can be decreased when Lisuride is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00714</drugbank-id>
      <name>Apomorphine</name>
      <description>The risk or severity of adverse effects can be decreased when Apomorphine is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00800</drugbank-id>
      <name>Fenoldopam</name>
      <description>The risk or severity of adverse effects can be decreased when Fenoldopam is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01049</drugbank-id>
      <name>Ergoloid mesylate</name>
      <description>The risk or severity of adverse effects can be decreased when Ergoloid mesylate is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Brexpiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11273</drugbank-id>
      <name>Dihydroergocornine</name>
      <description>The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Dihydroergocornine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12313</drugbank-id>
      <name>Dopexamine</name>
      <description>The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Dopexamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12478</drugbank-id>
      <name>Piribedil</name>
      <description>The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Piribedil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12890</drugbank-id>
      <name>Dihydrexidine</name>
      <description>The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Dihydrexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13316</drugbank-id>
      <name>Ibopamine</name>
      <description>The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Ibopamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13385</drugbank-id>
      <name>Dihydroergocryptine</name>
      <description>The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Dihydroergocryptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13520</drugbank-id>
      <name>Metergoline</name>
      <description>The risk or severity of adverse effects can be decreased when Aripiprazole is combined with Metergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Deutetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00260</drugbank-id>
      <name>Cycloserine</name>
      <description>Cycloserine may increase the neurotoxic activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00649</drugbank-id>
      <name>Stavudine</name>
      <description>Stavudine may increase the neurotoxic activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00900</drugbank-id>
      <name>Didanosine</name>
      <description>Didanosine may increase the neurotoxic activities of Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>Aripiprazole may increase the neurotoxic activities of Bismuth subsalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01598</drugbank-id>
      <name>Imipenem</name>
      <description>Aripiprazole may increase the neurotoxic activities of Imipenem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01627</drugbank-id>
      <name>Lincomycin</name>
      <description>Aripiprazole may increase the neurotoxic activities of Lincomycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09275</drugbank-id>
      <name>Bismuth subcitrate potassium</name>
      <description>Aripiprazole may increase the neurotoxic activities of Bismuth subcitrate potassium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11281</drugbank-id>
      <name>Bismuth subcarbonate</name>
      <description>Aripiprazole may increase the neurotoxic activities of Bismuth subcarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11537</drugbank-id>
      <name>Pirlimycin</name>
      <description>Aripiprazole may increase the neurotoxic activities of Pirlimycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>Aripiprazole may increase the neurotoxic activities of Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13909</drugbank-id>
      <name>Bismuth subgallate</name>
      <description>Aripiprazole may increase the neurotoxic activities of Bismuth subgallate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00781</drugbank-id>
      <name>Polymyxin B</name>
      <description>Aripiprazole may increase the neurotoxic activities of Polymyxin B.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>Aripiprazole may increase the neurotoxic activities of Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12141</drugbank-id>
      <name>Gilteritinib</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Gilteritinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01038</drugbank-id>
      <name>Carphenazine</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Carphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01425</drugbank-id>
      <name>Alizapride</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Alizapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09018</drugbank-id>
      <name>Bromopride</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Bromopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09207</drugbank-id>
      <name>AS-8112</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with AS-8112.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12579</drugbank-id>
      <name>JNJ-37822681</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with JNJ-37822681.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13511</drugbank-id>
      <name>Clebopride</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Clebopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15167</drugbank-id>
      <name>Fallypride</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Fallypride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15492</drugbank-id>
      <name>Eticlopride</name>
      <description>The therapeutic efficacy of Aripiprazole can be decreased when used in combination with Eticlopride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00268</drugbank-id>
      <name>Ropinirole</name>
      <description>The therapeutic efficacy of Ropinirole can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The risk or severity of adverse effects can be increased when Aripiprazole is combined with Benzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>The therapeutic efficacy of Pramipexole can be decreased when used in combination with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Venlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Imipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Chlorpromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The metabolism of Vilazodone can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The metabolism of Dosulepin can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The metabolism of Ritanserin can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The metabolism of Metoprolol can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00169</drugbank-id>
      <name>Cholecalciferol</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Cholecalciferol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Perhexiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tegaserod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06729</drugbank-id>
      <name>Sulfaphenazole</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Sulfaphenazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06819</drugbank-id>
      <name>Phenylbutyric acid</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Phenylbutyric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Rolapitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13174</drugbank-id>
      <name>Rhein</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Rhein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ranolazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The metabolism of Darifenacin can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Clobazam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Lorcaserin can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Bupropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Cinacalcet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Halofantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The metabolism of Cisapride can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09046</drugbank-id>
      <name>Metreleptin</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Metreleptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Medical Cannabis.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11737</drugbank-id>
      <name>Icotinib</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Icotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08970</drugbank-id>
      <name>Fluprednidene</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Fluprednidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08971</drugbank-id>
      <name>Fluocortolone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Fluocortolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13728</drugbank-id>
      <name>Halometasone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Halometasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14512</drugbank-id>
      <name>Mometasone furoate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Mometasone furoate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14631</drugbank-id>
      <name>Prednisolone phosphate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Prednisolone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14633</drugbank-id>
      <name>Prednisolone hemisuccinate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Prednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14634</drugbank-id>
      <name>Fluprednidene acetate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Fluprednidene acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14644</drugbank-id>
      <name>Methylprednisolone hemisuccinate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Methylprednisolone hemisuccinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14646</drugbank-id>
      <name>Prednisone acetate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Prednisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14652</drugbank-id>
      <name>Clocortolone acetate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Clocortolone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14659</drugbank-id>
      <name>Melengestrol acetate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Melengestrol acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14669</drugbank-id>
      <name>Betamethasone phosphate</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Betamethasone phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Cortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09256</drugbank-id>
      <name>Tegafur</name>
      <description>The metabolism of Tegafur can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01126</drugbank-id>
      <name>Dutasteride</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dutasteride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04856</drugbank-id>
      <name>Dexloxiglumide</name>
      <description>The metabolism of Dexloxiglumide can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dapsone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00367</drugbank-id>
      <name>Levonorgestrel</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Levonorgestrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00499</drugbank-id>
      <name>Flutamide</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Flutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00541</drugbank-id>
      <name>Vincristine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Vincristine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00688</drugbank-id>
      <name>Mycophenolate mofetil</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Mycophenolate mofetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00717</drugbank-id>
      <name>Norethisterone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Norethisterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00755</drugbank-id>
      <name>Tretinoin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tretinoin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Clopidogrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00762</drugbank-id>
      <name>Irinotecan</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Irinotecan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01058</drugbank-id>
      <name>Praziquantel</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Praziquantel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01103</drugbank-id>
      <name>Quinacrine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Quinacrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01216</drugbank-id>
      <name>Finasteride</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Finasteride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The metabolism of Rivaroxaban can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The metabolism of Apixaban can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06626</drugbank-id>
      <name>Axitinib</name>
      <description>The metabolism of Axitinib can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06652</drugbank-id>
      <name>Vicriviroc</name>
      <description>The metabolism of Vicriviroc can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06772</drugbank-id>
      <name>Cabazitaxel</name>
      <description>The metabolism of Cabazitaxel can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06789</drugbank-id>
      <name>Hydroxyprogesterone caproate</name>
      <description>The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The metabolism of Ponatinib can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The metabolism of Ibrutinib can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09102</drugbank-id>
      <name>Daclatasvir</name>
      <description>The metabolism of Daclatasvir can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09297</drugbank-id>
      <name>Paritaprevir</name>
      <description>The metabolism of Paritaprevir can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11712</drugbank-id>
      <name>Tezacaftor</name>
      <description>The metabolism of Tezacaftor can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>The metabolism of Valbenazine can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12301</drugbank-id>
      <name>Doravirine</name>
      <description>The metabolism of Doravirine can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12483</drugbank-id>
      <name>Copanlisib</name>
      <description>The metabolism of Copanlisib can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14541</drugbank-id>
      <name>Hydrocortisone cypionate</name>
      <description>The metabolism of Hydrocortisone cypionate can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14542</drugbank-id>
      <name>Hydrocortisone phosphate</name>
      <description>The metabolism of Hydrocortisone phosphate can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15444</drugbank-id>
      <name>Elexacaftor</name>
      <description>The metabolism of Elexacaftor can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Simvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01098</drugbank-id>
      <name>Rosuvastatin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Rosuvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09237</drugbank-id>
      <name>Levamlodipine</name>
      <description>The metabolism of Levamlodipine can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11951</drugbank-id>
      <name>Lemborexant</name>
      <description>The metabolism of Lemborexant can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Amitriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nortriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The metabolism of Argatroban can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00877</drugbank-id>
      <name>Sirolimus</name>
      <description>The metabolism of Sirolimus can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The metabolism of Temsirolimus can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06730</drugbank-id>
      <name>Gestodene</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Gestodene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05804</drugbank-id>
      <name>Prasterone sulfate</name>
      <description>The metabolism of Prasterone sulfate can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06691</drugbank-id>
      <name>Mepyramine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Mepyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The metabolism of Eliglustat can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09049</drugbank-id>
      <name>Naloxegol</name>
      <description>The metabolism of Naloxegol can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01562</drugbank-id>
      <name>1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Levosalbutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00592</drugbank-id>
      <name>Piperazine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Piperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01429</drugbank-id>
      <name>Aprindine</name>
      <description>The metabolism of Aprindine can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06608</drugbank-id>
      <name>Tafenoquine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06735</drugbank-id>
      <name>Enclomiphene</name>
      <description>The metabolism of Enclomiphene can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The metabolism of Elagolix can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06506</drugbank-id>
      <name>Repinotan</name>
      <description>The metabolism of Repinotan can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09173</drugbank-id>
      <name>Butyrfentanyl</name>
      <description>The metabolism of Butyrfentanyl can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04889</drugbank-id>
      <name>Bicifadine</name>
      <description>The metabolism of Bicifadine can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Cevimeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Mexiletine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The metabolism of Ciclesonide can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Phenacetin can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The metabolism of Trabectedin can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The metabolism of Dasabuvir can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The metabolism of Ixazomib can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11718</drugbank-id>
      <name>Encorafenib</name>
      <description>The metabolism of Encorafenib can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>The metabolism of Ipecac can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Protriptyline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Amoxapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Trimipramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Doxepin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The metabolism of Opipramol can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The metabolism of Sotalol can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The metabolism of Procainamide can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The metabolism of Flecainide can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Theophylline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Aripiprazole can be increased when combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>The serum concentration of Aripiprazole can be increased when it is combined with Givosiran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06119</drugbank-id>
      <name>Cenobamate</name>
      <description>The serum concentration of Aripiprazole can be decreased when it is combined with Cenobamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Trospium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00574</drugbank-id>
      <name>Fenfluramine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Fenfluramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00613</drugbank-id>
      <name>Amodiaquine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Amodiaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00792</drugbank-id>
      <name>Tripelennamine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Tripelennamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Atorvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorpheniramine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Chlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Proguanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01191</drugbank-id>
      <name>Dexfenfluramine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Dexfenfluramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04938</drugbank-id>
      <name>Ospemifene</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Ospemifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06217</drugbank-id>
      <name>Vernakalant</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Vernakalant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06727</drugbank-id>
      <name>Sparteine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Sparteine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11638</drugbank-id>
      <name>Artenimol</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Artenimol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11994</drugbank-id>
      <name>Diacerein</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Diacerein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Niacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01096</drugbank-id>
      <name>Oxamniquine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Oxamniquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14635</drugbank-id>
      <name>Curcumin sulfate</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Curcumin sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Aripiprazole can be decreased when combined with Nevirapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00445</drugbank-id>
      <name>Epirubicin</name>
      <description>The risk or severity of QTc prolongation can be increased when Epirubicin is combined with Aripiprazole.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.21</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-4.8</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>7.77e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>aripiprazole</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>448.385</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>447.148032537</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C23H27Cl2N3O2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>CEUORZQYGODEFX-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>44.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>124.34</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>49.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>7</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>13.51</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>7.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>0.00001%</value>
      <source>https://medsafe.govt.nz/profs/Datasheet/a/Abilifytab.pdf</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>137-140</value>
      <source>http://www.chemspider.com/Chemical-Structure.54790.html</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>7.6</value>
      <source>https://medsafe.govt.nz/profs/Datasheet/a/Abilifytab.pdf</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>20435</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>31236</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>60795</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505745</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C12564</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D01164</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>54790</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50130293</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA10026</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>9SC</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP000076</identifier>
    </external-identifier>
    <external-identifier>
      <resource>IUPHAR</resource>
      <identifier>34</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Guide to Pharmacology</resource>
      <identifier>34</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Aripiprazole</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1112</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic/abilify.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/aripiprazole.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01238</drugbank-id>
        <name>Aripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02462</drugbank-id>
        <name>Aripiprazole unnamed metabolite 5</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01238</drugbank-id>
        <name>Aripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02463</drugbank-id>
        <name>Aripiprazole unnamed metabolite 6</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01238</drugbank-id>
        <name>Aripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02464</drugbank-id>
        <name>Aripiprazole unnamed metabolite 7</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01238</drugbank-id>
        <name>Aripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01611</drugbank-id>
        <name>dehydro-aripiprazole</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01238</drugbank-id>
        <name>Aripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01612</drugbank-id>
        <name>4-Hydroxyaripiprazole</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002363</drugbank-id>
          <name>Cytochrome P450 2D6</name>
          <uniprot-id>P10635</uniprot-id>
        </enzyme>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01238</drugbank-id>
        <name>Aripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01613</drugbank-id>
        <name>2,3-dichlorophenylpiperazine</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB01238</drugbank-id>
        <name>Aripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET01614</drugbank-id>
        <name>4-[(2-oxo-3,4- dihydro-1H-quinolin-7-yl)oxy]butanal</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002638</drugbank-id>
          <name>Cytochrome P450 3A4</name>
          <uniprot-id>P08684</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET01611</drugbank-id>
        <name>dehydro-aripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02455</drugbank-id>
        <name>Dehydro-aripiprazole unnamed glutathione conjugate metabolite 1</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET01611</drugbank-id>
        <name>dehydro-aripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02456</drugbank-id>
        <name>Dehydro-aripiprazole unnamed epoxide metabolite</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET01612</drugbank-id>
        <name>4-Hydroxyaripiprazole</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02458</drugbank-id>
        <name>Aripiprazole unnamed metabolite 1</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>2</sequence>
      <left-element>
        <drugbank-id>DBMET02464</drugbank-id>
        <name>Aripiprazole unnamed metabolite 7</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02465</drugbank-id>
        <name>Aripiprazole unnamed metabolite 8</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DBMET02456</drugbank-id>
        <name>Dehydro-aripiprazole unnamed epoxide metabolite</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02457</drugbank-id>
        <name>Dehydro-aripiprazole unnamed glutathione conjugate metabolite 2</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DBMET02458</drugbank-id>
        <name>Aripiprazole unnamed metabolite 1</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02459</drugbank-id>
        <name>Aripiprazole unnamed metabolite 2</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DBMET02458</drugbank-id>
        <name>Aripiprazole unnamed metabolite 1</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02460</drugbank-id>
        <name>Aripiprazole unnamed metabolite 3</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>3</sequence>
      <left-element>
        <drugbank-id>DBMET02465</drugbank-id>
        <name>Aripiprazole unnamed metabolite 8</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02466</drugbank-id>
        <name>Aripiprazole unnamed metabolite 9</name>
      </right-element>
      <enzymes/>
    </reaction>
    <reaction>
      <sequence>4</sequence>
      <left-element>
        <drugbank-id>DBMET02460</drugbank-id>
        <name>Aripiprazole unnamed metabolite 3</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02461</drugbank-id>
        <name>Aripiprazole unnamed metabolite 4</name>
      </right-element>
      <enzymes/>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000291</id>
      <name>5-hydroxytryptamine receptor 1A</name>
      <organism>Humans</organism>
      <actions>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A11181</ref-id>
            <pubmed-id>12063084</pubmed-id>
            <citation>Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002 Apr 26;441(3):137-40.</citation>
          </article>
          <article>
            <ref-id>A11182</ref-id>
            <pubmed-id>14647959</pubmed-id>
            <citation>Marona-Lewicka D, Nichols DE: Aripiprazole (OPC-14597) fully substitutes for the 5-HT1A receptor agonist LY293284 in the drug discrimination assay in rats. Psychopharmacology (Berl). 2004 Apr;172(4):415-21. Epub 2003 Nov 28.</citation>
          </article>
          <article>
            <ref-id>A11183</ref-id>
            <pubmed-id>14709325</pubmed-id>
            <citation>Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004 Jan 1;483(1):45-53.</citation>
          </article>
          <article>
            <ref-id>A11184</ref-id>
            <pubmed-id>15257633</pubmed-id>
            <citation>Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.</citation>
          </article>
          <article>
            <ref-id>A11185</ref-id>
            <pubmed-id>15862515</pubmed-id>
            <citation>Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A: Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res. 2005 May 10;1043(1-2):32-41.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08908" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 1A</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling inhibits adenylate cyclase activity and activates a phosphatidylinositol-calcium second messenger system that regulates the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of 5-hydroxytryptamine release and in the regulation of dopamine and 5-hydroxytryptamine metabolism. Plays a role in the regulation of dopamine and 5-hydroxytryptamine levels in the brain, and thereby affects neural activity, mood and behavior. Plays a role in the response to anxiogenic stimuli.</specific-function>
        <gene-name>HTR1A</gene-name>
        <locus>5q11.2-q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>37-62
74-98
111-132
153-178
192-217
346-367
379-403</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.05</theoretical-pi>
        <molecular-weight>46106.335</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5286</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR1A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M28269</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189928</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08908</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT1A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-1A</synonym>
          <synonym>ADRB2RL1</synonym>
          <synonym>ADRBRL1</synonym>
          <synonym>G-21</synonym>
          <synonym>Serotonin receptor 1A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0018934|5-hydroxytryptamine receptor 1A
MDVLSPGQGNNTTSPPAPFETGGNTTGISDVTVSYQVITSLLLGTLIFCAVLGNACVVAA
IALERSLQNVANYLIGSLAVTDLMVSVLVLPMAALYQVLNKWTLGQVTCDLFIALDVLCC
TSSILHLCAIALDRYWAITDPIDYVNKRTPRRAAALISLTWLIGFLISIPPMLGWRTPED
RSDPDACTISKDHGYTIYSTFGAFYIPLLLMLVLYGRIFRAARFRIRKTVKKVEKTGADT
RHGASPAPQPKKSVNGESGSRNWRLGVESKAGGALCANGAVRQGDDGAALEVIEVHRVGN
SKEHLPLPSEAGPTPCAPASFERKNERNAEAKRKMALARERKTVKTLGIIMGTFILCWLP
FFIVALVLPFCESSCHMPTLLGAIINWLGYSNSLLNPVIYAYFNKDFQNAFKKIIKCKFC
RQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018935|5-hydroxytryptamine receptor 1A (HTR1A)
ATGGATGTGCTCAGCCCTGGTCAGGGCAACAACACCACATCACCACCGGCTCCCTTTGAG
ACCGGCGGCAACACTACTGGTATCTCCGACGTGACCGTCAGCTACCAAGTGATCACCTCT
CTGCTGCTGGGCACGCTCATCTTCTGCGCGGTGCTGGGCAATGCGTGCGTGGTGGCTGCC
ATCGCCTTGGAGCGCTCCCTGCAGAACGTGGCCAATTATCTTATTGGCTCTTTGGCGGTC
ACCGACCTCATGGTGTCGGTGTTGGTGCTGCCCATGGCCGCGCTGTATCAGGTGCTCAAC
AAGTGGACACTGGGCCAGGTAACCTGCGACCTGTTCATCGCCCTCGACGTGCTGTGCTGC
ACCTCATCCATCTTGCACCTGTGCGCCATCGCGCTGGACAGGTACTGGGCCATCACGGAC
CCCATCGACTACGTGAACAAGAGGACGCCCCGGCGCGCCGCTGCGCTCATCTCGCTCACT
TGGCTTATTGGCTTCCTCATCTCTATCCCGCCCATGCTGGGCTGGCGCACCCCGGAAGAC
CGCTCGGACCCCGACGCATGCACCATTAGCAAGGATCATGGCTACACTATCTATTCCACC
TTTGGAGCTTTCTACATCCCGCTGCTGCTCATGCTGGTTCTCTATGGGCGCATATTCCGA
GCTGCGCGCTTCCGCATCCGCAAGACGGTCAAAAAGGTGGAGAAGACCGGAGCGGACACC
CGCCATGGAGCATCTCCCGCCCCGCAGCCCAAGAAGAGTGTGAATGGAGAGTCGGGGAGC
AGGAACTGGAGGCTGGGCGTGGAGAGCAAGGCTGGGGGTGCTCTGTGCGCCAATGGCGCG
GTGAGGCAAGGTGACGATGGCGCCGCCCTGGAGGTGATCGAGGTGCACCGAGTGGGCAAC
TCCAAAGAGCACTTGCCTCTGCCCAGCGAGGCTGGTCCTACCCCTTGTGCCCCCGCCTCT
TTCGAGAGGAAAAATGAGCGCAACGCCGAGGCGAAGCGCAAGATGGCCCTGGCCCGAGAG
AGGAAGACAGTGAAGACGCTGGGCATCATCATGGGCACCTTCATCCTCTGCTGGCTGCCC
TTCTTCATCGTGGCTCTTGTTCTGCCCTTCTGCGAGAGCAGCTGCCACATGCCCACCCTG
TTGGGCGCCATAATCAATTGGCTGGGCTACTCCAACTCTCTGCTTAACCCCGTCATTTAC
GCATACTTCAACAAGGACTTTCAAAACGCGTTTAAGAAGATCATTAAGTGTAAGTTCTGC
CGCCAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exploration behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of serotonin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0000756</id>
      <name>Dopamine D2 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A6573</ref-id>
            <pubmed-id>16366516</pubmed-id>
            <citation>Hirose T, Kikuchi T: Aripiprazole, a novel antipsychotic agent: dopamine D2 receptor partial agonist. J Med Invest. 2005 Nov;52 Suppl:284-90.</citation>
          </article>
          <article>
            <ref-id>A6574</ref-id>
            <pubmed-id>9083792</pubmed-id>
            <citation>Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, Misu Y, Nakata Y: Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol. 1997 Feb 19;321(1):105-11.</citation>
          </article>
          <article>
            <ref-id>A6575</ref-id>
            <pubmed-id>16925992</pubmed-id>
            <citation>Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C, Hill M, Rourke C, Newson M, Jones DN, Forbes IT, Gribble A: Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol. 2006 Sep 28;546(1-3):88-94. Epub 2006 Jul 21.</citation>
          </article>
          <article>
            <ref-id>A6576</ref-id>
            <pubmed-id>16981227</pubmed-id>
            <citation>Kim E, Yu KS, Cho JY, Shin YW, Yoo SY, Kim YY, Jang IJ, Shin SG, Kwon JS: Effects of DRD2 and CYP2D6 genotypes on delta EEG power response to aripiprazole in healthy male volunteers: a preliminary study. Hum Psychopharmacol. 2006 Dec;21(8):519-28.</citation>
          </article>
          <article>
            <ref-id>A6577</ref-id>
            <pubmed-id>17501690</pubmed-id>
            <citation>Wood M, Reavill C: Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007 Jun;16(6):771-5.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P14416" source="Swiss-Prot">
        <name>D(2) dopamine receptor</name>
        <general-function>Potassium channel regulator activity</general-function>
        <specific-function>Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.</specific-function>
        <gene-name>DRD2</gene-name>
        <locus>11q23</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>38-60
71-93
109-130
152-172
189-213
374-395
410-431</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.85</theoretical-pi>
        <molecular-weight>50618.91</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3023</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DRD2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M30625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181432</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>215</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>215</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P14416</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DRD2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Dopamine D2 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001508|D(2) dopamine receptor
MDPLNLSWYDDDLERQNWSRPFNGSDGKADRPHYNYYATLLTLLIAVIVFGNVLVCMAVS
REKALQTTTNYLIVSLAVADLLVATLVMPWVVYLEVVGEWKFSRIHCDIFVTLDVMMCTA
SILNLCAISIDRYTAVAMPMLYNTRYSSKRRVTVMISIVWVLSFTISCPLLFGLNNADQN
ECIIANPAFVVYSSIVSFYVPFIVTLLVYIKIYIVLRRRRKRVNTKRSSRAFRAHLRAPL
KGNCTHPEDMKLCTVIMKSNGSFPVNRRRVEAARRAQELEMEMLSSTSPPERTRYSPIPP
SHHQLTLPDPSHHGLHSTPDSPAKPEKNGHAKDHPKIAKIFEIQTMPNGKTRTSLKTMSR
RKLSQQKEKKATQMLAIVLGVFIICWLPFFITHILNIHCDCNIPPVLYSAFTWLGYVNSA
VNPIIYTTFNIEFRKAFLKILHC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021274|D(2) dopamine receptor (DRD2)
ATGGATCCACTGAATCTGTCCTGGTATGATGATGATCTGGAGAGGCAGAACTGGAGCCGG
CCCTTCAACGGGTCAGACGGGAAGGCGGACAGACCCCACTACAACTACTATGCCACACTG
CTCACCCTGCTCATCGCTGTCATCGTCTTCGGCAACGTGCTGGTGTGCATGGCTGTGTCC
CGCGAGAAGGCGCTGCAGACCACCACCAACTACCTGATCGTCAGCCTCGCAGTGGCCGAC
CTCCTCGTCGCCACACTGGTCATGCCCTGGGTTGTCTACCTGGAGGTGGTAGGTGAGTGG
AAATTCAGCAGGATTCACTGTGACATCTTCGTCACTCTGGACGTCATGATGTGCACGGCG
AGCATCCTGAACTTGTGTGCCATCAGCATCGACAGGTACACAGCTGTGGCCATGCCCATG
CTGTACAATACGCGCTACAGCTCCAAGCGCCGGGTCACCGTCATGATCTCCATCGTCTGG
GTCCTGTCCTTCACCATCTCCTGCCCACTCCTCTTCGGACTCAATAACGCAGACCAGAAC
GAGTGCATCATTGCCAACCCGGCCTTCGTGGTCTACTCCTCCATCGTCTCCTTCTACGTG
CCCTTCATTGTCACCCTGCTGGTCTACATCAAGATCTACATTGTCCTCCGCAGACGCCGC
AAGCGAGTCAACACCAAACGCAGCAGCCGAGCTTTCAGGGCCCACCTGAGGGCTCCACTA
AAGGGCAACTGTACTCACCCCGAGGACATGAAACTCTGCACCGTTATCATGAAGTCTAAT
GGGAGTTTCCCAGTGAACAGGCGGAGAGTGGAGGCTGCCCGGCGAGCCCAGGAGCTGGAG
ATGGAGATGCTCTCCAGCACCAGCCCACCCGAGAGGACCCGGTACAGCCCCATCCCACCC
AGCCACCACCAGCTGACTCTCCCCGACCCGTCCCACCATGGTCTCCACAGCACTCCCGAC
AGCCCCGCCAAACCAGAGAAGAATGGGCATGCCAAAGACCACCCCAAGATTGCCAAGATC
TTTGAGATCCAGACCATGCCCAATGGCAAAACCCGGACCTCCCTCAAGACCATGAGCCGT
AGGAAGCTCTCCCAGCAGAAGGAGAAGAAAGCCACTCAGATGCTCGCCATTGTTCTCGGC
GTGTTCATCATCTGCTGGCTGCCCTTCTTCATCACACACATCCTGAACATACACTGTGAC
TGCAACATCCCGCCTGTCCTGTACAGCGCCTTCACGTGGCTGGGCTATGTCAACAGCGCC
GTGAACCCCATCATCTACACCACCTTCAACATTGAGTTCCGCAAGGCCTTCCTGAAGATC
CTCCACTGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>acrosomal vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ciliary membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nonmotile primary cilium</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sperm flagellum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>potassium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenohypophysis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult walking behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>associative learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>auditory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>branching morphogenesis of a nerve</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebral cortex GABAergic interneuron migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>grooming behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-term memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of circadian sleep/wake cycle, sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuron-neuron synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>orbitofrontal cortex development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peristalsis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pigmentation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokinesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of G-protein coupled receptor protein signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glial cell-derived neurotrophic factor secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of growth hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of long-term synaptic potentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuroblast proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of renal sodium excretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of urine volume</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cAMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart rate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion involved in locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of long-term neuronal synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of phosphoprotein phosphatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synapse structural plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to axon injury</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to inactivity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to iron ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to light stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of smell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>striatum development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synapse assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>temperature homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Wnt signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000451</id>
      <name>5-hydroxytryptamine receptor 2A</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A11186</ref-id>
            <pubmed-id>14642974</pubmed-id>
            <citation>Meltzer HY, Li Z, Kaneda Y, Ichikawa J: Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72.</citation>
          </article>
          <article>
            <ref-id>A10334</ref-id>
            <pubmed-id>17242925</pubmed-id>
            <citation>Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25.</citation>
          </article>
          <article>
            <ref-id>A11187</ref-id>
            <pubmed-id>17265076</pubmed-id>
            <citation>Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F: In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl). 2007 Apr;191(3):745-58. Epub 2007 Jan 30.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P28223" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 2A</name>
        <general-function>Virus receptor activity</general-function>
        <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates phospholipase C and a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and promotes the release of Ca(2+) ions from intracellular stores. Affects neural activity, perception, cognition and mood. Plays a role in the regulation of behavior, including responses to anxiogenic situations and psychoactive substances. Plays a role in intestinal smooth muscle contraction, and may play a role in arterial vasoconstriction.(Microbial infection) Acts as a receptor for human JC polyomavirus/JCPyV.</specific-function>
        <gene-name>HTR2A</gene-name>
        <locus>13q14-q21</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>76-99
111-132
149-171
192-215
234-254
325-346
363-384</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.72</theoretical-pi>
        <molecular-weight>52602.58</molecular-weight>
        <chromosome-location>13</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5293</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR2A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>S42168</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>36431</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P28223</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT2A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-2</synonym>
          <synonym>HTR2</synonym>
          <synonym>Serotonin receptor 2A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000899|5-hydroxytryptamine receptor 2A
MDILCEENTSLSSTTNSLMQLNDDTRLYSNDFNSGEANTSDAFNWTVDSENRTNLSCEGC
LSPSCLSLLHLQEKNWSALLTAVVIILTIAGNILVIMAVSLEKKLQNATNYFLMSLAIAD
MLLGFLVMPVSMLTILYGYRWPLPSKLCAVWIYLDVLFSTASIMHLCAISLDRYVAIQNP
IHHSRFNSRTKAFLKIIAVWTISVGISMPIPVFGLQDDSKVFKEGSCLLADDNFVLIGSF
VSFFIPLTIMVITYFLTIKSLQKEATLCVSDLGTRAKLASFSFLPQSSLSSEKLFQRSIH
REPGSYTGRRTMQSISNEQKACKVLGIVFFLFVVMWCPFFITNIMAVICKESCNEDVIGA
LLNVFVWIGYLSSAVNPLVYTLFNKTYRSAFSRYIQCQYKENKKPLQLILVNTIPALAYK
SSQLQMGQKKNSKQDAKTTDNDCSMVALGKQHSEEASKDNSDGVNEKVSCV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020465|5-hydroxytryptamine receptor 2A (HTR2A)
ATGGATATTCTTTGTGAAGAAAATACTTCTTTGAGCTCAACTACGAACTCCCTAATGCAA
TTAAATGATGACACCAGGCTCTACAGTAATGACTTTAACTCCGGAGAAGCTAACACTTCT
GATGCATTTAACTGGACAGTCGACTCTGAAAATCGAACCAACCTTTCCTGTGAAGGGTGC
CTCTCACCGTCGTGTCTCTCCTTACTTCATCTCCAGGAAAAAAACTGGTCTGCTTTACTG
ACAGCCGTAGTGATTATTCTAACTATTGCTGGAAACATACTCGTCATCATGGCAGTGTCC
CTAGAGAAAAAGCTGCAGAATGCCACCAACTATTTCCTGATGTCACTTGCCATAGCTGAT
ATGCTGCTGGGTTTCCTTGTCATGCCCGTGTCCATGTTAACCATCCTGTATGGGTACCGG
TGGCCTCTGCCGAGCAAGCTTTGTGCAGTCTGGATTTACCTGGACGTGCTCTTCTCCACG
GCCTCCATCATGCACCTCTGCGCCATCTCGCTGGACCGCTACGTCGCCATCCAGAATCCC
ATCCACCACAGCCGCTTCAACTCCAGAACTAAGGCATTTCTGAAAATCATTGCTGTTTGG
ACCATATCAGTAGGTATATCCATGCCAATACCAGTCTTTGGGCTACAGGACGATTCGAAG
GTCTTTAAGGAGGGGAGTTGCTTACTCGCCGATGATAACTTTGTCCTGATCGGCTCTTTT
GTGTCATTTTTCATTCCCTTAACCATCATGGTGATCACCTACTTTCTAACTATCAAGTCA
CTCCAGAAAGAAGCTACTTTGTGTGTAAGTGATCTTGGCACACGGGCCAAATTAGCTTCT
TTCAGCTTCCTCCCTCAGAGTTCTTTGTCTTCAGAAAAGCTCTTCCAGCGGTCGATCCAT
AGGGAGCCAGGGTCCTACACAGGCAGGAGGACTATGCAGTCCATCAGCAATGAGCAAAAG
GCATGCAAGGTGCTGGGCATCGTCTTCTTCCTGTTTGTGGTGATGTGGTGCCCTTTCTTC
ATCACAAACATCATGGCCGTCATCTGCAAAGAGTCCTGCAATGAGGATGTCATTGGGGCC
CTGCTCAATGTGTTTGTTTGGATCGGTTATCTCTCTTCAGCAGTCAACCCACTAGTCTAC
ACACTGTTCAACAAGACCTATAGGTCAGCCTTTTCACGGTATATTCAGTGTCAGTACAAG
GAAAACAAAAAACCATTGCAGTTAATTTTAGTGAACACAATACCGGCTTTGGCCTACAAG
TCTAGCCAACTTCAAATGGGACAAAAAAAGAATTCAAAGCAAGATGCCAAGACAACAGAT
AATGACTGCTCAATGGTTGCTCTAGGAAAGCAGCATTCTGAAGAGGCTTCTAAAGACAAT
AGCGACGGAGTGAATGAAAAGGTGAGCTGTGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell body fiber</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic membrane-bounded vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic shaft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>virus receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>artery smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of mechanical stimulus involved in sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of temperature stimulus involved in sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glycolytic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-tyrosine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphatidylinositol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization to cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>temperature homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>urinary bladder smooth muscle contraction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0000501</id>
      <name>Alpha-1A adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P35348" source="Swiss-Prot">
        <name>Alpha-1A adrenergic receptor</name>
        <general-function>Protein heterodimerization activity</general-function>
        <specific-function>This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.</specific-function>
        <gene-name>ADRA1A</gene-name>
        <locus>8p21-p11.2</locus>
        <cellular-location>Nucleus membrane</cellular-location>
        <transmembrane-regions>28-51
65-88
100-122
144-167
182-205
274-297
306-329</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.23</theoretical-pi>
        <molecular-weight>51486.005</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:277</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA1A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D25235</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>433201</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>22</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>22</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35348</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA1A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA1C</synonym>
          <synonym>Alpha-1A adrenoceptor</synonym>
          <synonym>Alpha-1A adrenoreceptor</synonym>
          <synonym>Alpha-1C adrenergic receptor</synonym>
          <synonym>Alpha-adrenergic receptor 1c</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001000|Alpha-1A adrenergic receptor
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSV
THYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCII
SIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINE
EPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKN
APAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPD
FKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTL
HPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCT
TARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010352|Alpha-1A adrenergic receptor (ADRA1A)
ATGGTGTTTCTCTCGGGAAATGCTTCCGACAGCTCCAACTGCACCCAACCGCCGGCACCG
GTGAACATTTCCAAGGCCATTCTGCTCGGGGTGATCTTGGGGGGCCTCATTCTTTTCGGG
GTGCTGGGTAACATCCTAGTGATCCTCTCCGTAGCCTGTCACCGACACCTGCACTCAGTC
ACGCACTACTACATCGTCAACCTGGCGGTGGCCGACCTCCTGCTCACCTCCACGGTGCTG
CCCTTCTCCGCCATCTTCGAGGTCCTAGGCTACTGGGCCTTCGGCAGGGTCTTCTGCAAC
ATCTGGGCGGCAGTGGATGTGCTGTGCTGCACCGCGTCCATCATGGGCCTCTGCATCATC
TCCATCGACCGCTACATCGGCGTGAGCTACCCGCTGCGCTACCCAACCATCGTCACCCAG
AGGAGGGGTCTCATGGCTCTGCTCTGCGTCTGGGCACTCTCCCTGGTCATATCCATTGGA
CCCCTGTTCGGCTGGAGGCAGCCGGCCCCCGAGGACGAGACCATCTGCCAGATCAACGAG
GAGCCGGGCTACGTGCTCTTCTCAGCGCTGGGCTCCTTCTACCTGCCTCTGGCCATCATC
CTGGTCATGTACTGCCGCGTCTACGTGGTGGCCAAGAGGGAGAGCCGGGGCCTCAAGTCT
GGCCTCAAGACCGACAAGTCGGACTCGGAGCAAGTGACGCTCCGCATCCATCGGAAAAAC
GCCCCGGCAGGAGGCAGCGGGATGGCCAGCGCCAAGACCAAGACGCACTTCTCAGTGAGG
CTCCTCAAGTTCTCCCGGGAGAAGAAAGCGGCCAAAACGCTGGGCATCGTGGTCGGCTGC
TTCGTCCTCTGCTGGCTGCCTTTTTTCTTAGTCATGCCCATTGGGTCTTTCTTCCCTGAT
TTCAAGCCCTCTGAAACAGTTTTTAAAATAGTATTTTGGCTCGGATATCTAAACAGCTGC
ATCAACCCCATCATATACCCATGCTCCAGCCAAGAGTTCAAAAAGGCCTTTCAGAATGTC
TTGAGAATCCAGTGTCTCTGCAGAAAGCAGTCTTCCAAACATGCCCTGGGCTACACCCTG
CACCCGCCCAGCCAGGCCGTGGAAGGGCAACACAAGGACATGGTGCGCATCCCCGTGGGA
TCAAGAGAGACCTTCTACAGGATCTCCAAGACGGATGGCGTTTGTGAATGGAAATTTTTC
TCTTCCATGCCCCGTGGATCTGCCAGGATTACAGTGTCCAAAGACCAATCCTCCTGTACC
ACAGCCCGGGTGAGAAGTAAAAGCTTTTTGCAGGTCTGCTGCTGTGTAGGGCCCTCAACC
CCCAGCCTTGACAAGAACCATCAAGTTCCAACCATTAAGGTCCACACCATCTCCCTCAGT
GAGAACGGGGAGGAAGTCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha1-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of Rho protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein kinase C signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0000575</id>
      <name>Alpha-1B adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P35368" source="Swiss-Prot">
        <name>Alpha-1B adrenergic receptor</name>
        <general-function>Protein heterodimerization activity</general-function>
        <specific-function>This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.</specific-function>
        <gene-name>ADRA1B</gene-name>
        <locus>5q23-q32</locus>
        <cellular-location>Nucleus membrane</cellular-location>
        <transmembrane-regions>46-70
84-105
116-141
162-184
202-224
296-319
327-351</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.79</theoretical-pi>
        <molecular-weight>56835.375</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:278</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA1B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M99589</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>23</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>23</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35368</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA1B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Alpha-1B adrenoceptor</synonym>
          <synonym>Alpha-1B adrenoreceptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010399|Alpha-1B adrenergic receptor
MNPDLDTGHNTSAPAHWGELKNANFTGPNQTSSNSTLPQLDITRAISVGLVLGAFILFAI
VGNILVILSVACNRHLRTPTNYFIVNLAMADLLLSFTVLPFSAALEVLGYWVLGRIFCDI
WAAVDVLCCTASILSLCAISIDRYIGVRYSLQYPTLVTRRKAILALLSVWVLSTVISIGP
LLGWKEPAPNDDKECGVTEEPFYALFSSLGSFYIPLAVILVMYCRVYIVAKRTTKNLEAG
VMKEMSNSKELTLRIHSKNFHEDTLSSTKAKGHNPRSSIAVKLFKFSREKKAAKTLGIVV
GMFILCWLPFFIALPLGSLFSTLKPPDAVFKVVFWLGYFNSCLNPIIYPCSSKEFKRAFV
RILGCQCRGRGRRRRRRRRRLGGCAYTYRPWTRGGSLERSQSRKDSLDDSGSCLSGSQRT
LPSASPSPGYLGRGAPPPVELCAFPEWKAPGALLSLPAPEPPGRRGRHDSGPLFTFKLLT
EPESPGTDGGASNGGCEAAADVANGQPGFKSNMPLAPGQF</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010400|Alpha-1B adrenergic receptor (ADRA1B)
ATGAATCCCGACCTGGACACCGGCCACAACACATCAGCACCTGCCCACTGGGGAGAGTTG
AAAAATGCCAACTTCACTGGCCCCAACCAGACCTCGAGCAACTCCACACTGCCCCAGCTG
GACATCACCAGGGCCATCTCTGTGGGCCTGGTGCTGGGCGCCTTCATCCTCTTTGCCATC
GTGGGCAACATCCTAGTCATCTTGTCTGTGGCCTGCAACCGGCACCTGCGGACGCCCACC
AACTACTTCATTGTCAACCTGGCCATGGCCGACCTGCTGTTGAGCTTCACCGTCCTGCCC
TTCTCAGCGGCCCTAGAGGTGCTCGGCTACTGGGTGCTGGGGCGGATCTTCTGTGACATC
TGGGCAGCCGTGGATGTCCTGTGCTGCACAGCGTCCATTCTGAGCCTGTGCGCCATCTCC
ATCGATCGCTACATCGGGGTGCGCTACTCTCTGCAGTATCCCACGCTGGTCACCCGGAGG
AAGGCCATCTTGGCGCTGCTCAGTGTCTGGGTCTTGTCCACCGTCATCTCCATCGGGCCT
CTCCTTGGGTGGAAGGAGCCGGCACCCAACGATGACAAGGAGTGCGGGGTCACCGAAGAA
CCCTTCTATGCCCTCTTCTCCTCTCTGGGCTCCTTCTACATCCCTCTGGCGGTCATTCTA
GTCATGTACTGCCGTGTCTATATAGTGGCCAAGAGAACCACCAAGAACCTAGAGGCAGGA
GTCATGAAGGAGATGTCCAACTCCAAGGAGCTGACCCTGAGGATCCATTCCAAGAACTTT
CACGAGGACACCCTTAGCAGTACCAAGGCCAAGGGCCACAACCCCAGGAGTTCCATAGCT
GTCAAACTTTTTAAGTTCTCCAGGGAAAAGAAAGCAGCTAAGACGTTGGGCATTGTGGTC
GGTATGTTCATCTTGTGCTGGCTACCCTTCTTCATCGCTCTACCGCTTGGCTCCTTGTTC
TCCACCCTGAAGCCCCCCGACGCCGTGTTCAAGGTGGTGTTCTGGCTGGGCTACTTCAAC
AGCTGCCTCAACCCCATCATCTACCCATGCTCCAGCAAGGAGTTCAAGCGCGCTTTCGTG
CGCATCCTCGGGTGCCAGTGCCGCGGCCGCGGCCGCCGCCGACGCCGCCGCCGCCGTCGC
CTGGGCGGCTGCGCCTACACCTACCGGCCGTGGACGCGCGGCGGCTCGCTGGAGCGCTCG
CAGTCGCGCAAGGACTCGCTGGACGACAGCGGCAGCTGCCTGAGCGGCAGCCAGCGGACC
CTGCCCTCGGCCTCGCCGAGCCCGGGCTACCTGGGCCGCGGCGCGCCACCGCCAGTCGAG
CTGTGCGCCTTCCCCGAGTGGAAGGCGCCCGGCGCCCTCCTGAGCCTGCCCGCGCCTGAG
CCCCCCGGCCGCCGCGGCCGCCACGACTCGGGCCCGCTCTTCACCTTCAAGCTCCTGACC
GAGCCCGAGAGCCCCGGGACCGACGGCGGCGCCAGCAACGGAGGCTGCGAGGCCGCGGCC
GACGTGGCCAACGGGCAGCCGGGCTTCAAAAGCAACATGCCCCTGGCGCCCGGGCAGTTT
TAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha1-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult heart development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood vessel remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>multicellular organismal development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glycogen catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organ growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of glycogen catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of heart rate by epinephrine-norepinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of the force of heart contraction by epinephrine-norepinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cardiac muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction of artery involved in baroreceptor response to lowering of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="6">
      <id>BE0000581</id>
      <name>Dopamine D3 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35462" source="Swiss-Prot">
        <name>D(3) dopamine receptor</name>
        <general-function>G-protein coupled amine receptor activity</general-function>
        <specific-function>Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.</specific-function>
        <gene-name>DRD3</gene-name>
        <locus>3q13.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>33-55
66-88
105-126
150-170
188-212
330-351
367-388</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.07</theoretical-pi>
        <molecular-weight>44224.335</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3024</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DRD3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U32499</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>927342</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>216</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>216</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35462</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DRD3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Dopamine D3 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001159|D(3) dopamine receptor
MASLSQLSSHLNYTCGAENSTGASQARPHAYYALSYCALILAIVFGNGLVCMAVLKERAL
QTTTNYLVVSLAVADLLVATLVMPWVVYLEVTGGVWNFSRICCDVFVTLDVMMCTASILN
LCAISIDRYTAVVMPVHYQHGTGQSSCRRVALMITAVWVLAFAVSCPLLFGFNTTGDPTV
CSISNPDFVIYSSVVSFYLPFGVTVLVYARIYVVLKQRRRKRILTRQNSQCNSVRPGFPQ
QTLSPDPAHLELKRYYSICQDTALGGPGFQERGGELKREEKTRNSLSPTIAPKLSLEVRK
LSNGRLSTSLKLGPLQPRGVPLREKKATQMVAIVLGAFIVCWLPFFLTHVLNTHCQTCHV
SPELYSATTWLGYVNSALNPVIYTTFNIEFRKAFLKILSC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021269|D(3) dopamine receptor (DRD3)
ATGGCATCTCTGAGCCAGCTGAGTGGCCACCTGAACTACACCTGTGGGGCAGAGAACTCC
ACAGGTGCCAGCCAGGCCCGCCCACATGCCTACTATGCCCTCTCCTACTGCGCGCTCATC
CTGGCCATCGTCTTCGGCAATGGCCTGGTGTGCATGGCTGTGCTGAAGGAGCGGGCCCTG
CAGACTACCACCAACTACTTAGTAGTGAGCCTGGCTGTGGCAGACTTGCTGGTGGCCACC
TTGGTGATGCCCTGGGTGGTATACCTGGAGGTGACAGGTGGAGTCTGGAATTTCAGCCGC
ATTTGCTGTGATGTTTTTGTCACCCTGGATGTCATGATGTGTACAGCCAGCATCCTTAAT
CTCTGTGCCATCAGCATAGACAGGTACACTGCAGTGGTCATGCCCGTTCACTACCAGCAT
GGCACGGGACAGAGCTCCTGTCGGCGCGTGGCCCTCATGATCACGGCCGTCTGGGTACTG
GCCTTTGCTGTGTCCTGCCCTCTTCTGTTTGGCTTTAATACCACAGGGGACCCCACTGTC
TGCTCCATCTCCAACCCTGATTTTGTCATCTACTCTTCAGTGGTGTCCTTCTACCTGCCC
TTTGGAGTGACTGTCCTTGTCTATGCCAGAATCTATGTGGTGCTGAAACAAAGGAGACGG
AAAAGGATCCTCACTCGACAGAACAGTCAGTGCAACAGTGTCAGGCCTGGCTTCCCCCAA
CAAACCCTCTCTCCTGACCCGGCACATCTGGAGCTGAAGCGTTACTACAGCATCTGCCAG
GACACTGCCTTGGGTGGACCAGGCTTCCAAGAAAGAGGAGGAGAGTTGAAAAGAGAGGAG
AAGACTCGGAATTCCCTGAGTCCCACCATAGCGCCCAAGCTCAGCTTAGAAGTTCGAAAA
CTCAGCAATGGCAGATTATCGACATCTTTGAAGCTGGGGCCCCTGCAACCTCGGGGAGTG
CCACTTCGGGAGAAGAAGGCAACCCAAATGGTGGCCATTGTGCTTGGGGCCTTCATTGTC
TGCTGGCTGCCCTTCTTCTTGACCCATGTTCTCAATACCCACTGCCAGACATGCCACGTG
TCCCCAGAGCTTTACAGTGCCACGACATGGCTGGGCTACGTGAATAGCGCCCTCAACCCT
GTGATCTATACCACCTTCAATATCGAGTTCCGGAAAGCCTTCCTCAAGATCCTGTCTTGC
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical part of cell</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endocytic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled amine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gastric emptying</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning or memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>musculoskeletal movement, spinal reflex action</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of oligodendrocyte differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase B signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sodium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokinesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of mitotic nuclear division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of renal sodium excretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood volume by renin-angiotensin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cAMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian sleep/wake cycle, sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion involved in locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="7">
      <id>BE0000659</id>
      <name>5-hydroxytryptamine receptor 1D</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P28221" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 1D</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Regulates the release of 5-hydroxytryptamine in the brain, and thereby affects neural activity. May also play a role in regulating the release of other neurotransmitters. May play a role in vasoconstriction.</specific-function>
        <gene-name>HTR1D</gene-name>
        <locus>1p36.3-p34.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>39-64
76-98
113-134
155-176
195-217
303-326
336-360</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.85</theoretical-pi>
        <molecular-weight>41906.38</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5289</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR1D</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M89955</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177772</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P28221</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT1D_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-1D</synonym>
          <synonym>5-HT-1D-alpha</synonym>
          <synonym>HTR1DA</synonym>
          <synonym>HTRL</synonym>
          <synonym>Serotonin 1D alpha receptor</synonym>
          <synonym>Serotonin receptor 1D</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010458|5-hydroxytryptamine receptor 1D
MSPLNQSAEGLPQEASNRSLNATETSEAWDPRTLQALKISLAVVLSVITLATVLSNAFVL
TTILLTRKLHTPANYLIGSLATTDLLVSILVMPISIAYTITHTWNFGQILCDIWLSSDIT
CCTASILHLCVIALDRYWAITDALEYSKRRTAGHAATMIAIVWAISICISIPPLFWRQAK
AQEEMSDCLVNTSQISYTIYSTCGAFYIPSVLLIILYGRIYRAARNRILNPPSLYGKRFT
TAHLITGSAGSSLCSLNSSLHEGHSHSAGSPLFFNHVKIKLADSALERKRISAARERKAT
KILGIILGAFIICWLPFFVVSLVLPICRDSCWIHPALFDFFTWLGYLNSLINPIIYTVFN
EEFRQAFQKIVPFRKAS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010459|5-hydroxytryptamine receptor 1D (HTR1D)
ATGTCCCCACTGAACCAGTCAGCAGAAGGCCTTCCCCAGGAGGCCTCCAACAGATCCCTG
AATGCCACAGAAACCTCAGAGGCTTGGGATCCCAGGACCCTCCAGGCGCTCAAGATCTCC
CTTGCCGTGGTCCTTTCCGTCATCACACTGGCCACAGTCCTCTCCAATGCCTTTGTACTC
ACCACCATCTTACTCACCAGGAAGCTCCACACCCCTGCCAACTACCTGATTGGCTCCCTG
GCCACCACCGACCTCTTGGTTTCCATCTTGGTAATGCCCATCAGCATCGCCTATACCATC
ACCCACACCTGGAACTTTGGCCAAATCTTGTGTGACATCTGGCTGTCCTCTGACATCACG
TGCTGCACAGCCTCCATCCTGCATCTCTGTGTCATTGCTCTGGACAGGTACTGGGCAATC
ACAGATGCCCTGGAATACAGTAAACGCAGGACGGCTGGCCACGCGGCCACCATGATCGCC
ATTGTCTGGGCCATCTCCATCTGCATCTCCATCCCCCCGCTCTTCTGGCGGCAGGCCAAG
GCCCAGGAGGAGATGTCGGACTGTCTGGTGAACACCTCTCAGATCTCCTACACCATCTAC
TCCACCTGTGGGGCCTTCTACATTCCCTCGGTGTTGCTCATCATCCTATATGGCCGGATC
TACCGGGCTGCCCGGAACCGCATCCTGAATCCACCCTCACTCTATGGGAAGCGCTTCACC
ACGGCCCACCTCATCACAGGCTCTGCCGGGTCCTCGCTCTGCTCGCTCAACTCCAGCCTC
CATGAGGGGCACTCGCACTCGGCTGGCTCCCCTCTCTTTTTCAACCACGTGAAAATCAAG
CTTGCTGACAGTGCCCTGGAACGCAAGAGGATTTCTGCTGCTCGAGAAAGGAAAGCCACT
AAAATCCTGGGCATCATTCTGGGGGCCTTTATCATCTGCTGGCTGCCCTTCTTCGTGGTG
TCTCTGGTCCTCCCCATCTGCCGGGACTCCTGCTGGATCCACCCGGCGCTCTTTGACTTC
TTCACCTGGCTAGGCTATTTAAACTCCCTCATCAATCCAATAATCTACACTGTGTTTAAT
GAAGAGTTTCGGCAAGCTTTTCAGAAAATTGTCCCTTTCCGGAAGGCCTCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestine smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="8">
      <id>BE0000650</id>
      <name>5-hydroxytryptamine receptor 7</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P34969" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 7</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.</specific-function>
        <gene-name>HTR7</gene-name>
        <locus>10q21-q24</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>84-104
118-138
158-178
202-222
237-257
326-346
368-388</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.97</theoretical-pi>
        <molecular-weight>53554.43</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5302</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U68487</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1857143</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>12</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>12</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P34969</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT7R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-7</synonym>
          <synonym>5-HT-X</synonym>
          <synonym>Serotonin receptor 7</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001296|5-hydroxytryptamine receptor 7
MMDVNSSGRPDLYGHLRSFLLPEVGRGLPDLSPDGGADPVAGSWAPHLLSEVTASPAPTW
DAPPDNASGCGEQINYGRVEKVVIGSILTLITLLTIAGNCLVVISVCFVKKLRQPSNYLI
VSLALADLSVAVAVMPFVSVTDLIGGKWIFGHFFCNVFIAMDVMCCTASIMTLCVISIDR
YLGITRPLTYPVRQNGKCMAKMILSVWLLSASITLPPLFGWAQNVNDDKVCLISQDFGYT
IYSTAVAFYIPMSVMLFMYYQIYKAARKSAAKHKFPGFPRVEPDSVIALNGIVKLQKEVE
ECANLSRLLKHERKNISIFKREQKAATTLGIIVGAFTVCWLPFFLLSTARPFICGTSCSC
IPLWVERTFLWLGYANSLINPFIYAFFNRDLRTTYRSLLQCQYRNINRKLSAAGMHEALK
LAERPERPEFVLRACTRRVLLRPEKRPPVSVWVLQSPDHHNWLADKMLTTVEKKVMIHD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010453|5-hydroxytryptamine receptor 7 (HTR7)
ATGATGGACGTTAACAGCAGCGGCCGCCCGGACCTCTACGGGCACCTCCGCTCTTTCCTT
CTGCCAGAAGTGGGGCGCGGGCTGCCCGACTTGAGCCCCGACGGTGGCGCCGACCCGGTC
GCGGGCTCCTGGGCGCCGCACCTGCTGAGCGAGGTGACAGCCAGCCCGGCGCCCACCTGG
GACGCGCCCCCGGACAATGCCTCCGGCTGTGGGGAACAGATCAACTACGGCAGAGTCGAG
AAAGTTGTGATCGGCTCCATCCTGACGCTCATCACGCTGCTGACGATCGCGGGCAACTGC
CTGGTGGTGATCTCCGTGTGCTTCGTCAAGAAGCTCCGCCAGCCCTCCAACTACCTGATC
GTGTCCCTGGCGCTGGCCGACCTCTCGGTGGCTGTGGCGGTCATGCCCTTCGTCAGCGTC
ACCGACCTCATCGGGGGCAAGTGGATCTTTGGACACTTTTTCTGTAATGTCTTCATCGCC
ATGGACGTCATGTGCTGCACGGCCTCGATCATGACCCTGTGCGTGATCAGCATTGACAGG
TACCTTGGGATCACAAGGCCCCTCACATACCCTGTGAGGCAGAATGGGAAATGCATGGCG
AAGATGATTCTCTCCGTCTGGCTTCTCTCCGCCTCCATCACCTTACCTCCACTCTTTGGA
TGGGCTCAGAATGTAAATGATGATAAGGTGTGCTTGATCAGCCAGGACTTTGGCTATACG
ATTTACTCTACCGCAGTGGCATTTTATATCCCCATGTCCGTCATGCTTTTCATGTACTAC
CAGATTTACAAGGCTGCCAGGAAGAGTGCTGCCAAACACAAGTTTCCTGGCTTCCCTCGA
GTGGAGCCAGACAGCGTCATCGCCCTGAATGGCATAGTGAAGCTCCAGAAGGAGGTGGAA
GAGTGTGCAAACCTTTCGAGACTCCTCAAGCATGAAAGGAAAAACATCTCCATCTTTAAG
CGAGAACAGAAAGCAGCCACCACCCTGGGGATCATCGTCGGGGCCTTTACCGTGTGCTGG
CTGCCATTTTTCCTCCTCTCGACAGCCAGACCCTTCATCTGTGGCACTTCCTGCAGCTGC
ATCCCACTGTGGGTGGAGAGGACATTTCTGTGGCTAGGCTATGCAAACTCTCTCATTAAC
CCTTTTATATATGCCTTCTTCAACCGGGACCTGAGGACCACCTATCGCAGCCTGCTCCAG
TGCCAGTACCGGAATATCAACCGGAAGCTCTCAGCTGCAGGCATGCATGAAGCCCTGAAG
CTTGCTGAGAGGCCAGAGAGACCTGAGTTTGTGCTACAAAATGCTGACTACTGTAGAAAA
AAAGGTCATGATTCATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood circulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="9">
      <id>BE0000289</id>
      <name>Alpha-2A adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P08913" source="Swiss-Prot">
        <name>Alpha-2A adrenergic receptor</name>
        <general-function>Thioesterase binding</general-function>
        <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline &gt; clonidine &gt; epinephrine &gt; norepinephrine &gt; phenylephrine &gt; dopamine &gt; p-synephrine &gt; p-tyramine &gt; serotonin = p-octopamine. For antagonists, the rank order is yohimbine &gt; phentolamine = mianserine &gt; chlorpromazine = spiperone = prazosin &gt; propanolol &gt; alprenolol = pindolol.</specific-function>
        <gene-name>ADRA2A</gene-name>
        <locus>10q24-q26</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>34-59
71-96
107-129
152-172
195-217
375-395
410-429</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.2</theoretical-pi>
        <molecular-weight>48956.275</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:281</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA2A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M23533</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178196</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>25</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>25</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08913</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA2A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA2R</synonym>
          <synonym>ADRAR</synonym>
          <synonym>Alpha-2 adrenergic receptor subtype C10</synonym>
          <synonym>Alpha-2A adrenoceptor</synonym>
          <synonym>Alpha-2A adrenoreceptor</synonym>
          <synonym>Alpha-2AAR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021255|Alpha-2A adrenergic receptor
MGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFT
SRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSS
IVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGG
PQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVA
APPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSD
HAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKAS
RWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSS
LNPVIYTIFNHDFRRAFKKILCRGDRKRIV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021256|Alpha-2A adrenergic receptor (ADRA2A)
ATGTTCCGCCAGGAGCAGCCGTTGGCCGAGGGCAGCTTTGCGCCCATGGGCTCCCTGCAG
CCGGACGCGGGCAACGCGAGCTGGAACGGGACCGAGGCGCCGGGGGGCGGCGCCCGGGCC
ACCCCTTACTCCCTGCAGGTGACGCTGACGCTGGTGTGCCTGGCCGGCCTGCTCATGCTG
CTCACCGTGTTCGGCAACGTGCTCGTCATCATCGCCGTGTTCACGAGCCGCGCGCTCAAG
GCGCCCCAAAACCTCTTCCTGGTGTCTCTGGCCTCGGCCGACATCCTGGTGGCCACGCTC
GTCATCCCTTTCTCGCTGGCCAACGAGGTCATGGGCTACTGGTACTTCGGCAAGGCTTGG
TGCGAGATCTACCTGGCGCTCGACGTGCTCTTCTGCACGTCGTCCATCGTGCACCTGTGC
GCCATCAGCCTGGACCGCTACTGGTCCATCACACAGGCCATCGAGTACAACCTGAAGCGC
ACGCCGCGCCGCATCAAGGCCATCATCATCACCGTGTGGGTCATCTCGGCCGTCATCTCC
TTCCCGCCGCTCATCTCCATCGAGAAGAAGGGCGGCGGCGGCGGCCCGCAGCCGGCCGAG
CCGCGCTGCGAGATCAACGACCAGAAGTGGTACGTCATCTCGTCGTGCATCGGCTCCTTC
TTCGCTCCCTGCCTCATCATGATCCTGGTCTACGTGCGCATCTACCAGATCGCCAAGCGT
CGCACCCGCGTGCCACCCAGCCGCCGGGGTCCGGACGCCGTCGCCGCGCCGCCGGGGGGC
ACCGAGCGCAGGCCCAACGGTCTGGGCCCCGAGCGCAGCGCGGGCCCGGGGGGCGCAGAG
GCCGAACCGCTGCCCACCCAGCTCAACGGCGCCCCTGGCGAGCCCGCGCCGGCCGGGCCG
CGCGACACCGACGCGCTGGACCTGGAGGAGAGCTCGTCTTCCGACCACGCCGAGCGGCCT
CCAGGGCCCCGCAGACCCGAGCGCGGTCCCCGGGGCAAAGGCAAGGCCCGAGCGAGCCAG
GTGAAGCCGGGCGACAGCCTGCCGCGGCGCGGGCCGGGGGCGACGGGGATCGGGACGCCG
GCTGCAGGGCCGGGGGAGGAGCGCGTCGGGGCTGCCAAGGCGTCGCGCTGGCGCGGGCGG
CAGAACCGCGAGAAGCGCTTCACGTTCGTGCTGGCCGTGGTCATCGGAGTGTTCGTGGTG
TGCTGGTTCCCCTTCTTCTTCACCTACACGCTCACGGCCGTCGGGTGCTCCGTGCCACGC
ACGCTCTTCAAATTCTTCTTCTGGTTCGGCTACTGCAACAGCTCGTTGAACCCGGTCATC
TACACCATCTTCAACCACGATTTCCGCCGCGCCTTCAAGAAGATCCTCTGTCGGGGGGAC
AGGAAGCGGATCGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-1B adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-2C adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha2-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heterotrimeric G-protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>thioesterase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>actin cytoskeleton organization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase B activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hormone stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>DNA replication</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestinal absorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>movement of cell or subcellular component</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion-dependent exocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion involved in cellular response to glucose stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of uterine smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epidermal growth factor-activated receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of membrane protein ectodomain proteolysis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasodilation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of wound healing</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Rho protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thermoception</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="10">
      <id>BE0000342</id>
      <name>Alpha-2C adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P18825" source="Swiss-Prot">
        <name>Alpha-2C adrenergic receptor</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.</specific-function>
        <gene-name>ADRA2C</gene-name>
        <locus>4p16</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>52-76
89-114
125-147
169-191
208-231
380-407
421-441</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.69</theoretical-pi>
        <molecular-weight>49521.585</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:283</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA2C</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03853</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178194</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>27</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>27</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P18825</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA2C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA2L2</synonym>
          <synonym>ADRA2RL2</synonym>
          <synonym>Alpha-2 adrenergic receptor subtype C4</synonym>
          <synonym>Alpha-2C adrenoceptor</synonym>
          <synonym>Alpha-2C adrenoreceptor</synonym>
          <synonym>Alpha-2CAR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000681|Alpha-2C adrenergic receptor
MASPALAAALAVAAAAGPNASGAGERGSGGVANASGASWGPPRGQYSAGAVAGLAAVVGF
LIVFTVVGNVLVVIAVLTSRALRAPQNLFLVSLASADILVATLVMPFSLANELMAYWYFG
QVWCGVYLALDVLFCTSSIVHLCAISLDRYWSVTQAVEYNLKRTPRRVKATIVAVWLISA
VISFPPLVSLYRQPDGAAYPQCGLNDETWYILSSCIGSFFAPCLIMGLVYARIYRVAKLR
TRTLSEKRAPVGPDGASPTTENGLGAAAGAGENGHCAPPPADVEPDESSAAAERRRRRGA
LRRGGRRRAGAEGGAGGADGQGAGPGAAESGALTASRSPGPGGRLSRASSRSVEFFLSRR
RRARSSVCRRKVAQAREKRFTFVLAVVMGVFVLCWFPFFFSYSLYGICREACQVPGPLFK
FFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILFRRRRRGFRQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010255|Alpha-2C adrenergic receptor (ADRA2C)
ATGGCGTCCCCGGCGCTGGCGGCGGCGCTGGCGGTGGCGGCAGCGGCGGGCCCCAATGCG
AGCGGCGCGGGCGAGAGGGGCAGCGGCGGGGTTGCCAATGCCTCGGGGGCTTCCTGGGGG
CCGCCGCGCGGCCAGTACTCGGCGGGCGCGGTGGCAGGGCTGGCTGCCGTGGTGGGCTTC
CTCATCGTCTTCACCGTGGTGGGCAACGTGCTGGTGGTGATCGCCGTGCTGACCAGCCGG
GCGCTGCGCGCGCCACAGAACCTCTTCCTGGTGTCGCTGGCCTCGGCCGACATCCTGGTG
GCCACGCTGGTCATGCCCTTCTCGTTGGCCAACGAGCTCATGGCCTACTGGTACTTCGGG
CAGGTGTGGTGCGGCGTGTACCTGGCGCTCGATGTGCTGTTTTGCACCTCGTCGATCGTG
CATCTGTGTGCCATCAGCCTGGACCGCTACTGGTCGGTGACGCAGGCCGTCGAGTACAAC
CTGAAGCGCACACCACGCCGCGTCAAGGCCACCATCGTGGCCGTGTGGCTCATCTCGGCC
GTCATCTCCTTCCCGCCGCTGGTCTCGCTCTACCGCCAGCCCGACGGCGCCGCCTACCCG
CAGTGCGGCCTCAACGACGAGACCTGGTACATCCTGTCCTCCTGCATCGGCTCCTTCTTC
GCGCCCTGCCTCATCATGGGCCTGGTCTACGCGCGCATCTACCGAGTGGCCAAGCTGCGC
ACGCGCACGCTCAGCGAGAAGCGCGCCCCCGTGGGCCCCGACGGTGCGTCCCCGACTACC
GAAAACGGGCTGGGCGCGGCGGCAGGCGCAGGCGAGAACGGGCACTGCGCGCCCCCGCCC
GCCGACGTGGAGCCGGACGAGAGCAGCGCAGCGGCCGAGAGGCGGCGGCGCCGGGGCGCG
TTGCGGCGGGGCGGGCGGCGGCGAGCGGGCGCGGAGGGGGGCGCGGGCGGTGCGGACGGG
CAGGGGGCGGGGCCGGGGGCGGCTGAGTCGGGGGCGCTGACCGCCTCCAGGTCCCCGGGG
CCCGGTGGCCGCCTGTCGCGCGCCAGCTCGCGCTCCGTCGAGTTCTTCCTGTCGCGCCGG
CGCCGGGCGCGCAGCAGCGTGTGCCGCCGCAAGGTGGCCCAGGCGCGCGAGAAGCGCTTC
ACCTTTGTGCTGGCTGTGGTCATGGGCGTGTTCGTGCTCTGCTGGTTCCCCTTCTTCTTC
AGCTACAGCCTGTACGGCATCTGCCGCGAGGCCTGCCAGGTGCCCGGCCCGCTCTTCAAG
TTCTTCTTCTGGATCGGCTACTGCAACAGCTCGCTCAACCCGGTCATCTACACGGTCTTC
AACCAGGATTTCCGGCGATCCTTTAAGCACATCCTCTTCCGACGGAGGAGAAGGGGCTTC
AGGCAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-2A adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha2-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase B activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of insulin secretion involved in cellular response to glucose stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of uterine smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="11">
      <id>BE0000442</id>
      <name>Histamine H1 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P35367" source="Swiss-Prot">
        <name>Histamine H1 receptor</name>
        <general-function>Histamine receptor activity</general-function>
        <specific-function>In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.</specific-function>
        <gene-name>HRH1</gene-name>
        <locus>3p25</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>30-52
63-83
102-123
144-164
190-210
417-438
451-470</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.58</theoretical-pi>
        <molecular-weight>55783.61</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5182</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HRH1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Z34897</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>510296</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>262</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>262</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35367</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HRH1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>H1R</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016092|Histamine H1 receptor
MSLPNSSCLLEDKMCEGNKTTMASPQLMPLVVVLSTICLVTVGLNLLVLYAVRSERKLHT
VGNLYIVSLSVADLIVGAVVMPMNILYLLMSKWSLGRPLCLFWLSMDYVASTASIFSVFI
LCIDRYRSVQQPLRYLKYRTKTRASATILGAWFLSFLWVIPILGWNHFMQQTSVRREDKC
ETDFYDVTWFKVMTAIINFYLPTLLMLWFYAKIYKAVRQHCQHRELINRSLPSFSEIKLR
PENPKGDAKKPGKESPWEVLKRKPKDAGGGSVLKSPSQTPKEMKSPVVFSQEDDREVDKL
YCFPLDIVHMQAAAEGSSRDYVAVNRSHGQLKTDEQGLNTHGASEISEDQMLGDSQSFSR
TDSDTTTETAPGKGKLRSGSNTGLDYIKFTWKRLRSHSRQYVSGLHMNRERKAAKQLGFI
MAAFILCWIPYFIFFMVIAFCKNCCNEHLHMFTIWLGYINSTLNPLIYPLCNENFKKTFK
RILHIRS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016093|Histamine H1 receptor (HRH1)
ATGAGCCTCCCCAATTCCTCCTGCCTCTTAGAAGACAAGATGTGTGAGGGCAACAAGACC
ACTATGGCCAGCCCCCAGCTGATGCCCCTGGTGGTGGTCCTGAGCACTATCTGCTTGGTC
ACAGTAGGGCTCAACCTGCTGGTGCTGTATGCCGTACGGAGTGAGCGGAAGCTCCACACT
GTGGGGAACCTGTACATCGTCAGCCTCTCGGTGGCGGACTTGATCGTGGGTGCCGTCGTC
ATGCCTATGAACATCCTCTACCTGCTCATGTCCAAGTGGTCACTGGGCCGTCCTCTCTGC
CTCTTTTGGCTTTCCATGGACTATGTGGCCAGCACAGCGTCCATTTTCAGTGTCTTCATC
CTGTGCATTGATCGCTACCGCTCTGTCCAGCAGCCCCTCAGGTACCTTAAGTATCGTACC
AAGACCCGAGCCTCGGCCACCATTCTGGGGGCCTGGTTTCTCTCTTTTCTGTGGGTTATT
CCCATTCTAGGCTGGAATCACTTCATGCAGCAGACCTCGGTGCGCCGAGAGGACAAGTGT
GAGACAGACTTCTATGATGTCACCTGGTTCAAGGTCATGACTGCCATCATCAACTTCTAC
CTGCCCACCTTGCTCATGCTCTGGTTCTATGCCAAGATCTACAAGGCCGTACGACAACAC
TGCCAGCACCGGGAGCTCATCAATAGGTCCCTCCCTTCCTTCTCAGAAATTAAGCTGAGG
CCAGAGAACCCCAAGGGGGATGCCAAGAAACCAGGGAAGGAGTCTCCCTGGGAGGTTCTG
AAAAGGAAGCCAAAAGATGCTGGTGGTGGATCTGTCTTGAAGTCACCATCCCAAACCCCC
AAGGAGATGAAATCCCCAGTTGTCTTCAGCCAAGAGGATGATAGAGAAGTAGACAAACTC
TACTGCTTTCCACTTGATATTGTGCACATGCAGGCTGCGGCAGAGGGGAGTAGCAGGGAC
TATGTAGCCGTCAACCGGAGCCATGGCCAGCTCAAGACAGATGAGCAGGGCCTGAACACA
CATGGGGCCAGCGAGATATCAGAGGATCAGATGTTAGGTGATAGCCAATCCTTCTCTCGA
ACGGACTCAGATACCACCACAGAGACAGCACCAGGCAAAGGCAAATTGAGGAGTGGGTCT
AACACAGGCCTGGATTACATCAAGTTTACTTGGAAGAGGCTCCGCTCGCATTCAAGACAG
TATGTATCTGGGTTGCACATGAACCGCGAAAGGAAGGCCGCCAAACAGTTGGGTTTTATC
ATGGCAGCCTTCATCCTCTGCTGGATCCCTTATTTCATCTTCTTCATGGTCATTGCCTTC
TGCAAGAACTGTTGCAATGAACATTTGCACATGTTCACCATCTGGCTGGGCTACATCAAC
TCCACACTGAACCCCCTCATCTACCCCTTGTGCAATGAGAACTTCAAGAAGACATTCAAG
AGAATTCTGCATATTCGCTCCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eosinophil chemotaxis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inositol phosphate-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>modulation of synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of inositol trisphosphate biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vascular permeability</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="12">
      <id>BE0000797</id>
      <name>5-hydroxytryptamine receptor 1B</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P28222" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 1B</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. Arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Regulates the release of 5-hydroxytryptamine, dopamine and acetylcholine in the brain, and thereby affects neural activity, nociceptive processing, pain perception, mood and behavior. Besides, plays a role in vasoconstriction of cerebral arteries.</specific-function>
        <gene-name>HTR1B</gene-name>
        <locus>6q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>50-75
85-110
124-145
166-187
206-228
316-336
350-371</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.82</theoretical-pi>
        <molecular-weight>43567.535</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5287</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR1B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D10995</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>219679</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P28222</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT1B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-1B</synonym>
          <synonym>5-HT-1D-beta</synonym>
          <synonym>HTR1DB</synonym>
          <synonym>S12</synonym>
          <synonym>Serotonin 1D beta receptor</synonym>
          <synonym>Serotonin receptor 1B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019014|5-hydroxytryptamine receptor 1B
MEEPGAQCAPPPPAGSETWVPQANLSSAPSQNCSAKDYIYQDSISLPWKVLLVMLLALIT
LATTLSNAFVIATVYRTRKLHTPANYLIASLAVTDLLVSILVMPISTMYTVTGRWTLGQV
VCDFWLSSDITCCTASILHLCVIALDRYWAITDAVEYSAKRTPKRAAVMIALVWVFSISI
SLPPFFWRQAKAEEEVSECVVNTDHILYTVYSTVGAFYFPTLLLIALYGRIYVEARSRIL
KQTPNRTGKRLTRAQLITDSPGSTSSVTSINSRVPDVPSESGSPVYVNQVKVRVSDALLE
KKKLMAARERKATKTLGIILGAFIVCWLPFFIISLVMPICKDACWFHLAIFDFFTWLGYL
NSLINPIIYTMSNEDFKQAFHKLIRFKCTS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019015|5-hydroxytryptamine receptor 1B (HTR1B)
ATGGAGGAACCGGGTGCTCAGTGCGCTCCACCGCCGCCCGCGGGCTCCGAGACCTGGGTT
CCTCAAGCCAACTTATCCTCTGCTCCCTCCCAAAACTGCAGCGCCAAGGACTACATTTAC
CAGGACTCCATCTCCCTACCCTGGAAAGTACTGCTGGTTATGCTATTGGCGCTCATCACC
TTGGCCACCACGCTCTCCAATGCCTTTGTGATTGCCACAGTGTACCGGACCCGGAAACTG
CACACCCCGGCTAACTACCTGATCGCCTCTCTGGCGGTCACCGACCTGCTTGTGTCCATC
CTGGTGATGCCCATCAGCACCATGTACACTGTCACCGGCCGCTGGACACTGGGCCAGGTG
GTCTGTGACTTCTGGCTGTCGTCGGACATCACTTGTTGCACTGCCTCCATCCTGCACCTC
TGTGTCATCGCCCTGGACCGCTACTGGGCCATCACGGACGCCGTGGAGTACTCAGCTAAA
AGGACTCCCAAGAGGGCGGCGGTCATGATCGCGCTGGTGTGGGTCTTCTCCATCTCTATC
TCGCTGCCGCCCTTCTTCTGGCGTCAGGCTAAGGCCGAAGAGGAGGTGTCGGAATGCGTG
GTGAACACCGACCACATCCTCTACACGGTCTACTCCACGGTGGGTGCTTTCTACTTCCCC
ACCCTGCTCCTCATCGCCCTCTATGGCCGCATCTACGTAGAAGCCCGCTCCCGGATTTTG
AAACAGACGCCCAACAGGACCGGCAAGCGCTTGACCCGAGCCCAGCTGATAACCGACTCC
CCCGGGTCCACGTCCTCGGTCACCTCTATTAACTCGCGGGTTCCCGACGTGCCCAGCGAA
TCCGGATCTCCTGTGTATGTGAACCAAGTCAAAGTGCGAGTCTCCGACGCCCTGCTGGAA
AAGAAGAAACTCATGGCCGCTAGGGAGCGCAAAGCCACCAAGACCCTAGGGATCATTTTG
GGAGCCTTTATTGTGTGTTGGCTACCCTTCTTCATCATCTCCCTAGTGATGCCTATCTGC
AAAGATGCCTGCTGGTTCCACCTAGCCATCTTTGACTTCTTCACATGGCTGGGCTATCTC
AACTCCCTCATCAACCCCATAATCTATACCATGTCCAATGAGGACTTTAAACAAGCATTC
CATAAACTGATACGTTTTAAGTGCACAAGTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bone remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to alkaloid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to temperature stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drinking behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of serotonin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, GABAergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to mineralocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="13">
      <id>BE0000533</id>
      <name>5-hydroxytryptamine receptor 2C</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P28335" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 2C</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Regulates neuronal activity via the activation of short transient receptor potential calcium channels in the brain, and thereby modulates the activation of pro-opiomelacortin neurons and the release of CRH that then regulates the release of corticosterone. Plays a role in the regulation of appetite and eating behavior, responses to anxiogenic stimuli and stress. Plays a role in insulin sensitivity and glucose homeostasis.</specific-function>
        <gene-name>HTR2C</gene-name>
        <locus>Xq24</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>53-78
90-110
128-150
171-193
214-235
312-333
349-371</transmembrane-regions>
        <signal-regions>1-32</signal-regions>
        <theoretical-pi>9.11</theoretical-pi>
        <molecular-weight>51820.705</molecular-weight>
        <chromosome-location>X</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5295</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR2C</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M81778</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>338028</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P28335</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT2C_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-1C</synonym>
          <synonym>5-HT-2C</synonym>
          <synonym>5-HT1C</synonym>
          <synonym>5-hydroxytryptamine receptor 1C</synonym>
          <synonym>HTR1C</synonym>
          <synonym>Serotonin receptor 2C</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001064|5-hydroxytryptamine receptor 2C
MVNLRNAVHSFLVHLIGLLVWQCDISVSPVAAIVTDIFNTSDGGRFKFPDGVQNWPALSI
VIIIIMTIGGNILVIMAVSMEKKLHNATNYFLMSLAIADMLVGLLVMPLSLLAILYDYVW
PLPRYLCPVWISLDVLFSTASIMHLCAISLDRYVAIRNPIEHSRFNSRTKAIMKIAIVWA
ISIGVSVPIPVIGLRDEEKVFVNNTTCVLNDPNFVLIGSFVAFFIPLTIMVITYCLTIYV
LRRQALMLLHGHTEEPPGLSLDFLKCCKRNTAEEENSANPNQDQNARRRKKKERRPRGTM
QAINNERKASKVLGIVFFVFLIMWCPFFITNILSVLCEKSCNQKLMEKLLNVFVWIGYVC
SGINPLVYTLFNKIYRRAFSNYLRCNYKVEKKPPVRQIPRVAATALSGRELNVNIYRHTN
EPVIEKASDNEPGIEMQVENLELPVNPSSVVSERISSV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010373|5-hydroxytryptamine receptor 2C (HTR2C)
ATGGTGAACCTGAGGAATGCGGTGCATTCATTCCTTGTGCACCTAATTGGCCTATTGGTT
TGGCAATGTGATATTTCTGTGAGCCCAGTAGCAGCTATAGTAACTGACATTTTCAATACC
TCCGATGGTGGACGCTTCAAATTCCCAGACGGGGTACAAAACTGGCCAGCACTTTCAATC
GTCATCATAATAATCATGACAATAGGTGGCAACATCCTTGTGATCATGGCAGTAAGCATG
GAAAAGAAACTGCACAATGCCACCAATTACTTCTTAATGTCCCTAGCCATTGCTGATATG
CTAGTGGGACTACTTGTCATGCCCCTGTCTCTCCTGGCAATCCTTTATGATTATGTCTGG
CCACTACCTAGATATTTGTGCCCCGTCTGGATTTCTTTAGATGTTTTATTTTCAACAGCG
TCCATCATGCACCTCTGCGCTATATCGCTGGATCGGTATGTAGCAATACGTAATCCTATT
GAGCATAGCCGTTTCAATTCGCGGACTAAGGCCATCATGAAGATTGCTATTGTTTGGGCA
ATTTCTATAGGTGTATCAGTTCCTATCCCTGTGATTGGACTGAGGGACGAAGAAAAGGTG
TTCGTGAACAACACGACGTGCGTGCTCAACGACCCAAATTTCGTTCTTATTGGGTCCTTC
GTAGCTTTCTTCATACCGCTGACGATTATGGTGATTACGTATTGCCTGACCATCTACGTT
CTGCGCCGACAAGCTTTGATGTTACTGCACGGCCACACCGAGGAACCGCCTGGACTAAGT
CTGGATTTCCTGAAGTGCTGCAAGAGGAATACGGCCGAGGAAGAGAACTCTGCAAACCCT
AACCAAGACCAGAACGCACGCCGAAGAAAGAAGAAGGAGAGACGTCCTAGGGGCACCATG
CAGGCTATCAACAATGAAAGAAAAGCTTCGAAAGTCCTTGGGATTGTTTTCTTTGTGTTT
CTGATCATGTGGTGCCCATTTTTCATTACCAATATTCTGTCTGTTCTTTGTGAGAAGTCC
TGTAACCAAAAGCTCATGGAAAAGCTTCTGAATGTGTTTGTTTGGATTGGCTATGTTTGT
TCAGGAATCAATCCTCTGGTGTATACTCTGTTCAACAAAATTTACCGAAGGGCATTCTCC
AACTATTTGCGTTGCAATTATAAGGTAGAGAAAAAGCCTCCTGTCAGGCAGATTCCAAGA
GTTGCCGCCACTGCTTTGTCTGGGAGGGAGCTTAATGTTAACATTTATCGGCATACCAAT
GAACCGGTGATCGAGAAAGCCAGTGACAATGAGCCCGGTATAGAGATGCAAGTTGAGAAT
TTAGAGTTACCAGTAAATCCCTCCAGTGTGGTTAGCGAAAGGATTAGCAGTGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Gq/11-coupled serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphatidylinositol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of appetite</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of corticotropin-releasing hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="14">
      <id>BE0000311</id>
      <name>5-hydroxytryptamine receptor 3A</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P46098" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 3A</name>
        <general-function>Voltage-gated potassium channel activity</general-function>
        <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.</specific-function>
        <gene-name>HTR3A</gene-name>
        <locus>11q23.1</locus>
        <cellular-location>Cell junction</cellular-location>
        <transmembrane-regions>242-268
274-292
303-321
456-475</transmembrane-regions>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi>7.43</theoretical-pi>
        <molecular-weight>55279.835</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5297</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR3A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D49394</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>681914</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>373</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P46098</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT3A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-3</synonym>
          <synonym>5-HT3-A</synonym>
          <synonym>5-HT3R</synonym>
          <synonym>5-hydroxytryptamine receptor 3</synonym>
          <synonym>5HT3R</synonym>
          <synonym>HTR3</synonym>
          <synonym>Serotonin receptor 3A</synonym>
          <synonym>Serotonin-gated ion channel receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000619|5-hydroxytryptamine receptor 3A
MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVRPVRDWRKPTT
VSIDVIVYAILNVDEKNQVLTTYIWYRQYWTDEFLQWNPEDFDNITKLSIPTDSIWVPDI
LINEFVDVGKSPNIPYVYIRHQGEVQNYKPLQVVTACSLDIYNFPFDVQNCSLTFTSWLH
TIQDINISLWRLPEKVKSDRSVFMNQGEWELLGVLPYFREFSMESSNYYAEMKFYVVIRR
RPLFYVVSLLLPSIFLMVMDIVGFYLPPNSGERVSFKITLLLGYSVFLIIVSDTLPATAI
GTPLIGVYFVVCMALLVISLAETIFIVRLVHKQDLQQPVPAWLRHLVLERIAWLLCLREQ
STSQRPPATSQATKTDDCSAMGNHCSHMGGPQDFEKSPRDRCSPPPPPREASLAVCGLLQ
ELSSIRQFLEKRDEIREVARDWLRVGSVLDKLLFHIYLLAVLAYSITLVMLWSIWQYA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010242|5-hydroxytryptamine receptor 3A (HTR3A)
ATGCTTGGAAAGCTCGCTATGCTGCTGTGGGTCCAGCAGGCGCTGCTCGCCTTGCTCCTC
CCCACACTCCTGGCACAGGGAGAAGCCAGGAGGAGCCGAAACACCACCAGGCCCGCTCTG
CTGAGGCTGTCGGATTACCTTTTGACCAACTACAGGAAGGGTGTGCGCCCCGTGAGGGAC
TGGAGGAAGCCAACCACCGTATCCATTGACGTCATTGTCTATGCCATCCTCAACGTGGAT
GAGAAGAATCAGGTGCTGACCACCTACATCTGGTACCGGCAGTACTGGACTGATGAGTTT
CTCCAGTGGAACCCTGAGGACTTTGACAACATCACCAAGTTGTCCATCCCCACGGACAGC
ATCTGGGTCCCGGACATTCTCATCAATGAGTTCGTGGATGTGGGGAAGTCTCCAAATATC
CCGTACGTGTATATTCGGCATCAAGGCGAAGTTCAGAACTACAAGCCCCTTCAGGTGGTG
ACTGCCTGTAGCCTCGACATCTACAACTTCCCCTTCGATGTCCAGAACTGCTCGCTGACC
TTCACCAGTTGGCTGCACACCATCCAGGACATCAACATCTCTTTGTGGCGCTTGCCAGAA
AAGGTGAAATCCGACAGGAGTGTCTTCATGAACCAGGGAGAGTGGGAGTTGCTGGGGGTG
CTGCCCTACTTTCGGGAGTTCAGCATGGAAAGCAGTAACTACTATGCAGAAATGAAGTTC
TATGTGGTCATCCGCCGGCGGCCCCTCTTCTATGTGGTCAGCCTGCTACTGCCCAGCATC
TTCCTCATGGTCATGGACATCGTGGGCTTCTACCTGCCCCCCAACAGTGGCGAGAGGGTC
TCTTTCAAGATTACACTCCTCCTGGGCTACTCGGTCTTCCTGATCATCGTTTCTGACACG
CTGCCGGCCACTGCCATCGGCACTCCTCTCATTGGTGTCTACTTTGTGGTGTGCATGGCT
CTGCTGGTGATAAGTTTGGCCGAGACCATCTTCATTGTGCGGCTGGTGCACAAGCAAGAC
CTGCAGCAGCCCGTGCCTGCTTGGCTGCGTCACCTGGTTCTGGAGAGAATCGCCTGGCTA
CTTTGCCTGAGGGAGCAGTCAACTTCCCAGAGGCCCCCAGCCACCTCCCAAGCCACCAAG
ACTGATGACTGCTCAGCCATGGGAAACCACTGCAGCCACATGGGAGGACCCCAGGACTTC
GAGAAGAGCCCGAGGGACAGATGTAGCCCTCCCCCACCACCTCGGGAGGCCTCGCTGGCG
GTGTGTGGGCTGCTGCAGGAGCTGTCCTCCATCCGGCAATTCCTGGAAAAGCGGGATGAG
ATCCGAGAGGTGGCCCGAGACTGGCTGCGCGTGGGCTCCGTGCTGGACAAGCTGCTATTC
CACATTTACCTGCTAGCGGTGCTGGCCTACAGCATCACCCTGGTTATGCTCTGGTCCATC
TGGCAGTACGCTTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF02931</identifier>
            <name>Neur_chan_LBD</name>
          </pfam>
          <pfam>
            <identifier>PF02932</identifier>
            <name>Neur_chan_memb</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin-activated cation-selective channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated potassium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="15">
      <id>BE0000945</id>
      <name>5-hydroxytryptamine receptor 6</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P50406" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 6</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase. It has a high affinity for tricyclic psychotropic drugs (By similarity). Controls pyramidal neurons migration during corticogenesis, through the regulation of CDK5 activity (By similarity). Is an activator of TOR signaling (PubMed:23027611).</specific-function>
        <gene-name>HTR6</gene-name>
        <locus>1p36-p35</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>35-57
65-85
101-122
145-166
185-208
266-290
296-320</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.02</theoretical-pi>
        <molecular-weight>46953.625</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5301</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L41147</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1162924</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>11</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P50406</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT6R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-6</synonym>
          <synonym>Serotonin receptor 6</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010665|5-hydroxytryptamine receptor 6
MVPEPGPTANSTPAWGAGPPSAPGGSGWVAAALCVVIALTAAANSLLIALICTQPALRNT
SNFFLVSLFTSDLMVGLVVMPPAMLNALYGRWVLARGLCLLWTAFDVMCCSASILNLCLI
SLDRYLLILSPLRYKLRMTPLRALALVLGAWSLAALASFLPLLLGWHELGHARPPVPGQC
RLLASLPFVLVASGLTFFLPSGAICFTYCRILLAARKQAVQVASLTTGMASQASETLQVP
RTPRPGVESADSRRLATKHSRKALKASLTLGILLGMFFVTWLPFFVANIVQAVCDCISPG
LFDVLTWLGYCNSTMNPIIYPLFMRDFKRALGRFLPCPRCPRERQASLASPSLRTSHSGP
RPGLSLQQVLPLPLPPDSDSDSDAGSGGSSGLRLTAQLLLPGEATQDPPLPTRAAAAVNF
FNIDPAEPELRPHPLGIPTN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010666|5-hydroxytryptamine receptor 6 (HTR6)
ATGGTCCCAGAGCCGGGCCCAACCGCCAATAGCACCCCGGCCTGGGGGGCAGGGCCGCCG
TCGGCCCCGGGGGGCAGCGGCTGGGTGGCGGCCGCGCTGTGCGTGGTCATCGCGCTGACG
GCGGCGGCCAACTCGCTGCTGATCGCGCTCATCTGCACTCAGCCCGCGCTGCGCAACACG
TCCAACTTCTTCCTGGTGTCGCTCTTCACGTCTGACCTGATGGTGGGGCTGGTGGTGATG
CCGCCGGCCATGCTGAACGCGCTGTACGGGCGCTGGGTGCTGGCGCGCGGCCTCTGCCTG
CTCTGGACCGCCTTCGACGTGATGTGCTGCAGCGCCTCCATCCTCAACCTCTGCCTCATC
AGCCTGGACCGCTACCTGCTCATCCTCTCGCCGCTGCGCTACAAGCTGCGCATGACGCCC
CTGCGTGCCCTGGCCCTAGTCCTGGGCGCCTGGAGCCTCGCCGCTCTCGCCTCCTTCCTG
CCCCTGCTGCTGGGCTGGCACGAGCTGGGCCACGCACGGCCACCCGTCCCTGGCCAGTGC
CGCCTGCTGGCCAGCCTGCCTTTTGTCCTTGTGGCGTCGGGCCTCACCTTCTTCCTGCCC
TCGGGTGCCATATGCTTCACCTACTGCAGGATCCTGCTAGCTGCCCGCAAGCAGGCCGTG
CAGGTGGCCTCCCTCACCACCGGCATGGCCAGTCAGGCCTCGGAGACGCTGCAGGTGCCC
AGGACCCCACGCCCAGGGGTGGAGTCTGCTGACAGCAGGCGTCTAGCCACGAAGCACAGC
AGGAAGGCCCTGAAGGCCAGCCTGACGCTGGGCATCCTGCTGGGCATGTTCTTTGTGACC
TGGTTGCCCTTCTTTGTGGCCAACATAGTCCAGGCCGTGTGCGACTGCATCTCCCCAGGC
CTCTTCGATGTCCTCACATGGCTGGGTTACTGTAACAGCACCATGAACCCCATCATCTAC
CCACTCTTCATGCGGGACTTCAAGCGGGCGCTGGGCAGGTTCCTGCCATGTCCACGCTGT
CCCCGGGAGCGCCAGGCCAGCCTGGCCTCGCCATCACTGCGCACCTCTCACAGCGGCCCC
CGGCCCGGCCTTAGCCTACAGCAGGTGCTGCCGCTGCCCCTGCCGCCGGACTCAGATTCG
GACTCAGACGCAGGCTCAGGCGGCTCCTCGGGCCTGCGGCTCACGGCCCAGCTGCTGCTT
CCTGGCGAGGCCACCCAGGACCCCCCGCTGCCCACCAGGGCCGCTGCCGCCGTCAATTTC
TTCAACATCGACCCCGCGGAGCCCGAGCTGCGGCCGCATCCACTTGGCATCCCCACGAAC
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cilium</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebral cortex cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of TOR signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="16">
      <id>BE0000020</id>
      <name>Dopamine D1 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>partial agonist</action>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P21728" source="Swiss-Prot">
        <name>D(1A) dopamine receptor</name>
        <general-function>G-protein coupled amine receptor activity</general-function>
        <specific-function>Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.</specific-function>
        <gene-name>DRD1</gene-name>
        <locus>5q35.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>24-49
61-87
97-119
139-163
193-218
273-299
313-337</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.34</theoretical-pi>
        <molecular-weight>49292.765</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3020</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DRD1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X55760</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>30397</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>214</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>214</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P21728</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DRD1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Dopamine D1 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021252|D(1A) dopamine receptor
MRTLNTSAMDGTGLVVERDFSVRILTACFLSLLILSTLLGNTLVCAAVIRFRHLRSKVTN
FFVISLAVSDLLVAVLVMPWKAVAEIAGFWPFGSFCNIWVAFDIMCSTASILNLCVISVD
RYWAISSPFRYERKMTPKAAFILISVAWTLSVLISFIPVQLSWHKAKPTSPSDGNATSLA
ETIDNCDSSLSRTYAISSSVISFYIPVAIMIVTYTRIYRIAQKQIRRIAALERAAVHAKN
CQTTTGNGKPVECSQPESSFKMSFKRETKVLKTLSVIMGVFVCCWLPFFILNCILPFCGS
GETQPFCIDSNTFDVFVWFGWANSSLNPIIYAFNADFRKAFSTLLGCYRLCPATNNAIET
VSINNNGAAMFSSHHEPRGSISKECNLVYLIPHAVGSSEDLKKEEAAGIARPLEKLSPAL
SVILDYDTDVSLEKIQPITQNGQHPT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021253|D(1A) dopamine receptor (DRD1)
ATGAGGACTCTGAACACCTCTGCCATGGACGGGACTGGGCTGGTGGTGGAGAGGGACTTC
TCTGTTCGTATCCTCACTGCCTGTTTCCTGTCGCTGCTCATCCTGTCCACGCTCCTGGGG
AACACGCTGGTCTGTGCTGCCGTTATCAGGTTCCGACACCTGCGGTCCAAGGTGACCAAC
TTCTTTGTCATCTCCTTGGCTGTGTCAGATCTCTTGGTGGCCGTCCTGGTCATGCCCTGG
AAGGCAGTGGCTGAGATTGCTGGCTTCTGGCCCTTTGGGTCCTTCTGTAACATCTGGGTG
GCCTTTGACATCATGTGCTCCACTGCATCCATCCTCAACCTCTGTGTGATCAGCGTGGAC
AGGTATTGGGCTATCTCCAGCCCTTTCCGGTATGAGAGAAAGATGACCCCCAAGGCAGCC
TTCATCCTGATCAGTGTGGCATGGACCTTGTCTGTACTCATCTCCTTCATCCCAGTGCAG
CTCAGCTGGCACAAGGCAAAACCCACAAGCCCCTCTGATGGAAATGCCACTTCCCTGGCT
GAGACCATAGACAACTGTGACTCCAGCCTCAGCAGGACATATGCCATCTCATCCTCTGTA
ATAAGCTTTTACATCCCTGTGGCCATCATGATTGTCACCTACACCAGGATCTACAGGATT
GCTCAGAAACAAATACGGCGCATTGCGGCCTTGGAGAGGGCAGCAGTCCACGCCAAGAAT
TGCCAGACCACCACAGGTAATGGAAAGCCTGTCGAATGTTCTCAACCGGAAAGTTCTTTT
AAGATGTCCTTCAAAAGAGAAACTAAAGTCCTGAAGACTCTGTCGGTGATCATGGGTGTG
TTTGTGTGCTGTTGGCTACCTTTCTTCATCTTGAACTGCATTTTGCCCTTCTGTGGGTCT
GGGGAGACGCAGCCCTTCTGCATTGATTCCAACACCTTTGACGTGTTTGTGTGGTTTGGG
TGGGCTAATTCATCCTTGAACCCCATCATTTATGCCTTTAATGCTGATTTTCGGAAGGCA
TTTTCAACCCTCTTAGGATGCTACAGACTTTGCCCTGCGACGAATAATGCCATAGAGACG
GTGAGTATCAATAACAATGGGGCCGCGATGTTTTCCAGCCATCATGAGCCACGAGGCTCC
ATCTCCAAGGAGTGCAATCTGGTTTACCTGATCCCACATGCTGTGGGCTCCTCTGAGGAC
CTGAAAAAGGAGGAGGCAGCTGGCATCGCCAGACCCTTGGAGAAGCTGTCCCCAGCCCTA
TCAGTCATATTGGACTATGACACTGACGTCTCTCTGGAGAAGATCCAACCCATCACACAA
AACGGTCAGCACCCAACCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ciliary membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic shaft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine head</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine neck</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nonmotile primary cilium</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity, coupled via Gs</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled amine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult walking behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>astrocyte development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to catecholamine stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to insulin stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebral cortex GABAergic interneuron migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>conditioned taste aversion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dentate gyrus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glucose import</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>grooming behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>habituation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long term synaptic depression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-term synaptic potentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maternal behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mating behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of circadian sleep/wake cycle, sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuronal action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>operant conditioning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>orbitofrontal cortex development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>peristalsis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G-protein coupled signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of long-term synaptic potentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of long-term neuronal synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amino acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to antidepressant</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to food</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nicotine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensitization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>striatum development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synapse assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>temperature homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasodilation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="17">
      <id>BE0000389</id>
      <name>Dopamine D4 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>partial agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P21917" source="Swiss-Prot">
        <name>D(4) dopamine receptor</name>
        <general-function>Sh3 domain binding</general-function>
        <specific-function>Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).</specific-function>
        <gene-name>DRD4</gene-name>
        <locus>11p15.5</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>38-60
71-93
110-131
152-175
192-213
395-417
427-449</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.37</theoretical-pi>
        <molecular-weight>48359.86</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3025</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DRD4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L12398</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>291946</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>217</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>217</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P21917</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DRD4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>D(2C) dopamine receptor</synonym>
          <synonym>Dopamine D4 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000775|D(4) dopamine receptor
MGNRSTADADGLLAGRGPAAGASAGASAGLAGQGAAALVGGVLLIGAVLAGNSLVCVSVA
TERALQTPTNSFIVSLAAADLLLALLVLPLFVYSEVQGGAWLLSPRLCDALMAMDVMLCT
ASIFNLCAISVDRFVAVAVPLRYNRQGGSRRQLLLIGATWLLSAAVAAPVLCGLNDVRGR
DPAVCRLEDRDYVVYSSVCSFFLPCPLMLLLYWATFRGLQRWEVARRAKLHGRAPRRPSG
PGPPSPTPPAPRLPQDPCGPDCAPPAPGLPRGPCGPDCAPAAPGLPPDPCGPDCAPPAPG
LPQDPCGPDCAPPAPGLPRGPCGPDCAPPAPGLPQDPCGPDCAPPAPGLPPDPCGSNCAP
PDAVRAAALPPQTPPQTRRRRRAKITGRERKAMRVLPVVVGAFLLCWTPFFVVHITQALC
PACSVPPRLVSAVTWLGYVNSALNPVIYTVFNAEFRNVFRKALRACC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010271|D(4) dopamine receptor (DRD4)
ATGGGGAACCGCAGCACCGCGGACGCGGACGGGCTGCTGGCTGGGCGCGGGCCGGCCGCG
GGGGCATCTGCGGGGGCATCTGCGGGGCTGGCTGGGCAGGGCGCGGCGGCGCTGGTGGGG
GGCGTGCTGCTCATCGGCGCGGTGCTCGCGGGGAACTCGCTCGTGTGCGTGAGCGTGGCC
ACCGAGCGCGCCCTGCAGACGCCCACCAACTCCTTCATCGTGAGCCTGGCGGCCGCCGAC
CTCCTCCTCGCTCTCCTGGTGCTGCCGCTCTTCGTCTACTCCGAGGTCCAGGGTGGCGCG
TGGCTGCTGAGCCCCCGCCTGTGCGACGCCCTCATGGCCATGGACGTCATGCTGTGCACC
GCCTCCATCTTCAACCTGTGCGCCATCAGCGTGGACAGGTTCGTGGCCGTGGCCGTGCCG
CTGCGCTACAACCGGCAGGGTGGGAGCCGCCGGCAGCTGCTGCTCATCGGCGCCACGTGG
CTGCTGTCCGCGGCGGTGGCGGCGCCCGTACTGTGCGGCCTCAACGACGTGCGCGGCCGC
GACCCCGCCGTGTGCCGCCTGGAGGACCGCGACTACGTGGTCTACTCGTCCGTGTGCTCC
TTCTTCCTACCCTGCCCGCTCATGCTGCTGCTCTACTGGGCCACGTTCCGCGGCCTGCAG
CGCTGGGAGGTGGCACGTCGCGCCAAGCTGCACGGCCGCGCGCCCCGCCGACCCAGCGGC
CCTGGCCCGCCTTCCCCCACGCCACCCGCGCCCCGCCTCCCCCAGGACCCCTGCGGCCCC
GACTGTGCGCCCCCCGCGCCCGGCCTTCCCCGGGGTCCCTGCGGCCCCGACTGTGCGCCC
GCCGCGCCCAGCCTCCCCCAGGACCCCTGCGGCCCCGACTGTGCGCCCCCCGCGCCCGGC
CTCCCCCCGGACCCCTGCGGCTCCAACTGTGCTCCCCCCGACGCCGTCAGAGCCGCCGCG
CTCCCACCCCAGACTCCACCGCAGACCCGCAGGAGGCGGCGTGCCAAGATCACCGGCCGG
GAGCGCAAGGCCATGAGGGTCCTGCCGGTGGTGGTCGGGGCCTTCCTGCTGTGCTGGACG
CCCTTCTTCGTGGTGCACATCACGCAGGCGCTGTGTCCTGCCTGCTCCGTGCCCCCGCGG
CTGGTCAGCGCCGTCACCTGGCTGGGCTACGTCAACAGCGCCCTCAACCCCGTCATCTAC
ACTGTCTTCAACGCCGAGTTCCGCAACGTCTTCCGCAAGGCCCTGCGTGCCTGCTGCTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell cortex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>terminal bouton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity, coupled via Gi/Go</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled amine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>potassium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>SH3 domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inhibitory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>olfactory learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>photoperiodism</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of penile erection</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sodium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of neurotransmitter secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to histamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to steroid hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina development in camera-type eye</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>short-term memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="18">
      <id>BE0000572</id>
      <name>Alpha-2B adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P18089" source="Swiss-Prot">
        <name>Alpha-2B adrenergic receptor</name>
        <general-function>Epinephrine binding</general-function>
        <specific-function>Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine &gt; norepinephrine &gt; epinephrine = oxymetazoline &gt; dopamine &gt; p-tyramine = phenylephrine &gt; serotonin &gt; p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine &gt; chlorpromazine &gt; phentolamine &gt; mianserine &gt; spiperone &gt; prazosin &gt; alprenolol &gt; propanolol &gt; pindolol.</specific-function>
        <gene-name>ADRA2B</gene-name>
        <locus>2p13-q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>13-38
49-69
87-107
129-149
173-193
370-393
403-423</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.52</theoretical-pi>
        <molecular-weight>49565.8</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:282</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRA2B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M34041</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178198</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>26</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>26</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P18089</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADA2B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRA2L1</synonym>
          <synonym>ADRA2RL1</synonym>
          <synonym>Alpha-2 adrenergic receptor subtype C2</synonym>
          <synonym>Alpha-2B adrenoceptor</synonym>
          <synonym>Alpha-2B adrenoreceptor</synonym>
          <synonym>Alpha-2BAR</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010396|Alpha-2B adrenergic receptor
MDHQDPYSVQATAAIAAAITFLILFTIFGNALVILAVLTSRSLRAPQNLFLVSLAAADIL
VATLIIPFSLANELLGYWYFRRTWCEVYLALDVLFCTSSIVHLCAISLDRYWAVSRALEY
NSKRTPRRIKCIILTVWLIAAVISLPPLIYKGDQGPQPRGRPQCKLNQEAWYILASSIGS
FFAPCLIMILVYLRIYLIAKRSNRRGPRAKGGPGQGESKQPRPDHGGALASAKLPALASV
ASAREVNGHSKSTGEKEEGETPEDTGTRALPPSWAALPNSGQGQKEGVCGASPEDEAEEE
EEEEEECEPQAVPVSPASACSPPLQQPQGSRVLATLRGQVLLGRGVGAIGGQWWRRRAQL
TREKRFTFVLAVVIGVFVLCWFPFFFSYSLGAICPKHCKVPHGLFQFFFWIGYCNSSLNP
VIYTIFNQDFRRAFRRILCRPWTQTAW</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010397|Alpha-2B adrenergic receptor (ADRA2B)
ATGGACCACCAGGACCCCTACTCCGTGCAGGCCACAGCGGCCATAGCGGCGGCCATCACC
TTCCTCATTCTCTTTACCATCTTCGGCAACGCTCTGGTCATCCTGGCTGTGTTGACCAGC
CGCTCGCTGCGCGCCCCTCAGAACCTGTTCCTGGTGTCGCTGGCCGCCGCCGACATCCTG
GTGGCCACGCTCATCATCCCTTTCTCGCTGGCCAACGAGCTGCTGGGCTACTGGTACTTC
CGGCGCACGTGGTGCGAGGTGTACCTGGCGCTCGACGTGCTCTTCTGCACCTCGTCCATC
GTGCACCTGTGCGCCATCAGCCTGGACCGCTACTGGGCCGTGAGCCGCGCGCTGGAGTAC
AACTCCAAGCGCACCCCGCGCCGCATCAAGTGCATCATCCTCACTGTGTGGCTCATCGCC
GCCGTCATCTCGCTGCCGCCCCTCATCTACAAGGGCGACCAGGGCCCCCAGCCGCGCGGG
CGCCCCCAGTGCAAGCTCAACCAGGAGGCCTGGTACATCCTGGCCTCCAGCATCGGATCT
TTCTTTGCTCCTTGCCTCATCATGATCCTTGTCTACCTGCGCATCTACCTGATCGCCAAA
CGCAGCAACCGCAGAGGTCCCAGGGCCAAGGGGGGGCCTGGGCAGGGTGAGTCCAAGCAG
CCCCGACCCGACCATGGTGGGGCTTTGGCCTCAGCCAAACTGCCAGCCCTGGCCTCTGTG
GCTTCTGCCAGAGAGGTCAACGGACACTCGAAGTCCACTGGGGAGAAGGAGGAGGGGGAG
ACCCCTGAAGATACTGGGACCCGGGCCTTGCCACCCAGTTGGGCTGCCCTTCCCAACTCA
GGCCAGGGCCAGAAGGAGGGTGTTTGTGGGGCATCTCCAGAGGATGAAGCTGAAGAGGAG
GAAGAGGAGGAGGAGGAGGAGGAAGAGTGTGAACCCCAGGCAGTGCCAGTGTCTCCGGCC
TCAGCTTGCAGCCCCCCGCTGCAGCAGCCACAGGGCTCCCGGGTGCTGGCCACCCTACGT
GGCCAGGTGCTCCTGGGCAGGGGCGTGGGTGCTATAGGTGGGCAGTGGTGGCGTCGACGG
GCGCAGCTGACCCGGGAGAAGCGCTTCACCTTCGTGCTGGCTGTGGTCATTGGCGTTTTT
GTGCTCTGCTGGTTCCCCTTCTTCTTCAGCTACAGCCTGGGAGCCATCTGCCCGAAGCAC
TGCAAGGTGCCCCATGGCCTCTTCCAGTTCTTCTTCTGGATCGGCTACTGCAACAGCTCA
CTGAACCCTGTTATCTACACCATCTTCAACCAGGACTTCCGCCGTGCCTTCCGGAGGATC
CTGTGCCGCCCGTGGACCCAGACGGCCTGGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha2-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity by adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of protein kinase B activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of epinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="19">
      <id>BE0000476</id>
      <name>5-hydroxytryptamine receptor 1E</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P28566" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 1E</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various alkaloids and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity.</specific-function>
        <gene-name>HTR1E</gene-name>
        <locus>6q14-q15</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>23-47
60-82
97-118
139-159
180-202
292-314
325-347</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.98</theoretical-pi>
        <molecular-weight>41681.57</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5291</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR1E</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M91467</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177774</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P28566</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT1E_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-1E</synonym>
          <synonym>S31</synonym>
          <synonym>Serotonin receptor 1E</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010335|5-hydroxytryptamine receptor 1E
MNITNCTTEASMAIRPKTITEKMLICMTLVVITTLTTLLNLAVIMAIGTTKKLHQPANYL
ICSLAVTDLLVAVLVMPLSIIYIVMDRWKLGYFLCEVWLSVDMTCCTCSILHLCVIALDR
YWAITNAIEYARKRTAKRAALMILTVWTISIFISMPPLFWRSHRRLSPPPSQCTIQHDHV
IYTIYSTLGAFYIPLTLILILYYRIYHAAKSLYQKRGSSRHLSNRSTDSQNSFASCKLTQ
TFCVSDFSTSDPTTEFEKFHASIRIPPFDNDLDHPGERQQISSTRERKAARILGLILGAF
ILSWLPFFIKELIVGLSIYTVSSEVADFLTWLGYVNSLINPLLYTSFNEDFKLAFKKLIR
CREHT</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010336|5-hydroxytryptamine receptor 1E (HTR1E)
ATGAACATCACAAACTGTACCACAGAGGCCAGCATGGCTATAAGACCCAAGACCATCACT
GAGAAGATGCTCATTTGCATGACTCTGGTGGTCATCACCACCCTCACCACGTTGCTGAAC
TTGGCTGTGATCATGGCTATTGGCACCACCAAGAAGCTCCACCAGCCTGCCAACTACCTA
ATCTGTTCTCTGGCCGTGACGGACCTCCTGGTGGCAGTGCTCGTCATGCCCCTGAGCATC
ATCTACATTGTCATGGATCGCTGGAAGCTTGGGTACTTCCTCTGTGAGGTGTGGCTGAGT
GTGGACATGACCTGCTGCACCTGCTCCATCCTCCACCTCTGTGTCATTGCCCTGGACAGG
TACTGGGCCATCACCAATGCTATTGAATACGCCAGGAAGAGGACGGCCAAGAGGGCCGCG
CTGATGATCCTTACCGTCTGGACCATCTCCATTTTCATCTCCATGCCCCCTCTGTTCTGG
AGAAGCCACCGCCGCCTAAGCCCTCCCCCTAGTCAGTGCACCATCCAGCACGACCATGTT
ATCTACACCATTTACTCCACGCTGGGTGCGTTTTATATCCCCTTGACTTTGATACTGATT
CTCTATTACCGGATTTACCACGCGGCCAAGAGCCTTTACCAGAAAAGGGGATCAAGTCGG
CACTTAAGCAACAGAAGCACAGATAGCCAGAATTCTTTTGCAAGTTGTAAACTTACACAG
ACTTTCTGTGTGTCTGACTTCTCCACCTCAGACCCTACCACAGAGTTTGAAAAGTTCCAT
GCCTCCATCAGGATCCCCCCCTTCGACAATGATCTAGATCACCCAGGAGAACGTCAGCAG
ATCTCTAGCACCAGGGAACGGAAGGCAGCACGCATCCTGGGGCTGATTCTGGGTGCATTC
ATTTTATCCTGGCTGCCATTTTTCATCAAAGAGTTGATTGTGGGTCTGAGCATCTACACC
GTGTCCTCGGAAGTGGCCGACTTTCTGACGTGGCTCGGTTATGTGAATTCTCTGATCAAC
CCTCTGCTCTATACGAGTTTTAATGAAGACTTTAAGCTGGCTTTTAAAAAGCTCATTAGA
TGCCGAGAGCATACTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="20">
      <id>BE0000145</id>
      <name>Dopamine D5 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>antagonist</action>
        <action>partial agonist</action>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A4393</ref-id>
            <pubmed-id>17848919</pubmed-id>
            <citation>Nasrallah HA: Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008 Jan;13(1):27-35. Epub 2007 Sep 11.</citation>
          </article>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P21918" source="Swiss-Prot">
        <name>D(1B) dopamine receptor</name>
        <general-function>G-protein coupled amine receptor activity</general-function>
        <specific-function>Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.</specific-function>
        <gene-name>DRD5</gene-name>
        <locus>4p16.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>40-66
78-104
115-136
159-180
224-246
297-320
341-360</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.08</theoretical-pi>
        <molecular-weight>52950.5</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:3026</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>DRD5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X58454</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>32049</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>218</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>218</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P21918</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>DRD5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>D(5) dopamine receptor</synonym>
          <synonym>D1beta dopamine receptor</synonym>
          <synonym>Dopamine D5 receptor</synonym>
          <synonym>DRD1B</synonym>
          <synonym>DRD1L2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009965|D(1B) dopamine receptor
MLPPGSNGTAYPGQFALYQQLAQGNAVGGSAGAPPLGPSQVVTACLLTLLIIWTLLGNVL
VCAAIVRSRHLRANMTNVFIVSLAVSDLFVALLVMPWKAVAEVAGYWPFGAFCDVWVAFD
IMCSTASILNLCVISVDRYWAISRPFRYKRKMTQRMALVMVGLAWTLSILISFIPVQLNW
HRDQAASWGGLDLPNNLANWTPWEEDFWEPDVNAENCDSSLNRTYAISSSLISFYIPVAI
MIVTYTRIYRIAQVQIRRISSLERAAEHAQSCRSSAACAPDTSLRASIKKETKVLKTLSV
IMGVFVCCWLPFFILNCMVPFCSGHPEGPPAGFPCVSETTFDVFVWFGWANSSLNPVIYA
FNADFQKVFAQLLGCSHFCSRTPVETVNISNELISYNQDIVFHKEIAAAYIHMMPNAVTP
GNREVDNDEEEGPFDRMFQIYQTSPDGDPVAESVWELDCEGEISLDKITPFTPNGFH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009966|D(1B) dopamine receptor (DRD5)
ATGCTGCCGCCAGGCAGCAACGGCACCGCGTACCCGGGGCAGTTCGCTCTATACCAGCAG
CTGGCGCAGGGGAACGCCGTGGGGGGCTCGGCGGGGGCACCGCCACTGGGGCCCTCACAG
GTGGTCACCGCCTGCCTGCTGACCCTACTCATCATCTGGACCCTGCTGGGCAACGTGCTG
GTGTGCGCAGCCATCGTGCGGAGCCGCCACCTGCGCGCCAACATGACCAACGTCTTCATC
GTGTCTCTGGCCGTGTCAGACCTTTTCGTGGCGCTGCTGGTCATGCCCTGGAAGGCAGTC
GCCGAGGTGGCCGGTTACTGGCCCTTTGGAGCGTTCTGCGACGTCTGGGTGGCCTTCGAC
ATCATGTGCTCCACTGCCTCCATCCTGAACCTGTGCGTCATCAGCGTGGACCGCTACTGG
GCCATCTCCAGGCCCTTCCGCTACAAGCGCAAGATGACTCAGCGCATGGCCTTGGTCATG
GTCGGCCTGGCATGGACCTTGTCCATCCTCATCTCCTTCATTCCGGTCCAGCTCAACTGG
CACAGGGACCAGGCGGCCTCTTGGGGCGGGCTGGACCTGCCAAACAACCTGGCCAACTGG
ACGCCCTGGGAGGAGGACTTTTGGGAGCCCGACGTGAATGCAGAGAACTGTGACTCCAGC
CTGAATCGAACCTACGCCATCTCTTCCTCGCTCATCAGCTTCTACATCCCCGTTGCCATC
ATGATCGTGACCTACACGCGCATCTACCGCATCGCCCAGGTGCAGATCCGCAGGATTTCC
TCCCTGGAGAGGGCCGCAGAGCACGCGCAGAGCTGCCGGAGCAGCGCAGCCTGCGCGCCC
GACACCAGCCTGCGCGCTTCCATCAAGAAGGAGACCAAGGTTCTCAAGACCCTGTCGGTG
ATCATGGGGGTCTTCGTGTGTTGCTGGCTGCCCTTCTTCATCCTTAACTGCATGGTCCCT
TTCTGCAGTGGACACCCCGAAGGCCCTCCGGCCGGCTTCCCCTGCGTCAGTGAGACCACC
TTCGACGTCTTCGTCTGGTTCGGCTGGGCTAACTCCTCACTCAACCCCGTCATCTATGCC
TTCAACGCCGACTTTCAGAAGGTGTTTGCCCAGCTGCTGGGGTGCAGCCACTTCTGCTCC
CGCACGCCGGTGGAGACGGTGAACATCAGCAATGAGCTCATCTCCTACAACCAAGACATC
GTCTTCCACAAGGAAATCGCAGCTGCCTACATCCACATGATGCCCAACGCCGTTACCCCC
GGCAACCGGGAGGTGGACAACGACGAGGAGGAGGGTCCTTTCGATCGCATGTTCCAGATC
TATCAGACGTCCCCAGATGGTGACCCTGTTGCTGAGTCTGTCTGGGAGCTGGACTGCGAG
GGGGAGATTTCTTTAGACAAAATAACACCTTTCACCCCGAATGGATTCCATTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>brush border membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>ciliary membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nonmotile primary cilium</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine neurotransmitter receptor activity, coupled via Gs</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled amine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>associative learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to catecholamine stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long term synaptic depression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of NAD(P)H oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>reactive oxygen species metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of female receptivity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of systemic arterial blood pressure by vasopressin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensitization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="26">
      <id>BE0000393</id>
      <name>5-hydroxytryptamine receptor 2B</name>
      <organism>Humans</organism>
      <actions>
        <action>inverse agonist</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P41595" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 2B</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins and mediate activation of alternative signaling pathways. Signaling activates a phosphatidylinositol-calcium second messenger system that modulates the activity of phosphatidylinositol 3-kinase and down-stream signaling cascades and promotes the release of Ca(2+) ions from intracellular stores. Plays a role in the regulation of dopamine and 5-hydroxytryptamine release, 5-hydroxytryptamine uptake and in the regulation of extracellular dopamine and 5-hydroxytryptamine levels, and thereby affects neural activity. May play a role in the perception of pain. Plays a role in the regulation of behavior, including impulsive behavior. Required for normal proliferation of embryonic cardiac myocytes and normal heart development. Protects cardiomyocytes against apoptosis. Plays a role in the adaptation of pulmonary arteries to chronic hypoxia. Plays a role in vasoconstriction. Required for normal osteoblast function and proliferation, and for maintaining normal bone density. Required for normal proliferation of the interstitial cells of Cajal in the intestine.</specific-function>
        <gene-name>HTR2B</gene-name>
        <locus>2q36.3-q37.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>57-79
91-113
130-151
172-192
217-239
325-345
361-382</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.47</theoretical-pi>
        <molecular-weight>54297.41</molecular-weight>
        <chromosome-location>2</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5294</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HTR2B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X77307</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>475198</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P41595</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT2B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-2B</synonym>
          <synonym>Serotonin receptor 2B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016078|5-hydroxytryptamine receptor 2B
MALSYRVSELQSTIPEHILQSTFVHVISSNWSGLQTESIPEEMKQIVEEQGNKLHWAALL
ILMVIIPTIGGNTLVILAVSLEKKLQYATNYFLMSLAVADLLVGLFVMPIALLTIMFEAM
WPLPLVLCPAWLFLDVLFSTASIMHLCAISVDRYIAIKKPIQANQYNSRATAFIKITVVW
LISIGIAIPVPIKGIETDVDNPNNITCVLTKERFGDFMLFGSLAAFFTPLAIMIVTYFLT
IHALQKKAYLVKNKPPQRLTWLTVSTVFQRDETPCSSPEKVAMLDGSRKDKALPNSGDET
LMRRTSTIGKKSVQTISNEQRASKVLGIVFFLFLLMWCPFFITNITLVLCDSCNQTTLQM
LLEIFVWIGYVSSGVNPLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNP
MAENSKFFKKHGIRNGINPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEGDKTEEQVSY
V</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016079|5-hydroxytryptamine receptor 2B (HTR2B)
ATGGCTCTCTCTTACAGAGTGTCTGAACTTCAAAGCACAATTCCTGAGCACATTTTGCAG
AGCACCTTTGTTCACGTTATCTCTTCTAACTGGTCTGGATTACAGACAGAATCAATACCA
GAGGAAATGAAACAGATTGTTGAGGAACAGGGAAATAAACTGCACTGGGCAGCTCTTCTG
ATACTCATGGTGATAATACCCACAATTGGTGGAAATACCCTTGTTATTCTGGCTGTTTCA
CTGGAGAAGAAGCTGCAGTATGCTACTAATTACTTTCTAATGTCCTTGGCGGTGGCTGAT
TTGCTGGTTGGATTGTTTGTGATGCCAATTGCCCTCTTGACAATAATGTTTGAGGCTATG
TGGCCCCTCCCACTTGTTCTATGTCCTGCCTGGTTATTTCTTGACGTTCTCTTTTCAACC
GCATCCATCATGCATCTCTGTGCCATTTCAGTGGATCGTTACATAGCCATCAAAAAGCCA
ATCCAGGCCAATCAATATAACTCACGGGCTACAGCATTCATCAAGATTACAGTGGTGTGG
TTAATTTCAATAGGCATTGCCATTCCAGTCCCTATTAAAGGGATAGAGACTGATGTGGAC
AACCCAAACAATATCACTTGTGTGCTGACAAAGGAACGTTTTGGCGATTTCATGCTCTTT
GGCTCACTGGCTGCCTTCTTCACACCTCTTGCAATTATGATTGTCACCTACTTTCTCACT
ATCCATGCTTTACAGAAGAAGGCTTACTTAGTCAAAAACAAGCCACCTCAACGCCTAACA
TGGTTGACTGTGTCTACAGTTTTCCAAAGGGATGAAACACCTTGCTCGTCACCGGAAAAG
GTGGCAATGCTGGATGGTTCTCGAAAGGACAAGGCTCTGCCCAACTCAGGTGATGAAACA
CTTATGCGAAGAACATCCACAATTGGGAAAAAGTCAGTGCAGACCATTTCCAACGAACAG
AGAGCCTCAAAGGTCCTAGGGATTGTGTTTTTCCTCTTTTTGCTTATGTGGTGTCCCTTC
TTTATTACAAATATAACTTTAGTTTTATGTGATTCCTGTAACCAAACTACTCTCCAAATG
CTCCTGGAGATATTTGTGTGGATAGGCTATGTTTCCTCAGGAGTGAATCCTTTGGTCTAC
ACCCTCTTCAATAAGACATTTCGGGATGCATTTGGCCGATATATCACCTGCAATTACCGG
GCCACAAAGTCAGTAAAAACTCTCAGAAAACGCTCCAGTAAGATCTACTTCCGGAATCCA
ATGGCAGAGAACTCTAAGTTTTTCAAGAAACATGGAATTCGAAATGGGATTAACCCTGCC
ATGTACCAGAGTCCAATGAGGCTCCGAAGTTCAACCATTCAGTCTTCATCAATCATTCTA
CTAGATACGCTTCTCCTCACTGAAAATGAAGGTGACAAAACTGAAGAGCAAGTTAGTTAT
GTATAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein alpha-subunit binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>GTPase activator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac muscle hypertrophy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to amine stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to serotonin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to temperature stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cGMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryonic morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor internalization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heart morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hepatic stellate cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inositol phosphate metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestine smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of autophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neural crest cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neural crest cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol 3-kinase signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell division</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of endothelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric-oxide synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphatidylinositol biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein kinase C signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>release of sequestered calcium ion into cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="27">
      <id>BE0004688</id>
      <name>5-hydroxytryptamine receptor 5A</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P47898" source="Swiss-Prot">
        <name>5-hydroxytryptamine receptor 5A</name>
        <general-function>Serotonin receptor activity</general-function>
        <specific-function>This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins.</specific-function>
        <gene-name>HTR5A</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>41-63
79-99
116-137
159-181
199-219
283-303
321-341</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>40254.69</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5300</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>10</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P47898</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>5HT5A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5-HT-5</synonym>
          <synonym>Serotonin receptor 5A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0020790|5-hydroxytryptamine receptor 5A
MDLPVNLTSFSLSTPSPLETNHSLGKDDLRPSSPLLSVFGVLILTLLGFLVAATFAWNLL
VLATILRVRTFHRVPHNLVASMAVSDVLVAALVMPLSLVHELSGRRWQLGRRLCQLWIAC
DVLCCTASIWNVTAIALDRYWSITRHMEYTLRTRKCVSNVMIALTWALSAVISLAPLLFG
WGETYSEGSEECQVSREPSYAVFSTVGAFYLPLCVVLFVYWKIYKAAKFRVGSRKTNSVS
PISEAVEVKDSAKQPQMVFTVRHATVTFQPEGDTWREQKEQRAALMVGILIGVFVLCWIP
FFLTELISPLCSCDIPAIWKSIFLWLGYSNSFFNPLIYTAFNKNYNSAFKNFFSRQH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020791|5-hydroxytryptamine receptor 5A (HTR5A)
ATGGATTTACCTGTGAACCTAACCTCCTTTTCCCTCTCCACCCCCTCCCCTTTGGAGACC
AACCACAGCCTCGGCAAAGACGACCTGCGCCCCAGCTCGCCCCTGCTCTCGGTCTTCGGA
GTGCTTATTCTCACCTTGCTGGGCTTTCTGGTGGCGGCGACGTTCGCCTGGAACCTGCTG
GTGCTGGCGACCATCCTCCGTGTACGCACCTTCCACCGCGTGCCCCACAACCTGGTGGCA
TCCATGGCCGTCTCGGATGTCCTGGTGGCCGCGCTGGTCATGCCGCTGAGCCTGGTGCAC
GAGCTGTCCGGGCGCCGCTGGCAGCTAGGTCGGAGGCTGTGCCAGCTTTGGATCGCGTGC
GACGTGCTTTGCTGCACGGCCAGCATCTGGAACGTGACGGCCATAGCCCTGGACCGCTAC
TGGTCCATCACGCGCCACATGGAATACACGCTCCGCACCCGCAAGTGCGTCTCCAACGTC
ATGATCGCGCTCACCTGGGCACTCTCCGCTGTCATCTCTCTGGCCCCGCTGCTTTTTGGC
TGGGGAGAGACGTACTCTGAGGGCAGCGAGGAGTGCCAGGTAAGCCGCGAGCCTTCCTAC
GCCGTGTTCTCCACCGTAGGCGCCTTCTACCTGCCGCTCTGTGTGGTGCTCTTCGTGTAC
TGGAAGATCTACAAGGCTGCCAAGTTCCGCGTGGGCTCCAGGAAGACCAATAGCGTCTCA
CCCATATCCGAAGCTGTGGAGGTGAAGGACTCTGCCAAACAGCCCCAGATGGTGTTCACG
GTCCGCCACGCCACCGTCACCTTCCAGCCAGAAGGGGACACGTGGCGGGAGCAGAAGGAG
CAGCGGGCCGCCCTCATGGTGGGCATCCTCATTGGCGTGTTCGTGCTCTGCTGGATCCCC
TTCTTTCTCACCGAGCTCATCAGTCCCCTCTGCTCCTGTGACATCCCCGCCATCTGGAAA
AGCATCTTCCTGTGGCTTGGCTACTCCAACTCCTTCTTTAACCCCCTGATCTATACGGCT
TTCAACAAGAACTACAACAGCGCCTTCAAGAACTTCTTTTCTAGGCAACACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>rough endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hippocampus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="28">
      <id>BE0000172</id>
      <name>Beta-1 adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08588" source="Swiss-Prot">
        <name>Beta-1 adrenergic receptor</name>
        <general-function>Receptor signaling protein activity</general-function>
        <specific-function>Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.</specific-function>
        <gene-name>ADRB1</gene-name>
        <locus>10q24-q26</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>56-84
94-120
133-154
173-196
223-248
320-349
355-377</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.03</theoretical-pi>
        <molecular-weight>51322.1</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:285</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRB1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03019</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>178200</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>28</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>28</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08588</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADRB1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRB1R</synonym>
          <synonym>B1AR</synonym>
          <synonym>Beta-1 adrenoceptor</synonym>
          <synonym>Beta-1 adrenoreceptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010188|Beta-1 adrenergic receptor
MGAGVLVLGASEPGNLSSAAPLPDGAATAARLLVPASPPASLLPPASESPEPLSQQWTAG
MGLLMALIVLLIVAGNVLVIVAIAKTPRLQTLTNLFIMSLASADLVMGLLVVPFGATIVV
WGRWEYGSFFCELWTSVDVLCVTASIETLCVIALDRYLAITSPFRYQSLLTRARARGLVC
TVWAISALVSFLPILMHWWRAESDEARRCYNDPKCCDFVTNRAYAIASSVVSFYVPLCIM
AFVYLRVFREAQKQVKKIDSCERRFLGGPARPPSPSPSPVPAPAPPPGPPRPAAAAATAP
LANGRAGKRRPSRLVALREQKALKTLGIIMGVFTLCWLPFFLANVVKAFHRELVPDRLFV
FFNWLGYANSAFNPIIYCRSPDFRKAFQRLLCCARRAARRRHATHGDRPRASGCLARPGP
PPSPGAASDDDDDDVVGATPPARLLEPWAGCNGGAAADSDSSLDEPCRPGFASESKV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010189|Beta-1 adrenergic receptor (ADRB1)
ATGGGCGCGGGGGTGCTCGTCCTGGGCGCCTCCGAGCCCGGTAACCTGTCGTCGGCCGCA
CCGCTCCCCGACGGCGCGGCCACCGCGGCGCGGCTGCTGGTGCCCGCGTCGCCGCCCGCC
TCGTTGCTGCCTCCCGCCAGCGAAAGCCCCGAGCCGCTGTCTCAGCAGTGGACAGCGGGC
ATGGGTCTGCTGATGGCGCTCATCGTGCTGCTCATCGTGGCGGGCAATGTGCTGGTGATC
GTGGCCATCGCCAAGACGCCGCGGCTGCAGACGCTCACCAACCTCTTCATCATGTCCCTG
GCCAGCGCCGACCTGGTCATGGGGCTGCTGGTGGTGCCGTTCGGGGCCACCATCGTGGTG
TGGGGCCGCTGGGAGTACGGCTCCTTCTTCTGCGAGCTGTGGACCTCAGTGGACGTGCTG
TGCGTGACGGCCAGCATCGAGACCCTGTGTGTCATTGCCCTGGACCGCTACCTCGCCATC
ACCTCGCCCTTCCGCTACCAGAGCCTGCTGACGCGCGCGCGGGCGCGGGGCCTCGTGTGC
ACCGTGTGGGCCATCTCGGCCCTGGTGTCCTTCCTGCCCATCCTCATGCACTGGTGGCGG
GCGGAGAGCGACGAGGCGCGCCGCTGCTACAACGACCCCAAGTGCTGCGACTTCGTCACC
AACCGGGCCTACGCCATCGCCTCGTCCGTAGTCTCCTTCTACGTGCCCCTGTGCATCATG
GCCTTCGTGTACCTGCGGGTGTTCCGCGAGGCCCAGAAGCAGGTGAAGAAGATCGACAGC
TGCGAGCGCCGTTTCCTCGGCGGCCCAGCGCGGCCGCCCTCGCCCTCGCCCTCGCCCGTC
CCCGCGCCCGCGCCGCCGCCCGGACCCCCGCGCCCCGCCGCCGCCGCCGCCACCGCCCCG
CTGGCCAACGGGCGTGCGGGTAAGCGGCGGCCCTCGCGCCTCGTGGCCCTGCGCGAGCAG
AAGGCGCTCAAGACGCTGGGCATCATCATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTC
TTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAGCTGGTGCCCGACCGCCTCTTCGTC
TTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACTGCCGCAGC
CCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGG
CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCC
CCGCCATCGCCCGGGGCCGCCTCGGACGACGACGACGACGATGTCGTCGGGGCCACGCCG
CCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCGGGGCGGCGGCGGACAGCGAC
TCGAGCCTGGACGAGCCGTGCCGCCCCGGCTTCGCCTCGGAATCCAAGGTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>early endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>alpha-2A adrenergic receptor binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta1-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>PDZ domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Ras guanyl-nucleotide exchange factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor signaling protein activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diet induced thermogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heat generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of GTPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of heart rate by epinephrine-norepinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of the force of heart contraction by epinephrine-norepinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cold</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>temperature homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="29">
      <id>BE0000694</id>
      <name>Beta-2 adrenergic receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P07550" source="Swiss-Prot">
        <name>Beta-2 adrenergic receptor</name>
        <general-function>Protein homodimerization activity</general-function>
        <specific-function>Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.</specific-function>
        <gene-name>ADRB2</gene-name>
        <locus>5q31-q32</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>35-58
72-95
107-129
151-174
197-220
275-298
306-329</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.44</theoretical-pi>
        <molecular-weight>46458.32</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:286</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ADRB2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>Y00106</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>29371</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>29</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>29</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P07550</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ADRB2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>ADRB2R</synonym>
          <synonym>B2AR</synonym>
          <synonym>Beta-2 adrenoceptor</synonym>
          <synonym>Beta-2 adrenoreceptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037061|Beta-2 adrenergic receptor
MGQPGNGSAFLLAPNGSHAPDHDVTQERDEVWVVGMGIVMSLIVLAIVFGNVLVITAIAK
FERLQTVTNYFITSLACADLVMGLAVVPFGAAHILMKMWTFGNFWCEFWTSIDVLCVTAS
IETLCVIAVDRYFAITSPFKYQSLLTKNKARVIILMVWIVSGLTSFLPIQMHWYRATHQE
AINCYANETCCDFFTNQAYAIASSIVSFYVPLVIMVFVYSRVFQEAKRQLQKIDKSEGRF
HVQNLSQVEQDGRTGHGLRRSSKFCLKEHKALKTLGIIMGTFTLCWLPFFIVNIVHVIQD
NLIRKEVYILLNWIGYVNSGFNPLIYCRSPDFRIAFQELLCLRRSSLKAYGNGYSSNGNT
GEQSGYHVEQEKENKLLCEDLPGTEDFVGHQGTVPSDNIDSQGRNCSTNDSLL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020478|Beta-2 adrenergic receptor (ADRB2)
ATGGGGCAACCCGGGAACGGCAGCGCCTTCTTGCTGGCACCCAATAGAAGCCATGCGCCG
GACCACGACGTCACGCAGCAAAGGGACGAGGTGTGGGTGGTGGGCATGGGCATCGTCATG
TCTCTCATCGTCCTGGCCATCGTGTTTGGCAATGTGCTGGTCATCACAGCCATTGCCAAG
TTCGAGCGTCTGCAGACGGTCACCAACTACTTCATCACTTCACTGGCCTGTGCTGATCTG
GTCATGGGCCTGGCAGTGGTGCCCTTTGGGGCCGCCCATATTCTTATGAAAATGTGGACT
TTTGGCAACTTCTGGTGCGAGTTTTGGACTTCCATTGATGTGCTGTGCGTCACGGCCAGC
ATTGAGACCCTGTGCGTGATCGCAGTGGATCGCTACTTTGCCATTACTTCACCTTTCAAG
TACCAGAGCCTGCTGACCAAGAATAAGGCCCGGGTGATCATTCTGATGGTGTGGATTGTG
TCAGGCCTTACCTCCTTCTTGCCCATTCAGATGCACTGGTACCGGGCCACCCACCAGGAA
GCCATCAACTGCTATGCCAATGAGACCTGCTGTGACTTCTTCACGAACCAAGCCTATGCC
ATTGCCTCTTCCATCGTGTCCTTCTACGTTCCCCTGGTGATCATGGTCTTCGTCTACTCC
AGGGTCTTTCAGGAGGCCAAAAGGCAGCTCCAGAAGATTGACAAATCTGAGGGCCGCTTC
CATGTCCAGAACCTTAGCCAGGTGGAGCAGGATGGGCGGACGGGGCATGGACTCCGCAGA
TCTTCCAAGTTCTGCTTGAAGGAGCACAAAGCCCTCAAGACGTTAGGCATCATCATGGGC
ACTTTCACCCTCTGCTGGCTGCCCTTCTTCATCGTTAACATTGTGCATGTGATCCAGGAT
AACCTCATCCGTAAGGAAGTTTACATCCTCCTAAATTGGATAGGCTATGTCAATTCTGGT
TTCAATCCCCTTATCTACTGCCGGAGCCCAGATTTCAGGATTGCCTTCCAGGAGCTTCTG
TGCCTGCGCAGGTCTTCTTTGAAGGCCTATGGGAATGGCTACTCCAGCAACGGCAACACA
GGGGAGCAGAGTGGATATCACGTGGAACAGGAGAAAGAAAATAAACTGCTGTGTGAAGAC
CTCCCAGGCACGGAAGACTTTGTGGGCCATCAAGGTACTGTGCCTAGCGATAACATTGAT
TCACAAGGGAGGAATTGTAGTACAAATGACTCACTGCTGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apical plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>early endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta2-adrenergic receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>epinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>norepinephrine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>potassium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of transmembrane receptor protein tyrosine kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating adrenergic receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>aging</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>associative learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bone resorption</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>desensitization of G-protein coupled receptor protein signaling pathway by arrestin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diaphragm contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>diet induced thermogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>endosome to lysosome transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>estrous cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>female pregnancy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heat generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>liver regeneration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mitophagy in response to mitochondrial depolarization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of ossification</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of platelet aggregation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of urine volume</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ATPase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of autophagosome maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of bone mineralization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of lipophagy</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of potassium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein ubiquitination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of skeletal muscle tissue growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of sodium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of the force of heart contraction by epinephrine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasodilation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cold</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to dexamethasone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to monoamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to progesterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to testosterone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasodilation by norepinephrine-epinephrine involved in regulation of systemic arterial blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>wound healing</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="30">
      <id>BE0000112</id>
      <name>Histamine H2 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P25021" source="Swiss-Prot">
        <name>Histamine H2 receptor</name>
        <general-function>Histamine receptor activity</general-function>
        <specific-function>The H2 subclass of histamine receptors mediates gastric acid secretion. Also appears to regulate gastrointestinal motility and intestinal secretion. Possible role in regulating cell growth and differentiation. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase and, through a separate G protein-dependent mechanism, the phosphoinositide/protein kinase (PKC) signaling pathway (By similarity).</specific-function>
        <gene-name>HRH2</gene-name>
        <locus>5q35.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>23-44
58-81
93-114
135-159
181-204
235-258
268-289</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.39</theoretical-pi>
        <molecular-weight>40097.65</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5183</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HRH2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M64799</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>184088</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>263</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>263</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P25021</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HRH2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Gastric receptor I</synonym>
          <synonym>H2R</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000224|Histamine H2 receptor
MAPNGTASSFCLDSTACKITITVVLAVLILITVAGNVVVCLAVGLNRRLRNLTNCFIVSL
AITDLLLGLLVLPFSAIYQLSCKWSFGKVFCNIYTSLDVMLCTASILNLFMISLDRYCAV
MDPLRYPVLVTPVRVAISLVLIWVISITLSFLSIHLGWNSRNETSKGNHTTSKCKVQVNE
VYGLVDGLVTFYLPLLIMCITYYRIFKVARDQAKRINHISSWKAATIREHKATVTLAAVM
GAFIICWFPYFTAFVYRGLRGDDAINEVLEAIVLWLGYANSALNPILYAALNRDFRTGYQ
QLFCCRLANRNSHKTSLRSNASQLSRTQSREPRQQEEKPLKLQVWSGTEVTAPQGATDR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0018919|Histamine H2 receptor (HRH2)
ATGGCACCCAATGGCACAGCCTCTTCCTTTTGCCTGGACTCTACCGCATGCAAGATCACC
ATCACCGTGGTCCTTGCGGTCCTCATCCTCATCACCGTTGCTGGCAATGTGGTCGTCTGT
CTGGCCGTGGGCTTGAACCGCCGGCTCCGCAACCTGACCAATTGTTTCATCGTGTCCTTG
GCTATCACTGACCTGCTCCTCGGCCTCCTGGTGCTGCCCTTCTCTGCCATCTACCAGCTG
TCCTGCAAGTGGAGCTTTGGCAAGGTCTTCTGCAATATCTACACCAGCCTGGATGTGATG
CTCTGCACAGCCTCCATTCTTAACCTCTTCATGATCAGCCTCGACCGGTACTGCGCTGTC
ATGGACCCACTGCGGTACCCTGTGCTGGTCACCCCAGTTCGGGTCGCCATCTCTCTGGTC
TTAATTTGGGTCATCTCCATTACCCTGTCCTTTCTGTCTATCCACCTGGGGTGGAACAGC
AGGAACGAGACCAGCAAGGGCAATCATACCACCTCTAAGTGCAAAGTCCAGGTCAATGAA
GTGTACGGGCTGGTGGATGGGCTGGTCACCTTCTACCTCCCGCTACTGATCATGTGCATC
ACCTACTACCGCATCTTCAAGGTCGCCCGGGATCAGGCCAAGAGGATCAATCACATTAGC
TCCTGGAAGGCAGCCACCATCAGGGAGCACAAAGCCACAGTGACACTGGCCGCCGTCATG
GGGGCCTTCATCATCTGCTGGTTTCCCTACTTCACCGCGTTTGTGTACCGTGGGCTGAGA
GGGGATGATGCCATCAATGAGGTGTTAGAAGCCATCGTTCTGTGGCTGGGCTATGCCAAC
TCAGCCCTGAACCCCATCCTGTATGCTGCGCTGAACAGAGACTTCCGCACCGGGTACCAA
CAGCTCTTCTGCTGCAGGCTGGCCAACCGCAACTCCCACAAAACTTCTCTGAGGTCCAAC
GCCTCTCAGCTGTCCAGGACCCAAAGCCGAGAACCCAGGCAACAGGAAGAGAAACCCCTG
AAGCTCCAGGTGTGGAGTGGGACAGAAGTCACGGCCCCCCAGGGAGCCACAGACAGACCA
TGGCTTTGCCTTCCAGAATGCTGGTCTGTGGAACTGACCCATTCATTCATTCATTTGTTC
ATTCATTCATTTGCAAACATTCATCCAATTCCCACCACATGCCAGGAATTATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestive tract development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epithelial cell morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gastrin-induced gastric acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gland development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>histamine-induced gastric acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of adenylate cyclase activity involved in G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toxin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="31">
      <id>BE0000968</id>
      <name>Histamine H3 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9Y5N1" source="Swiss-Prot">
        <name>Histamine H3 receptor</name>
        <general-function>Histamine receptor activity</general-function>
        <specific-function>The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. Signals through the inhibition of adenylate cyclase and displays high constitutive activity (spontaneous activity in the absence of agonist). Agonist stimulation of isoform 3 neither modified adenylate cyclase activity nor induced intracellular calcium mobilization.</specific-function>
        <gene-name>HRH3</gene-name>
        <locus>20q13.33</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>40-60
71-91
109-129
157-177
197-217
360-380
396-416</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.53</theoretical-pi>
        <molecular-weight>48670.81</molecular-weight>
        <chromosome-location>20</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5184</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HRH3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF140538</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>5031291</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>264</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>264</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9Y5N1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HRH3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>G-protein coupled receptor 97</synonym>
          <synonym>GPCR97</synonym>
          <synonym>H3R</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001927|Histamine H3 receptor
MERAPPDGPLNASGALAGEAAAAGGARGFSAAWTAVLAALMALLIVATVLGNALVMLAFV
ADSSLRTQNNFFLLNLAISDFLVGAFCIPLYVPYVLTGRWTFGRGLCKLWLVVDYLLCTS
SAFNIVLISYDRFLSVTRAVSYRAQQGDTRRAVRKMLLVWVLAFLLYGPAILSWEYLSGG
SSIPEGHCYAEFFYNWYFLITASTLEFFTPFLSVTFFNLSIYLNIQRRTRLRLDGAREAA
GPEPPPEAQPSPPPPPGCWGCWQKGHGEAMPLHRYGVGEAAVGAEAGEATLGGGGGGGSV
ASPTSSSGSSSRGTERPRSLKRGSKPSASSASLEKRMKMVSQSFTQRFRLSRDRKVAKSL
AVIVSIFGLCWAPYTLLMIIRAACHGHCVPDYWYETSFWLLWANSAVNPVLYPLCHHSFR
RAFTKLLCPQKLKIQPHSSLEHCWK</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016270|Histamine H3 receptor (HRH3)
ATGGAGCGCGCGCCGCCCGACGGGCCGCTGAACGCTTCGGGGGCGCTGGCGGGCGAGGCG
GCGGCGGCGGGCGGGGCGCGCGGCTTCTCGGCAGCCTGGACCGCGGTGCTGGCCGCGCTC
ATGGCGCTGCTCATCGTGGCCACGGTGCTGGGCAACGCGCTGGTCATGCTCGCCTTCGTG
GCCGACTCGAGCCTCCGCACCCAGAACAACTTCTTCCTGCTCAACCTCGCCATCTCCGAC
TTCCTCGTCGGCGCCTTCTGCATCCCACTGTATGTACCCTACGTGCTGACAGGCCGCTGG
ACCTTCGGCCGGGGCCTCTGCAAGCTGTGGCTGGTAGTGGACTACCTGCTGTGCACCTCC
TCTGCCTTCAACATCGTGCTCATCAGCTACGACCGCTTCCTGTCGGTCACCCGAGCGGTC
TCATACCGGGCCCAGCAGGGTGACACGCGGCGGGCAGTGCGGAAGATGCTGCTGGTGTGG
GTGCTGGCCTTCCTGCTGTACGGACCAGCCATCCTGAGCTGGGAGTACCTGTCCGGGGGC
AGCTCCATCCCCGAGGGCCACTGCTATGCCGAGTTCTTCTACAACTGGTACTTCCTCATC
ACGGCTTCCACCCTGGAGTTCTTTACGCCCTTCCTCAGCGTCACCTTCTTTAACCTCAGC
ATCTACCTGAACATCCAGAGGCGCACCCGCCTCCGGCTGGATGGGGCTCGAGAGGCAGCC
GGCCCCGAGCCCCCTCCCGAGGCCCAGCCCTCACCACCCCCACCGCCTGGCTGCTGGGGC
TGCTGGCAGAAGGGGCACGGGGAGGCCATGCCGCTGCACAGGTATGGGGTGGGTGAGGCG
GCCGTAGGCGCTGAGGCCGGGGAGGCGACCCTCGGGGGTGGCGGTGGGGGCGGCTCCGTG
GCTTCACCCACCTCCAGCTCCGGCAGCTCCTCGAGGGGCACTGAGAGGCCGCGCTCACTC
AAGAGGGGCTCCAAGCCGTCGGCGTCCTCGGCCTCGCTGGAGAAGCGCATGAAGATGGTG
TCCCAGAGCTTCACCCAGCGCTTTCGGCTGTCTCGGGACAGGAAAGTGGCCAAGTCGCTG
GCCGTCATCGTGAGCATCTTTGGGCTCTGCTGGGCCCCATACACGCTGCTGATGATCATC
CGGGCCGCCTGCCATGGCCACTGCGTCCCTGACTACTGGTACGAAACCTCCTTCTGGCTC
CTGTGGGCCAACTCGGCTGTCAACCCTGTCCTCTACCCTCTGTGCCACCACAGCTTCCGC
CGGGCCTTCACCAAGCTGCTCTGCCCCCAGAAGCTCAAAATCCAGCCCCACAGCTCCCTG
GAGCACTGCTGGAAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cognition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of glutamate secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of serotonin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of norepinephrine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="32">
      <id>BE0000146</id>
      <name>Histamine H4 receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9H3N8" source="Swiss-Prot">
        <name>Histamine H4 receptor</name>
        <general-function>Histamine receptor activity</general-function>
        <specific-function>The H4 subclass of histamine receptors could mediate the histamine signals in peripheral tissues. Displays a significant level of constitutive activity (spontaneous activity in the absence of agonist).</specific-function>
        <gene-name>HRH4</gene-name>
        <locus>18q11.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>20-40
53-73
88-108
132-152
173-193
305-325
342-362</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.92</theoretical-pi>
        <molecular-weight>44495.375</molecular-weight>
        <chromosome-location>18</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:17383</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>HRH4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AB044934</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>10241847</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>265</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>265</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9H3N8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HRH4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>AXOR35</synonym>
          <synonym>G-protein coupled receptor 105</synonym>
          <synonym>GPCR105</synonym>
          <synonym>GPRv53</synonym>
          <synonym>H4R</synonym>
          <synonym>Pfi-013</synonym>
          <synonym>SP9144</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000291|Histamine H4 receptor
MPDTNSTINLSLSTRVTLAFFMSLVAFAIMLGNALVILAFVVDKNLRHRSSYFFLNLAIS
DFFVGVISIPLYIPHTLFEWDFGKEICVFWLTTDYLLCTASVYNIVLISYDRYLSVSNAV
SYRTQHTGVLKIVTLMVAVWVLAFLVNGPMILVSESWKDEGSECEPGFFSEWYILAITSF
LEFVIPVILVAYFNMNIYWSLWKRDHLSRCQSHPGLTAVSSNICGHSFRGRLSSRRSLSA
STEVPASFHSERQRRKSSLMFSSRTKMNSNTIASKMGSFSQSDSVALHQREHVELLRARR
LAKSLAILLGVFAVCWAPYSLFTIVLSFYSSATGPKSVWYRIAFWLQWFNSFVNPLLYPL
CHKRFQKAFLKIFCIKKQPLPSQHSRSVSS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009967|Histamine H4 receptor (HRH4)
ATGCCAGATACTAATAGCACAATCAATTTATCACTAAGCACTCGTGTTACTTTAGCATTT
TTTATGTCCTTAGTAGCTTTTGCTATAATGCTAGGAAATGCTTTGGTCATTTTAGCTTTT
GTGGTGGACAAAAACCTTAGACATCGAAGTAGTTATTTTTTTCTTAACTTGGCCATCTCT
GACTTCTTTGTGGTTTCAGAGTCTTGGAAGGATGAAGGTAGTGAATGTGAACCTGGATTT
TTTTCGGAATGGTACATCCTTGCCATCACATCATTCTTGGAATTCGTGATCCCAGTCATC
TTAGTCGCTTATTTCAACATGAATATTTATTGGAGCCTGTGGAAGCGTGATCATCTCAGT
AGGTGCCAAAGCCATCCTGGACTGACTGCTGTCTCTTCCAACATCTGTGGACACTCATTC
AGAGGTAGACTATCTTCAAGGAGATCTCTTTCTGCATCGACAGAAGTTCCTGCATCCTTT
CATTCAGAGAGACAGAGGAGAAAGAGTAGTCTCATGTTTTCCTCAAGAACCAAGATGAAT
AGCAATACAATTGCTTCCAAAATGGGTTCCTTCTCCCAATCAGATTCTGTAGCTCTTCAC
CAAAGGGAACATGTTGAACTGCTTAGAGCCAGGAGATTAGCCAAGTCACTGGCCATTCTC
TTAGGGGTTTTTGCTGTTTGCTGGGCTCCATATTCTCTGTTCACAATTGTCCTTTCATTT
TATTCCTCAGCAACAGGTCCTAAATCAGTTTGGTATAGAATTGCATTTTGGCTTCAGTGG
TTCAATTCCTTTGTCAATCCTCTTTTGTATCCATTGTGTCACAAGCGCTTTCAAAAGGCT
TTCTTGAAAATATTTTGTATAAAAAAGCAACCTCTACCATCACAACACAGTCGGTCAGTA
TCTTCTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>histamine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="33">
      <id>BE0000092</id>
      <name>Muscarinic acetylcholine receptor M1</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P11229" source="Swiss-Prot">
        <name>Muscarinic acetylcholine receptor M1</name>
        <general-function>Phosphatidylinositol phospholipase c activity</general-function>
        <specific-function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.</specific-function>
        <gene-name>CHRM1</gene-name>
        <locus>11q13</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>25-47
62-82
100-121
142-164
187-209
367-387
402-421</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.67</theoretical-pi>
        <molecular-weight>51420.375</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1950</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRM1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X52068</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>34451</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>13</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>13</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P11229</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACM1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000184|Muscarinic acetylcholine receptor M1
MNTSAPPAVSPNITVLAPGKGPWQVAFIGITTGLLSLATVTGNLLVLISFKVNTELKTVN
NYFLLSLACADLIIGTFSMNLYTTYLLMGHWALGTLACDLWLALDYVASNASVMNLLLIS
FDRYFSVTRPLSYRAKRTPRRAALMIGLAWLVSFVLWAPAILFWQYLVGERTVLAGQCYI
QFLSQPIITFGTAMAAFYLPVTVMCTLYWRIYRETENRARELAALQGSETPGKGGGSSSS
SERSQPGAEGSPETPPGRCCRCCRAPRLLQAYSWKEEEEEDEGSMESLTSSEGEEPGSEV
VIKMPMVDPEAQAPTKQPPRSSPNTVKRPTKKGRDRAGKGQKPRGKEQLAKRKTFSLVKE
KKAARTLSAILLAFILTWTPYNIMVLVSTFCKDCVPETLWELGYWLCYVNSTINPMCYAL
CNKAFRDTFRLLLLCRWDKRRWRKIPKRPGSVHRTPSRQC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009929|Muscarinic acetylcholine receptor M1 (CHRM1)
ATGAACACTTCAGCCCCACCTGCTGTCAGCCCCAACATCACCGTCCTGGCACCAGGAAAG
GGTCCCTGGCAAGTGGCCTTCATTGGGATCACCACGGGCCTCCTGTCGCTAGCCACAGTG
ACAGGCAACCTGCTGGTACTCATCTCTTTCAAGGTCAACACGGAGCTCAAGACAGTCAAT
AACTACTTCCTGCTGAGCCTGGCCTGTGCTGACCTCATCATCGGTACCTTCTCCATGAAC
CTCTATACCACGTACCTGCTCATGGGCCACTGGGCTCTGGGCACGCTGGCTTGTGACCTC
TGGCTGGCCCTGGACTATGTGGCCAGCAATGCCTCCGTCATGAATCTGCTGCTCATCAGC
TTTGACCGCTACTTCTCCGTGACTCGGCCCCTGAGCTACCGTGCCAAGCGCACACCCCGC
CGGGCAGCTCTGATGATCGGCCTGGCCTGGCTGGTTTCCTTTGTGCTCTGGGCCCCAGCC
ATCCTCTTCTGGCAGTACCTGGTAGGGGAGCGGACAGTGCTAGCTGGGCAGTGCTACATC
CAGTTCCTCTCCCAGCCCATCATCACCTTTGGCACAGCCATGGCTGCCTTCTACCTCCCT
GTCACAGTCATGTGCACGCTCTACTGGCGCATCTACCGGGAGACAGAGAACCGAGCACGG
GAGCTGGCAGCCCTTCAGGGCTCCGAGACGCCAGGCAAAGGGGGTGGCAGCAGCAGCAGC
TCAGAGAGGTCTCAGCCAGGGGCTGAGGGCTCACCAGAGACTCCTCCAGGCCGCTGCTGT
CGCTGCTGCCGGGCCCCCAGGCTGCTGCAGGCCTACAGCTGGAAGGAAGAAGAGGAAGAG
GACGAAGGCTCCATGGAGTCCCTCACATCCTCAGAGGGAGAGGAGCCTGGCTCCGAAGTG
GTGATCAAGATGCCAATGGTGGACCCCGAGGCACAGGCCCCCACCAAGCAGCCCCCACGG
AGCTCCCCAAATACAGTCAAGAGGCCGACTAAGAAAGGGCGTGATCGAGCTGGCAAGGGC
CAGAAGCCCCGTGGAAAGGAGCAGCTGGCCAAGCGGAAGACCTTCTCGCTGGTCAAGGAG
AAGAAGGCGGCTCGGACCCTGAGTGCCATCCTCCTGGCCTTCATCCTCACCTGGACACCG
TACAACATCATGGTGCTGGTGTCCACCTTCTGCAAGGACTGTGTTCCCGAGACCCTGTGG
GAGCTGGGCTACTGGCTGTGCTACGTCAACAGCACCATCAACCCCATGTGCTACGCACTC
TGCAACAAAGCCTTCCGGGACACCTTTCGCCTGCTGCTGCTTTGCCGCTGGGACAAGAGA
CGCTGGCGCAAGATCCCCAAGCGCCCTGGCTCCGTGCACCGCACTCCCTCCCGCCAATGC
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein modification process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cognition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>entrainment of circadian clock</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phototransduction, visible light</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of intracellular protein transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein kinase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>saliva secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="34">
      <id>BE0000560</id>
      <name>Muscarinic acetylcholine receptor M2</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08172" source="Swiss-Prot">
        <name>Muscarinic acetylcholine receptor M2</name>
        <general-function>G-protein coupled acetylcholine receptor activity</general-function>
        <specific-function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol.</specific-function>
        <gene-name>CHRM2</gene-name>
        <locus>7q31-q35</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>23-45
60-80
98-119
140-162
185-209
388-410
419-442</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.08</theoretical-pi>
        <molecular-weight>51714.605</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1951</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRM2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M16404</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177990</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>14</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>14</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08172</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACM2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016133|Muscarinic acetylcholine receptor M2
MNNSTNSSNNSLALTSPYKTFEVVFIVLVAGSLSLVTIIGNILVMVSIKVNRHLQTVNNY
FLFSLACADLIIGVFSMNLYTLYTVIGYWPLGPVVCDLWLALDYVVSNASVMNLLIISFD
RYFCVTKPLTYPVKRTTKMAGMMIAAAWVLSFILWAPAILFWQFIVGVRTVEDGECYIQF
FSNAAVTFGTAIAAFYLPVIIMTVLYWHISRASKSRIKKDKKEPVANQDPVSPSLVQGRI
VKPNNNNMPSSDDGLEHNKIQNGKAPRDPVTENCVQGEEKESSNDSTSVSAVASNMRDDE
ITQDENTVSTSLGHSKDENSKQTCIRIGTKTPKSDSCTPTNTTVEVVGSSGQNGDEKQNI
VARKIVKMTKQPAKKKPPPSREKKVTRTILAILLAFIITWAPYNVMVLINTFCAPCIPNT
VWTIGYWLCYINSTINPACYALCNATFKKTFKHLLMCHYKNIGATR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016134|Muscarinic acetylcholine receptor M2 (CHRM2)
ATGAATAACTCAACAAACTCCTCTAACAATAGCCTGGCTCTTACAAGTCCTTATAAGACA
TTTGAAGTGGTGTTTATTGTCCTGGTGGCTGGATCCCTCAGTTTGGTGACCATTATCGGG
AACATCCTAGTCATGGTTTCCATTAAAGTCAACCGCCACCTCCAGACCGTCAACAATTAC
TTTTTATTCAGCTTGGCCTGTGCTGACCTTATCATAGGTGTTTTCTCCATGAACTTGTAC
ACCCTCTACACTGTGATTGGTTACTGGCCTTTGGGACCTGTGGTGTGTGACCTTTGGCTA
GCCCTGGACTATGTGGTCAGCAATGCCTCAGTTATGAATCTGCTCATCATCAGCTTTGAC
AGGTACTTCTGTGTCACAAAACCTCTGACCTACCCAGTCAAGCGGACCACAAAAATGGCA
GGTATGATGATTGCAGCTGCCTGGGTCCTCTCTTTCATCCTCTGGGCTCCAGCCATTCTC
TTCTGGCAGTTCATTGTAGGGGTGAGAACTGTGGAGGATGGGGAGTGCTACATTCAGTTT
TTTTCCAATGCTGCTGTCACCTTTGGTACGGCTATTGCAGCCTTCTATTTGCCAGTGATC
ATCATGACTGTGCTATATTGGCACATATCCCGAGCCAGCAAGAGCAGGATAAAGAAGGAC
AAGAAGGAGCCTGTTGCCAACCAAGACCCCGTTTCTCCAAGTCTGGTACAAGGAAGGATA
GTGAAGCCAAACAATAACAACATGCCCAGCAGTGACGATGGCCTGGAGCACAACAAAATC
CAGAATGGCAAAGCCCCCAGGGATCCTGTGACTGAAAACTGTGTTCAGGGAGAGGAGAAG
GAGAGCTCCAATGACTCCACCTCAGTCAGTGCTGTTGCCTCTAATATGAGAGATGATGAA
ATAACCCAGGATGAAAACACAGTTTCCACTTCCCTGGGCCATTCCAAAGATGAGAACTCT
AAGCAAACATGCATCAGAATTGGCACCAAGACCCCAAAAAGTGACTCATGTACCCCAACT
AATACCACCGTGGAGGTAGTGGGGTCTTCAGGTCAGAATGGAGATGAAAAGCAGAATATT
GTAGCCCGCAAGATTGTGAAGATGACTAAGCAGCCTGCAAAAAAGAAGCCTCCTCCTTCC
CGGGAAAAGAAAGTCACCAGGACAATCTTGGCTATTCTGTTGGCTTTCATCATCACTTGG
GCCCCATACAATGTCATGGTGCTCATTAACACCTTTTGTGCACCTTGCATCCCCAACACT
GTGTGGACAATTGGTTACTGGCTTTGTTACATCAACAGCACTATCAACCCTGCCTGCTAT
GCACTTTGCAATGCCACCTTCAAGAAGACCTTTAAACACCTTCTCATGTGTCATTATAAG
AACATAGGCGCTACAAGGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>symmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-modulating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of heart contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="35">
      <id>BE0000045</id>
      <name>Muscarinic acetylcholine receptor M3</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P20309" source="Swiss-Prot">
        <name>Muscarinic acetylcholine receptor M3</name>
        <general-function>Receptor activity</general-function>
        <specific-function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.</specific-function>
        <gene-name>CHRM3</gene-name>
        <locus>1q43</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>68-91
105-130
143-164
185-206
230-252
492-514
527-546</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.62</theoretical-pi>
        <molecular-weight>66127.445</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1952</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRM3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X15266</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>32324</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>15</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>15</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P20309</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACM3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0009898|Muscarinic acetylcholine receptor M3
MTLHNNSTTSPLFPNISSSWIHSPSDAGLPPGTVTHFGSYNVSRAAGNFSSPDGTTDDPL
GGHTVWQVVFIAFLTGILALVTIIGNILVIVSFKVNKQLKTVNNYFLLSLACADLIIGVI
SMNLFTTYIIMNRWALGNLACDLWLAIDYVASNASVMNLLVISFDRYFSITRPLTYRAKR
TTKRAGVMIGLAWVISFVLWAPAILFWQYFVGKRTVPPGECFIQFLSEPTITFGTAIAAF
YMPVTIMTILYWRIYKETEKRTKELAGLQASGTEAETENFVHPTGSSRSCSSYELQQQSM
KRSNRRKYGRCHFWFTTKSWKPSSEQMDQDHSSSDSWNNNDAAASLENSASSDEEDIGSE
TRAIYSIVLKLPGHSTILNSTKLPSSDNLQVPEEELGMVDLERKADKLQAQKSVDDGGSF
PKSFSKLPIQLESAVDTAKTSDVNSSVGKSTATLPLSFKEATLAKRFALKTRSQITKRKR
MSLVKEKKAAQTLSAILLAFIITWTPYNIMVLVNTFCDSCIPKTFWNLGYWLCYINSTVN
PVCYALCNKTFRTTFKMLLLCQCDKKKRRKQQYQQRQSVIFHKRAPEQAL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0009899|Muscarinic acetylcholine receptor M3 (CHRM3)
ATGACCTTGCACAATAACAGTACAACCTCGCCTTTGTTTCCAAACATCAGCTCCTCCTGG
ATACACAGCCCCTCCGATGCAGGGCTGCCCCCGGGAACCGTCACTCATTTCGGCAGCTAC
AATGTTTCTCGAGCAGCTGGCAATTTCTCCTCTCCAGACGGTACCACCGATGACCCTCTG
GGAGGTCATACCGTCTGGCAAGTGGTCTTCATCGCTTTCTTAACGGGCATCCTGGCCTTG
GTGACCATCATCGGCAACATCCTGGTAATTGTGTCATTTAAGGTCAACAAGCAGCTGAAG
ACGGTCAACAACTACTTCCTCTTAAGCCTGGCCTGTGCCGATCTGATTATCGGGGTCATT
TCAATGAATCTGTTTACGACCTACATCATCATGAATCGATGGGCCTTAGGGAACTTGGCC
TGTGACCTCTGGCTTGCCATTGACTACGTAGCCAGCAATGCCTCTGTTATGAATCTTCTG
GTCATCAGCTTTGACAGATACTTTTCCATCACGAGGCCGCTCACGTACCGAGCCAAACGA
ACAACAAAGAGAGCCGGTGTGATGATCGGTCTGGCTTGGGTCATCTCCTTTGTCCTTTGG
GCTCCTGCCATCTTGTTCTGGCAATACTTTGTTGGAAAGAGAACTGTGCCTCCGGGAGAG
TGCTTCATTCAGTTCCTCAGTGAGCCCACCATTACTTTTGGCACAGCCATCGCTGCTTTT
TATATGCCTGTCACCATTATGACTATTTTATACTGGAGGATCTATAAGGAAACTGAAAAG
CGTACCAAAGAGCTTGCTGGCCTGCAAGCCTCTGGGACAGAGGCAGAGACAGAAAACTTT
GTCCACCCCACGGGCAGTTCTCGAAGCTGCAGCAGTTACGAACTTCAACAGCAAAGCATG
AAACGCTCCAACAGGAGGAAGTATGGCCGCTGCCACTTCTGGTTCACAACCAAGAGCTGG
AAACCCAGCTCCGAGCAGATGGACCAAGACCACAGCAGCAGTGACAGTTGGAACAACAAT
GATGCTGCTGCCTCCCTGGAGAACTCCGCCTCCTCCGACGAGGAGGACATTGGCTCCGAG
ACGAGAGCCATCTACTCCATCGTGCTCAAGCTTCCGGGTCACAGCACCATCCTCAACTCC
ACCAAGTTACCCTCATCGGACAACCTGCAGGTGCCTGAGGAGGAGCTGGGGATGGTGGAC
TTGGAGAGGAAAGCCGACAAGCTGCAGGCCCAGAAGAGCGTGGACGATGGAGGCAGTTTT
CCAAAAAGCTTCTCCAAGCTTCCCATCCAGCTAGAGTCAGCCGTGGACACAGCTAAGACT
TCTGACGTCAACTCCTCAGTGGGTAAGAGCACGGCCACTCTACCTCTGTCCTTCAAGGAA
GCCACTCTGGCCAAGAGGTTTGCTCTGAAGACCAGAAGTCAGATCACTAAGCGGAAAAGG
ATGTCCCTGGTCAAGGAGAAGAAAGCGGCCCAGACCCTCAGTGCGATCTTGCTTGCCTTC
ATCATCACTTGGACCCCATACAACATCATGGTTCTGGTGAACACCTTTTGTGACAGCTGC
ATACCCAAAACCTTTTGGAATCTGGGCTACTGGCTGTGCTACATCAACAGCACCGTGAAC
CCCGTGTGCTATGCTCTGTGCAACAAAACATTCAGAACCACTTTCAAGATGCTGCTGCTG
TGCCAGTGTGACAAAAAAAAGAGGCGCAAGCAGCAGTACCAGCAGAGACAGTCGGTCATT
TTTCACAAGCGCGCACCCGAGCAGGCCTTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>acetylcholine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular protein modification process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>energy reserve metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nervous system development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of insulin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of vascular smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>saliva secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="36">
      <id>BE0000405</id>
      <name>Muscarinic acetylcholine receptor M4</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08173" source="Swiss-Prot">
        <name>Muscarinic acetylcholine receptor M4</name>
        <general-function>Guanyl-nucleotide exchange factor activity</general-function>
        <specific-function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.</specific-function>
        <gene-name>CHRM4</gene-name>
        <locus>11p12-p11.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>32-54
69-89
107-128
149-171
194-216
402-422
437-456</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>10.34</theoretical-pi>
        <molecular-weight>53048.65</molecular-weight>
        <chromosome-location>11</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1953</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRM4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M16405</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>61970253</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>16</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>16</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08173</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACM4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010280|Muscarinic acetylcholine receptor M4
MANFTPVNGSSGNQSVRLVTSSSHNRYETVEMVFIATVTGSLSLVTVVGNILVMLSIKVN
RQLQTVNNYFLFSLACADLIIGAFSMNLYTVYIIKGYWPLGAVVCDLWLALDYVVSNASV
MNLLIISFDRYFCVTKPLTYPARRTTKMAGLMIAAAWVLSFVLWAPAILFWQFVVGKRTV
PDNQCFIQFLSNPAVTFGTAIAAFYLPVVIMTVLYIHISLASRSRVHKHRPEGPKEKKAK
TLAFLKSPLMKQSVKKPPPGEAAREELRNGKLEEAPPPALPPPPRPVADKDTSNESSSGS
ATQNTKERPATELSTTEATTPAMPAPPLQPRALNPASRWSKIQIVTKQTGNECVTAIEIV
PATPAGMRPAANVARKFASIARNQVRKKRQMAARERKVTRTIFAILLAFILTWTPYNVMV
LVNTFCQSCIPDTVWSIGYWLCYVNSTINPACYALCNATFKKTFRHLLLCQYRNIGTAR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010281|Muscarinic acetylcholine receptor M4 (CHRM4)
ATGGCCAACTTCACACCTGTCAATGGCAGCTCGGGCAATCAGTCCGTGCGCCTGGTCACG
TCATCATCCCACAATCGCTATGAGACGGTGGAAATGGTCTTCATTGCCACAGTGACAGGC
TCCCTGAGCCTGGTGACTGTCGTGGGCAACATCCTGGTGATGCTGTCCATCAAGGTCAAC
AGGCAGCTGCAGACAGTCAACAACTACTTCCTCTTCAGCCTGGCGTGTGCTGATCTCATC
ATAGGCGCCTTCTCCATGAACCTCTACACCGTGTACATCATCAAGGGCTACTGGCCCCTG
GGCGCCGTGGTCTGCGACCTGTGGCTGGCCCTGGACTACGTGGTGAGCAACGCCTCCGTC
ATGAACCTTCTCATCATCAGCTTTGACCGCTACTTCTGCGTCACCAAGCCTCTCACCTAC
CCTGCCCGGCGCACCACCAAGATGGCAGGCCTCATGATTGCTGCTGCCTGGGTACTGTCC
TTCGTGCTCTGGGCGCCTGCCATCTTGTTCTGGCAGTTTGTGGTGGGTAAGCGGACGGTG
CCCGACAACCAGTGCTTCATCCAGTTCCTGTCCAACCCAGCAGTGACCTTTGGCACAGCC
ATTGCTGCCTTCTACCTGCCTGTGGTCATCATGACGGTGCTGTACATCCACATCTCCCTG
GCCAGTCGCAGCCGAGTCCACAAGCACCGGCCCGAGGGCCCGAAGGAGAAGAAAGCCAAG
ACGCTGGCCTTCCTCAAGAGCCCACTAATGAAGCAGAGCGTCAAGAAGCCCCCGCCCGGG
GAGGCCGCCCGGGAGGAGCTGCGCAATGGCAAGCTGGAGGAGGCCCCCCCGCCAGCGCTG
CCACCGCCACCGCGCCCCGTGGCTGATAAGGACACTTCCAATGAGTCCAGCTCAGGCAGT
GCCACCCAGAACACCAAGGAACGCCCAGCCACAGAGCTGTCCACCACAGAGGCCACCACG
CCCGCCATGCCCGCCCCTCCCCTGCAGCCGCGGGCCCTCAACCCAGCCTCCAGATGGTCC
AAGATCCAGATTGTGACGAAGCAGACAGGCAATGAGTGTGTGACAGCCATTGAGATTGTG
CCTGCCACGCCGGCTGGCATGCGCCCTGCGGCCAACGTGGCCCGCAAGTTCGCCAGCATC
GCTCGCAACCAGGTGCGCAAGAAGCGGCAGATGGCGGCCCGGGAGCGCAAAGTGACACGA
ACGATCTTTGCCATTCTGCTAGCCTTCATCCTCACCTGGACGCCCTACAACGTCATGGTC
CTGGTGAACACCTTCTGCCAGAGCTGCATCCCTGACACGGTGTGGTCCATTGGCTACTGG
CTCTGCTACGTCAACAGCACCATCAACCCTGCCTGCTATGCTCTGTGCAACGCCACCTTT
AAAAAGACCTTCCGGCACCTGCTGCTGTGCCAGTATCGGAACATCGGCACTGCCAGGTAG
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>asymmetric synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>guanyl-nucleotide exchange factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to organic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="37">
      <id>BE0000247</id>
      <name>Muscarinic acetylcholine receptor M5</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P08912" source="Swiss-Prot">
        <name>Muscarinic acetylcholine receptor M5</name>
        <general-function>Phosphatidylinositol phospholipase c activity</general-function>
        <specific-function>The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.</specific-function>
        <gene-name>CHRM5</gene-name>
        <locus>15q26</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>30-53
67-87
105-126
147-169
192-214
444-464
479-498</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.64</theoretical-pi>
        <molecular-weight>60073.205</molecular-weight>
        <chromosome-location>15</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1954</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CHRM5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M80333</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>177988</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>17</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>17</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08912</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ACM5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010217|Muscarinic acetylcholine receptor M5
MEGDSYHNATTVNGTPVNHQPLERHRLWEVITIAAVTAVVSLITIVGNVLVMISFKVNSQ
LKTVNNYYLLSLACADLIIGIFSMNLYTTYILMGRWALGSLACDLWLALDYVASNASVMN
LLVISFDRYFSITRPLTYRAKRTPKRAGIMIGLAWLISFILWAPAILCWQYLVGKRTVPL
DECQIQFLSEPTITFGTAIAAFYIPVSVMTILYCRIYRETEKRTKDLADLQGSDSVTKAE
KRKPAHRALFRSCLRCPRPTLAQRERNQASWSSSRRSTSTTGKPSQATGPSANWAKAEQL
TTCSSYPSSEDEDKPATDPVLQVVYKSQGKESPGEEFSAEETEETFVKAETEKSDYDTPN
YLLSPAAAHRPKSQKCVAYKFRLVVKADGNQETNNGCHKVKIMPCPFPVAKEPSTKGLNP
NPSHQMTKRKRVVLVKERKAAQTLSAILLAFIITWTPYNIMVLVSTFCDKCVPVTLWHLG
YWLCYVNSTVNPICYALCNRTFRKTFKMLLLCRWKKKKVEEKLYWQGNSKLP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010218|Muscarinic acetylcholine receptor M5 (CHRM5)
ATGGAAGGGGATTCTTACCACAATGCAACCACCGTCAATGGCACCCCAGTAAATCACCAG
CCTTTGGAACGCCACAGGTTGTGGGAAGTCATCACCATTGCAGCTGTGACTGCTGTGGTA
AGCCTGATCACCATTGTGGGCAATGTCTTGGTCATGATCTCCTTCAAAGTCAACAGCCAG
CTCAAGACAGTTAACAACTATTACCTGCTCAGCTTAGCCTGTGCAGATCTCATCATTGGA
ATCTTCTCCATGAACCTCTACACCACCTACATCCTCATGGGACGCTGGGCTCTCGGGAGT
CTGGCTTGTGACCTTTGGCTTGCACTGGACTACGTGGCCAGCAACGCTTCTGTCATGAAC
CTTCTGGTGATCAGTTTTGACCGTTACTTTTCCATCACAAGACCCTTGACATATCGGGCC
AAGCGTACTCCGAAAAGGGCTGGCATCATGATTGGCTTGGCCTGGCTGATCTCCTTCATC
CTCTGGGCCCCAGCAATCCTCTGCTGGCAGTACTTGGTTGGGAAGCGGACAGTTCCACTG
GATGAGTGCCAGATCCAGTTTCTCTCTGAGCCCACCATCACTTTTGGCACTGCCATTGCT
GCCTTCTACATCCCTGTTTCTGTCATGACCATCCTCTACTGTCGAATCTACCGGGAAACA
GAGAAGCGAACCAAGGACCTGGCTGACCTCCAGGGTTCTGACTCTGTGACCAAAGCTGAG
AAGAGAAAGCCAGCTCATAGGGCTCTGTTCAGATCCTGCTTGCGCTGTCCTCGACCCACC
CTGGCCCAGCGGGAAAGGAACCAGGCCTCCTGGTCATCCTCCCGCAGGAGCACCTCCACC
ACTGGGAAGCCATCCCAAGCCACTGGCCCAAGCGCCAATTGGGCCAAAGCTGAGCAGCTC
ACCACCTGTAGCAGCTACCCTTCCTCAGAGGATGAGGACAAGCCCGCCACTGACCCTGTC
CTCCAAGTGGTCTACAAGAGTCAGGGTAAGGAAAGCCCAGGGGAAGAATTCAGTGCTGAA
GAGACTGAGGAAACTTTTGTGAAAGCTGAAACTGAAAAAAGTGACTATGACACCCCAAAC
TACCTTCTGTCTCCAGCAGCTGCTCATAGACCCAAGAGTCAGAAATGTGTGGCCTATAAG
TTCCGATTGGTGGTAAAAGCTGACGGGAACCAGGAGACCAACAATGGCTGTCACAAGGTG
AAAATCATGCCCTGCCCCTTCCCAGTGGCCAAGGAACCTTCAACGAAAGGCCTCAATCCC
AACCCCAGCCATCAAATGACCAAACGAAAGAGAGTGGTCCTAGTCAAAGAGAGGAAAGCA
GCCCAGACACTGAGTGCCATTCTCCTGGCCTTCATCATCACATGGACCCCGTATAACATC
ATGGTCCTGGTTTCTACCTTCTGTGACAAGTGTGTCCCAGTCACCCTGTGGCACTTGGGC
TATTGGTTGTGCTATGTCAATAGCACTGTCAACCCCATCTGCTATGCCCTCTGCAACAGA
ACCTTCAGGAAGACCTTTAAGATGCTGCTTCTCTGCCGATGGAAAAAGAAAAAAGTGGAA
GAGAAGTTGTACTGGCAGGGGAACAGCAAGCTACCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled acetylcholine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phosphatidylinositol phospholipase C activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>gastric acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled acetylcholine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of phosphatidylinositol dephosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of chemical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, cholinergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmission of nerve impulse</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="38">
      <id>BE0000632</id>
      <name>Kappa-type opioid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P41145" source="Swiss-Prot">
        <name>Kappa-type opioid receptor</name>
        <general-function>Opioid receptor activity</general-function>
        <specific-function>G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.</specific-function>
        <gene-name>OPRK1</gene-name>
        <locus>8q11.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>58-85
96-119
133-154
174-196
223-247
275-296
312-333</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.79</theoretical-pi>
        <molecular-weight>42644.665</molecular-weight>
        <chromosome-location>8</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8154</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>OPRK1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U11053</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>532060</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>318</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P41145</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>OPRK_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>K-OR-1</synonym>
          <synonym>OPRK</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001260|Kappa-type opioid receptor
MDSPIQIFRGEPGPTCAPSACLPPNSSAWFPGWAEPDSNGSAGSEDAQLEPAHISPAIPV
IITAVYSVVFVVGLVGNSLVMFVIIRYTKMKTATNIYIFNLALADALVTTTMPFQSTVYL
MNSWPFGDVLCKIVISIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPLKAKIINI
CIWLLSSSVGISAIVLGGTKVREDVDVIECSLQFPDDDYSWWDLFMKICVFIFAFVIPVL
IIIVCYTLMILRLKSVRLLSGSREKDRNLRRITRLVLVVVAVFVVCWTPIHIFILVEALG
STSHSTAALSSYYFCIALGYTNSSLNPILYAFLDENFKRCFRDFCFPLKMRMERQSTSRV
RNTVQDPAYLRDIDGMNKPV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021645|Kappa-type opioid receptor (OPRK1)
ATGGACTCCCCGATCCAGATCTTCCGCGGGGAGCCGGGCCCTACCTGCGCCCCGAGCGCC
TGCCTGCCCCCCAACAGCAGCGCCTGGTTTCCCGGCTGGGCCGAGCCCGACAGCAACGGC
AGCGCCGGCTCGGAGGACGCGCAGCTGGAGCCCGCGCACATCTCCCCGGCCATCCCGGTC
ATCATCACGGCGGTCTACTCCGTAGTGTTCGTCGTGGGCTTGGTGGGCAACTCGCTGGTC
ATGTTCGTGATCATCCGATACACAAAGATGAAGACAGCAACCAACATTTACATATTTAAC
CTGGCTTTGGCAGATGCTTTAGTTACTACAACCATGCCCTTTCAGAGTACGGTCTACTTG
ATGAATTCCTGGCCTTTTGGGGATGTGCTGTGCAAGATAGTAATTTCCATTGATTACTAC
AACATGTTCACCAGCATCTTCACCTTGACCATGATGAGCGTGGACCGCTACATTGCCGTG
TGCCACCCCGTGAAGGCTTTGGACTTCCGCACACCCTTGAAGGCAAAGATCATCAATATC
TGCATCTGGCTGCTGTCGTCATCTGTTGGCATCTCTGCAATAGTCCTTGGAGGCACCAAA
GTCAGGGAAGACGTCGATGTCATTGAGTGCTCCTTGCAGTTCCCAGATGATGACTACTCC
TGGTGGGACCTCTTCATGAAGATCTGCGTCTTCATCTTTGCCTTCGTGATCCCTGTCCTC
ATCATCATCGTCTGCTACACCCTGATGATCCTGCGTCTCAAGAGCGTCCGGCTCCTTTCT
GGCTCCCGAGAGAAAGATCGCAACCTGCGTAGGATCACCAGACTGGTCCTGGTGGTGGTG
GCAGTCTTCGTCGTCTGCTGGACTCCCATTCACATATTCATCCTGGTGGAGGCTCTGGGG
AGCACCTCCCACAGCACAGCTGCTCTCTCCAGCTATTACTTCTGCATCGCCTTAGGCTAT
ACCAACAGTAGCCTGAATCCCATTCTCTACGCCTTTCTTGATGAAAACTTCAAGCGGTGT
TTCCGGGACTTCTGCTTTCCACTGAAGATGAGGATGGAGCGGCAGAGCACTAGCAGAGTC
CGAAATACAGTTCAGGATCCTGCTTACCTGAGGGACATCGATGGGATGAATAAACCAGTA
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perikaryon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dynorphin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neuropeptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>opioid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting opioid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eating behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>estrous cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maternal behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of luteinizing hormone secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuropeptide signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>opioid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of p38MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of potassium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of aerobic respiration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of energy homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of saliva secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to acrylamide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estrogen</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to insulin</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to radiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of temperature stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="39">
      <id>BE0000770</id>
      <name>Mu-type opioid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35372" source="Swiss-Prot">
        <name>Mu-type opioid receptor</name>
        <general-function>Voltage-gated calcium channel activity</general-function>
        <specific-function>Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling whereas morphine induces only low desensitization and endocytosis. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis. Isoform 12 couples to GNAS and is proposed to be involved in excitatory effects. Isoform 16 and isoform 17 do not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.</specific-function>
        <gene-name>OPRM1</gene-name>
        <locus>6q24-q25</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>69-93
107-131
143-165
186-207
231-255
284-307
315-338</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.29</theoretical-pi>
        <molecular-weight>44778.855</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8156</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>OPRM1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L25119</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>452073</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>319</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35372</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>OPRM_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hMOP</synonym>
          <synonym>M-OR-1</synonym>
          <synonym>MOP</synonym>
          <synonym>MOR1</synonym>
          <synonym>Mu opiate receptor</synonym>
          <synonym>Mu opioid receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001536|Mu-type opioid receptor
MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDSLCP
PTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALAT
STLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKALDF
RTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTWYWENLLKICVFI
FAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVFIVCWTPIHI
YVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENFKRCFREFCIPTSSNI
EQQNSTRIRQNTRDHPSTANTVDRTNHQLENLEAETAPLP</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021649|Mu-type opioid receptor (OPRM1)
ATGGACAGCAGCGCTGCCCCCACGAACGCCAGCAATTGCACTGATGCCTTGGCGTACTCA
AGTTGCTCCCCAGCACCCAGCCCCGGTTCCTGGGTCAACTTGTCCCACTTAGATGGCAAC
CTGTCCGACCCATGCGGTCCGAACCGCACCGACCTGGGCGGGAGAGACAGCCTGTGCCCT
CCGACCGGCAGTCCCTCCATGATCACGGCCATCACGATCATGGCCCTCTACTCCATCGTG
TGCGTGGTGGGGCTCTTCGGAAACTTCCTGGTCATGTATGTGATTGTCAGATACACCAAG
ATGAAGACTGCCACCAACATCTACATTTTCAACCTTGCTCTGGCAGATGCCTTAGCCACC
AGTACCCTGCCCTTCCAGAGTGTGAATTACCTAATGGGAACATGGCCATTTGGAACCATC
CTTTGCAAGATAGTGATCTCCATAGATTACTATAACATGTTCACCAGCATATTCACCCTC
TGCACCATGAGTGTTGATCGATACATTGCAGTCTGCCACCCTGTCAAGGCCTTAGATTTC
CGTACTCCCCGAAATGCCAAAATTATCAATGTCTGCAACTGGATCCTCTCTTCAGCCATT
GGTCTTCCTGTAATGTTCATGGCTACAACAAAATACAGGCAAGGTTCCATAGATTGTACA
CTAACATTCTCTCATCCAACCTGGTACTGGGAAAACCTGCTGAAGATCTGTGTTTTCATC
TTCGCCTTCATTATGCCAGTGCTCATCATTACCGTGTGCTATGGACTGATGATCTTGCGC
CTCAAGAGTGTCCGCATGCTCTCTGGCTCCAAAGAAAAGGACAGGAATCTTCGAAGGATC
ACCAGGATGGTGCTGGTGGTGGTGGCTGTGTTCATCGTCTGCTGGACTCCCATTCACATT
TACGTCATCATTAAAGCCTTGGTTACAATCCCAGAAACTACGTTCCAGACTGTTTCTTGG
CACTTCTGCATTGCTCTAGGTTACACAAACAGCTGCCTCAACCCAGTCCTTTATGCATTT
CTGGATGAAAACTTCAAACGATGCTTCAGAGAGTTCTGTATCCCAACCTCTTCCAACATT
GAGCAACAAAACTCCACTCGAATTCGTCAGAACACTAGAGACCACCCCTCCACGGCCAAT
ACAGTGGATAGAACTAATCATCAGCTAGAAAATCTGGAAGCAGAAACTGCTCCGTTGCCC
TAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>beta-endorphin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein alpha-subunit binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein beta-subunit binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>G-protein coupled receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>morphine receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neuropeptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-activating dopamine receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of adenylate cyclase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of Wnt protein secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuropeptide signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>opioid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cAMP-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of neurogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of N-methyl-D-aspartate selective glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="40">
      <id>BE0000420</id>
      <name>Delta-type opioid receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P41143" source="Swiss-Prot">
        <name>Delta-type opioid receptor</name>
        <general-function>Opioid receptor activity</general-function>
        <specific-function>G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain and in opiate-mediated analgesia. Plays a role in developing analgesic tolerance to morphine.</specific-function>
        <gene-name>OPRD1</gene-name>
        <locus>1p36.1-p34.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>48-75
86-110
123-144
164-186
207-238
262-284
300-321</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>9.17</theoretical-pi>
        <molecular-weight>40368.235</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:8153</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>OPRD1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U07882</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>27545517</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>317</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>317</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P41143</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>OPRD_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>D-OR-1</synonym>
          <synonym>OPRD</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010290|Delta-type opioid receptor
MEPAPSAGAELQPPLFANASDAYPSACPSAGANASGPPGARSASSLALAIAITALYSAVC
AVGLLGNVLVMFGIVRYTKMKTATNIYIFNLALADALATSTLPFQSAKYLMETWPFGELL
CKAVLSIDYYNMFTSIFTLTMMSVDRYIAVCHPVKALDFRTPAKAKLINICIWVLASGVG
VPIMVMAVTRPRDGAVVCMLQFPSPSWYWDTVTKICVFLFAFVVPILIITVCYGLMLLRL
RSVRLLSGSKEKDRSLRRITRMVLVVVGAFVVCWAPIHIFVIVWTLVDIDRRDPLVVAAL
HLCIALGYANSSLNPVLYAFLDENFKRCFRQLCRKPCGRPDPSSFSRAREATARERVTAC
TPSDGPGGGAAA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010291|Delta-type opioid receptor (OPRD1)
ATGGAACCGGCCCCCTCCGCCGGCGCCGAGCTGCAGCCCCCGCTCTTCGCCAACGCCTCG
GACGCCTACCCTAGCGCCTGCCCCAGCGCTGGCGCCAATGCGTCGGGGCCGCCAGGCGCG
CGGAGCGCCTCGTCCCTCGCCCTGGCAATCGCCATCACCGCGCTCTACTCGGCCGTGTGC
GCCGTGGGGCTGCTGGGCAACGTGCTTGTCATGTTCGGCATCGTCCGGTACACTAAGATG
AAGACGGCCACCAACATCTACATCTTCAACCTGGCCTTAGCCGATGCGCTGGCCACCAGC
ACGCTGCCTTTCCAGAGTGCCAAGTACCTGATGGAGACGTGGCCCTTCGGCGAGCTGCTC
TGCAAGGCTGTGCTCTCCATCGACTACTACAATATGTTCACCAGCATCTTCACGCTCACC
ATGATGAGTGTTGACCGCTACATCGCTGTCTGCCACCCTGTCAAGGCCCTGGACTTCCGC
ACGCCTGCCAAGGCCAAGCTGATCAACATCTGTATCTGGGTCCTGGCCTCAGGCGTTGGC
GTGCCCATCATGGTCATGGCTGTGACCCGTCCCCGGGACGGGGCAGTGGTGTGCATGCTC
CAGTTCCCCAGCCCCAGCTGGTACTGGGACACGGTGACCAAGATCTGCGTGTTCCTCTTC
GCCTTCGTGGTGCCCATCCTCATCATCACCGTGTGCTATGGCCTCATGCTGCTGCGCCTG
CGCAGTGTGCGCCTGCTGTCGGGCTCCAAGGAGAAGGACCGCAGCCTGCGGCGCATCACG
CGCATGGTGCTGGTGGTTGTGGGCGCCTTCGTGGTGTGTTGGGCGCCCATCCACATCTTC
GTCATCGTCTGGACGCTGGTGGACATCGACCGGCGCGACCCGCTGGTGGTGGCTGCGCTG
CACCTGTGCATCGCGCTGGGCTACGCCAATAGCAGCCTCAACCCCGTGCTCTACGCTTTC
CTCGACGAGAACTTCAAGCGCTGCTTCCGCCAGCTCTGCCGCAAGCCCTGCGGCCGCCCA
GACCCCAGCAGCTTCAGCCGCGCCCGCGAAGCCACGGCCCGCGAGCGTGTCACCGCCTGC
ACCCCGTCCGATGGTCCCGGCGGTGGCGCTGCCGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon terminus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enkephalin receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neuropeptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>opioid receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to growth factor stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>eating behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuropeptide signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>opioid receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipase C-activating G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of CREB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptidyl-serine phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein import into nucleus, translocation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of mitochondrial membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="41">
      <id>BE0004852</id>
      <name>Glutamate (NMDA) receptor</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q05586" source="Swiss-Prot">
        <name>Glutamate receptor ionotropic, NMDA 1</name>
        <general-function>Voltage-gated cation channel activity</general-function>
        <specific-function>NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).</specific-function>
        <gene-name>GRIN1</gene-name>
        <locus>9q34.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>560-580
637-657
813-833</transmembrane-regions>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>9.2</theoretical-pi>
        <molecular-weight>105371.945</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4584</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GRIN1</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D13515</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>219920</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>455</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q05586</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NMDZ1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GluN1</synonym>
          <synonym>Glutamate [NMDA] receptor subunit zeta-1</synonym>
          <synonym>N-methyl-D-aspartate receptor subunit NR1</synonym>
          <synonym>NMD-R1</synonym>
          <synonym>NMDAR1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0000727|Glutamate receptor ionotropic, NMDA 1
MSTMRLLTLALLFSCSVARAACDPKIVNIGAVLSTRKHEQMFREAVNQANKRHGSWKIQL
NATSVTHKPNAIQMALSVCEDLISSQVYAILVSHPPTPNDHFTPTPVSYTAGFYRIPVLG
LTTRMSIYSDKSIHLSFLRTVPPYSHQSSVWFEMMRVYSWNHIILLVSDDHEGRAAQKRL
ETLLEERESKAEKVLQFDPGTKNVTALLMEAKELEARVIILSASEDDAATVYRAAAMLNM
TGSGYVWLVGEREISGNALRYAPDGILGLQLINGKNESAHISDAVGVVAQAVHELLEKEN
ITDPPRGCVGNTNIWKTGPLFKRVLMSSKYADGVTGRVEFNEDGDRKFANYSIMNLQNRK
LVQVGIYNGTHVIPNDRKIIWPGGETEKPRGYQMSTRLKIVTIHQEPFVYVKPTLSDGTC
KEEFTVNGDPVKKVICTGPNDTSPGSPRHTVPQCCYGFCIDLLIKLARTMNFTYEVHLVA
DGKFGTQERVNNSNKKEWNGMMGELLSGQADMIVAPLTINNERAQYIEFSKPFKYQGLTI
LVKKEIPRSTLDSFMQPFQSTLWLLVGLSVHVVAVMLYLLDRFSPFGRFKVNSEEEEEDA
LTLSSAMWFSWGVLLNSGIGEGAPRSFSARILGMVWAGFAMIIVASYTANLAAFLVLDRP
EERITGINDPRLRNPSDKFIYATVKQSSVDIYFRRQVELSTMYRHMEKHNYESAAEAIQA
VRDNKLHAFIWDSAVLEFEASQKCDLVTTGELFFRSGFGIGMRKDSPWKQNVSLSILKSH
ENGFMEDLDKTWVRYQECDSRSNAPATLTFENMAGVFMLVAGGIVAGIFLIFIEIAYKRH
KDARRKQMQLAFAAVNVWRKNLQDRKSGRAEPDPKKKATFRAITSTLASSFKRRRSSKDT
STGGGRGALQNQKDTVLPRRAIEREEGQLQLCSRHRES</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016071|Glutamate receptor ionotropic, NMDA 1 (GRIN1)
ATGAGCACCATGCGCCTGCTGACGCTCGCCCTGCTGTTCTCCTGCTCCGTCGCCCGTGCC
GCGTGCGACCCCAAGATCGTCAACATTGGCGCGGTGCTGAGCACGCGGAAGCACGAGCAG
ATGTTCCGCGAGGCCGTGAACCAGGCCAACAAGCGGCACGGCTCCTGGAAGATTCAGCTC
AATGCCACCTCCGTCACGCACAAGCCCAACGCCATCCAGATGGCTCTGTCGGTGTGCGAG
GACCTCATCTCCAGCCAGGTCTACGCCATCCTAGTTAGCCATCCACCTACCCCCAACGAC
CACTTCACTCCCACCCCTGTCTCCTACACAGCCGGCTTCTACCGCATACCCGTGCTGGGG
CTGACCACCCGCATGTCCATCTACTCGGACAAGAGCATCCACCTGAGCTTCCTGCGCACC
GTGCCGCCCTACTCCCACCAGTCCAGCGTGTGGTTTGAGATGATGCGTGTCTACAGCTGG
AACCACATCATCCTGCTGGTCAGCGACGACCACGAGGGCCGGGCGGCTCAGAAACGCCTG
GAGACGCTGCTGGAGGAGCGTGAGTCCAAGGCAGAGAAGGTGCTGCAGTTTGACCCAGGG
ACCAAGAACGTGACGGCCCTGCTGATGGAGGCGAAAGAGCTGGAGGCCCGGGTCATCATC
CTTTCTGCCAGCGAGGACGATGCTGCCACTGTATACCGCGCAGCCGCGATGCTGAACATG
ACGGGCTCCGGGTACGTGTGGCTGGTCGGCGAGCGCGAGATCTCGGGGAACGCCCTGCGC
TACGCCCCAGACGGCATCCTCGGGCTGCAGCTCATCAACGGCAAGAACGAGTCGGCCCAC
ATCAGCGACGCCGTGGGCGTGGTGGCCCAGGCCGTGCACGAGCTCCTCGAGAAGGAGAAC
ATCACCGACCCGCCGCGGGGCTGCGTGGGCAACACCAACATCTGGAAGACCGGGCCGCTC
TTCAAGAGAGTGCTGATGTCTTCCAAGTATGCGGATGGGGTGACTGGTCGCGTGGAGTTC
AATGAGGATGGGGACCGGAAGTTCGCCAACTACAGCATCATGAACCTGCAGAACCGCAAG
CTGGTGCAAGTGGGCATCTACAATGGCACCCACGTCATCCCTAATGACAGGAAGATCATC
TGGCCAGGCGGAGAGACAGAGAAGCCTCGAGGGTACCAGATGTCCACCAGACTGAAGATT
GTGACGATCCACCAGGAGCCCTTCGTGTACGTCAAGCCCACGCTGAGTGATGGGACATGC
AAGGAGGAGTTCACAGTCAACGGCGACCCAGTCAAGAAGGTGATCTGCACCGGGCCCAAC
GACACGTCGCCGGGCAGCCCCCGCCACACGGTGCCTCAGTGTTGCTACGGCTTTTGCATC
GACCTGCTCATCAAGCTGGCACGGACCATGAACTTCACCTACGAGGTGCACCTGGTGGCA
GATGGCAAGTTCGGCACACAGGAGCGGGTGAACAACAGCAACAAGAAGGAGTGGAATGGG
ATGATGGGCGAGCTGCTCAGCGGGCAGGCAGACATGATCGTGGCGCCGCTAACCATAAAC
AACGAGCGCGCGCAGTACATCGAGTTTTCCAAGCCCTTCAAGTACCAGGGCCTGACTATT
CTGGTCAAGAAGGAGATTCCCCGGAGCACGCTGGACTCGTTCATGCAGCCGTTCCAGAGC
ACACTGTGGCTGCTGGTGGGGCTGTCGGTGCACGTGGTGGCCGTGATGCTGTACCTGCTG
GACCGCTTCAGCCCCTTCGGCCGGTTCAAGGTGAACAGCGAGGAGGAGGAGGAGGACGCA
CTGACCCTGTCCTCGGCCATGTGGTTCTCCTGGGGCGTCCTGCTCAACTCCGGCATCGGG
GAAGGCGCCCCCAGAAGCTTCTCAGCGCGCATCCTGGGCATGGTGTGGGCCGGCTTTGCC
ATGATCATCGTGGCCTCCTACACCGCCAACCTGGCGGCCTTCCTGGTGCTGGACCGGCCG
GAGGAGCGCATCACGGGCATCAACGACCCTCGGCTGAGGAACCCCTCGGACAAGTTTATC
TACGCCACGGTGAAGCAGAGCTCCGTGGATATCTACTTCCGGCGCCAGGTGGAGCTGAGC
ACCATGTACCGGCATATGGAGAAGCACAACTACGAGAGTGCGGCGGAGGCCATCCAGGCC
GTGAGAGACAACAAGCTGCATGCCTTCATCTGGGACTCGGCGGTGCTGGAGTTCGAGGCC
TCGCAGAAGTGCGACCTGGTGACGACTGGAGAGCTGTTTTTCCGCTCGGGCTTCGGCATA
GGCATGCGCAAAGACAGCCCCTGGAAGCAGAACGTCTCCCTGTCCATCCTCAAGTCCCAC
GAGAATGGCTTCATGGAAGACCTGGACAAGACGTGGGTTCGGTATCAGGAATGTGACTCG
CGCAGCAACGCCCCTGCGACCCTTACTTTTGAGAACATGGCCGGGGTCTTCATGCTGGTA
GCTGGGGGCATCGTGGCCGGGATCTTCCTGATTTTCATCGAGATTGCCTACAAGCGGCAC
AAGGATGCTCGCCGGAAGCAGATGCAGCTGGCCTTTGCCGCCGTTAACGTGTGGCGGAAG
AACCTGCAGCAGTACCATCCCACTGATATCACGGGCCCGCTCAACCTCTCAGATCCCTCG
GTCAGCACCGTGGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01094</identifier>
            <name>ANF_receptor</name>
          </pfam>
          <pfam>
            <identifier>PF00060</identifier>
            <name>Lig_chan</name>
          </pfam>
          <pfam>
            <identifier>PF10613</identifier>
            <name>Lig_chan-Glu_bd</name>
          </pfam>
          <pfam>
            <identifier>PF10562</identifier>
            <name>CaM_bdg_C0</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic branch</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendritic spine</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>excitatory synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>NMDA selective glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic cleft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>terminal bouton</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calmodulin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular-glutamate-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glutamate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glycine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neurotransmitter binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NMDA glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cation transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular calcium ion homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to manganese ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebral cortex development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>conditioned taste aversion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ephrin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ionotropic glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-term memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>male mating behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>olfactory learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>pons maturation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>propylene metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein tetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of axonogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dendrite morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of long-term neuronal synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of membrane potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of respiratory gaseous exchange</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of synapse assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>respiratory gaseous exchange</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to calcium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to fungicide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to morphine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhythmic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suckling behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q12879" source="Swiss-Prot">
        <name>Glutamate receptor ionotropic, NMDA 2A</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>NMDA receptor subtype of glutamate-gated ion channels possesses high calcium permeability and voltage-dependent sensitivity to magnesium. Activation requires binding of agonist to both types of subunits.</specific-function>
        <gene-name>GRIN2A</gene-name>
        <locus>16p13.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>556-576
634-654
817-837</transmembrane-regions>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi>7.11</theoretical-pi>
        <molecular-weight>165281.215</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4585</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GRIN2A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U09002</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>558749</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>456</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>456</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q12879</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NMDE1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GluN2A</synonym>
          <synonym>Glutamate [NMDA] receptor subunit epsilon-1</synonym>
          <synonym>hNR2A</synonym>
          <synonym>N-methyl D-aspartate receptor subtype 2A</synonym>
          <synonym>NMDAR2A</synonym>
          <synonym>NR2A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001516|Glutamate receptor ionotropic, NMDA 2A
MGRVGYWTLLVLPALLVWRGPAPSAAAEKGPPALNIAVMLGHSHDVTERELRTLWGPEQA
AGLPLDVNVVALLMNRTDPKSLITHVCDLMSGARIHGLVFGDDTDQEAVAQMLDFISSHT
FVPILGIHGGASMIMADKDPTSTFFQFGASIQQQATVMLKIMQDYDWHVFSLVTTIFPGY
REFISFVKTTVDNSFVGWDMQNVITLDTSFEDAKTQVQLKKIHSSVILLYCSKDEAVLIL
SEARSLGLTGYDFFWIVPSLVSGNTELIPKEFPSGLISVSYDDWDYSLEARVRDGIGILT
TAASSMLEKFSYIPEAKASCYGQMERPEVPMHTLHPFMVNVTWDGKDLSFTEEGYQVHPR
LVVIVLNKDREWEKVGKWENHTLSLRHAVWPRYKSFSDCEPDDNHLSIVTLEEAPFVIVE
DIDPLTETCVRNTVPCRKFVKINNSTNEGMNVKKCCKGFCIDILKKLSRTVKFTYDLYLV
TNGKHGKKVNNVWNGMIGEVVYQRAVMAVGSLTINEERSEVVDFSVPFVETGISVMVSRS
NGTVSPSAFLEPFSASVWVMMFVMLLIVSAIAVFVFEYFSPVGYNRNLAKGKAPHGPSFT
IGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEFVD
QVTGLSDKKFQRPHDYSPPFRFGTVPNGSTERNIRNNYPYMHQYMTKFNQKGVEDALVSL
KTGKLDAFIYDAAVLNYKAGRDEGCKLVTIGSGYIFATTGYGIALQKGSPWKRQIDLALL
QFVGDGEMEELETLWLTGICHNEKNEVMSSQLDIDNMAGVFYMLAAAMALSLITFIWEHL
FYWKLRFCFTGVCSDRPGLLFSISRGIYSCIHGVHIEEKKKSPDFNLTGSQSNMLKLLRS
AKNISSMSNMNSSRMDSPKRAADFIQRGSLIMDMVSDKGNLMYSDNRSFQGKESIFGDNM
NELQTFVANRQKDNLNNYVFQGQHPLTLNESNPNTVEVAVSTESKANSRPRQLWKKSVDS
IRQDSLSQNPVSQRDEATAENRTHSLKSPRYLPEEMAHSDISETSNRATCHREPDNSKNH
KTKDNFKRSVASKYPKDCSEVERTYLKTKSSSPRDKIYTIDGEKEPGFHLDPPQFVENVT
LPENVDFPDPYQDPSENFRKGDSTLPMNRNPLHNEEGLSNNDQYKLYSKHFTLKDKGSPH
SETSERYRQNSTHCRSCLSNMPTYSGHFTMRSPFKCDACLRMGNLYDIDEDQMLQETGNP
ATGEQVYQQDWAQNNALQLQKNKLRISRQHSYDNIVDKPRELDLSRPSRSISLKDRERLL
EGNFYGSLFSVPSSKLSGKKSSLFPQGLEDSKRSKSLLPDHTSDNPFLHSHRDDQRLVIG
RCPSDPYKHSLPSQAVNDSYLRSSLRSTASYCSRDSRGHNDVYISEHVMPYAANKNNMYS
TPRVLNSCSNRRVYKKMPSIESDV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016199|Glutamate receptor ionotropic, NMDA 2A (GRIN2A)
ATGGGCAGAGTGGGCTATTGGACCCTGCTGGTGCTGCCGGCCCTTCTGGTCTGGCGCGGT
CCGGCGCCGAGCGCGGCGGCGGAGAAGGGTCCCCCCGCGCTAAATATTGCGGTGATGCTG
GGTCACAGCCACGACGTGACAGAGCGCGAACTTCGAACACTGTGGGGCCCCGAGCAGGCG
GCGGGGCTGCCCCTGGACGTGAACGTGGTAGCTCTGCTGATGAACCGCACCGACCCCAAG
AGCCTCATCACGCACGTGTGCGACCTCATGTCCGGGGCACGCATCCACGGCCTCGTGTTT
GGGGACGACACGGACCAGGAGGCCGTAGCCCAGATGCTGGATTTTATCTCCTCCCACACC
TTCGTCCCCATCTTGGGCATTCATGGGGGCGCATCTATGATCATGGCTGACAAGGATCCG
ACGTCTACCTTCTTCCAGTTTGGAGCGTCCATCCAGCAGCAAGCCACGGTCATGCTGAAG
ATCATGCAGGATTATGACTGGCATGTCTTCTCCCTGGTGACCACTATCTTCCCTGGCTAC
AGGGAATTCATCAGCTTCGTCAAGACCACAGTGGACAACAGCTTTGTGGGCTGGGACATG
CAGAATGTGATCACACTGGACACTTCCTTTGAGGATGCAAAGACACAAGTCCAGCTGAAG
AAGATCCACTCTTCTGTCATCTTGCTCTACTGTTCCAAAGACGAGGCTGTTCTCATTCTG
AGTGAGGCCCGCTCCCTTGGCCTCACCGGGTATGATTTCTTCTGGATTGTCCCCAGCTTG
GTCTCTGGGAACACGGAGCTCATCCCAAAAGAGTTTCCATCGGGACTCATTTCTGTCTCC
TACGATGACTGGGACTACAGCCTGGAGGCGAGAGTGAGGGACGGCATTGGCATCCTAACC
ACCGCTGCATCTTCTATGCTGGAGAAGTTCTCCTACATCCCCGAGGCCAAGGCCAGCTGC
TACGGGCAGATGGAGAGGCCAGAGGTCCCGATGCACACCTTGCACCCATTTATGGTCAAT
GTTACATGGGATGGCAAAGACTTATCCTTCACTGAGGAAGGCTACCAGGTGCACCCCAGG
CTGGTGGTGATTGTGCTGAACAAAGACCGGGAATGGGAAAAGGTGGGCAAGTGGGAGAAC
CATACGCTGAGCCTGAGGCACGCCGTGTGGCCCAGGTACAAGTCCTTCTCCGACTGTGAG
CCGGATGACAACCATCTCAGCATCGTCACCCTGGAGGAGGCCCCATTCGTCATCGTGGAA
GACATAGACCCCCTGACCGAGACGTGTGTGAGGAACACCGTGCCATGTCGGAAGTTCGTC
AAAATCAACAATTCAACCAATGAGGGGATGAATGTGAAGAAATGCTGCAAGGGGTTCTGC
ATTGATATTCTGAAGAAGCTTTCCAGAACTGTGAAGTTTACTTACGACCTCTATCTGGTG
ACCAATGGGAAGCATGGCAAGAAAGTTAACAATGTGTGGAATGGAATGATCGGTGAAGTG
GTCTATCAACGGGCAGTCATGGCAGTTGGCTCGCTCACCATCAATGAGGAACGTTCTGAA
GTGGTGGACTTCTCTGTGCCCTTTGTGGAAACGGGAATCAGTGTCATGGTTTCAAGAAGT
AATGGCACCGTCTCACCTTCTGCTTTTCTAGAACCATTCAGCGCCTCTGTCTGGGTGATG
ATGTTTGTGATGCTGCTCATTGTTTCTGCCATAGCTGTTTTTGTCTTTGAATACTTCAGC
CCTGTTGGATACAACAGAAACTTAGCCAAAGGGAAAGCACCCCATGGGCCTTCTTTTACA
ATTGGAAAAGCTATATGGCTTCTTTGGGGCCTGGTGTTCAATAACTCCGTGCCTGTCCAG
AATCCTAAAGGGACCACCAGCAAGATCATGGTATCTGTATGGGCCTTCTTCGCTGTCATA
TTCCTGGCTAGCTACACAGCCAATCTGGCTGCCTTCATGATCCAAGAGGAATTTGTGGAC
CAAGTGACCGGCCTCAGTGACAAAAAGTTTCAGAGACCTCATGACTATTCCCCACCTTTT
CGATTTGGGACAGTGCCTAATGGAAGCACGGAGAGAAACATTCGGAATAACTATCCCTAC
ATGCATCAGTACATGACCAAATTTAATCAGAAAGGAGTAGAGGACGCCTTGGTCAGCCTG
AAAACGGGGAAGCTGGACGCTTTCATCTACGATGCCGCAGTCTTGAATTACAAGGCTGGG
AGGGATGAAGGCTGCAAGCTGGTGACCATCGGGAGTGGGTACATCTTTGCCACCACCGGT
TATGGAATTGCCCTTCAGAAAGGCTCTCCTTGGAAGAGGCAGATCGACCTGGCCTTGCTT
CAGTTTGTGGGTGATGGTGAGATGGAGGAGCTGGAGACCCTGTGGCTCACTGGGATCTGC
CACAACGAGAAGAACGAGGTGATGAGCAGCCAGCTGGACATTGACAACATGGCGGGCGTA
TTCTACATGCTGGCTGCCGCCATGGCCCTTAGCCTCATCACCTTCATCTGGGAGCACCTC
TTCTACTGGAAGCTGCGCTTCTGTTTCACGGGCGTGTGCTCCGACCGGCCTGGGTTGCTC
TTCTCCATCAGCAGGGGCATCTACAGCTGCATTCATGGAGTGCACATTGAAGAAAAGAAG
AAGTCTCCAGACTTCAATCTGACGGGATCCCAGAGCAACATGTTAAAACTCCTCCGGTCA
GCCAAAAACATTTCCAGCATGTCCAACATGAACTCCTCAAGAATGGACTCACCCAAAAGA
GCTGCTGACTTCATCCAAAGAGGTTCCCTCATCATGGACATGGTTTCAGATAAGGGGAAT
TTGATGTACTCAGACAACAGGTCCTTTCAGGGGAAAGAGAGCATTTTTGGAGACAACATG
AACGAACTCCAAACATTTGTGGCCAACCGGCAGAAGGATAACCTCAATAACTATGTATTC
CAGGGACAACATCCTCTTACTCTCAATGAGTCCAACCCTAACACGGTGGAGGTGGCCGTG
AGCACAGAATCCAAAGCGAACTCTAGACCCCGGCAGCTGTGGAAGAAATCCGTGGATTCC
ATACGCCAGGATTCACTATCCCAGAATCCAGTCTCCCAGAGGGATGAGGCAACAGCAGAG
AATAGGACCCACTCCCTAAAGAGCCCTAGGTATCTTCCAGAAGAGATGGCCCACTCTGAC
ATTTCAGAAACGTCAAATCGGGCCACGTGCCACAGGGAACCTGACAACAGTAAGAACCAC
AAAACCAAGGACAACTTTAAAAGGTCAGTGGCCTCCAAATACCCCAAGGACTGTAGTGAG
GTCGAGCGCACCTACCTGAAAACCAAATCAAGCTCCCCTAGAGACAAGATCTACACTATA
GATGGTGAGAAGGAGCCTGGTTTCCACTTAGATCCACCCCAGTTTGTTGAAAATGTGACC
CTGCCCGAGAACGTGGACTTCCCGGACCCCTACCAGGATCCCAGTGAAAACTTCCGCAAG
GGGGACTCCACGCTGCCAATGAACCGGAACCCCTTGCATAATGAAGAGGGGCTTTCCAAC
AACGACCAGTATAAACTCTACTCCAAGCACTTCACCTTGAAAGACAAGGGTTCCCCGCAC
AGTGAGACCAGCGAGCGATACCGGCAGAACTCCACGCACTGCAGAAGCTGCCTTTCCAAC
ATGCCCACCTATTCAGGCCACTTCACCATGAGGTCCCCCTTCAAGTGCGATGCCTGCCTG
CGGATGGGGAACCTCTATGACATCGATGAAGACCAGATGCTTCAGGAGACAGGTAACCCA
GCCACCGGGGAGCAGGTCTACCAGCAGGACTGGGCACAGAACAATGCCCTTCAATTACAA
AAGAACAAGCTAAGGATTAGCCGTCAGCATTCCTACGATAACATTGTCGACAAACCTAGG
GAGCTAGACCTTAGCAGGCCCTCCCGGAGCATAAGCCTCAAGGACAGGGAACGGCTTCTG
GAGGGAAATTTTTACGGCAGCCTGTTTAGTGTCCCCTCAAGCAAACTCTCGGGGAAAAAA
AGCTCCCTTTTCCCCCAAGGTCTGGAGGACAGCAAGAGGAGCAAGTCTCTCTTGCCAGAC
CACACCTCCGATAACCCTTTCCTCCACTCCCACAGGGATGACCAACGCTTGGTTATTGGG
AGATGCCCCTCGGACCCTTACAAACACTCGTTGCCATCCCAGGCGGTGAATGACAGCTAT
CTTCGGTCGTCCTTGAGGTCAACGGCATCGTACTGTTCCAGGGACAGTCGGGGCCACAAT
GATGTGTATATTTCGGAGCATGTTATGCCTTATGCTGCAAATAAGAATAATATGTACTCT
ACCCCCAGGGTTTTAAATTCCTGCAGCAATAGACGCGTGTACAAGAAAATGCCTAGTATC
GAATCTGATGTTTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01094</identifier>
            <name>ANF_receptor</name>
          </pfam>
          <pfam>
            <identifier>PF00060</identifier>
            <name>Lig_chan</name>
          </pfam>
          <pfam>
            <identifier>PF10613</identifier>
            <name>Lig_chan-Glu_bd</name>
          </pfam>
          <pfam>
            <identifier>PF10565</identifier>
            <name>NMDAR2_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>NMDA selective glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>presynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>terminal bouton</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular-glutamate-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glutamate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neurotransmitter binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NMDA glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>voltage-gated cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>action potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to amino acid stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to dsRNA</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to magnesium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to manganese ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to zinc ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cerebral cortex development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>directional locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hippocampus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ionotropic glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning or memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-term synaptic potentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein tetramerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of long-term neuronal synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amphetamine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to calcium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to carbohydrate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to fungicide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to methylmercury</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to other organism</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to wounding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>rhythmic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>spinal cord development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>startle response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>visual learning</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q13224" source="Swiss-Prot">
        <name>Glutamate receptor ionotropic, NMDA 2B</name>
        <general-function>Zinc ion binding</general-function>
        <specific-function>NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an irreversible neuronal death (By similarity).</specific-function>
        <gene-name>GRIN2B</gene-name>
        <locus>12p12</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>558-578
635-655
818-838</transmembrane-regions>
        <signal-regions>1-26</signal-regions>
        <theoretical-pi>6.92</theoretical-pi>
        <molecular-weight>166365.885</molecular-weight>
        <chromosome-location>12</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4586</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GRIN2B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U90278</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1899202</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>457</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q13224</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NMDE2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GluN2B</synonym>
          <synonym>Glutamate [NMDA] receptor subunit epsilon-2</synonym>
          <synonym>hNR3</synonym>
          <synonym>N-methyl D-aspartate receptor subtype 2B</synonym>
          <synonym>N-methyl-D-aspartate receptor subunit 3</synonym>
          <synonym>NMDAR2B</synonym>
          <synonym>NR2B</synonym>
          <synonym>NR3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010288|Glutamate receptor ionotropic, NMDA 2B
MKPRAECCSPKFWLVLAVLAVSGSRARSQKSPPSIGIAVILVGTSDEVAIKDAHEKDDFH
HLSVVPRVELVAMNETDPKSIITRICDLMSDRKIQGVVFADDTDQEAIAQILDFISAQTL
TPILGIHGGSSMIMADKDESSMFFQFGPSIEQQASVMLNIMEEYDWYIFSIVTTYFPGYQ
DFVNKIRSTIENSFVGWELEEVLLLDMSLDDGDSKIQNQLKKLQSPIILLYCTKEEATYI
FEVANSVGLTGYGYTWIVPSLVAGDTDTVPAEFPTGLISVSYDEWDYGLPARVRDGIAII
TTAASDMLSEHSFIPEPKSSCYNTHEKRIYQSNMLNRYLINVTFEGRNLSFSEDGYQMHP
KLVIILLNKERKWERVGKWKDKSLQMKYYVWPRMCPETEEQEDDHLSIVTLEEAPFVIVE
SVDPLSGTCMRNTVPCQKRIVTENKTDEEPGYIKKCCKGFCIDILKKISKSVKFTYDLYL
VTNGKHGKKINGTWNGMIGEVVMKRAYMAVGSLTINEERSEVVDFSVPFIETGISVMVSR
SNGTVSPSAFLEPFSADVWVMMFVMLLIVSAVAVFVFEYFSPVGYNRCLADGREPGGPSF
TIGKAIWLLWGLVFNNSVPVQNPKGTTSKIMVSVWAFFAVIFLASYTANLAAFMIQEEYV
DQVSGLSDKKFQRPNDFSPPFRFGTVPNGSTERNIRNNYAEMHAYMGKFNQRGVDDALLS
LKTGKLDAFIYDAAVLNYMAGRDEGCKLVTIGSGKVFASTGYGIAIQKDSGWKRQVDLAI
LQLFGDGEMEELEALWLTGICHNEKNEVMSSQLDIDNMAGVFYMLGAAMALSLITFICEH
LFYWQFRHCFMGVCSGKPGMVFSISRGIYSCIHGVAIEERQSVMNSPTATMNNTHSNILR
LLRTAKNMANLSGVNGSPQSALDFIRRESSVYDISEHRRSFTHSDCKSYNNPPCEENLFS
DYISEVERTFGNLQLKDSNVYQDHYHHHHRPHSIGSASSIDGLYDCDNPPFTTQSRSISK
KPLDIGLPSSKHSQLSDLYGKFSFKSDRYSGHDDLIRSDVSDISTHTVTYGNIEGNAAKR
RKQQYKDSLKKRPASAKSRREFDEIELAYRRRPPRSPDHKRYFRDKEGLRDFYLDQFRTK
ENSPHWEHVDLTDIYKERSDDFKRDSVSGGGPCTNRSHIKHGTGDKHGVVSGVPAPWEKN
LTNVEWEDRSGGNFCRSCPSKLHNYSTTVTGQNSGRQACIRCEACKKAGNLYDISEDNSL
QELDQPAAPVAVTSNASTTKYPQSPTNSKAQKKNRNKLRRQHSYDTFVDLQKEEAALAPR
SVSLKDKGRFMDGSPYAHMFEMSAGESTFANNKSSVPTAGHHHHNNPGGGYMLSKSLYPD
RVTQNPFIPTFGDDQCLLHGSKSYFFRQPTVAGASKARPDFRALVTNKPVVSALHGAVPA
RFQKDICIGNQSNPCVPNNKNPRAFNGSSNGHVYEKLSSIESDV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010289|Glutamate receptor ionotropic, NMDA 2B (GRIN2B)
ATGAAGCCCAGAGCGGAGTGCTGTTCTCCCAAGTTCTGGTTGGTGTTGGCCGTCCTGGCC
GTGTCAGGCAGCAGAGCTCGTTCTCAGAAGAGCCCCCCCAGCATTGGCATTGCTGTCATC
CTCGTGGGCACTTCCGACGAGGTGGCCATCAAGGATGCCCACGAGAAAGATGATTTCCAC
CATCTCTCCGTGGTACCCCGGGTGGAACTGGTAGCCATGAATGAGACCGACCCAAAGAGC
ATCATCACCCGCATCTGTGATCTCATGTCTGACCGGAAGATCCAGGGGGTGGTGTTTGCT
GATGACACAGACCAGGAAGCCATCGCCCAGATCCTCGATTTCATTTCAGCACAGACTCTC
ACCCCCATCCTGGGCATCCACGGGGGCTCCTCTATGATAATGGCAGATAAGGATGAATCC
TCCATGTTCTTCCAGTTTGGCCCATCAATTGAACAGCAAGCTTCCGTAATGCTCAACATC
ATGGAAGAATATGACTGGTACATCTTTTCTATCGTCACCACCTATTTCCCTGGCTACCAG
GACTTTGTAAACAAGATCCGCAGCACCATTGAGAATAGCTTTGTGGGCTGGGAGCTAGAG
GAGGTCCTCCTACTGGACATGTCCCTGGACGATGGAGATTCTAAGATCCAGAATCAGCTC
AAGAAACTTCAAAGCCCCATCATTCTTCTTTACTGTACCAAGGAAGAAGCCACCTACATC
TTTGAAGTGGCCAACTCAGTAGGGCTGACTGGCTATGGCTACACGTGGATCGTGCCCAGT
CTGGTGGCAGGGGATACAGACACAGTGCCTGCGGAGTTCCCCACTGGGCTCATCTCTGTA
TCATATGATGAATGGGACTATGGCCTCCCCGCCAGAGTGAGAGATGGAATTGCCATAATC
ACCACTGCTGCTTCTGACATGCTGTCTGAGCACAGCTTCATCCCTGAGCCCAAAAGCAGT
TGTTACAACACCCACGAGAAGAGAATCTACCAGTCCAATATGCTAAATAGGTATCTGATC
AATGTCACTTTTGAGGGGAGGAATTTGTCCTTCAGTGAAGATGGCTACCAGATGCACCCG
AAACTGGTGATAATTCTTCTGAACAAGGAGAGGAAGTGGGAAAGGGTGGGGAAGTGGAAA
GACAAGTCCCTGCAGATGAAGTACTATGTGTGGCCCCGAATGTGTCCAGAGACTGAAGAG
CAGGAGGATGACCATCTGAGCATTGTGACCCTGGAGGAGGCACCATTTGTCATTGTGGAA
AGTGTGGACCCTCTGAGTGGAACCTGCATGAGGAACACAGTCCCCTGCCAAAAACGCATA
GTCACTGAGAATAAAACAGACGAGGAGCCGGGTTACATCAAAAAATGCTGCAAGGGGTTC
TGTATTGACATCCTTAAGAAAATTTCTAAATCTGTGAAGTTCACCTATGACCTTTACCTG
GTTACCAATGGCAAGCATGGGAAGAAAATCAATGGAACCTGGAATGGTATGATTGGAGAG
GTGGTCATGAAGAGGGCCTACATGGCAGTGGGCTCACTCACCATCAATGAGGAACGATCG
GAGGTGGTCGACTTCTCTGTGCCCTTCATAGAGACAGGCATCAGTGTCATGGTGTCACGC
AGCAATGGGACTGTCTCACCTTCTGCCTTCTTAGAGCCATTCAGCGCTGACGTATGGGTG
ATGATGTTTGTGATGCTGCTCATCGTCTCAGCCGTGGCTGTCTTTGTCTTTGAGTACTTC
AGCCCTGTGGGTTATAACAGGTGCCTCGCTGATGGCAGAGAGCCTGGTGGACCCTCTTTC
ACCATCGGCAAAGCTATTTGGTTGCTCTGGGGTCTGGTGTTTAACAACTCCGTACCTGTG
CAGAACCCAAAGGGGACCACCTCCAAGATCATGGTGTCAGTGTGGGCCTTCTTTGCTGTC
ATCTTCCTGGCCAGCTACACTGCCAACTTAGCTGCCTTCATGATCCAAGAGGAATATGTG
GACCAGGTTTCTGGCCTGAGCGACAAAAAGTTCCAGAGACCTAATGACTTCTCACCCCCT
TTCCGCTTTGGGACCGTGCCCAACGGCAGCACAGAGAGAAATATTCGCAATAACTATGCA
GAAATGCATGCCTACATGGGAAAGTTCAACCAGAGGGGTGTAGATGATGCATTGCTCTCC
CTGAAAACAGGGAAACTGGATGCCTTCATCTATGATGCAGCAGTGCTGAACTATATGGCA
GGCAGAGATGAAGGCTGCAAGCTGGTGACCATTGGCAGTGGGAAGGTCTTTGCTTCCACT
GGCTATGGCATTGCCATCCAAAAAGATTCTGGGTGGAAGCGCCAGGTGGACCTTGCTATC
CTGCAGCTCTTTGGAGATGGGGAGATGGAAGAACTGGAAGCTCTCTGGCTCACTGGCATT
TGTCACAATGAGAAGAATGAGGTCATGAGCAGCCAGCTGGACATTGACAACATGGCAGGG
GTCTTCTACATGTTGGGGGCGGCCATGGCTCTCAGCCTCATCACCTTCATCTGCGAACAC
CTTTTCTATTGGCAGTTCCGACATTGCTTTATGGGTGTCTGTTCTGGCAAGCCTGGCATG
GTCTTCTCCATCAGCAGAGGTATCTACAGCTGCATCCATGGGGTGGCGATCGAGGAGCGC
CAGTCTGTAATGAACTCCCCCACCGCAACCATGAACAACACACACTCCAACATCCTGCGC
CTGCTGCGCACGGCCAAGAACATGGCTAACCTGTCTGGTGTGAATGGCTCACCGCAGAGC
GCCCTGGACTTCATCCGACGGGAGTCATCCGTCTATGACATCTCAGAGCACCGCCGCAGC
TTCACGCATTCTGACTGCAAATCCTACAACAACCCGCCCTGTGAGGAGAACCTCTTCAGT
GACTACATCAGTGAGGTAGAGAGAACGTTCGGGAACCTGCAGCTGAAGGACAGCAACGTG
TACCAAGATCACTACCACCATCACCACCGGCCCCATAGTATTGGCAGTGCCAGCTCCATC
GATGGGCTCTACGACTGTGACAACCCACCCTTCACCACCCAGTCCAGGTCCATCAGCAAG
AAGCCCCTGGACATCGGCCTCCCCTCCTCCAAGCACAGCCAGCTCAGTGACCTGTACGGC
AAATTCTCCTTCAAGAGCGACCGCTACAGTGGCCACGACGACTTGATCCGCTCCGATGTC
TCTGACATCTCAACCCACACCGTCACCTATGGGAACATCGAGGGCAATGCCGCCAAGAGG
CGTAAGCAGCAATATAAGGACAGCCTGAAGAAGCGGCCTGCCTCGGCCAAGTCCCGCAGG
GAGTTTGACGAGATCGAGCTGGCCTACCGTCGCCGACCGCCCCGCTCCCCTGACCACAAG
CGCTACTTCAGGGACAAGGAAGGGCTACGGGACTTCTACCTGGACCAGTTCCGAACAAAG
GAGAACTCACCCCACTGGGAGCACGTAGACCTGACCGACATCTACAAGGAGCGGAGTGAT
GACTTTAAGCGCGACTCCGTCAGCGGAGGAGGGCCCTGTACCAACAGGTCTCACATCAAG
CACGGGACGGGCGACAAACACGGCGTGGTCAGCGGGGTACCTGCACCTTGGGAGAAGAAC
CTGACCAACGTGGAGTGGGAGGACCGGTCCGGGGGCAACTTCTGCCGCAGCTGTCCCTCC
AAGCTGCACAACTACTCCACGACGGTGACGGGTCAGAACTCGGGCAGGCAGGCGTGCATC
CGGTGTGAGGCTTGCAAGAAAGCAGGCAACCTGTATGACATCAGTGAGGACAACTCCCTG
CAGGAACTGGACCAGCCGGCTGCCCCAGTGGCGGTGACGTCAAACGCCTCCACCACTAAG
TACCCTCAGAGCCCGACTAATTCCAAGGCCCAGAAGAAGAACCGGAACAAACTGCGCCGG
CAGCACTCCTACGACACCTTCGTGGACCTGCAGAAGGAAGAAGCCGCCCTGGCCCCGCGC
AGCGTAAGCCTGAAAGACAAGGGCCGATTCATGGATGGGAGCCCCTACGCCCACATGTTT
GAGATGTCAGCTGGCGAGAGCACCTTTGCCAACAACAAGTCCTCAGTGCCCACTGCCGGA
CATCACCACCACAACAACCCCGGCGGCGGGTACATGCTCAGCAAGTCGCTCTACCCTGAC
CGGGTCACGCAAAACCCTTTCATCCCCACTTTTGGGGACGACCAGTGCTTGCTCCATGGC
AGCAAATCCTACTTCTTCAGGCAGCCCACGGTGGCGGGGGCGTCGAAAGCCAGGCCGGAC
TTCCGGGCCCTTGTCACCAACAAGCCGGTGGTCTCGGCCCTTCATGGGGCCGTGCCAGCC
CGTTTCCAGAAGGACATCTGTATAGGGAACCAGTCCAACCCCTGTGTGCCTAACAACAAA
AACCCCAGGGCTTTCAATGGCTCCAGCAATGGGCATGTTTATGAGAAACTTTCTAGTATT
GAGTCTGATGTCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01094</identifier>
            <name>ANF_receptor</name>
          </pfam>
          <pfam>
            <identifier>PF00060</identifier>
            <name>Lig_chan</name>
          </pfam>
          <pfam>
            <identifier>PF10613</identifier>
            <name>Lig_chan-Glu_bd</name>
          </pfam>
          <pfam>
            <identifier>PF10565</identifier>
            <name>NMDAR2_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>NMDA selective glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synaptic vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular-glutamate-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glycine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NMDA glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>zinc ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral response to pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of mechanical stimulus involved in sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ephrin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>in utero embryonic development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ionotropic glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning or memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>long-term synaptic potentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of protein kinase A signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory organ development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>startle response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>suckling behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q14957" source="Swiss-Prot">
        <name>Glutamate receptor ionotropic, NMDA 2C</name>
        <general-function>Nmda glutamate receptor activity</general-function>
        <specific-function>NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.</specific-function>
        <gene-name>GRIN2C</gene-name>
        <locus>17q25</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>554-574
627-647
815-835</transmembrane-regions>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>8.61</theoretical-pi>
        <molecular-weight>134207.77</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4587</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GRIN2C</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L76224</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1196449</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>458</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q14957</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NMDE3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GluN2C</synonym>
          <synonym>Glutamate [NMDA] receptor subunit epsilon-3</synonym>
          <synonym>N-methyl D-aspartate receptor subtype 2C</synonym>
          <synonym>NMDAR2C</synonym>
          <synonym>NR2C</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010317|Glutamate receptor ionotropic, NMDA 2C
MGGALGPALLLTSLFGAWAGLGPGQGEQGMTVAVVFSSSGPPQAQFRARLTPQSFLDLPL
EIQPLTVGVNTTNPSSLLTQICGLLGAAHVHGIVFEDNVDTEAVAQILDFISSQTHVPIL
SISGGSAVVLTPKEPGSAFLQLGVSLEQQLQVLFKVLEEYDWSAFAVITSLHPGHALFLE
GVRAVADASHVSWRLLDVVTLELGPGGPRARTQRLLRQLDAPVFVAYCSREEAEVLFAEA
AQAGLVGPGHVWLVPNLALGSTDAPPATFPVGLISVVTESWRLSLRQKVRDGVAILALGA
HSYWRQHGTLPAPAGDCRVHPGPVSPAREAFYRHLLNVTWEGRDFSFSPGGYLVQPTMVV
IALNRHRLWEMVGRWEHGVLYMKYPVWPRYSASLQPVVDSRHLTVATLEERPFVIVESPD
PGTGGCVPNTVPCRRQSNHTFSSGDVAPYTKLCCKGFCIDILKKLARVVKFSYDLYLVTN
GKHGKRVRGVWNGMIGEVYYKRADMAIGSLTINEERSEIVDFSVPFVETGISVMVARSNG
TVSPSAFLEPYSPAVWVMMFVMCLTVVAITVFMFEYFSPVSYNQNLTRGKKSGGPAFTIG
KSVWLLWALVFNNSVPIENPRGTTSKIMVLVWAFFAVIFLASYTANLAAFMIQEQYIDTV
SGLSDKKFQRPQDQYPPFRFGTVPNGSTERNIRSNYRDMHTHMVKFNQRSVEDALTSLKM
GKLDAFIYDAAVLNYMAGKDEGCKLVTIGSGKVFATTGYGIAMQKDSHWKRAIDLALLQF
LGDGETQKLETVWLSGICQNEKNEVMSSKLDIDNMAGVFYMLLVAMGLALLVFAWEHLVY
WKLRHSVPNSSQLDFLLAFSRGIYSCFSGVQSLASPPRQASPDLTASSAQASVLKMLQAA
RDMVTTAGVSSSLDRATRTIENWGGGRRAPPPSPCPTPRSGPSPCLPTPDPPPEPSPTGW
GPPDGGRAALVRRAPQPPGRPPTPGPPLSDVSRVSRRPAWEARWPVRTGHCGRHLSASER
PLSPARCHYSSFPRADRSGRPFLPLFPELEDLPLLGPEQLARREALLHAAWARGSRPRHA
SLPSSVAEAFARPSSLPAGCTGPACARPDGHSACRRLAQAQSMCLPIYREACQEGEQAGA
PAWQHRQHVCLHAHAHLPFCWGAVCPHLPPCASHGSWLSGAWGPLGHRGRTLGLGTGYRD
SGGLDEISRVARGTQGFPGPCTWRRISSLESEV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010318|Glutamate receptor ionotropic, NMDA 2C (GRIN2C)
ATGGGTGGGGCCCTGGGGCCGGCCCTGTTGCTCACCTCGCTCTTCGGTGCCTGGGCAGGG
CTGGGTCCGGGGCAGGGCGAGCAGGGCATGACGGTGGCCGTGGTGTTTAGCAGCTCAGGG
CCGCCCCAGGCCCAGTTCCGTGCCCGCCTCACCCCCCAGAGCTTCCTGGACCTACCCCTG
GAGATCCAGCCGCTCACAGTTGGGGTCAACACCACCAACCCCAGCAGCCTCCTCACCCAG
ATCTGCGGCCTCCTGGGTGCTGCCCACGTCCACGGCATTGTCTTTGAGGACAACGTGGAC
ACCGAGGCGGTGGCCCAGATCCTTGACTTCATCTCCTCCCAGACCCATGTGCCCATCCTC
AGCATCAGCGGAGGCTCTGCTGTGGTCCTCACCCCCAAGGAGCCGGGCTCCGCCTTCCTG
CAGCTGGGCGTGTCCCTGGAGCAGCAGCTGCAGGTGCTGTTCAAGGTGCTGGAAGAGTAC
GACTGGAGCGCCTTCGCCGTCATCACCAGCCTGCACCCGGGCCACGCGCTCTTCCTGGAG
GGCGTGCGCGCCGTCGCCGACGCCAGCCACGTGAGTTGGCGGCTGCTGGACGTGGTCACG
CTGGAGCTGGGCCCGGGAGGGCCGCGCGCGCGCACGCAGCGCCTGCTGCGCCAGCTCGAC
GCGCCCGTGTTTGTGGCCTACTGCTCGCGCGAGGAGGCCGAGGTGCTCTTCGCCGAGGCG
GCGCAGGCCGGTCTGGTGGGGCCCGGCCACGTGTGGCTGGTGCCCAACCTGGCGCTGGGC
AGCACCGATGCGCCCCCCGCCACCTTCCCCGTGGGCCTCATCAGCGTCGTCACCGAGAGC
TGGCGCCTCAGCCTGCGCCAGAAGGTGCGCGACGGCGTGGCCATTCTGGCCCTGGGCGCC
CACAGCTACTGGCGCCAGCATGGAACCCTGCCAGCCCCGGCCGGGGACTGCCGTGTTCAC
CCTGGGCCCGTCAGCCCTGCCCGGGAGGCCTTCTACAGGCACCTACTGAATGTCACCTGG
GAGGGCCGAGACTTCTCCTTCAGCCCTGGTGGGTACCTGGTCCAGCCCACCATGGTGGTG
ATCGCCCTCAACCGGCACCGCCTCTGGGAGATGGTGGGGCGCTGGGAGCATGGCGTCCTA
TACATGAAGTACCCCGTGTGGCCTCGCTACAGTGCCTCTCTGCAGCCTGTGGTGGACAGT
CGGCACCTGACGGTGGCCACGCTGGAAGAGCGGCCCTTTGTCATCGTGGAGAGCCCTGAC
CCTGGCACAGGAGGCTGTGTCCCCAACACCGTGCCCTGCCGCAGGCAGAGCAACCACACC
TTCAGCAGCGGGGACGTGGCCCCCTACACCAAGCTCTGCTGTAAGGGATTCTGCATCGAC
ATCCTCAAGAAGCTGGCCAGAGTGGTCAAATTCTCCTACGACCTGTACCTGGTGACCAAC
GGCAAGCATGGCAAGCGGGTGCGCGGCGTATGGAACGGCATGATTGGGGAGGTGTACTAC
AAGCGGGCAGACATGGCCATCGGCTCCCTCACCATCAATGAGGAACGCTCCGAGATCGTA
GACTTCTCTGTACCCTTTGTGGAGACGGGCATCAGTGTGATGGTGGCTCGCAGCAATGGC
ACCGTCTCCCCCTCGGCCTTCTTGGAGCCATATAGCCCTGCAGTGTGGGTGATGATGTTT
GTCATGTGCCTCACTGTGGTGGCCATCACCGTCTTCATGTTCGAGTACTTCAGCCCTGTC
AGCTACAACCAGAACCTCACCAGAGGCAAGAAGTCCGGGGGCCCAGCTTTCACTATCGGC
AAGTCCGTGTGGCTGCTGTGGGCGCTGGTCTTCAACAACTCAGTGCCCATCGAGAACCCG
CGGGGCACCACCAGCAAGATCATGGTTCTGGTCTGGGCCTTCTTTGCTGTCATCTTCCTC
GCCAGCTACACGGCCAACCTGGCCGCCTTCATGATCCAAGAGCAATACATCGACACTGTG
TCGGGCCTCAGTGACAAGAAGTTTCAGCGGCCTCAAGATCAGTACCCACCTTTCCGCTTC
GGCACGGTGCCCAACGGCAGCACGGAGCGGAACATCCGCAGTAACTACCGTGACATGCAC
ACCCACATGGTCAAGTTCAACCAGCGCTCGGTGGAGGACGCGCTCACCAGCCTCAAGATG
GGGAAGCTGGATGCCTTCATCTATGATGCTGCTGTCCTCAACTACATGGCAGGCAAGGAC
GAGGGCTGCAAGCTGGTCACCATTGGGTCTGGCAAGGTCTTTGCTACCACTGGCTACGGC
ATCGCCATGCAGAAGGACTCCCACTGGAAGCGGGCCATAGACCTGGCGCTCTTGCAGTTC
CTGGGGGACGGAGAGACACAGAAACTGGAGACAGTGTGGCTCTCAGGGATCTGCCAGAAT
GAGAAGAACGAGGTGATGAGCAGCAAGCTGGACATCGACAACATGGCAGGCGTCTTCTAC
ATGCTGCTGGTGGCCATGGGGCTGGCCCTGCTGGTCTTCGCCTGGGAGCACCTGGTCTAC
TGGAAGCTGCGCCACTCGGTGCCCAACTCATCCCAGCTGGACTTCCTGCTGGCTTTCAGC
AGGGGCATCTACAGCTGCTTCAGCGGGGTGCAGAGCCTCGCCAGCCCACCGCGGCAGGCC
AGCCCGGACCTCACGGCCAGCTCGGCCCAGGCCAGCGTGCTCAAGATGCTGCAGGCAGCC
CGCGACATGGTGACCACGGCGGGCGTAAGCAGCTCCCTGGACCGCGCCACTCGCACCATC
GAGAATTGGGGTGGCGGCCGCCGTGCGCCCCCACCGTCCCCCTGCCCGACCCCGCGGTCT
GGCCCCAGCCCATGCCTGCCCACCCCCGACCCGCCCCCAGAGCCGAGCCCCACGGGCTGG
GGACCGCCAGACGGGGGTCGCGCGGCGCTTGTGCGCAGGGCTCCGCAGCCCCCGGGCCGC
CCCCCGACGCCGGGGCCGCCCCTGTCCGACGTCTCCCGAGTGTCGCGCCGCCCAGCCTGG
GAGGCGCGGTGGCCGGTGCGGACCGGGCACTGCGGGAGGCACCTCTCGGCCTCCGAGCGG
CCCCTGTCGCCCGCGCGCTGTCACTACAGCTCCTTTCCTCGAGCCGACCGATCCGGCCGC
CCCTTCCTCCCGCTCTTCCCGGAGCTGGAGGACCTGCCGCTGCTCGGTCCGGAGCAGCTG
GCCCGGCGGGAGGCCCTGCTGCACGCGGCCTGGGCCCGGGGCTCGCGCCCGCGTCACGCT
TCCCTGCCCAGCTCCGTGGCCGAGGCCTTCGCTCGGCCCAGCTCGCTGCCCGCTGGGTGC
ACCGGCCCCGCCTGCGCCCGCCCCGACGGCCACTCGGCCTGCAGGCGCTTGGCGCAGGCG
CAGTCGATGTGCTTGCCGATCTACCGGGAGGCCTGCCAGGAGGGCGAGCAGGCAGGGGCC
CCCGCCTGGCAGCACAGACAGCACGTCTGCCTGCACGCCCACGCCCACCTGCCATTTTGC
TGGGGGGCTGTCTGTCCTCACCTTCCACCCTGTGCCAGCCACGGCTCCTGGCTCTCCGGG
GCCTGGGGGCCTCTGGGGCACAGGGGCAGGACTCTGGGGCTGGGCACAGGCTACAGAGAC
AGTGGGGGACTGGACGAGATCAGCAGGGTAGCCCGTGGGACGCAAGGCTTCCCGGGACCC
TGCACCTGGAGACGGATCTCCAGTCTGGAGTCAGAAGTGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01094</identifier>
            <name>ANF_receptor</name>
          </pfam>
          <pfam>
            <identifier>PF00060</identifier>
            <name>Lig_chan</name>
          </pfam>
          <pfam>
            <identifier>PF10613</identifier>
            <name>Lig_chan-Glu_bd</name>
          </pfam>
          <pfam>
            <identifier>PF10565</identifier>
            <name>NMDAR2_C</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>NMDA selective glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular-glutamate-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NMDA glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>directional locomotion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ionotropic glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of protein catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuromuscular process controlling balance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein localization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to wounding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O15399" source="Swiss-Prot">
        <name>Glutamate receptor ionotropic, NMDA 2D</name>
        <general-function>Nmda glutamate receptor activity</general-function>
        <specific-function>NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine.</specific-function>
        <gene-name>GRIN2D</gene-name>
        <locus>19q13.1-qter</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>584-604
657-677
845-865</transmembrane-regions>
        <signal-regions>1-27</signal-regions>
        <theoretical-pi>8.27</theoretical-pi>
        <molecular-weight>143750.685</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:4588</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GRIN2D</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U77783</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2444026</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>459</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NMDE4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>EB11</synonym>
          <synonym>GluN2D</synonym>
          <synonym>Glutamate [NMDA] receptor subunit epsilon-4</synonym>
          <synonym>N-methyl D-aspartate receptor subtype 2D</synonym>
          <synonym>NMDAR2D</synonym>
          <synonym>NR2D</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0016080|Glutamate receptor ionotropic, NMDA 2D
MRGAGGPRGPRGPAKMLLLLALACASPFPEEAPGPGGAGGPGGGLGGARPLNVALVFSGP
AYAAEAARLGPAVAAAVRSPGLDVRPVALVLNGSDPRSLVLQLCDLLSGLRVHGVVFEDD
SRAPAVAPILDFLSAQTSLPIVAVHGGAALVLTPKEKGSTFLQLGSSTEQQLQVIFEVLE
EYDWTSFVAVTTRAPGHRAFLSYIEVLTDGSLVGWEHRGALTLDPGAGEAVLSAQLRSVS
AQIRLLFCAREEAEPVFRAAEEAGLTGSGYVWFMVGPQLAGGGGSGAPGEPPLLPGGAPL
PAGLFAVRSAGWRDDLARRVAAGVAVVARGAQALLRDYGFLPELGHDCRAQNRTHRGESL
HRYFMNITWDNRDYSFNEDGFLVNPSLVVISLTRDRTWEVVGSWEQQTLRLKYPLWSRYG
RFLQPVDDTQHLTVATLEERPFVIVEPADPISGTCIRDSVPCRSQLNRTHSPPPDAPRPE
KRCCKGFCIDILKRLAHTIGFSYDLYLVTNGKHGKKIDGVWNGMIGEVFYQRADMAIGSL
TINEERSEIVDFSVPFVETGISVMVARSNGTVSPSAFLEPYSPAVWVMMFVMCLTVVAVT
VFIFEYLSPVGYNRSLATGKRPGGSTFTIGKSIWLLWALVFNNSVPVENPRGTTSKIMVL
VWAFFAVIFLASYTANLAAFMIQEEYVDTVSGLSDRKFQRPQEQYPPLKFGTVPNGSTEK
NIRSNYPDMHSYMVRYNQPRVEEALTQLKAGKLDAFIYDAAVLNYMARKDEGCKLVTIGS
GKVFATTGYGIALHKGSRWKRPIDLALLQFLGDDEIEMLERLWLSGICHNDKIEVMSSKL
DIDNMAGVFYMLLVAMGLSLLVFAWEHLVYWRLRHCLGPTHRMDFLLAFSRGMYSCCSAE
AAPPPAKPPPPPQPLPSPAYPAPRPAPGPAPFVPRERASVDRWRRTKGAGPPGGAGLADG
FHRYYGPIEPQGLGLGLGEARAAPRGAAGRPLSPPAAQPPQKPPPSYFAIVRDKEPAEPP
AGAFPGFPSPPAPPAAAATAVGPPLCRLAFEDESPPAPARWPRSDPESQPLLGPGAGGAG
GTGGAGGGAPAAPPPCRAAPPPCPYLDLEPSPSDSEDSESLGGASLGGLEPWWFADFPYP
YAERLGPPPGRYWSVDKLGGWRAGSWDYLPPRSGPAAWHCRHCASLELLPPPRHLSCSHD
GLDGGWWAPPPPPWAAGPLPRRRARCGCPRSHPHRPRASHRTPAAAAPHHHRHRRAAGGW
DLPPPAPTSRSLEDLSSCPRAAPARRLTGPSRHARRCPHAAHWGPPLPTASHRRHRGGDL
GTRRGSAHFSSLESEV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016081|Glutamate receptor ionotropic, NMDA 2D (GRIN2D)
ATGCGCGGCGCCGGTGGCCCCCGCGGCCCTCGGGGCCCCGCTAAGATGCTGCTGCTGCTG
GCGCTGGCCTGCGCCAGCCCGTTCCCGGAGGAGGCGCCGGGGCCGGGCGGGGCCGGTGGG
CCCGGCGGCGGCCTCGGCGGGGCGCGGCCGCTCAACGTGGCGCTCGTGTTCTCGGGGCCC
GCGTACGCGGCCGAGGCGGCACGCCTGGGCCCGGCCGTGGCGGCGGCGGTGCGCAGCCCG
GGCCTAGACGTGCGGCCCGTGGCGCTGGTGCTCAACGGCTCGGACCCGCGCAGCCTCGTG
CTGCAGCTCTGCGACCTGCTGTCGGGGTTGCGCGTGCACGGCGTGGTCTTCGAAGACGAC
TCGCGCGCGCCCGCCGTCGCGCCCATCCTCGACTTCCTGTCGGCGCAGACCTCGCTGCCC
ATCGTGGCCGTGCACGGCGGCGCCGCGCTCGTGCTCACGCCCAAGGAGAAGGGCTCCACC
TTCCTGCAGCTGGGCTCTTCCACCGAGCAACAGCTTCAGGTCATCTTTGAGGTGCTGGAG
GAGTATGACTGGACGTCCTTTGTAGCCGTGACCACTCGTGCCCCTGGCCACCGGGCCTTC
CTGTCCTACATTGAGGTGCTGACTGACGGTAGTCTGGTGGGCTGGGAGCACCGCGGAGCG
CTGACGCTGGACCCTGGGGCGGGCGAGGCCGTGCTCAGTGCCCAGCTCCGCAGTGTCAGC
GCGCAGATCCGCCTGCTCTTCTGCGCCCGAGAGGAGGCCGAGCCCGTGTTCCGCGCAGCT
GAGGAGGCTGGCCTCACTGGATCTGGCTACGTCTGGTTCATGGTGGGGCCCCAGCTGGCT
GGAGGCGGGGGCTCTGGGGCCCCTGGTGAGCCCCCTCTTCTGCCAGGAGGCGCCCCCCTG
CCTGCCGGGCTGTTTGCAGTGCGCTCGGCTGGCTGGCGGGATGACCTGGCTCGGCGAGTG
GCAGCTGGCGTGGCCGTAGTGGCCAGAGGTGCCCAGGCCCTGCTGCGTGATTATGGTTTC
CTTCCTGAGCTCGGCCACGACTGTCGCGCCCAGAACCGCACCCACCGCGGCGAGAGTCTG
CATAGGTACTTCATGAACATCACGTGGGATAACCGGGATTACTCCTTCAATGAGGACGGC
TTCCTAGTGAACCCCTCCCTGGTGGTCATCTCCCTCACCAGAGACAGGACGTGGGAGGTG
GTGGGCAGCTGGGAGCAGCAGACGCTCCGCCTCAAGTACCCGCTGTGGTCCCGCTATGGT
CGCTTCCTGCAGCCAGTGGACGACACGCAGCACCTCACGGTGGCCACGCTGGAGGAAAGG
CCGTTTGTCATCGTGGAGCCTGCAGACCCTATCAGCGGCACCTGCATCCGAGACTCCGTC
CCCTGCCGGAGCCAGCTCAACCGAACCCACAGCCCTCCACCGGATGCCCCCCGCCCGGAA
AAGCGCTGCTGCAAGGGTTTCTGCATCGACATTCTGAAGCGGCTGGCGCATACCATCGGC
TTCAGCTACGACCTCTACCTGGTCACCAATGGCAAGCACGGAAAGAAGATCGATGGCGTC
TGGAACGGCATGATCGGGGAGGTGTTCTACCAGCGCGCAGACATGGCCATCGGCTCCCTC
ACCATCAACGAGGAGCGCTCCGAGATCGTGGACTTCTCCGTCCCCTTCGTGGAGACCGGC
ATCAGCGTCATGGTGGCGCGCAGCAATGGCACGGTGTCCCCCTCGGCCTTCCTCGAGCCC
TACAGCCCCGCCGTGTGGGTGATGATGTTCGTCATGTGCCTCACTGTGGTCGCCGTCACT
GTTTTCATCTTCGAGTACCTCAGTCCTGTTGGTTACAACCGCAGCCTGGCCACGGGCAAG
CGCCCTGGCGGTTCAACCTTCACCATTGGGAAATCCATCTGGCTGCTCTGGGCCCTGGTG
TTCAATAATTCGGTGCCCGTGGAGAACCCCCGGGGAACCACCAGCAAAATCATGGTGCTG
GTGTGGGCCTTCTTCGCCGTCATCTTCCTCGCCAGCTACACAGCCAACCTGGCCGCCTTC
ATGATCCAGGAGGAGTACGTGGATACTGTGTCTGGGCTCAGTGACCGCAAGTTCCAGAGG
CCCCAGGAGCAGTACCCGCCCCTGAAGTTTGGGACCGTGCCCAACGGCTCCACGGAGAAG
AACATCCGCAGCAACTATCCCGACATGCACAGCTACATGGTGCGCTACAACCAGCCCCGC
GTAGAGGAAGCGCTCACTCAGCTCAAGGCAGGGAAGCTGGACGCCTTCATCTACGATGCT
GCAGTGCTCAATTACATGGCCCGCAAGGACGAGGGCTGCAAGCTTGTCACCATCGGCTCC
GGCAAGGTCTTCGCCACGACAGGCTATGGCATCGCCCTGCACAAGGGCTCCCGCTGGAAG
CGGCCCATCGACCTGGCGTTGCTGCAGTTCCTGGGGGATGATGAGATCGAGATGCTGGAG
CGGCTGTGGCTCTCTGGGATCTGCCACAATGACAAAATCGAGGTGATGAGCAGCAAGCTG
GACATCGACAACATGGCGGGCGTCTTCTACATGCTCCTGGTGGCCATGGGCCTGTCCCTG
CTGGTCTTCGCCTGGGAGCACCTGGTGTACTGGCGCCTGCGGCACTGCCTGGGGCCCACC
CACCGCATGGACTTCCTGCTGGCCTTCTCCAGGGGCATGTACAGCTGCTGCAGCGCTGAG
GCCGCCCCACCGCCCGCCAAGCCCCCGCCGCCGCCACAGCCCCTGCCCAGCCCCGCGTAC
CCCGCGCCGCGGCCGGCTCCCGGGCCCGCACCTTTCGTGCCCCGCGAGCGCGCCTCAGTG
GACCGCTGGCGCCGGACCAAGGGCGCGGGGCCGCCGGGGGGCGCGGGCCTGGCCGACGGC
TTCCACCGCTACTACGGCCCCATCGAGCCGCAGGGCCTAGGCCTCGGCCTGGGCGAAGCG
CGCGCGGCACCGCGGGGCGCAGCCGGGCGCCCGCTGTCCCCGCCGGCCGCTCAGCCCCCG
CAGAAGCCGCCGCCCTCCTATTTCGCCATCGTACGCGACAAGGAGCCAGCCGAGCCCCCC
GCCGGCGCCTTCCCCGGCTTCCCGTCGCCGCCCGCGCCCCCCGCCGCCGCGGCCACCGCC
GTCGGGCCGCCACTCTGCCGCTTGGCCTTCGAGGACGAGAGCCCGCCGGCGCCCGCGCGG
TGGCCGCGCTCGGACCCCGAGAGCCAACCCCTGCTGGGGCCAGGCGCGGGCGGCGCGGGG
GGCACGGGGGGCGCAGGCGGAGGAGCCCCGGCCGCTCCGCCCCCGTGCCGCGCCGCGCCG
CCCCCGTGCCCTTACCTCGATCTCGAGCCGTCGCCGTCGGACTCGGAGGACTCGGAGAGC
CTGGGCGGCGCGTCGCTGGGCGGCCTGGAGCCCTGGTGGTTCGCCGACTTCCCTTACCCG
TATGCCGAGCGCCTCGGGCCGCCGCCCGGCCGCTACTGGTCGGTCGACAAGCTCGGGGGC
TGGCGCGCCGGGAGCTGGGACTACCTGCCCCCGCGCAGCGGTCCGGCCGCCTGGCACTGT
CGGCACTGCGCCAGCCTGGAGCTGCTGCCGCCGCCGCGCCATCTCAGCTGCTCGCACGAT
GGCCTGGACGGCGGCTGGTGGGCGCCACCGCCTCCACCCTGGGCCGCCGGGCCCCTGCCC
CGACGCCGGGCCCGCTGCGGGTGCCCGCGGTCGCACCCGCACCGCCCGCGGGCCTCGCAC
CGCACGCCCGCCGCCGCCGCGCCCCACCACCACAGGCACCGGCGCGCCGCTGGGGGCTGG
GACCTCCCGCCGCCCGCGCCCACCTCGCGCTCGCTCGAGGACCTCAGCTCGTGCCCTCGC
GCCGCCCCTGCGCGCAGGCTTACCGGGCCCTCCCGCCACGCTCGCAGGTGTCCGCACGCC
GCGCACTGGGGGCCGCCGCTGCCCACAGCTTCCCACCGGAGACACCGGGGCGGGGACCTG
GGCACCCGCAGGGGCTCGGCGCACTTCTCTAGCCTCGAGTCCGAGGTATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01094</identifier>
            <name>ANF_receptor</name>
          </pfam>
          <pfam>
            <identifier>PF00060</identifier>
            <name>Lig_chan</name>
          </pfam>
          <pfam>
            <identifier>PF10613</identifier>
            <name>Lig_chan-Glu_bd</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>NMDA selective glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular-glutamate-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NMDA glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPKK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adult locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>insulin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ionotropic glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Ras protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small GTPase mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>startle response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vascular endothelial growth factor receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="Q8TCU5" source="Swiss-Prot">
        <name>Glutamate receptor ionotropic, NMDA 3A</name>
        <general-function>Protein phosphatase 2a binding</general-function>
        <specific-function>NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).</specific-function>
        <gene-name>GRIN3A</gene-name>
        <locus>9q31.1</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>675-695
749-769
931-951</transmembrane-regions>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi>7.81</theoretical-pi>
        <molecular-weight>125464.07</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:16767</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GRIN3A</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AJ416950</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>20372905</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>460</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q8TCU5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NMD3A_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GluN3A</synonym>
          <synonym>KIAA1973</synonym>
          <synonym>N-methyl-D-aspartate receptor subtype 3A</synonym>
          <synonym>NMDAR-L</synonym>
          <synonym>NMDAR3A</synonym>
          <synonym>NR3A</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037055|Glutamate receptor ionotropic, NMDA 3A
MRRLSLWWLLSRVCLLLPPPCALVLAGVPSSSSHPQPCQILKRIGHAVRVGAVHLQPWTT
APRAASRAPDDSRAGAQRDEPEPGTRRSPAPSPGARWLGSTLHGRGPPGSRKPGEGARAE
ALWPRDALLFAVDNLNRVEGLLPYNLSLEVVMAIEAGLGDLPLLPFSSPSSPWSSDPFSF
LQSVCHTVVVQGVSALLAFPQSQGEMMELDLVSLVLHIPVISIVRHEFPRESQNPLHLQL
SLENSLSSDADVTVSILTMNNWYNFSLLLCQEDWNITDFLLLTQNNSKFHLGSIINITAN
LPSTQDLLSFLQIQLESIKNSTPTVVMFGCDMESIRRIFEITTQFGVMPPELRWVLGDSQ
NVEELRTEGLPLGLIAHGKTTQSVFEHYVQDAMELVARAVATATMIQPELALIPSTMNCM
EVETTNLTSGQYLSRFLANTTFRGLSGSIRVKGSTIVSSENNFFIWNLQHDPMGKPMWTR
LGSWQGGKIVMDYGIWPEQAQRHKTHFQHPSKLHLRVVTLIEHPFVFTREVDDEGLCPAG
QLCLDPMTNDSSTLDSLFSSLHSSNDTVPIKFKKCCYGYCIDLLEKIAEDMNFDFDLYIV
GDGKYGAWKNGHWTGLVGDLLRGTAHMAVTSFSINTARSQVIDFTSPFFSTSLGILVRTR
DTAAPIGAFMWPLHWTMWLGIFVALHITAVFLTLYEWKSPFGLTPKGRNRSKVFSFSSAL
NICYALLFGRTVAIKPPKCWTGRFLMNLWAIFCMFCLSTYTANLAAVMVGEKIYEELSGI
HDPKLHHPSQGFRFGTVRESSAEDYVRQSFPEMHEYMRRYNVPATPDGVEYLKNDPEKLD
AFIMDKALLDYEVSIDADCKLLTVGKPFAIEGYGIGLPPNSPLTANISELISQYKSHGFM
DMLHDKWYRVVPCGKRSFAVTETLQMGIKHFSGLFVLLCIGFGLSILTTIGEHIVYRLLL
PRIKNKSKLQYWLHTSQRLHRAINTSFIEEKQQHFKTKRVEKRSNVGPRQLTVWNTSNLS
HDNRRKYIFSDEEGQNQLGIRIHQDIPLPPRRRELPALRTTNGKADSLNVSRNSVMQELS
ELEKQIQVIRQELQLAVSRKTELEEYQRTSRTCES</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016161|Glutamate receptor ionotropic, NMDA 3A (GRIN3A)
ATGAGGAGACTGAGTTTGTGGTGGCTGCTGAGCAGGGTCTGTCTGCTGTTGCCGCCGCCC
TGCGCACTGGTGCTGGCCGGGGTGCCCAGCTCCTCCTCGCACCCGCAGCCCTGCCAGATC
CTCAAGCGCATCGGGCACGCGGTGAGGGTGGGCGCGGTGCACTTGCAGCCCTGGACCACC
GCCCCCCGCGCGGCCAGCCGCGCTCCGGACGACAGCCGAGCAGGAGCCCAGAGGGATGAG
CCGGAGCCAGGGACTAGGCGGTCCCCGGCGCCCTCGCCGGGCGCACGCTGGTTGGGGAGC
ACCCTGCATGGCCGGGGGCCGCCGGGCTCCCGTAAGCCCGGGGAGGGCGCCAGGGCGGAG
GCCCTGTGGCCACGGGACGCCCTCCTATTTGCCGTGGACAACCTGAACCGCGTGGAAGGG
CTGCTACCCTACAACCTGTCTTTGGAAGTAGTGATGGCCATCGAGGCAGGCCTGGGCGAT
CTGCCACTTTTGCCCTTCTCCTCCCCTAGTTCGCCATGGAGCAGTGACCCTTTCTCCTTC
CTGCAAAGTGTGTGCCATACCGTGGTGGTGCAAGGGGTGTCGGCGCTGCTCGCCTTCCCC
CAGAGCCAGGGCGAAATGATGGAGCTCGACTTGGTCAGCTTAGTCCTGCACATTCCAGTG
ATCAGCATCGTGCGCCACGAGTTTCCACGGGAGAGTCAGAATCCCCTTCACCTACAACTG
AGTTTAGAAAATTCATTAAGTTCTGATGCTGATGTCACTGTCTCAATCCTGACCATGAAC
AACTGGTACAATTTTAGCTTGTTGCTGTGCCAGGAAGACTGGAACATCACCGACTTCCTC
CTCCTTACCCAGAATAATTCCAAGTTCCACCTTGGTTCTATCATCAACATCACCGCTAAC
CTCCCCTCCACCCAGGACCTCTTGAGCTTCCTACAGATCCAGCTTGAGAGTATTAAGAAC
AGCACACCCACAGTGGTGATGTTTGGCTGCGACATGGAAAGTATCCGGCGGATTTTCGAA
ATTACAACCCAGTTTGGGGTCATGCCCCCTGAACTTCGTTGGGTGCTGGGAGATTCCCAG
AATGTGGAGGAACTGAGGACAGAGGGTCTGCCCTTAGGGCTCATTGCTCATGGAAAAACA
ACACAGTCTGTCTTTGAGCACTACGTACAAGATGCTATGGAGCTGGTCGCAAGAGCTGTA
GCCACAGCCACCATGATCCAACCAGAACTTGCTCTCATTCCCAGCACGATGAACTGCATG
GAGGTGGAAACTACAAATCTCACTTCAGGACAATATTTATCAAGGTTTCTAGCCAATACC
ACTTTCAGAGGCCTCAGTGGTTCCATCAGAGTAAAAGGTTCCACCATCGTCAGCTCAGAA
AACAACTTTTTCATCTGGAATCTTCAACATGACCCCATGGGAAAGCCAATGTGGACCCGC
TTGGGCAGCTGGCAGGGGGGAAAGATTGTCATGGACTATGGAATATGGCCAGAGCAGGCC
CAGAGACACAAAACCCACTTCCAACATCCAAGTAAGCTACACTTGAGAGTGGTTACCCTG
ATTGAGCATCCTTTTGTCTTCACAAGGGAGGTAGATGATGAAGGCTTGTGCCCTGCTGGC
CAACTCTGTCTAGACCCCATGACTAATGACTCTTCCACATTGGACAGCCTTTTTAGCAGC
CTCCATAGCAGTAATGATACAGTGCCCATTAAATTCAAGAAGTGCTGCTATGGATATTGC
ATTGATCTGCTGGAAAAGATAGCAGAAGACATGAACTTTGACTTCGACCTCTATATTGTA
GGGGATGGAAAGTATGGAGCATGGAAAAATGGGCACTGGACTGGGCTAGTGGGTGATCTC
CTGAGAGGGACTGCCCACATGGCAGTCACTTCCTTTAGCATCAATACTGCACGGAGCCAG
GTGATAGATTTCACCAGCCCTTTCTTCTCCACCAGCTTGGGCATCTTAGTGAGGACCCGA
GATACAGCAGCTCCCATTGGAGCCTTCATGTGGCCACTCCACTGGACAATGTGGCTGGGG
ATTTTTGTGGCTCTGCACATCACTGCCGTCTTCCTCACTCTGTATGAATGGAAGAGTCCA
TTTGGTTTGACTCCCAAGGGGCGAAATAGAAGTAAAGTCTTCTCCTTTTCTTCAGCCTTG
AACATCTGTTATGCCCTCTTGTTTGGCAGAACAGTGGCCATCAAACCTCCAAAATGTTGG
ACTGGAAGGTTTCTAATGAACCTTTGGGCCATTTTCTGTATGTTTTGCCTTTCCACATAC
ACGGCAAACTTGGCTGCTGTCATGGTAGGTGAGAAGATCTATGAAGAGCTTTCTGGAATA
CATGACCCCAAGTTACATCATCCTTCCCAAGGATTCCGCTTTGGAACTGTCCGAGAAAGC
AGTGCTGAAGATTATGTGAGACAAAGTTTCCCAGAGATGCATGAATATATGAGAAGGTAC
AATGTTCCAGCCACCCCTGATGGAGTGGAGTATCTGAAGAATGATCCAGAGAAACTAGAC
GCCTTCATCATGGACAAAGCCCTTCTGGATTATGAAGTGTCAATAGATGCTGACTGCAAA
CTTCTCACTGTGGGGAAGCCATTTGCCATAGAAGGATACGGCATTGGCCTCCCACCCAAC
TCTCCATTGACCGCCAACATATCCGAGCTAATCAGTCAATACAAGTCACATGGGTTTATG
GATATGCTCCATGACAAGTGGTACAGGGTGGTTCCCTGTGGCAAGAGAAGTTTTGCTGTC
ACGGAGACTTTGCAAATGGGCATCAAACACTTCTCTGGGCTCTTTGTGCTGCTGTGCATT
GGATTTGGTCTGTCCATTTTGACCACCATTGGTGAGCACATAGTATACAGGCTGCTGCTA
CCACGAATCAAAAACAAATCCAAGCTGCAATACTGGCTCCACACCAGCCAGAGATTACAC
AGAGCAATAAATACATCATTTATAGAGGAAAAGCAGCAGCATTTCAAGACCAAACGTGTG
GAAAAGAGGTCTAATGTGGGACCCCGTCAGCTTACCGTATGGAATACTTCCAATCTGAGT
CATGACAACCGACGGAAATACATCTTTAGTGATGAGGAAGGACAAAACCAGCTGGGCATC
CGGATCCACCAGGACATCCCCCTCCCTCCAAGGAGAAGAGAGCTCCCTGCCTTGCGGACC
ACCAATGGGAAAGCAGACTCCCTAAATGTATCTCGGAACTCAGTGATGCAGGAACTCTCA
GAGCTCGAGAAGCAGATTCAGGTGATCCGTCAGGAGCTGCAGCTGGCTGTGAGCAGGAAA
ACGGAGCTGGAGGAGTATCAAAGGACAAGTCGGACTTGTGAGTCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00060</identifier>
            <name>Lig_chan</name>
          </pfam>
          <pfam>
            <identifier>PF10613</identifier>
            <name>Lig_chan-Glu_bd</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>NMDA selective glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic density</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>synapse</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular-glutamate-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glycine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NMDA glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein phosphatase 2A binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dendrite development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ionotropic glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to ethanol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <polypeptide id="O60391" source="Swiss-Prot">
        <name>Glutamate receptor ionotropic, NMDA 3B</name>
        <general-function>Nmda glutamate receptor activity</general-function>
        <specific-function>NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine.</specific-function>
        <gene-name>GRIN3B</gene-name>
        <locus>19p13.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>565-585
649-669
831-851</transmembrane-regions>
        <signal-regions>1-22</signal-regions>
        <theoretical-pi>9.5</theoretical-pi>
        <molecular-weight>112990.98</molecular-weight>
        <chromosome-location>19</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:16768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>GRIN3B</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AC004528</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>3025446</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>461</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O60391</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NMD3B_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>GluN3B</synonym>
          <synonym>N-methyl-D-aspartate receptor subtype 3B</synonym>
          <synonym>NMDAR3B</synonym>
          <synonym>NR3B</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001066|Glutamate receptor ionotropic, NMDA 3B
MEFVRALWLGLALALGPGSAGGHPQPCGVLARLGGSVRLGALLPRAPLARARARAALARA
ALAPRLPHNLSLELVVAAPPARDPASLTRGLCQALVPPGVAALLAFPEARPELLQLHFLA
AATETPVLSLLRREARAPLGAPNPFHLQLHWASPLETLLDVLVAVLQAHAWEDVGLALCR
TQDPGGLVALWTSRAGRPPQLVLDLSRRDTGDAGLRARLAPMAAPVGGEAPVPAAVLLGC
DIARARRVLEAVPPGPHWLLGTPLPPKALPTAGLPPGLLALGEVARPPLEAAIHDIVQLV
ARALGSAAQVQPKRALLPAPVNCGDLQPAGPESPGRFLARFLANTSFQGRTGPVWVTGSS
QVHMSRHFKVWSLRRDPRGAPAWATVGSWRDGQLDLEPGGASARPPPPQGAQVWPKLRVV
TLLEHPFVFARDPDEDGQCPAGQLCLDPGTNDSATLDALFAALANGSAPRALRKCCYGYC
IDLLERLAEDTPFDFELYLVGDGKYGALRDGRWTGLVGDLLAGRAHMAVTSFSINSARSQ
VVDFTSPFFSTSLGIMVRARDTASPIGAFMWPLHWSTWLGVFAALHLTALFLTVYEWRSP
YGLTPRGRNRSTVFSYSSALNLCYAILFRRTVSSKTPKCPTGRLLMNLWAIFCLLVLSSY
TANLAAVMVGDKTFEELSGIHDPKLHHPAQGFRFGTVWESSAEAYIKKSFPDMHAHMRRH
SAPTTPRGVAMLTSDPPKLNAFIMDKSLLDYEVSIDADCKLLTVGKPFAIEGYGIGLPQN
SPLTSNLSEFISRYKSSGFIDLLHDKWYKMVPCGKRVFAVTETLQMSIYHFAGLFVLLCL
GLGSALLSSLGEHAFFRLALPRIRKGSRLQYWLHTSQKIHRALNTEPPEGSKEETAEAEP
SGPEVEQQQQQQDQPTAPEGWKRARRAVDKERRVRFLLEPAVVVAPEADAEAEAAPREGP
VWLCSYGRPPAARPTGAPQPGELQELERRIEVARERLRQALVRRGQLLAQLGDSARHRPR
RLLQARAAPAEAPPHSGRPGSQE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016125|Glutamate receptor ionotropic, NMDA 3B (GRIN3B)
ATGGAGTTTGTGCGGGCGCTGTGGCTGGGCCTGGCGCTGGCGCTGGGGCCGGGGTCCGCG
GGGGGCCACCCTCAGCCGTGCGGCGTCCTGGCGCGCCTCGGGGGCTCCGTGCGCCTGGGC
GCCCTCCTGCCCCGCGCGCCTCTCGCCCGCGCCCGCGCCCGCGCCGCCCTGGCCCGGGCC
GCCCTGGCGCCGCGGCTGCCGCACAACCTGAGCTTGGAGCTGGTGGTCGCCGCGCCCCCC
GCCCGCGACCCCGCCTCGCTGACCCGCGGCCTGTGCCAGGCGCTGGTGCCTCCGGGCGTG
GCGGCCCTGCTCGCCTTTCCCGAGGCTCGGCCCGAGCTGCTGCAGCTGCACTTCCTGGCG
GCGGCCACCGAGACCCCCGTGCTCAGCCTGCTGCGGCGGGAGGCGCGCGCGCCCCTCGGA
GCCCCGAACCCATTCCACCTGCAGCTGCACTGGGCCAGCCCCCTGGAGACGCTGCTGGAT
GTGCTGGTGGCGGTGCTGCAGGCGCACGCCTGGGAAGACGTCGGCCTGGCCCTGTGCCGC
ACTCAGGACCCCGGCGGCCTGGTGGCCCTCTGGACAAGCCGGGCTGGCCGGCCCCCACAG
CTGGTCCTGGACCTAAGCCGGCGGGACACGGGAGATGCAGGACTGCGGGCACGCCTGGCC
CCGATGGCGGCGCCAGTGGGGGGTGAAGCACCGGTACCCGCGGCGGTCCTCCTCGGCTGT
GACATCGCCCGTGCCCGTCGGGTGCTGGAGGCCGTACCTCCCGGCCCCCACTGGCTGTTG
GGGACACCACTGCCGCCCAAGGCCCTGCCCACCGCGGGGCTGCCACCAGGGCTGCTGGCG
CTGGGCGAGGTGGCACGACCCCCGCTGGAGGCCGCCATCCATGACATTGTGCAACTGGTG
GCCCGGGCGCTGGGCAGTGCGGCCCAGGTGCAGCCGAAGCGAGCCCTCCTCCCCGCCCCG
GTCAACTGCGGGGACCTGCAGCCGGCCGGGCCCGAGTCCCCGGGGCGCTTCTTGGCACGG
TTCCTGGCCAACACGTCCTTCCAGGGCCGCACGGGCCCCGTGTGGGTGACAGGCAGCTCC
CAGGTACACATGTCTCGGCACTTTAAGGTGTGGAGCCTTCGCCGGGACCCACGGGGCGCC
CCGGCCTGGGCCACGGTGGGCAGCTGGCGGGACGGCCAGCTGGACTTGGAACCGGGAGGT
GCCTCTGCACGGCCCCCGCCCCCACAGGGTGCCCAGGTCTGGCCCAAGCTGCGTGTGGTA
ACGCTGTTGGAACACCCATTTGTGTTTGCCCGTGATCCAGACGAAGACGGGCAGTGCCCA
GCGGGGCAGCTGTGCCTGGACCCTGGCACCAACGACTCGGCCACCCTGGACGCACTGTTC
GCCGCGCTGGCCAACGGCTCAGCGCCCCGTGCCCTGCGCAAGTGCTGCTACGGCTACTGC
ATTGACCTGCTGGAGCGGCTGGCGGAGGACACGCCCTTCGACTTCGAGCTGTACCTCGTG
GGTGACGGCAAGTACGGCGCCCTGCGGGACGGCCGCTGGACCGGCCTGGTCGGGGACCTG
CTGGCCGGCCGGGCCCACATGGCGGTCACCAGCTTCAGTATCAACTCCGCCCGCTCACAG
GTGGTGGACTTCACCAGCCCCTTCTTCTCCACCAGCCTGGGCATCATGGTGCGGGCACGG
GACACGGCCTCACCCATCGGTGCCTTTATGTGGCCCCTGCACTGGTCCACGTGGCTGGGC
GTCTTTGCGGCCCTGCACCTCACCGCGCTCTTCCTCACCGTGTACGAGTGGCGTAGCCCC
TACGGCCTCACGCCACGTGGCCGCAACCGCAGCACCGTCTTCTCCTACTCCTCAGCCCTC
AACCTGTGCTACGCCATCCTCTTCAGACGCACCGTGTCCAGCAAGACGCCCAAGTGCCCC
ACGGGCCGCCTGCTCATGAACCTCTGGGCCATCTTCTGCCTGCTGGTGCTGTCCAGCTAC
ACGGCCAACCTGGCTGCCGTCATGGTCGGGGACAAGACCTTCGAGGAGCTGTCGGGGATC
CACGACCCCAAGCTGCACCACCCGGCGCAGGGCTTCCGCTTCGGCACCGTGTGGGAGAGC
AGCGCCGAGGCGTACATCAAGAAGAGCTTCCCCGACATGCACGCACACATGCGGCGCCAC
AGCGCGCCCACCACGCCCCGCGGCGTCGCCATGCTCACGAGCGACCCCCCCAAGCTCAAC
GCCTTCATCATGGACAAGTCGCTCCTGGACTACGAGGTCTCCATCGACGCCGACTGCAAA
CTGCTGACCGTGGGAAAGCCCTTCGCCATTGAGGGCTATGGGATCGGACTGCCCCAGAAC
TCGCCGCTCACCTCCAACCTGTCCGAGTTCATCAGCCGCTACAAGTCCTCCGGCTTCATC
GACCTGCTCCACGACAAGTGGTACAAGATGGTGCCTTGCGGCAAGCGGGTCTTTGCGGTT
ACAGAGACCCTGCAGATGAGCATCTACCACTTCGCGGGCCTCTTCGTGTTGCTGTGCCTG
GGCCTGGGCAGCGCTCTGCTCAGCTCGCTGGGCGAGCACGCCTTCTTCCGCCTGGCGCTG
CCGCGCATCCGCAAGGGGAGCAGGCTGCAGTACTGGCTGCACACCAGCCAGAAAATCCAC
CGCGCCCTCAACACGGAGCCACCAGAGGGGTCGAAGGAGGAGACGGCAGAGGCGGAGCCC
AGCGGCCCCGAGGTGGAGCAGCAGCAGCAGCAGCAGGACCAGCCAACGGCTCCGGAGGGC
TGGAAACGGGCGCGCCGGGCCGTGGACAAGGAGCGCCGCGTGCGCTTCCTGCTGGAGCCC
GCCGTGGTTGTGGCACCCGAAGCGGACGCGGAGGCGGAGGCTGCGCCGCGAGAGGGCCCC
GTCTGGCTGTGCTCCTACGGCCGCCCGCCCGCCGCAAGGCCCACGGGGGCCCCCCAGCCC
GGGGAGCTGCAGGAGCTGGAGCGCCGCATCGAAGTCGCGCGTGAGCGGCTCCGCCAGGCC
CTGGTGCGGCGCGGCCAGCTCCTGGCACAGCTCGGGGACAGCGCACGTCACCGGCCTCGG
CGCTTGCTTCAGGCCAGAGCGGCCCCCGCGGAGGCCCCACCACACTCTGGCCGACCGGGG
AGCCAGGAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00060</identifier>
            <name>Lig_chan</name>
          </pfam>
          <pfam>
            <identifier>PF10613</identifier>
            <name>Lig_chan-Glu_bd</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell junction</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>NMDA selective glutamate receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>postsynaptic membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cation channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>extracellular-glutamate-gated ion channel activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>glycine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neurotransmitter binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neurotransmitter receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>NMDA glutamate receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ion transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ionotropic glutamate receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein insertion into membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission, glutamatergic</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="42">
      <id>BE0000647</id>
      <name>Sodium-dependent dopamine transporter</name>
      <organism>Humans</organism>
      <actions>
        <action>modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q01959" source="Swiss-Prot">
        <name>Sodium-dependent dopamine transporter</name>
        <general-function>Monoamine transmembrane transporter activity</general-function>
        <specific-function>Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.</specific-function>
        <gene-name>SLC6A3</gene-name>
        <locus>5p15.3</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>69-89
96-116
140-160
238-256
265-282
318-335
347-368
401-420
447-465
481-501
522-541
560-578</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.92</theoretical-pi>
        <molecular-weight>68494.255</molecular-weight>
        <chromosome-location>5</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11049</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC6A3</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M96670</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>553260</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>927</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q01959</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SC6A3_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>DA transporter</synonym>
          <synonym>DAT1</synonym>
          <synonym>Solute carrier family 6 member 3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010450|Sodium-dependent dopamine transporter
MSKSKCSVGLMSSVVAPAKEPNAVGPKEVELILVKEQNGVQLTSSTLTNPRQSPVEAQDR
ETWGKKIDFLLSVIGFAVDLANVWRFPYLCYKNGGGAFLVPYLLFMVIAGMPLFYMELAL
GQFNREGAAGVWKICPILKGVGFTVILISLYVGFFYNVIIAWALHYLFSSFTTELPWIHC
NNSWNSPNCSDAHPGDSSGDSSGLNDTFGTTPAAEYFERGVLHLHQSHGIDDLGPPRWQL
TACLVLVIVLLYFSLWKGVKTSGKVVWITATMPYVVLTALLLRGVTLPGAIDGIRAYLSV
DFYRLCEASVWIDAATQVCFSLGVGFGVLIAFSSYNKFTNNCYRDAIVTTSINSLTSFSS
GFVVFSFLGYMAQKHSVPIGDVAKDGPGLIFIIYPEAIATLPLSSAWAVVFFIMLLTLGI
DSAMGGMESVITGLIDEFQLLHRHRELFTLFIVLATFLLSLFCVTNGGIYVFTLLDHFAA
GTSILFGVLIEAIGVAWFYGVGQFSDDIQQMTGQRPSLYWRLCWKLVSPCFLLFVVVVSI
VTFRPPHYGAYIFPDWANALGWVIATSSMAMVPIYAAYKFCSLPGSFREKLAYAIAPEKD
RELVDRGEVRQFTLRHWLKV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010451|Sodium-dependent dopamine transporter (SLC6A3)
ATGAGTAAGAGCAAATGCTCCGTGGGACTCATGTCTTCCGTGGTGGCCCCGGCTAAGGAG
CCCAATGCCGTGGGCCCGAAGGAGGTGGAGCTCATCCTTGTCAAGGAGCAGAACGGAGTG
CAGCTCACCAGCTCCACCCTCACCAACCCGCGGCAGAGCCCCGTGGAGGCCCAGGATCGG
GAGACCTGGGGCAAGAAGATCGACTTTCTCCTGTCCGTCATTGGCTTTGCTGTGGACCTG
GCCAACGTCTGGCGGTTCCCCTACCTGTGCTACAAAAATGGTGGCGGTGCCTTCCTGGTC
CCCTACCTGCTCTTCATGGTCATTGCTGGGATGCCACTTTTCTACATGGAGCTGGCCCTC
GGCCAGTTCAACAGGGAAGGGGCCGCTGGTGTCTGGAAGATCTGCCCCATACTGAAAGGT
GTGGGCTTCACGGTCATCCTCATCTCACTGTATGTCGGCTTCTTCTACAACGTCATCATC
GCCTGGGCGCTGCACTATCTCTTCTCCTCCTTCACCACGGAGCTCCCCTGGATCCACTGC
AACAACTCCTGGAACAGCCCCAACTGCTCGGATGCCCATCCTGGTGACTCCAGTGGAGAC
AGCTCGGGCCTCAACGACACTTTTGGGACCACACCTGCTGCCGAGTACTTTGAACGTGGC
GTGCTGCACCTCCACCAGAGCCATGGCATCGACGACCTGGGGCCTCCGCGGTGGCAGCTC
ACAGCCTGCCTGGTGCTGGTCATCGTGCTGCTCTACTTCAGCCTCTGGAAGGGCGTGAAG
ACCTCAGGGAAGGTGGTATGGATCACAGCCACCATGCCATACGTGGTCCTCACTGCCCTG
CTCCTGCGTGGGGTCACCCTCCCTGGAGCCATAGACGGCATCAGAGCATACCTGAGCGTT
GACTTCTACCGGCTCTGCGAGGCGTCTGTTTGGATTGACGCGGCCACCCAGGTGTGCTTC
TCCCTGGGCGTGGGGTTCGGGGTGCTGATCGCCTTCTCCAGCTACAACAAGTTCACCAAC
AACTGCTACAGGGACGCGATTGTCACCACCTCCATCAACTCCCTGACGAGCTTCTCCTCC
GGCTTCGTCGTCTTCTCCTTCCTGGGGTACATGGCACAGAAGCACAGTGTGCCCATCGGG
GACGTGGCCAAGGACGGGCCAGGGCTGATCTTCATCATCTACCCGGAAGCCATCGCCACG
CTCCCTCTGTCCTCAGCCTGGGCCGTGGTCTTCTTCATCATGCTGCTCACCCTGGGTATC
GACAGCGCCATGGGTGGTATGGAGTCAGTGATCACCGGGCTCATCGATGAGTTCCAGCTG
CTGCACAGACACCGTGAGCTCTTCACGCTCTTCATCGTCCTGGCGACCTTCCTCCTGTCC
CTGTTCTGCGTCACCAACGGTGGCATCTACGTCTTCACGCTCCTGGACCATTTTGCAGCC
GGCACGTCCATCCTCTTTGGAGTGCTCATCGAAGCCATCGGAGTGGCCTGGTTCTATGGT
GTTGGGCAGTTCAGCGACGACATCCAGCAGATGACCGGGCAGCGGCCCAGCCTGTACTGG
CGGCTGTGCTGGAAGCTGGTCAGCCCCTGCTTTCTCCTGTTCGTGGTCGTGGTCAGCATT
GTGACCTTCAGACCCCCCCACTACGGAGCCTACATCTTCCCCGACTGGGCCAACGCGCTG
GGCTGGGTCATCGCCACATCCTCCATGGCCATGGTGCCCATCTATGCGGCCTACAAGTTC
TGCAGCCTGCCTGGGTCCTTTCGAGAGAAACTGGCCTACGCCATTGCACCCGAGAAGGAC
CGTGAGCTGGTGGACAGAGGGGAGGTGCGCCAGTTCACGCTCCGCCACTGGCTCAAGGTG
TAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00209</identifier>
            <name>SNF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>axon</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>flotillin complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monoamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenohypophysis development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ammonium transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine uptake involved in synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of multicellular organism growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prepulse inhibition</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dopamine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to cocaine</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of smell</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="43">
      <id>BE0000749</id>
      <name>Sodium-dependent serotonin transporter</name>
      <organism>Humans</organism>
      <actions>
        <action>modulator</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A187310</ref-id>
            <pubmed-id>26346901</pubmed-id>
            <citation>de Bartolomeis A, Tomasetti C, Iasevoli F: Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS Drugs. 2015 Sep;29(9):773-99. doi: 10.1007/s40263-015-0278-3.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P31645" source="Swiss-Prot">
        <name>Sodium-dependent serotonin transporter</name>
        <general-function>Serotonin:sodium symporter activity</general-function>
        <specific-function>Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin and recycles it in a sodium-dependent manner.</specific-function>
        <gene-name>SLC6A4</gene-name>
        <locus>17q11.1-q12</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>88-108
116-135
160-180
253-271
280-297
333-350
362-383
417-436
464-482
498-518
539-558
577-595</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>6.17</theoretical-pi>
        <molecular-weight>70324.165</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11050</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SLC6A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X70697</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>36433</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>928</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P31645</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SC6A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>5HT transporter</synonym>
          <synonym>5HTT</synonym>
          <synonym>HTT</synonym>
          <synonym>SERT</synonym>
          <synonym>Solute carrier family 6 member 4</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001494|Sodium-dependent serotonin transporter
METTPLNSQKQLSACEDGEDCQENGVLQKVVPTPGDKVESGQISNGYSAVPSPGAGDDTR
HSIPATTTTLVAELHQGERETWGKKVDFLLSVIGYAVDLGNVWRFPYICYQNGGGAFLLP
YTIMAIFGGIPLFYMELALGQYHRNGCISIWRKICPIFKGIGYAICIIAFYIASYYNTIM
AWALYYLISSFTDQLPWTSCKNSWNTGNCTNYFSEDNITWTLHSTSPAEEFYTRHVLQIH
RSKGLQDLGGISWQLALCIMLIFTVIYFSIWKGVKTSGKVVWVTATFPYIILSVLLVRGA
TLPGAWRGVLFYLKPNWQKLLETGVWIDAAAQIFFSLGPGFGVLLAFASYNKFNNNCYQD
ALVTSVVNCMTSFVSGFVIFTVLGYMAEMRNEDVSEVAKDAGPSLLFITYAEAIANMPAS
TFFAIIFFLMLITLGLDSTFAGLEGVITAVLDEFPHVWAKRRERFVLAVVITCFFGSLVT
LTFGGAYVVKLLEEYATGPAVLTVALIEAVAVSWFYGITQFCRDVKEMLGFSPGWFWRIC
WVAISPLFLLFIICSFLMSPPQLRLFQYNYPYWSIILGYCIGTSSFICIPTYIAYRLIIT
PGTFKERIIKSITPETPTEIPCGDIRLNAV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021275|Sodium-dependent serotonin transporter (SLC6A4)
ATGGAGACGACGCCCTTGAATTCTCAGAAGCAGCTATCAGCGTGTGAAGATGGAGAAGAT
TGTCAGGAAAACGGAGTTCTACAGAAGGTTGTTCCCACCCCAGGGGACAAAGTGGAGTCC
GGGCAAATATCCAATGGGTACTCAGCAGTTCCAAGTCCTGGTGCGGGAGATGACACACGG
CACTCTATCCCAGCGACCACCACCACCCTAGTGGCTGAGCTTCATCAAGGGGAACGGGAG
ACCTGGGGCAAGAAGGTGGATTTCCTTCTCTCAGTGATTGGCTATGCTGTGGACCTGGGC
AATGTCTGGCGCTTCCCCTACATATGTTACCAGAATGGAGGGGGGGCATTCCTCCTCCCC
TACACCATCATGGCCATTTTTGGGGGAATCCCGCTCTTTTACATGGAGCTCGCACTGGGA
CAGTACCACCGAAATGGATGCATTTCAATATGGAGGAAAATCTGCCCGATTTTCAAAGGG
ATTGGTTATGCCATCTGCATCATTGCCTTTTACATTGCTTCCTACTACAACACCATCATG
GCCTGGGCGCTATACTACCTCATCTCCTCCTTCACGGACCAGCTGCCCTGGACCAGCTGC
AAGAACTCCTGGAACACTGGCAACTGCACCAATTACTTCTCCGAGGACAACATCACCTGG
ACCCTCCATTCCACGTCCCCTGCTGAAGAATTTTACACGCGCCACGTCCTGCAGATCCAC
CGGTCTAAGGGGCTCCAGGACCTGGGGGGCATCAGCTGGCAGCTGGCCCTCTGCATCATG
CTGATCTTCACTGTTATCTACTTCAGCATCTGGAAAGGCGTCAAGACCTCTGGCAAGGTG
GTGTGGGTGACAGCCACCTTCCCTTATATCATCCTTTCTGTCCTGCTGGTGAGGGGTGCC
ACCCTCCCTGGAGCCTGGAGGGGTGTTCTCTTCTACTTGAAACCCAATTGGCAGAAACTC
CTGGAGACAGGGGTGTGGATAGATGCAGCCGCTCAGATCTTCTTCTCTCTTGGTCCGGGC
TTTGGGGTCCTGCTGGCTTTTGCTAGCTACAACAAGTTCAACAACAACTGCTACCAAGAT
GCCCTGGTGACCAGCGTGGTGAACTGCATGACGAGCTTCGTTTCGGGATTTGTCATCTTC
ACAGTGCTCGGTTACATGGCTGAGATGAGGAATGAAGATGTGTCTGAGGTGGCCAAAGAC
GCAGGTCCCAGCCTCCTCTTCATCACGTATGCAGAAGCGATAGCCAACATGCCAGCGTCC
ACTTTCTTTGCCATCATCTTCTTTCTGATGTTAATCACGCTGGGCTTGGACAGCACGTTT
GCAGGCTTGGAGGGGGTGATCACGGCTGTGCTGGATGAGTTCCCACACGTCTGGGCCAAG
CGCCGGGAGCGGTTCGTGCTCGCCGTGGTCATCACCTGCTTCTTTGGATCCCTGGTCACC
CTGACTTTTGGAGGGGCCTACGTGGTGAAGCTGCTGGAGGAGTATGCCACGGGGCCCGCA
GTGCTCACTGTCGCGCTGATCGAAGCAGTCGCTGTGTCTTGGTTCTATGGCATCACTCAG
TTCTGCAGGGACGTGAAGGAAATGCTCGGCTTCAGCCCGGGGTGGTTCTGGAGGATCTGC
TGGGTGGCCATCAGCCCTCTGTTTCTCCTGTTCATCATTTGCAGTTTTCTGATGAGCCCG
CCACAACTACGACTTTTCCAATATAATTATCCTTACTGGAGTATCATCTTGGGTTACTGC
ATAGGAACCTCATCTTTCATTTGCATCCCCACATATATAGCTTATCGGTTGATCATCACT
CCAGGGACATTTAAAGAGCGTATTATTAAAAGTATTACCCCAGAAACACCAACAGAAATT
CCTTGTGGGGACATCCGCTTGAATGCTGTGTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00209</identifier>
            <name>SNF</name>
          </pfam>
          <pfam>
            <identifier>PF03491</identifier>
            <name>5HT_transport_N</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endomembrane system</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane raft</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>actin filament binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>cocaine binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monoamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Rab GTPase binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>serotonin transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brain morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to cGMP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to retinoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>circadian rhythm</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cerebellar granule cell precursor proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neuron differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of organ growth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein homooligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>serotonin uptake</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>social behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sperm ejaculation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>thalamus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vasoconstriction</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="21">
      <id>BE0002638</id>
      <name>Cytochrome P450 3A4</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A38367</ref-id>
            <pubmed-id>17164689</pubmed-id>
            <citation>Molden E, Lunde H, Lunder N, Refsum H: Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit. 2006 Dec;28(6):744-9. doi: 10.1097/01.ftd.0000249944.42859.bf.</citation>
          </article>
          <article>
            <ref-id>A34329</ref-id>
            <pubmed-id>21739267</pubmed-id>
            <citation>Azuma J, Hasunuma T, Kubo M, Miyatake M, Koue T, Higashi K, Fujiwara T, Kitahara S, Katano T, Hara S: The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine. Eur J Clin Pharmacol. 2012 Jan;68(1):29-37. doi: 10.1007/s00228-011-1094-4. Epub 2011 Jul 8.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
          <link>
            <ref-id>L8201</ref-id>
            <title>Aripiprazole Therapy and CYP2D6 Genotype</title>
            <url>https://www.ncbi.nlm.nih.gov/books/NBK385288/</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P08684" source="Swiss-Prot">
        <name>Cytochrome P450 3A4</name>
        <general-function>Vitamin d3 25-hydroxylase activity</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,8-cineole 2-exo-monooxygenase. The enzyme also hydroxylates etoposide (PubMed:11159812). Catalyzes 4-beta-hydroxylation of cholesterol. May catalyze 25-hydroxylation of cholesterol in vitro (PubMed:21576599).</specific-function>
        <gene-name>CYP3A4</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions>2-22</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.25</theoretical-pi>
        <molecular-weight>57342.67</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2637</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M18907</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1337</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P08684</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1,8-cineole 2-exo-monooxygenase</synonym>
          <synonym>1.14.13.-</synonym>
          <synonym>Albendazole monooxygenase</synonym>
          <synonym>Albendazole sulfoxidase</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP3A3</synonym>
          <synonym>CYPIIIA3</synonym>
          <synonym>CYPIIIA4</synonym>
          <synonym>Cytochrome P450 3A3</synonym>
          <synonym>Cytochrome P450 HLp</synonym>
          <synonym>Cytochrome P450 NF-25</synonym>
          <synonym>Cytochrome P450-PCN1</synonym>
          <synonym>Nifedipine oxidase</synonym>
          <synonym>Quinine 3-monooxygenase</synonym>
          <synonym>Taurochenodeoxycholate 6-alpha-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021936|Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021937|Cytochrome P450 3A4 (CYP3A4)
ATGGCTCTCATCCCAGACTTGGCCATGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGAACCCATTCACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATATTTTGTCCTACCATAAGGGCTTTTGTATGTTT
GACATGGAATGTCATAAAAAGTATGGAAAAGTGTGGGGCTTTTATGATGGTCAACAGCCT
GTGCTGGCTATCACAGATCCTGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTTGGTCCAGTGGGATTTATGAAAAGTGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGATTACGATCATTGCTGTCTCCAACCTTCACCAGTGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAAGACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTGATTTTTTGGATCCATTCTTT
CTCTCAATAATCTTTCCATTCCTCATCCCAATTCTTGAAGTATTAAATATCTGTGTGTTT
CCAAGAGAAGTTACAAATTTTTTAAGAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTC
GAAGATACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAATTCA
AAAGAAACTGAGTCCCACAAAGCTCTGTCCGATCTGGAGCTCGTGGCCCAATCAATTATC
TTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATGTATGAACTG
GCCACTCACCCTGATGTCCAGCAGAAACTGCAGGAGGAAATTGATGCAGTTTTACCCAAT
AAGGCACCACCCACCTATGATACTGTGCTACAGATGGAGTATCTTGACATGGTGGTGAAT
GAAACGCTCAGATTATTCCCAATTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGATGTT
GAGATCAATGGGATGTTCATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGCTCTT
CACCGTGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGATTCAGCAAG
AAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTAAGCTTAGGAGGA
CTTCTTCAACCAGAAAAACCCGTTGTTCTAAAGGTTGAGTCAAGGGATGGCACCGTAAGT
GGAGCCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>albendazole monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>caffeine oxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quinine 3-monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>taurochenodeoxycholate 6alpha-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>testosterone 6-beta-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D 24-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>vitamin D3 25-hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>androgen metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>calcitriol biosynthetic process from calciol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin D metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="22">
      <id>BE0003612</id>
      <name>Cytochrome P450 3A7</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P24462" source="Swiss-Prot">
        <name>Cytochrome P450 3A7</name>
        <general-function>Oxygen binding</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.</specific-function>
        <gene-name>CYP3A7</gene-name>
        <locus>7q21-q22.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.59</theoretical-pi>
        <molecular-weight>57525.03</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2640</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>D00408</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>220149</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P24462</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A7_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIIA7</synonym>
          <synonym>Cytochrome P450-HFLA</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0006949|Cytochrome P450 3A7
MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTF
DMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISI
AEDEEWKRIRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYS
MDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITV
FPRKVISFLTKSVKQIKEGRLKETQKHRVDFLQLMIDSQNSKDSETHKALSDLELMAQSI
IFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVV
NETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKYWREPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFG
GLLLTEKPIVLKAESRDETVSGA</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019448|Cytochrome P450 3A7 (CYP3A7)
ATGGATCTCATCCCAAACTTGGCCGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGATA
CTCCTCTATCTATATGGAACCCGTACACATGGACTTTTTAAGAAGCTTGGAATTCCAGGG
CCCACACCTCTGCCTTTTTTGGGAAATGCTTTGTCCTTCCGTAAGGGCTATTGGACGTTT
GACATGGAATGTTATAAAAAGTATAGAAAAGTCTGGGGTATTTATGACTGTCAACAGCCT
ATGCTGGCTATCACAGATCCCGACATGATCAAAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAACCGGAGGCCTTTCGGGCCAGTGGGATTTATGAAAAATGCCATCTCTATA
GCTGAGGATGAAGAATGGAAGAGAATACGATCATTGCTGTCTCCAACATTCACCAGCGGA
AAACTCAAGGAGATGGTCCCTATCATTGCCCAGTATGGAGATGTGTTGGTGAGAAATCTG
AGGCGGGAAGCAGAGACAGGCAAGCCTGTCACCTTGAAACACGTCTTTGGGGCCTACAGC
ATGGATGTGATCACTAGCACATCATTTGGAGTGAGCATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAAAACACCAAGAAGCTTTTAAGATTTAATCCATTAGATCCATTCGTT
CTCTCAATAAAAGTCTTTCCATTCCTTACCCCAATTCTTGAAGCATTAAATATCACTGTG
TTTCCAAGAAAAGTTATAAGTTTTCTAACAAAATCTGTAAAACAGATAAAAGAAGGTCGC
CTCAAAGAGACACAAAAGCACCGAGTGGATTTCCTTCAGCTGATGATTGACTCTCAGAAT
TCAAAAGACTCTGAGACCCACAAAGCTCTGTCTGATCTGGAGCTCATGGCCCAATCAATT
ATCTTTATTTTTGCTGGCTATGAAACCACGAGCAGTGTTCTCTCCTTCATTATATATGAA
CTGGCCACTCACCCTGATGTCCAGCAGAAAGTGCAGAAGGAAATTGATACAGTTTTACCC
AATAAGGCACCACCCACCTATGATACTGTGCTACAGTTGGAGTATCTTGACATGGTGGTG
AATGAAACACTCAGATTATTCCCAGTTGCTATGAGACTTGAGAGGGTCTGCAAAAAAGAT
GTTGAAATCAATGGGATGTTTATTCCCAAAGGGGTGGTGGTGATGATTCCAAGCTATGTT
CTTCATCATGACCCAAAGTACTGGACAGAGCCTGAGAAGTTCCTCCCTGAAAGGTTCAGT
AAAAAGAACAAGGACAACATAGATCCTTACATATACACACCCTTTGGAAGTGGACCCAGA
AACTGCATTGGCATGAGGTTTGCTCTCGTGAACATGAAACTTGCTCTAGTCAGAGTCCTT
CAGAACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCCTGAAATTACGCTTTGGA
GGACTTCTTCTAACAGAAAAACCCATTGTTCTAAAGGCTGAGTCAAGGGATGAGACCTTT
GTAGATATGGAGCCCATTCACATGGACTTTTTAAGAAGCTTGGCATTCCAGGGCCCACAC
CTCTGCTTTTTTTGGGAACTACTTTGTCCTACCATCAGATCCCGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="23">
      <id>BE0002362</id>
      <name>Cytochrome P450 3A5</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P20815" source="Swiss-Prot">
        <name>Cytochrome P450 3A5</name>
        <general-function>Oxygen binding</general-function>
        <specific-function>Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.</specific-function>
        <gene-name>CYP3A5</gene-name>
        <locus>7q21.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>9.09</theoretical-pi>
        <molecular-weight>57108.065</molecular-weight>
        <chromosome-location>7</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2638</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP3A5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J04813</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181346</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1338</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P20815</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP3A5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>CYPIIIA5</synonym>
          <synonym>Cytochrome P450 HLp2</synonym>
          <synonym>Cytochrome P450-PCN3</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004639|Cytochrome P450 3A5
MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF
DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL
AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS
MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL
FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI
IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV
NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS
KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG
LLQPEKPIVLKVDSRDGTLSGE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016766|Cytochrome P450 3A5 (CYP3A5)
ATGGACCTCATCCCAAATTTGGCGGTGGAAACCTGGCTTCTCCTGGCTGTCAGCCTGGTG
CTCCTCTATCTATATGGGACCCGTACACATGGACTTTTTAAGAGACTGGGAATTCCAGGG
CCCACACCTCTGCCTTTGTTGGGAAATGTTTTGTCCTATCGTCAGGGTCTCTGGAAATTT
GACACAGAGTGCTATAAAAAGTATGGAAAAATGTGGGGAACGTATGAAGGTCAACTCCCT
GTGCTGGCCATCACAGATCCCGACGTGATCAGAACAGTGCTAGTGAAAGAATGTTATTCT
GTCTTCACAAATCGAAGGTCTTTAGGCCCAGTGGGATTTATGAAAAGTGCCATCTCTTTA
GCTGAGGATGAAGAATGGAAGAGAATACGGTCATTGCTGTCTCCAACCTTCACCAGCGGA
AAACTCAAGGAGATGTTCCCCATCATTGCCCAGTATGGAGATGTATTGGTGAGAAACTTG
AGGCGGGAAGCAGAGAAAGGCAAGCCTGTCACCTTGAAAGACATCTTTGGGGCCTACAGC
ATGGATGTGATTACTGGCACATCATTTGGAGTGAACATCGACTCTCTCAACAATCCACAA
GACCCCTTTGTGGAGAGCACTAAGAAGTTCCTAAAATTTGGTTTCTTAGATCCATTATTT
CTCTCAATAATACTCTTTCCATTCCTTACCCCAGTTTTTGAAGCATTAAATGTCTCTCTG
TTTCCAAAAGATACCATAAATTTTTTAAGTAAATCTGTAAACAGAATGAAGAAAAGTCGC
CTCAACGACAAACAAAAGCACCGACTAGATTTCCTTCAGCTGATGATTGACTCCCAGAAT
TCGAAAGAAACTGAGTCCCACAAAGCTCTGTCTGATCTGGAGCTCGCAGCCCAGTCAATA
ATCTTCATTTTTGCTGGCTATGAAACCACCAGCAGTGTTCTTTCCTTCACTTTATATGAA
CTGGCCACTCACCCTGATGTCCAGCAGAAACTGCAAAAGGAGATTGATGCAGTTTTGCCC
AATAAGGCACCACCTACCTATGATGCCGTGGTACAGATGGAGTACCTTGACATGGTGGTG
AATGAAACACTCAGATTATTCCCAGTTGCTATTAGACTTGAGAGGACTTGCAAGAAAGAT
GTTGAAATCAATGGGGTATTCATTCCCAAAGGGTCAATGGTGGTGATTCCAACTTATGCT
CTTCACCATGACCCAAAGTACTGGACAGAGCCTGAGGAGTTCCGCCCTGAAAGGTTCAGT
AAGAAGAAGGACAGCATAGATCCTTACATATACACACCCTTTGGAACTGGACCCAGAAAC
TGCATTGGCATGAGGTTTGCTCTCATGAACATGAAACTTGCTCTAATCAGAGTCCTTCAG
AACTTCTCCTTCAAACCTTGTAAAGAAACACAGATCCCCTTGAAATTAGACACGCAAGGA
CTTCTTCAACCAGAAAAACCCATTGTTCTAAAGGTGGATTCAAGAGATGGAACCCTAAGT
GGAGAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="24">
      <id>BE0002363</id>
      <name>Cytochrome P450 2D6</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A39214</ref-id>
            <pubmed-id>17214606</pubmed-id>
            <citation>Spina E, de Leon J: Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol. 2007 Jan;100(1):4-22. doi: 10.1111/j.1742-7843.2007.00017.x.</citation>
          </article>
          <article>
            <ref-id>A11184</ref-id>
            <pubmed-id>15257633</pubmed-id>
            <citation>Swainston Harrison T, Perry CM: Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715-36.</citation>
          </article>
          <article>
            <ref-id>A184112</ref-id>
            <pubmed-id>15770075</pubmed-id>
            <citation>Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T, Azuma J: Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic ARIPIPRAZOLE. Drug Metab Pharmacokinet. 2005 Feb;20(1):55-64.</citation>
          </article>
        </articles>
        <textbooks/>
        <links>
          <link>
            <ref-id>L162</ref-id>
            <title>Flockhart Table of Drug Interactions</title>
            <url>https://drug-interactions.medicine.iu.edu/Main-Table.aspx</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P10635" source="Swiss-Prot">
        <name>Cytochrome P450 2D6</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.</specific-function>
        <gene-name>CYP2D6</gene-name>
        <locus>22q13.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.26</theoretical-pi>
        <molecular-weight>55768.94</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2D6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M20403</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181350</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1329</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10635</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2D6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP2DL1</synonym>
          <synonym>CYPIID6</synonym>
          <synonym>Cytochrome P450-DB1</synonym>
          <synonym>Debrisoquine 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004641|Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6)
ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG
GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG
CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG
TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG
CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC
CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC
CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC
AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT
TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA
GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT
CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG
CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC
CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG
ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG
AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT
GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC
ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG
CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT
CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT
GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA
TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC
CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC
CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG
CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC
TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>isoquinoline alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular organofluorine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers>
    <carrier position="25">
      <id>BE0000530</id>
      <name>Serum albumin</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P02768" source="Swiss-Prot">
        <name>Serum albumin</name>
        <general-function>Toxic substance binding</general-function>
        <specific-function>Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.</specific-function>
        <gene-name>ALB</gene-name>
        <locus>4q11-q13</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-18</signal-regions>
        <theoretical-pi>6.21</theoretical-pi>
        <molecular-weight>69365.94</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:399</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALB</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>V00494</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>28590</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P02768</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>ALBU_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Serum albumin precursor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001058|Serum albumin
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010372|Serum albumin (ALB)
ATGAAGTGGGTAACCTTTATTTCCCTTCTTTTTCTCTTTAGCTCGGCTTATTCCAGGGGT
GTGTTTCGTCGAGATGCACACAAGAGTGAGGTTGCTCATCGGTTTAAAGATTTGGGAGAA
GAAAATTTCAAAGCCTTGGTGTTGATTGCCTTTGCTCAGTATCTTCAGCAGTGTCCATTT
GAAGATCATGTAAAATTAGTGAATGAAGTAACTGAATTTGCAAAAACATGTGTTGCTGAT
GAGTCAGCTGAAAATTGTGACAAATCACTTCATACCCTTTTTGGAGACAAATTATGCACA
GTTGCAACTCTTCGTGAAACCTATGGTGAAATGGCTGACTGCTGTGCAAAACAAGAACCT
GAGAGAAATGAATGCTTCTTGCAACACAAAGATGACAACCCAAACCTCCCCCGATTGGTG
AGACCAGAGGTTGATGTGATGTGCACTGCTTTTCATGACAATGAAGAGACATTTTTGAAA
AAATACTTATATGAAATTGCCAGAAGACATCCTTACTTTTATGCCCCGGAACTCCTTTTC
TTTGCTAAAAGGTATAAAGCTGCTTTTACAGAATGTTGCCAAGCTGCTGATAAAGCTGCC
TGCCTGTTGCCAAAGCTCGATGAACTTCGGGATGAAGGGAAGGCTTCGTCTGCCAAACAG
AGACTCAAGTGTGCCAGTCTCCAAAAATTTGGAGAAAGAGCTTTCAAAGCATGGGCAGTA
GCTCGCCTGAGCCAGAGATTTCCCAAAGCTGAGTTTGCAGAAGTTTCCAAGTTAGTGACA
GATCTTACCAAAGTCCACACGGAATGCTGCCATGGAGATCTGCTTGAATGTGCTGATGAC
AGGGCGGACCTTGCCAAGTATATCTGTGAAAATCAAGATTCGATCTCCAGTAAACTGAAG
GAATGCTGTGAAAAACCTCTGTTGGAAAAATCCCACTGCATTGCCGAAGTGGAAAATGAT
GAGATGCCTGCTGACTTGCCTTCATTAGCTGCTGATTTTGTTGAAAGTAAGGATGTTTGC
AAAAACTATGCTGAGGCAAAGGATGTCTTCCTGGGCATGTTTTTGTATGAATATGCAAGA
AGGCATCCTGATTACTCTGTCGTGCTGCTGCTGAGACTTGCCAAGACATATGAAACCACT
CTAGAGAAGTGCTGTGCCGCTGCAGATCCTCATGAATGCTATGCCAAAGTGTTCGATGAA
TTTAAACCTCTTGTGGAAGAGCCTCAGAATTTAATCAAACAAAATTGTGAGCTTTTTGAG
CAGCTTGGAGAGTACAAATTCCAGAATGCGCTATTAGTTCGTTACACCAAGAAAGTACCC
CAAGTGTCAACTCCAACTCTTGTAGAGGTCTCAAGAAACCTAGGAAAAGTGGGCAGCAAA
TGTTGTAAACATCCTGAAGCAAAAAGAATGCCCTGTGCAGAAGACTATCTATCCGTGGTC
CTGAACCAGTTATGTGTGTTGCATGAGAAAACGCCAGTAAGTGACAGAGTCACCAAATGC
TGCACAGAATCCTTGGTGAACAGGCGACCATGCTTTTCAGCTCTGGAAGTCGATGAAACA
TACGTTCCCAAAGAGTTTAATGCTGAAACATTCACCTTCCATGCAGATATATGCACACTT
TCTGAGAAGGAGAGACAAATCAAGAAACAAACTGCACTTGTTGAGCTCGTGAAACACAAG
CCCAAGGCAACAAAAGAGCAACTGAAAGCTGTTATGGATGATTTCGCAGCTTTTGTAGAG
AAGTGCTGCAAGGCTGACGATAAGGAGACCTGCTTTGCCGAGGAGGGTAAAAAACTTGTT
GCTGCAAGTCAAGCTGCCTTAGGCTTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00273</identifier>
            <name>Serum_albumin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>blood microparticle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>myelin sheath</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>platelet alpha granule lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antioxidant activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chaperone binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>copper ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>DNA binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>fatty acid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>pyridoxal phosphate binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>toxic substance binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid and bile salt transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bile acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>blood coagulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to starvation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hemolysis by symbiont of host erythrocytes</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoprotein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of mitochondrion location</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>platelet degranulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>receptor-mediated endocytosis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>retina homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sodium-independent organic anion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </carrier>
  </carriers>
  <transporters/>
</drug>